,BARCODE,COMBI_ID,Tissue,CELL_LINE_NAME,SIDM,COSMIC_ID,ANCHOR_ID,ANCHOR_NAME,ANCHOR_TARGET,ANCHOR_PATHWAY,ANCHOR_DRUG_TYPE,ANCHOR_Clin_Rel,ANCHOR_CONC,LIBRARY_ID,LIBRARY_NAME,LIBRARY_TARGET,LIBRARY_PATHWAY,LIBRARY_DRUG_TYPE,LIBRARY_Clin_Rel,LIBRARY_CONC,ANCHOR_VIABILITY,LIBRARY_RMSE,LIBRARY_EMAX,LIBRARY_XMID,LIBRARY_XMID_uM,LIBRARY_AUC,LIBRARY_fAUC,SYNERGY_RMSE,SYNERGY_EXP_EMAX,SYNERGY_OBS_EMAX,SYNERGY_DELTA_EMAX,SYNERGY_XMID,SYNERGY_XMID_uM,SYNERGY_DELTA_XMID,SYNERGY_DELTA_XMID_uM,SYNERGY_EXP_AUC,SYNERGY_OBS_AUC,SYNERGY_EXP_fAUC,SYNERGY_OBS_fAUC,SYNERGY_DELTA_AUC,SYNERGY_DELTA_fAUC,Synergy,DAY1_NORM_MEAN,DAY1_NORM_SD,GROWTH_RATE,DOUBLING_TIME
0,14577,1011:1012,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.251275587746141,0.0952072335648409,0.518506228631407,9.13333523314711,5.4841,0.850533909432513,0.882395231797411,0.0289044549864365,0.130287957349392,0.0401051066803375,0.0901828506690541,6.00924670720787,0.629,3.12408852593924,4.8551,0.213718407990677,0.16638297892555,0.221724380494286,0.169171537373141,0.0473354290651278,0.0525528431211453,True,0.45268617874145,0.0619180719759428,0.767468512851341,64.0728989737934
1,14578,1011:1021,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.241120404495817,0.0933354841089233,0.851742797969336,12.1477009993731,88.6242,0.930284863630387,0.971230147250321,0.0524064747297236,0.205372567972765,0.0713433125022409,0.134029255470524,7.43908581227599,3.3894,4.70861518709708,85.2348,0.224310662614895,0.176857614247395,0.234183405963529,0.188652502592965,0.0474530483674993,0.0455309033705646,True,0.45268617874145,0.0619180719759428,0.767468512851341,64.0728989737934
2,14579,1011:1049,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.325457399928819,0.0863145969041701,0.786029418718387,11.3425983839965,50.7215,0.897098452961029,0.956843023200917,0.0538307292298927,0.255819090883647,0.177828004623916,0.0779910862597309,9.33507529912242,12.6144,2.00752308487411,38.1071,0.291967329980862,0.247928521528047,0.311411642471001,0.290229526112238,0.0440388084528156,0.0211821163587623,True,0.45268617874145,0.0619180719759428,0.767468512851341,64.0728989737934
3,14579,1549:1049,Breast,CAL-120,SIDM00940,906826,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.966711479030238,0.0863145969041701,0.786029418718387,11.3425983839965,50.7215,0.897098452961029,0.956843023200917,0.0718190532343168,0.75986366193053,0.781730602764305,-0.0218669408337742,11.5948378660018,60.4121,-0.252239482005271,-9.6906,0.867235372297695,0.857944320768887,0.924991134158322,0.929905086161411,0.0092910515288079,-0.0049139520030888,True,0.45268617874145,0.0619180719759428,0.767468512851341,64.0728989737934
4,14580,1594:1053,Breast,CAL-120,SIDM00940,906826,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.920746926528932,0.0772702898055411,0.809786020696576,11.608093586369,60.9697,0.920837498197176,0.962177872762651,0.0280613771758807,0.745607989702467,0.486384711319636,0.25922327838283,9.20366305368975,11.5162,2.40443053267925,49.4535,0.847858296297641,0.815028290136597,0.885922319120357,0.815526264703865,0.0328300061610439,0.0703960544164918,True,0.45268617874145,0.0619180719759428,0.767468512851341,64.0728989737934
5,14580,1049:1053,Breast,CAL-120,SIDM00940,906826,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.905088072444634,0.0772702898055411,0.809786020696576,11.608093586369,60.9697,0.920837498197176,0.962177872762651,0.0963041236474514,0.732927668564874,0.499278894420508,0.233648774144367,9.3731897881133,12.9521,2.2349037982557,48.0176,0.833439036278021,0.730002223838844,0.870855716207626,0.808665149794041,0.103436812439177,0.0621905664135854,True,0.45268617874145,0.0619180719759428,0.767468512851341,64.0728989737934
6,14920,1049:1083,Breast,CAL-120,SIDM00940,906826,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.95097053850587,0.107418139415902,0.671179814068995,10.2846309900603,24.362,0.912435974327012,0.928555931844957,0.113397260461098,0.638272229219462,0.511769243963975,0.126502985255487,9.27530967739541,12.1025,1.0093213126649,12.2595,0.867699729857887,0.891168214120297,0.883029334539419,0.845453442260975,-0.0234684842624107,0.0375758922784438,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
7,14920,1011:1083,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.23030961524183,0.107418139415902,0.671179814068995,10.2846309900603,24.362,0.912435974327012,0.928555931844957,0.055989907975603,0.154579164736313,0.0474856767168322,0.107093488019481,6.57289128848941,1.8594,3.71173970157089,22.5026,0.210142778180059,0.118811864902602,0.213855359393731,0.165450051073264,0.0913309132774569,0.048405308320467,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
8,14920,1594:1083,Breast,CAL-120,SIDM00940,906826,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.936912437628772,0.107418139415902,0.671179814068995,10.2846309900603,24.362,0.912435974327012,0.928555931844957,0.0649762477461267,0.628836715686608,0.502478929501507,0.126357786185101,9.26197739570043,11.9912,1.02265359435988,12.3708,0.854872612886904,0.864308787904082,0.869975601579514,0.83238129175091,-0.009436175017178,0.0375943098286047,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
9,14922,1594:1372,Breast,CAL-120,SIDM00940,906826,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.723643478691944,0.103013269066662,0.754585634057502,11.0222445492323,4.0622,0.884576636258143,0.949529717548833,0.0938219476071176,0.546050973200337,0.339952471012832,0.206098502187505,8.78209466228683,0.8598,2.24014988694549,3.2024,0.640118114231461,0.560146778372549,0.687120987928417,0.625782271725453,0.0799713358589125,0.0613387162029639,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
10,14922,1011:1372,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.57815280611961,0.103013269066662,0.754585634057502,11.0222445492323,4.0622,0.884576636258143,0.949529717548833,0.0753550832545673,0.43626580178789,0.281689759033546,0.154576042754344,8.90797037593715,0.9382,2.11427417329517,3.124,0.511420464480491,0.447144306773678,0.548973270694819,0.503731566619655,0.0642761577068127,0.0452417040751631,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
11,14922,1058:1372,Breast,CAL-120,SIDM00940,906826,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.929552451415327,0.103013269066662,0.754585634057502,11.0222445492323,4.0622,0.884576636258143,0.949529717548833,0.195711655654058,0.701426925940939,0.387849452911519,0.31357747302942,8.39848583436557,0.6591,2.62375871486676,3.4031,0.822260380698481,0.615328971529569,0.882637676639221,0.784170827860137,0.206931409168912,0.0984668487790837,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
12,14922,1561:1372,Breast,CAL-120,SIDM00940,906826,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.903254558496361,0.103013269066662,0.754585634057502,11.0222445492323,4.0622,0.884576636258143,0.949529717548833,0.143431689170465,0.681582913738305,0.46585616131032,0.215726752427985,9.1134835576963,1.0818,1.90876099153603,2.9804,0.798997879039545,0.668171411401325,0.857667045803746,0.796168132517122,0.13082646763822,0.0614989132866237,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
13,14924,1011:1510,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.222871122719789,0.0542601784126793,0.91518280512338,13.2824731969349,194.6045,0.963749457945097,0.984107383438738,0.0942242187306682,0.203967819271693,0.0771111785566787,0.126856640715015,7.8536634193645,4.5177,5.42880977757038,190.0868,0.214791923712812,0.0888440732117773,0.219329117423825,0.18057643222826,0.125947850501034,0.038752685195565,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
14,14924,1594:1510,Breast,CAL-120,SIDM00940,906826,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.930061756875832,0.0542601784126793,0.91518280512338,13.2824731969349,194.6045,0.963749457945097,0.984107383438738,0.0306250155153674,0.851176527595604,0.569222851130275,0.281953676465329,9.82069424126037,17.6626,3.4617789556745,176.9419,0.896346514044548,0.841901584448776,0.915280641995511,0.848258594277147,0.0544449295957724,0.0670220477183642,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
15,14924,1083:1549,Breast,CAL-120,SIDM00940,906826,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.947637307213568,0.0774387521266379,0.919015001560451,13.3732366232639,103.6204,0.932210494489191,0.984856526202109,0.0936339070133051,0.87089290136762,0.598576302025799,0.27231659934182,9.97096790252702,9.8008,3.40226872073687,93.8196,0.883397442753966,0.788812829050071,0.933286786481876,0.869639574469951,0.094584613703895,0.0636472120119246,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
16,14924,1021:1549,Breast,CAL-120,SIDM00940,906826,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.92995784087484,0.0774387521266379,0.919015001560451,13.3732366232639,103.6204,0.932210494489191,0.984856526202109,0.0351142936377894,0.854645206582745,0.860060355209426,-0.0054151486266809,13.5189507303511,114.633,-0.145714107087164,-11.0126,0.866916458696035,0.91012350474369,0.915875048678409,0.916928119260239,-0.0432070460476545,-0.0010530705818299,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
17,14924,1594:1549,Breast,CAL-120,SIDM00940,906826,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.704606534349121,0.0774387521266379,0.919015001560451,13.3732366232639,103.6204,0.932210494489191,0.984856526202109,0.0652388502602909,0.647543975264361,0.408120852507769,0.239423122756593,9.57534319779758,7.4502,3.79789342546631,96.1702,0.656841605805909,0.592823877691876,0.693936343758382,0.635689027718316,0.0640177281140332,0.0582473160400663,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
18,14925,1021:1558,Breast,CAL-120,SIDM00940,906826,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.994762044608002,0.0695943433944192,0.862357438830148,12.303748128959,98.7478,0.971188424712462,0.973449920422527,0.0728732671163005,0.857840449033598,0.822110113132193,0.0357303359014044,11.8096955849227,70.1137,0.494052544036302,28.6341,0.966101383066594,0.929084530371056,0.96835103316301,0.960766491487333,0.0370168526955377,0.007584541675677,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
19,14925,1049:1558,Breast,CAL-120,SIDM00940,906826,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.866980720514686,0.0695943433944192,0.862357438830148,12.303748128959,98.7478,0.971188424712462,0.973449920422527,0.0781984162935851,0.74764727365816,0.48084898701259,0.26679828664557,9.39496177468034,13.1491,2.90878635427863,85.5987,0.842001640212733,0.775584623061123,0.843962313392886,0.775455159536773,0.0664170171516102,0.0685071538561131,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
20,14925,1510:1558,Breast,CAL-120,SIDM00940,906826,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.971742418904469,0.0695943433944192,0.862357438830148,12.303748128959,98.7478,0.971188424712462,0.973449920422527,0.138407305025049,0.83798930356907,0.525089597035836,0.312899706533235,9.29128156941735,12.2373,3.01246655954161,86.5105,0.943744989042109,0.903433383256604,0.945942580353749,0.864630514906017,0.0403116057855046,0.0813120654477326,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
21,14925,1083:1558,Breast,CAL-120,SIDM00940,906826,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.988843865371074,0.0695943433944192,0.862357438830148,12.303748128959,98.7478,0.971188424712462,0.973449920422527,0.115202398991996,0.852736863144302,0.592506141645587,0.260230721498715,9.72393031906919,16.5168,2.57981780988977,82.231,0.960353715896315,0.931452245186191,0.962589982055776,0.89812101638549,0.0289014707101241,0.064468965670285,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
22,14925,1012:1558,Breast,CAL-120,SIDM00940,906826,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.677574033847871,0.0695943433944192,0.862357438830148,12.303748128959,98.7478,0.971188424712462,0.973449920422527,0.119268978309833,0.584311008446861,0.334162134244823,0.250148874202038,8.95084139919557,9.665,3.35290672976339,89.0828,0.658052058558782,0.624956081172054,0.65958438932958,0.591824290149626,0.0330959773867281,0.0677600991799538,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
23,14925,1011:1558,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.194752539432721,0.0695943433944192,0.862357438830148,12.303748128959,98.7478,0.971188424712462,0.973449920422527,0.0359197075184253,0.167946301110869,0.0769691360964843,0.0909771650143845,8.23403342850054,5.8806,4.06971470045842,92.8672,0.189141411980416,0.151734377974171,0.189581844012867,0.162409547774548,0.0374070340062447,0.0271722962383193,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
24,14926,1054:1561,Breast,CAL-120,SIDM00940,906826,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.995946790055155,0.0567333503993024,0.529815391806319,9.21497335874426,11.6068,0.862055517445445,0.886251288923021,0.111309052418034,0.527667938791317,0.310737665352173,0.216930273439145,7.57629001070676,3.7275,1.63868334803749,7.8793,0.858561425449127,0.701880140360663,0.882659126385126,0.788620264120239,0.156681285088464,0.0940388622648869,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
25,14926,1011:1561,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.243602979169645,0.0567333503993024,0.529815391806319,9.21497335874426,11.6068,0.862055517445445,0.886251288923021,0.0523604017989413,0.129064607853952,0.0399203066723597,0.0891443011815922,6.0659304040885,1.3084,3.14904295465576,10.2984,0.20999929225934,0.120738225889359,0.215893454274586,0.165136293163557,0.0892610663699814,0.0507571611110288,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
26,14926,1058:1594,Breast,CAL-120,SIDM00940,906826,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.949258718784091,0.084550381132,0.35207155696884,7.90185462740802,1.8685,0.832104250155322,0.813330613585929,0.0773213450034831,0.334206995088561,0.192755095427262,0.141451899661299,6.53833913877055,0.7261,1.36351548863747,1.1424,0.789882214397237,0.667358939193303,0.772061176200457,0.679369273714663,0.122523275203934,0.092691902485794,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
27,14926,1083:1594,Breast,CAL-120,SIDM00940,906826,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.903250830577869,0.084550381132,0.35207155696884,7.90185462740802,1.8685,0.832104250155322,0.813330613585929,0.0320467938972194,0.318008926254948,0.211126209105298,0.10688271714965,6.86236931831573,0.909,1.03948530909228,0.9595,0.75159885508017,0.671118308177029,0.734641552255898,0.668924371493397,0.0804805469031403,0.0657171807625008,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
28,14926,1561:1594,Breast,CAL-120,SIDM00940,906826,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.913825377780318,0.084550381132,0.35207155696884,7.90185462740802,1.8685,0.832104250155322,0.813330613585929,0.0319592001056012,0.321731923552755,0.157132607146721,0.164599316406034,6.17001301460099,0.5625,1.73184161280702,1.306,0.760397980750795,0.633573731498975,0.743242155220459,0.627209528413622,0.12682424925182,0.116032626806837,True,0.294087485246129,0.046711832958562,1.18706798614615,41.6570546741743
29,15761,1561:1011,Breast,CAL-148,SIDM00938,924106,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.272989478566279,0.144270394023131,0.269009550962435,6.543854060454,1.8223,0.673065943051663,0.688539177513284,0.0425363751052771,0.073436777046584,0.0233638784165798,0.0500728986300042,3.17993607252141,0.177,3.36391798793259,1.6453,0.183739920834394,0.0874871675889683,0.187963951041806,0.119347896187615,0.0962527532454261,0.0686160548541915,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
30,15761,1083:1011,Breast,CAL-148,SIDM00938,924106,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.446959026231459,0.144270394023131,0.269009550962435,6.543854060454,1.8223,0.673065943051663,0.688539177513284,0.0482145054442016,0.120236246945132,0.0278774132875879,0.0923588336575443,2.34092591357875,0.099,4.20292814687524,1.7233,0.30083289849593,0.142655313300072,0.307748800303547,0.167347429166998,0.158177585195858,0.140401371136549,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
31,15761,1012:1011,Breast,CAL-148,SIDM00938,924106,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.492642974349669,0.144270394023131,0.269009550962435,6.543854060454,1.8223,0.673065943051663,0.688539177513284,0.0542731844365553,0.132525665314603,0.032109351858342,0.100416313456261,2.4564301822832,0.1072,4.0874238781708,1.7151,0.331581208118436,0.165665151621451,0.339203988366419,0.188638650374643,0.165916056496985,0.150565337991776,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
32,15761,1021:1011,Breast,CAL-148,SIDM00938,924106,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.713104705469936,0.144270394023131,0.269009550962435,6.543854060454,1.8223,0.673065943051663,0.688539177513284,0.0617113413081284,0.191831976607667,0.0557923091029522,0.136039667504715,2.93975883855165,0.1499,3.60409522190235,1.6724,0.479966491081701,0.289536542790097,0.491000527385122,0.298790678631105,0.190429948291604,0.192209848754017,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
33,15761,1594:1011,Breast,CAL-148,SIDM00938,924106,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.82123415915419,0.144270394023131,0.269009550962435,6.543854060454,1.8223,0.673065943051663,0.688539177513284,0.0794129475643218,0.220919832389082,0.1293976605659,0.0915221718231815,4.88094395861721,0.5755,1.66291010183679,1.2468,0.552744743797355,0.477701811568275,0.56545189248984,0.465996916287298,0.0750429322290795,0.0994549762025421,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
34,15762,1011:1021,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.553303159877639,0.098162397491293,0.523549181977611,9.23161246287892,11.7415,0.843449567819426,0.844790782006218,0.0705690306933027,0.289681416739565,0.113735918111337,0.175945498628229,5.67835726886919,1.0002,3.55325519400973,10.7413,0.466683311071918,0.337519108466071,0.467425409119542,0.34692107248443,0.129164202605846,0.120504336635113,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
35,15764,1053:1054,Breast,CAL-148,SIDM00938,924106,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.769086337464479,0.0968906168447721,0.834934639035315,12.9828218611631,63.2425,0.921125544909467,0.956503439719259,0.136373665091909,0.642136823557897,0.466744647056254,0.175392176501642,10.0668884356598,8.3796,2.91593342550333,54.8629,0.708425071679394,0.581326826655558,0.73563372722586,0.676792470420686,0.127098245023836,0.0588412568051738,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
36,15765,1053:1058,Breast,CAL-148,SIDM00938,924106,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.431440711408525,0.112252711530227,0.267372993191295,6.52336628415407,0.7187,0.702068908997331,0.687131082691171,0.0516083073799226,0.115355594393879,0.040629379749086,0.0747262146447929,3.4380130502878,0.0847,3.08535323386627,0.634,0.302901109555615,0.162838209133858,0.296456323147189,0.197111786202326,0.140062900421757,0.0993445369448627,True,0.881422581552557,0.144019781847702,0.113687909514015,400.083390307117
37,15077,1561:1372,Breast,CAL-148,SIDM00938,924106,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.766141517912436,0.0977772998865147,0.879455155526854,13.8827433370727,29.5021,0.926161663675484,0.969013652029865,0.0919120063508141,0.673787107791261,0.692225568930122,-0.0184384611388606,14.4962617183229,45.1377,-0.613518381250188,-15.6356,0.709570902840642,0.686159051055405,0.742401590244034,0.747386491693759,0.0234118517852366,-0.0049849014497255,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
38,15079,1561:1549,Breast,CAL-148,SIDM00938,924106,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.758700258327664,0.114419901574725,0.889972301392723,14.1362500823023,175.8472,0.90997528416858,0.971878217439823,0.117492934006141,0.675222214971124,0.464027769527633,0.211194445443491,10.1156729900434,10.8348,4.02057709225898,165.0124,0.69039848317049,0.581703541961967,0.737364254634623,0.669058955246547,0.108694941208523,0.0683052993880751,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
39,15080,1561:1558,Breast,CAL-148,SIDM00938,924106,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.654645326938717,0.121077646064987,0.841386009225705,13.099689183912,171.4468,0.932881539792048,0.958356208764362,0.0442508940850106,0.550809419091224,0.474565407347854,0.0762440117433693,11.3808271640647,52.0835,1.71886201984725,119.3633,0.610706540612259,0.632522668506642,0.627383413610295,0.60394100167346,-0.0218161278943826,0.0234424119368354,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
40,15080,1083:1558,Breast,CAL-148,SIDM00938,924106,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.561359035582842,0.121077646064987,0.841386009225705,13.099689183912,171.4468,0.932881539792048,0.958356208764362,0.111959014399887,0.472319638691837,0.310979711129147,0.16133992756269,9.53255564813423,14.4649,3.56713353577773,156.9819,0.5236814814907,0.432053896587504,0.537981917096791,0.481779005703505,0.0916275849031962,0.0562029113932859,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
41,15080,1011:1558,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.689289980287236,0.121077646064987,0.841386009225705,13.099689183912,171.4468,0.932881539792048,0.958356208764362,0.105884324719808,0.579958945713142,0.25362317526782,0.326335770445323,7.67069534195027,3.9796,5.42899384196168,167.4672,0.643025898173588,0.546789304207684,0.660585332247338,0.524860004190062,0.0962365939659039,0.135725328057276,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
42,15080,1053:1558,Breast,CAL-148,SIDM00938,924106,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.657982655931006,0.121077646064987,0.841386009225705,13.099689183912,171.4468,0.932881539792048,0.958356208764362,0.149031218438763,0.553617401013519,0.343064141303928,0.210553259709591,9.21032758735449,11.5695,3.88936159655747,159.8773,0.613819873221378,0.568441745137484,0.630581763570744,0.555210419766504,0.0453781280838937,0.0753713438042408,True,0.920602720223482,0.156348479856104,0.0702170609140754,610.559201373973
43,16401,1012:1561,Breast,CAL-148,SIDM00938,924106,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.47815547331094,0.102798760273758,0.106008989488468,3.76125966212114,0.2648,0.475054568335452,0.481650420534092,0.0503017072877972,0.0506887785440727,0.0157762780276681,0.0349125005164046,0.700563231224836,0.0317,3.0606964308963,0.2331,0.227149941970963,0.0852158248247303,0.230303784800892,0.125046688944984,0.141934117146232,0.105257095855908,True,0.954044599921099,0.155762534662919,0.0383552755018417,1069.87392189818
44,16401,1011:1561,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.696040657749009,0.102798760273758,0.106008989488468,3.76125966212114,0.2648,0.475054568335452,0.481650420534092,0.0920702465906673,0.0737865667708607,0.0234434184556618,0.0503431483151989,0.752948870272459,0.0329,3.00831079184868,0.2319,0.33065729421088,0.130222611693945,0.335248275513636,0.18434485981592,0.200434682516935,0.150903415697717,True,0.954044599921099,0.155762534662919,0.0383552755018417,1069.87392189818
45,16401,1053:1561,Breast,CAL-148,SIDM00938,924106,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.46141610845642,0.102798760273758,0.106008989488468,3.76125966212114,0.2648,0.475054568335452,0.481650420534092,0.0603642744133904,0.0489142553911662,0.0101231001496473,0.0387911552415189,-0.329947997323822,0.0155,4.09120765944496,0.2493,0.219197830225789,0.0675669703314519,0.222241262679239,0.0925763602064393,0.151630859894337,0.1296649024728,True,0.954044599921099,0.155762534662919,0.0383552755018417,1069.87392189818
46,16401,1012:1594,Breast,CAL-148,SIDM00938,924106,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.924436438820743,0.106996800793154,0.450999950498898,8.51687742886215,2.8617,0.781654862894962,0.809407496393338,0.051581104589848,0.416920788147533,0.36282496230898,0.0540958258385527,7.9265630361847,1.9007,0.590314392677449,0.961,0.722590237841535,0.732632942484356,0.748245783520671,0.717932426448448,-0.0100427046428213,0.0303133570722233,True,0.954044599921099,0.155762534662919,0.0383552755018417,1069.87392189818
47,16401,1011:1594,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.696040657749009,0.106996800793154,0.450999950498898,8.51687742886215,2.8617,0.781654862894962,0.809407496393338,0.109451604408689,0.313914302190023,0.118935722336858,0.194978579853165,5.11931799092338,0.2716,3.39755943793878,2.5901,0.544063564902121,0.398289799836895,0.563380526176598,0.407497955350116,0.145773765065226,0.155882570826482,True,0.954044599921099,0.155762534662919,0.0383552755018417,1069.87392189818
48,16401,1053:1594,Breast,CAL-148,SIDM00938,924106,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.687147870170045,0.106996800793154,0.450999950498898,8.51687742886215,2.8617,0.781654862894962,0.809407496393338,0.0468274366020158,0.309903655432114,0.158677097966125,0.151226557465989,6.04394680238561,0.5155,2.47293062647654,2.3462,0.537112474246331,0.451621261709603,0.556182637246351,0.4490336749737,0.0854912125367288,0.107148962272651,True,0.954044599921099,0.155762534662919,0.0383552755018417,1069.87392189818
49,14501,1021:1011,Breast,CAL-51,SIDM00933,910927,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.766098175641102,0.181170256291335,0.285757758730848,7.52883716012959,3.6069,0.838461844597573,0.799629672155096,0.0827337096403532,0.218918497638993,0.120679683916772,0.0982388137222203,6.30723096120414,1.5467,1.22160619892545,2.0602,0.642344089490874,0.546599459453613,0.612594833026511,0.540009889941672,0.0957446300372605,0.0725849430848386,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
50,15767,1011:1021,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.829537093911919,0.0714384552066378,0.529084372947906,9.18704179713313,11.3843,0.858386540322892,0.898047022866651,0.0762518215625136,0.438895113169416,0.122379138750322,0.316515974419094,6.18297803118931,1.419,3.00406376594382,9.9653,0.712063476112558,0.572991898956792,0.744963317545053,0.576103347026502,0.139071577155767,0.16885997051855,True,0.411687103763168,0.0498687498213965,0.862492322973888,57.1759451016027
51,14632,1561:1049,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.805559644237073,0.122559065668044,0.72421245429978,10.5504579934571,29.291,0.846412154057351,0.948301934910926,0.047137051758669,0.583396327037788,0.529632429269381,0.0537638977684076,10.0471447951681,20.6644,0.503313198289003,8.6266,0.681835473700375,0.727679573999082,0.763913769316173,0.751441828061117,-0.0458441002987071,0.0124719412550565,True,0.118054306599581,0.0194202103612205,2.07524751002625,23.9625571314569
52,14503,1058:1053,Breast,CAL-51,SIDM00933,910927,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.949598574216386,0.0678927386473653,0.629642216028038,9.85224206278945,18.053,0.897193861307822,0.925895308901402,0.0355534377362859,0.597907350606671,0.543385666998801,0.0545216836078696,9.46723426928657,13.8246,0.385007793502878,4.2284,0.851974011493602,0.85166428646834,0.879228865206412,0.864695342861374,0.000309725025262,0.0145335223450379,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
53,14503,1594:1053,Breast,CAL-51,SIDM00933,910927,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.935998305689012,0.0678927386473653,0.629642216028038,9.85224206278945,18.053,0.897193861307822,0.925895308901402,0.0569721195878052,0.589344047392518,0.371735650120559,0.217608397271959,8.3297834176329,6.2841,1.52245864515655,11.7689,0.839771934058704,0.809996879323039,0.866636440377117,0.797642534485002,0.0297750547356653,0.0689939058921144,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
54,14503,1058:1054,Breast,CAL-51,SIDM00933,910927,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.949598574216386,0.0937700939830954,0.776679327009613,11.001669738308,16.0185,0.898924666358986,0.959504725922578,0.0986999326382172,0.737533581551671,0.582647330496704,0.154886251054967,9.74250980202764,6.6923,1.25915993628032,9.3262,0.853617581502434,0.786979375751107,0.911144319689965,0.875298700871082,0.0666382057513275,0.0358456188188829,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
55,14504,1510:1058,Breast,CAL-51,SIDM00933,910927,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.941153696605154,0.0699824699797154,0.406165033107579,8.38999797577996,2.6208,0.844246909152709,0.85576898058847,0.107591562261147,0.382263722340953,0.171574623034494,0.210689099306459,6.58976937904869,0.7525,1.80022859673127,1.8683,0.794566099396548,0.609112715950493,0.805410139520863,0.685227845058311,0.185453383446055,0.120182294462552,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
56,14504,1083:1058,Breast,CAL-51,SIDM00933,910927,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.932003754875115,0.0699824699797154,0.406165033107579,8.38999797577996,2.6208,0.844246909152709,0.85576898058847,0.0596421088640874,0.378547335955239,0.169989747396606,0.208557588558634,6.59073069875979,0.753,1.79926727702017,1.8678,0.786841289372035,0.639400939295085,0.797579903214104,0.678638498016435,0.147440350076951,0.118941405197669,True,0.20582734564427,0.0370736838822833,1.52479319969527,32.4793821045494
57,14729,1058:1083,Breast,CAL-51,SIDM00933,910927,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.871823941054299,0.0864722120992243,0.593217198817172,9.60588975575877,15.2192,0.884677227178774,0.916356249073261,0.0671196408969341,0.517180956173979,0.303496006377835,0.213684949796144,7.99254748687265,4.9742,1.61334226888612,10.245,0.771282786759988,0.742549505386313,0.798901316476785,0.724600353219014,0.0287332813736756,0.0743009632577708,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
58,14729,1561:1083,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.65848557366793,0.0864722120992243,0.593217198817172,9.60588975575877,15.2192,0.884677227178774,0.916356249073261,0.050301834496143,0.390624967472808,0.194708425150899,0.195916542321909,7.60620597802787,3.8056,1.9996837777309,11.4136,0.582547191449769,0.538296549441804,0.603407370355199,0.530133738667995,0.0442506420079646,0.0732736316872036,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
59,14729,1011:1083,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.838016479349543,0.0864722120992243,0.593217198817172,9.60588975575877,15.2192,0.884677227178774,0.916356249073261,0.0754703164153933,0.497125788442365,0.111277547586324,0.385848240856041,5.98639585908289,1.2383,3.61949389667588,13.9809,0.741374095281073,0.573832114019331,0.767921637678327,0.568023068702363,0.167541981261741,0.199898568975965,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
60,14735,1012:1594,Breast,CAL-51,SIDM00933,910927,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.748714099374084,0.0904692259110303,0.522953753259946,9.14755281349543,4.4308,0.838262887157758,0.896182340132854,0.091419712515949,0.391542848386317,0.16903886132545,0.222503987060867,7.02094096634827,1.0146,2.12661184714716,3.4162,0.62761924259704,0.508137484413668,0.670984353667529,0.570583202082145,0.119481758183372,0.100401151585383,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
61,14735,1561:1594,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.907828251595208,0.0904692259110303,0.522953753259946,9.14755281349543,4.4308,0.838262887157758,0.896182340132854,0.0819780996102281,0.474752191487129,0.319191599001788,0.155560592485341,8.01713853990328,2.0239,1.13041427359214,2.4069,0.760998731225579,0.713235519033705,0.813579646953311,0.755967914648854,0.0477632121918737,0.0576117323044572,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
62,14735,1053:1594,Breast,CAL-51,SIDM00933,910927,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.950976385658,0.0904692259110303,0.522953753259946,9.14755281349543,4.4308,0.838262887157758,0.896182340132854,0.0742529361740049,0.497316670141429,0.292246905088246,0.205069765053183,7.69483285439584,1.6187,1.45271995909959,2.8121,0.797168210660525,0.731449813038664,0.85224824271007,0.771461174245976,0.0657183976218612,0.080787068464094,True,0.218939108051275,0.0311632196373379,1.45948419261854,33.8852467669645
63,14690,1549:1011,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.387640403133858,0.0933880103919374,0.524125849696347,9.19189280745398,11.4226,0.863681768437388,0.872813478427061,0.0311675335137845,0.203172355669168,0.0435804825663442,0.159591873102823,4.89462900231382,0.581,4.29726380514016,10.8416,0.334797948896432,0.197840109329516,0.33833776863813,0.22317967951076,0.136957839566916,0.11515808912737,True,0.678328971510318,0.0750169221954795,0.372078986621175,130.307810275055
64,14690,1558:1011,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.469348314662868,0.0933880103919374,0.524125849696347,9.19189280745398,11.4226,0.863681768437388,0.872813478427061,0.0448605152599703,0.245997584226224,0.0447084311316385,0.201289153094586,4.52730266151152,0.4504,4.66459014594246,10.9722,0.405367582421133,0.227750481938193,0.409653535114776,0.255690770625324,0.177617100482941,0.153962764489452,True,0.678328971510318,0.0750169221954795,0.372078986621175,130.307810275055
65,14690,1372:1011,Breast,UACC-893,SIDM01186,909778,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.816240328454772,0.0933880103919374,0.524125849696347,9.19189280745398,11.4226,0.863681768437388,0.872813478427061,0.0384949781308613,0.427812655707782,0.275217708248599,0.152594947459183,7.6570486698783,3.9421,1.53484413757568,7.4805,0.704971890349731,0.634111733066809,0.712425560311056,0.641992490892508,0.0708601572829227,0.0704330694185477,True,0.678328971510318,0.0750169221954795,0.372078986621175,130.307810275055
66,14690,1053:1011,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.418134946024171,0.0933880103919374,0.524125849696347,9.19189280745398,11.4226,0.863681768437388,0.872813478427061,0.0581720613634817,0.219155333872655,0.0759245044759499,0.143230829396705,6.00833316864812,1.2572,3.18355963880586,10.1654,0.361135529627628,0.239939282656178,0.364953816691268,0.278801689666796,0.12119624697145,0.0861521270244723,True,0.678328971510318,0.0750169221954795,0.372078986621175,130.307810275055
67,14692,1058:1049,Breast,UACC-893,SIDM01186,909778,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.654117139963455,0.105538432103282,0.827252419513771,12.1120578726838,86.4615,0.905486142880186,0.962589442428977,0.0638901355125295,0.541119986680196,0.471459673250761,0.0696603134294346,10.884031858898,36.9105,1.22802601378586,49.551,0.592294006057328,0.558062793028403,0.629646253040659,0.611886831599863,0.0342312130289247,0.0177594214407956,True,0.678328971510318,0.0750169221954795,0.372078986621175,130.307810275055
68,15797,1549:1053,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.400531181570822,0.0814024921127916,0.128168723186384,5.19059560201543,0.7133,0.5876725542068,0.600428970698226,0.0583139957399249,0.0513355701382658,0.0108646951650451,0.0404708749732208,1.8873056266132,0.0723,3.30328997540223,0.641,0.235381182513193,0.0848670971985181,0.240490525083113,0.130179065305925,0.150514085314675,0.110311459777188,True,0.901449070210816,0.0955196683609458,0.0938965642384567,485.544529453628
69,15970,1558:1083,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.262680713833525,0.060308654309724,0.920713523396115,13.8720706515943,292.8461,0.965724922693483,0.983698365180595,0.045464243293757,0.241853685561871,0.133001489675007,0.108852195886865,9.05026179636585,10.3545,4.82180885522848,282.4916,0.25367731205995,0.192152809203567,0.25839858876251,0.227490421935205,0.0615245028563833,0.0309081668273051,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
70,15972,1012:1372,Breast,UACC-893,SIDM01186,909778,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.927220937140398,0.136496407808915,0.395025101582205,8.15310315226336,0.556,0.722819423069726,0.817428440356158,0.110584556990925,0.366275544883033,0.268891598079923,0.0973839468031104,7.22092466485835,0.2914,0.932178487405013,0.2646,0.670213302841994,0.641509299366633,0.757936764512251,0.70208230674151,0.0287040034753608,0.0558544577707411,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
71,15972,1058:1372,Breast,UACC-893,SIDM01186,909778,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.971651315851023,0.136496407808915,0.395025101582205,8.15310315226336,0.556,0.722819423069726,0.817428440356158,0.122414497122377,0.383826659746534,0.178502929722195,0.205323730024339,6.03670842154737,0.1282,2.11639473071599,0.4278,0.702328443548377,0.576516146422925,0.79425541968611,0.650047610398947,0.125812297125452,0.144207809287164,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
72,15972,1011:1372,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.841539763212304,0.136496407808915,0.395025101582205,8.15310315226336,0.556,0.722819423069726,0.817428440356158,0.100376265054231,0.332429330448406,0.0606438423055129,0.271785488142893,3.92259702869144,0.0296,4.23050612357192,0.5264,0.608281286135352,0.388625758964908,0.687898536140324,0.415229618045365,0.219655527170445,0.272668918094959,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
73,15972,1594:1372,Breast,UACC-893,SIDM01186,909778,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.654884213997698,0.136496407808915,0.395025101582205,8.15310315226336,0.556,0.722819423069726,0.817428440356158,0.0347399405542477,0.258695703159024,0.0496489200736961,0.209046783085327,4.0314462778958,0.0319,4.12165687436756,0.5241,0.473363029739288,0.302315398450729,0.535320981662007,0.329193745984696,0.171047631288558,0.206127235677311,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
74,15972,1053:1372,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.752984696741479,0.136496407808915,0.395025101582205,8.15310315226336,0.556,0.722819423069726,0.817428440356158,0.086634546238171,0.297447856320149,0.0755267999031005,0.221921056417049,4.64099285048271,0.0487,3.51211030178065,0.5073,0.544271964079009,0.376515678647943,0.615511106269442,0.417447540890998,0.167756285431066,0.198063565378444,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
75,15974,1549:1510,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.414115089863689,0.0796694010809711,0.854145507116118,12.5118517455736,114.0703,0.939392042106842,0.968896668757295,0.071952366267246,0.353714543436058,0.147523024127681,0.206191519308376,7.82427367182197,4.4266,4.68757807375167,109.6437,0.389016419934309,0.287750643727993,0.401234731051056,0.33015167398766,0.101265776206316,0.0710830570633966,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
76,15974,1558:1510,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.448960956381189,0.0796694010809711,0.854145507116118,12.5118517455736,114.0703,0.939392042106842,0.968896668757295,0.0804805576176022,0.383477983763548,0.157419180549368,0.226058803214181,7.77552331846407,4.2795,4.73632842710957,109.7908,0.421750349641166,0.288591515114528,0.434996775039824,0.356543058022744,0.133158834526638,0.0784537170170792,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
77,15974,1561:1510,Breast,UACC-893,SIDM01186,909778,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.407272226315503,0.0796694010809711,0.854145507116118,12.5118517455736,114.0703,0.939392042106842,0.968896668757295,0.0605987782530639,0.347869742280566,0.181585892449399,0.166283849831167,8.56801078244729,7.4124,3.94384096312635,106.6579,0.38258828837192,0.302244688150253,0.394604703354458,0.342560769018011,0.0803436002216678,0.0520439343364472,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
78,15974,1372:1510,Breast,UACC-893,SIDM01186,909778,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.877115160315898,0.0796694010809711,0.854145507116118,12.5118517455736,114.0703,0.939392042106842,0.968896668757295,0.0665837731391265,0.749183973407258,0.578829411629652,0.170354561777606,10.3172352287739,24.9188,2.19461651679977,89.1515,0.823955001612022,0.756369596449176,0.849833956946595,0.805265657387562,0.0675854051628457,0.0445682995590331,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
79,15974,1011:1510,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.873309647738547,0.0796694010809711,0.854145507116118,12.5118517455736,114.0703,0.939392042106842,0.968896668757295,0.0741459989147747,0.74593351193704,0.409215361086677,0.336718150850362,8.74995470904555,8.4087,3.76189703652809,105.6616,0.820380133380721,0.684119445499097,0.846146808487485,0.74305210993552,0.136260687881623,0.103094698551965,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
80,15974,1053:1510,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.420339426259566,0.0796694010809711,0.854145507116118,12.5118517455736,114.0703,0.939392042106842,0.968896668757295,0.0561983830248745,0.359031032403375,0.198532393995949,0.160498638407425,8.77973984356437,8.5841,3.73211190200927,105.4862,0.394863512011992,0.313591405989074,0.407265469850246,0.358298034695645,0.0812721060229176,0.0489674351546013,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
81,15975,1058:1558,Breast,UACC-893,SIDM01186,909778,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.649569789924107,0.0738618191841835,0.101160756651387,4.65980204988074,0.4937,0.552171096275688,0.555978468232209,0.0582644621390993,0.0657109714466051,0.0120170254165867,0.0536939460300184,1.10935005990907,0.0421,3.55045198997167,0.4516,0.358673663009963,0.141795327077816,0.361146816811923,0.172946496170272,0.216878335932146,0.188200320641651,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
82,15975,1053:1558,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.405713085111334,0.0738618191841835,0.101160756651387,4.65980204988074,0.4937,0.552171096275688,0.555978468232209,0.0462148786653391,0.041042242673231,0.0090066120753492,0.0320356305978817,1.47906467078512,0.0544,3.18073737909562,0.4393,0.224023038979316,0.0836694427868954,0.225567739601963,0.119118994724351,0.140353596192421,0.106448744877613,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
83,15976,1558:1594,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.236760543955876,0.0680357278978972,0.331379688663416,7.60528384237243,1.5213,0.775764783336087,0.783144092506391,0.0429938139260985,0.078457635343879,0.0115403141809607,0.0669173211629183,3.09642207605964,0.0668,4.50886176631278,1.4545,0.183670492084464,0.0831236826304381,0.185417621337644,0.100270618539979,0.100546809454026,0.085147002797665,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
84,15976,1549:1594,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.719938797429655,0.0680357278978972,0.331379688663416,7.60528384237243,1.5213,0.775764783336087,0.783144092506391,0.0663848636425859,0.238573094548953,0.11036899188444,0.128204102664513,5.60451736511961,0.3801,2.00076647725282,1.1412,0.558503165203259,0.469593025632513,0.563815816173189,0.456740466426747,0.0889101395707463,0.107075349746442,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
85,15976,1561:1594,Breast,UACC-893,SIDM01186,909778,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.434724074009938,0.0680357278978972,0.331379688663416,7.60528384237243,1.5213,0.775764783336087,0.783144092506391,0.0371294300904059,0.144058728299905,0.0490721404121457,0.0949865878877592,4.90369460729103,0.2339,2.70158923508139,1.2874,0.337243627085301,0.244024370938309,0.340451590431194,0.250618039290265,0.0932192561469912,0.0898335511409286,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
86,15976,1053:1594,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.697264295974134,0.0680357278978972,0.331379688663416,7.60528384237243,1.5213,0.775764783336087,0.783144092506391,0.0379051739233057,0.231059225316024,0.0962216677462869,0.134837557569737,5.35995420084322,0.3208,2.24532964152921,1.2005,0.540913085494364,0.41832169034316,0.546058414307771,0.42841398689728,0.122591395151204,0.117644427410491,True,0.662784224955705,0.066362054321179,0.39629307250161,122.841440277152
87,14525,1372:1011,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.916980150196073,0.156899727025097,0.449009972504716,8.57620446871108,7.4546,0.852585577003347,0.836224411969395,0.0957150535907903,0.411733232026909,0.305480994521757,0.106252237505152,7.56294129850105,3.6932,1.01326317021003,3.7614,0.781804050455534,0.709820929182317,0.766801186885319,0.711287249729082,0.071983121273217,0.0555139371562373,True,0.861215134817706,0.0962582006702287,0.139139728297033,337.225557240147
88,14527,1372:1053,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.867438633294194,0.0674834339213733,0.8288319828011,12.2661253095111,96.2059,0.941361380164944,0.96146818858538,0.04021464758211,0.718960882391503,0.711105421178463,0.0078554612130397,12.1366274785218,87.9466,0.129497830989248,8.2593,0.816573229046215,0.835870968640209,0.834014651462346,0.832060473707752,-0.0192977395939946,0.001954177754593,True,0.861215134817706,0.0962582006702287,0.139139728297033,337.225557240147
89,14527,1510:1053,Breast,CAL-85-1,SIDM00928,910852,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.919295298119898,0.0674834339213733,0.8288319828011,12.2661253095111,96.2059,0.941361380164944,0.96146818858538,0.14734524644638,0.761941344720443,0.516713061468262,0.245228283252181,9.51680061951927,14.3078,2.7493246899918,81.8981,0.865389090617291,0.686395689363104,0.883873185058395,0.810812064867985,0.178993401254186,0.07306112019041,True,0.861215134817706,0.0962582006702287,0.139139728297033,337.225557240147
90,14755,1049:1372,Breast,CAL-85-1,SIDM00928,910852,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.897785644895238,0.137492871980275,0.361949288342634,7.82614169374824,0.4432,0.696896197732748,0.792470104019695,0.114584277378813,0.324952875254064,0.461215866634996,-0.136262991380932,9.11371381648696,1.082,-1.28757212273872,-0.6388,0.625663402306534,0.684082884600769,0.711468283397518,0.775367163823736,-0.0584194822942352,-0.0638988804262182,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
91,14755,1011:1372,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.740474464928098,0.137492871980275,0.361949288342634,7.82614169374824,0.4432,0.696896197732748,0.792470104019695,0.0809471907632818,0.268014205616618,0.136924018981023,0.131090186635594,5.92844673954349,0.119,1.89769495420475,0.3242,0.516033839126582,0.436637456714916,0.586803876245498,0.48699244650154,0.0793963824116666,0.0998114297439575,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
92,14755,1561:1372,Breast,CAL-85-1,SIDM00928,910852,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.864908836110302,0.137492871980275,0.361949288342634,7.82614169374824,0.4432,0.696896197732748,0.792470104019695,0.113019471332916,0.31305313771138,0.11265614513829,0.20039699257309,5.06846225057659,0.0655,2.75767944317165,0.3777,0.602751679270726,0.459974706019893,0.685414395319885,0.50918383411932,0.142776973250833,0.176230561200565,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
93,14755,1053:1372,Breast,CAL-85-1,SIDM00928,910852,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.948410929820582,0.137492871980275,0.361949288342634,7.82614169374824,0.4432,0.696896197732748,0.792470104019695,0.160522049835076,0.343276661104935,0.238292828132352,0.104983832972584,6.73903436183935,0.2086,1.08710733190889,0.2346,0.660943970880143,0.577348230009137,0.751587308208332,0.681776291502549,0.0835957408710061,0.0698110167057835,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
94,14757,1549:1510,Breast,CAL-85-1,SIDM00928,910852,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.615639781096815,0.095540653992585,0.604983528695768,9.88264765438249,18.4376,0.872893691644395,0.897018052265465,0.0889911318269868,0.372451927173442,0.239652843614187,0.132799083559255,8.06747286793832,5.2394,1.81517478644417,13.1982,0.537388081244746,0.432857301676576,0.552239997336603,0.496958879740851,0.104530779568171,0.0552811175957515,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
95,14757,1594:1510,Breast,CAL-85-1,SIDM00928,910852,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.846591401085026,0.095540653992585,0.604983528695768,9.88264765438249,18.4376,0.872893691644395,0.897018052265465,0.059128592085783,0.512173853191913,0.315552731418884,0.196621121773029,7.92222764863343,4.7376,1.96042000574906,13.7,0.738984293407509,0.659455036009427,0.759407769665981,0.67593441795097,0.0795292573980817,0.0834733517150118,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
96,14757,1083:1549,Breast,CAL-85-1,SIDM00928,910852,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.907369688031299,0.146921622003077,0.445579512680955,8.54747249165211,3.6538,0.726042226474699,0.834664471250201,0.116643501290324,0.404305343414456,0.180845888338252,0.223459455076204,6.12055283837627,0.6795,2.42691965327585,2.9743,0.658788708533897,0.548103187372027,0.757349240889104,0.610271832907677,0.110685521161869,0.147077407981427,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
97,14757,1510:1549,Breast,CAL-85-1,SIDM00928,910852,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.595073786383186,0.146921622003077,0.445579512680955,8.54747249165211,3.6538,0.726042226474699,0.834664471250201,0.0797058997948411,0.265152687745831,0.206221864938862,0.0589308228069689,7.6867225061073,2.012,0.860749985544818,1.6418,0.432048696782378,0.407194325542364,0.496686947266377,0.46633967221531,0.0248543712400139,0.0303472750510669,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
98,14758,1372:1558,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.81585202010802,0.0972443839708798,0.347270847670562,7.69332517161346,4.0425,0.763681933064926,0.784088400404123,0.0521735934485303,0.283321622596652,0.154093652429978,0.129227970166675,5.98241419053713,1.2349,1.71091098107633,2.8076,0.623051447811018,0.529824777639797,0.63970010541297,0.539998622856176,0.093226670171221,0.0997014825567937,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
99,14759,1372:1561,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.837648156764862,0.0735091921431816,0.350091027028598,7.71903832122803,4.1152,0.757531024395211,0.785725333531169,0.0699267261912054,0.293253103490423,0.163249564985096,0.130003538505327,6.06275129330312,1.3056,1.65628702792492,2.8096,0.634544466276847,0.524813807340936,0.65816137735584,0.559644234825256,0.109730658935911,0.0985171425305837,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
100,14759,1011:1561,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.77334144765743,0.0735091921431816,0.350091027028598,7.71903832122803,4.1152,0.757531024395211,0.785725333531169,0.0673922068165909,0.270739901654172,0.0976289350527807,0.173110966601392,4.9942065437524,0.6225,2.72483177747563,3.4927,0.585830139051208,0.42660485849931,0.607633966894111,0.450566635803412,0.159225280551898,0.157067331090699,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
101,14759,1510:1594,Breast,CAL-85-1,SIDM00928,910852,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.603317644709426,0.092626046143717,0.327207471448041,7.50741461152023,1.4215,0.742875492661952,0.772053684897835,0.0256142106051377,0.197410041005359,0.246036347037344,-0.0486263060319851,8.22757025683531,2.3417,-0.720155645315081,-0.9202,0.448189892545163,0.495841614624122,0.465793610761796,0.492706737296963,-0.0476517220789588,-0.0269131265351673,True,0.538758409193892,0.0714331582641527,0.597562110379776,81.9631720304769
102,16372,1021:1049,Breast,OCUB-M,SIDM00241,909256,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.69485947377877,0.089307834050801,0.854648713502996,11.4579412043743,54.9432,0.915982112080909,0.978225340220018,0.118444089949898,0.593860755330395,0.355345763350479,0.238514991979916,9.06323633136752,10.4481,2.39470487300673,44.4951,0.636478848391307,0.539715457190416,0.679729145142341,0.630273972717819,0.0967633912008915,0.0494551724245212,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
103,16372,1549:1049,Breast,OCUB-M,SIDM00241,909256,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.619012370552178,0.089307834050801,0.854648713502996,11.4579412043743,54.9432,0.915982112080909,0.978225340220018,0.0351873263348387,0.529038126134858,0.314420217193053,0.214617908941805,9.04406120639022,10.3101,2.41387999798403,44.6331,0.567004258582594,0.52889138594954,0.605533586783804,0.56089550984326,0.0381128726330542,0.044638076940544,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
104,16372,1011:1049,Breast,OCUB-M,SIDM00241,909256,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.662212220552305,0.089307834050801,0.854648713502996,11.4579412043743,54.9432,0.915982112080909,0.978225340220018,0.0758205148791225,0.565958822360989,0.223695736545392,0.342263085815598,8.06608429827381,5.2344,3.39185690610044,49.7088,0.606574548427289,0.498886802305398,0.647792774747632,0.562628889485955,0.107687746121891,0.0851638852616771,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
105,16373,1549:1053,Breast,OCUB-M,SIDM00241,909256,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.660341962365527,0.0527488398770326,0.0367377164563756,4.46782350466921,0.4322,0.540025646231945,0.544259275810404,0.0548171854112576,0.0242594557776313,0.0024070094320441,0.0218524463455871,1.21533506523009,0.0454,3.25248843943913,0.3868,0.356601594960515,0.140404385811279,0.359397238224283,0.162853428034812,0.216197209149235,0.196543810189471,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
106,16373,1561:1053,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.466623014955736,0.0527488398770326,0.0367377164563756,4.46782350466921,0.4322,0.540025646231945,0.544259275810404,0.0453312758185172,0.017142664015463,0.0009447022645457,0.0161979617509173,0.397204554241928,0.0257,4.07061895042728,0.4065,0.25198839519817,0.0552738903808845,0.253963904196277,0.0852248782436965,0.196714504817286,0.16873902595258,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
107,16373,1561:1054,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.466623014955736,0.0874347912049047,0.893895407741797,11.9569093493279,31.0584,0.927932348059159,0.98444952259631,0.056386802099082,0.417112170215565,0.37979376020665,0.0373184100089142,11.0474572664181,16.5351,0.909452082909782,14.5233,0.432994589926321,0.435357456559401,0.459366804305626,0.453303998411614,-0.0023628666330807,0.0060628058940115,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
108,16374,1549:1058,Breast,OCUB-M,SIDM00241,909256,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.629773125067896,0.0902713797425118,0.13967143182077,6.4775631865153,0.6962,0.709651148089934,0.727515114923284,0.0451980577072826,0.087961314100474,0.0111642028946716,0.0767971112058025,3.42966998179073,0.0842,3.04789320472456,0.612,0.446919221240619,0.261423516326844,0.458169467459366,0.280922166657698,0.185495704913774,0.177247300801669,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
109,16374,1558:1058,Breast,OCUB-M,SIDM00241,909256,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.634933158881283,0.0902713797425118,0.13967143182077,6.4775631865153,0.6962,0.709651148089934,0.727515114923284,0.0300312970360904,0.0886820234114333,0.0105138036916113,0.078168219719822,3.33341843239997,0.0787,3.14414475411533,0.6175,0.450581045160471,0.258650944699232,0.46192347005212,0.277466552127181,0.191930100461239,0.184456917924939,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
110,16374,1012:1058,Breast,OCUB-M,SIDM00241,909256,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.502097445649668,0.0902713797425118,0.13967143182077,6.4775631865153,0.6962,0.709651148089934,0.727515114923284,0.052118532205758,0.0701286691474404,0.0062842294962215,0.0638444396512189,2.9393473395305,0.0599,3.53821584698479,0.6363,0.35631402875831,0.17339004007778,0.365283480874506,0.200874818224962,0.182923988680531,0.164408662649543,True,0.514735242874012,0.0632060795802208,0.643216599582744,76.3072343025709
111,17530,1549:1083,Breast,OCUB-M,SIDM00241,909256,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.658118537650803,0.110708680493547,0.621796259593651,9.68981781949313,16.1308,0.875776982307604,0.93413824587208,0.0625524099543746,0.409215645080513,0.192574556062325,0.216641089018188,7.77525468007764,4.2787,1.9145631394155,11.8521,0.576365066904513,0.493897706597276,0.61477369633702,0.546069150004397,0.082467360307237,0.0687045463326227,True,0.616972729262291,0.0642704860222736,0.46687642032904,104.667299796029
112,17530,1510:1083,Breast,OCUB-M,SIDM00241,909256,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.90684630562683,0.110708680493547,0.621796259593651,9.68981781949313,16.1308,0.875776982307604,0.93413824587208,0.0565544711884161,0.563873640865084,0.415267791530545,0.148605849334539,8.76593774455373,8.5024,0.923880074939403,7.6284,0.794195120958664,0.795302653819509,0.847119817213823,0.808683811644064,-0.0011075328608448,0.0384360055697597,True,0.616972729262291,0.0642704860222736,0.46687642032904,104.667299796029
113,17530,1012:1083,Breast,OCUB-M,SIDM00241,909256,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.389643083060152,0.110708680493547,0.621796259593651,9.68981781949313,16.1308,0.875776982307604,0.93413824587208,0.0622480006583117,0.242278611623341,0.2516605393006,-0.0093819276772593,9.83380103832226,17.8238,-0.143983218829128,-1.693,0.341240443459451,0.351392824993024,0.363980506126,0.36603205140056,-0.0101523815335724,-0.0020515452745596,True,0.616972729262291,0.0642704860222736,0.46687642032904,104.667299796029
114,17530,1011:1083,Breast,OCUB-M,SIDM00241,909256,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.713838442052024,0.110708680493547,0.621796259593651,9.68981781949313,16.1308,0.875776982307604,0.93413824587208,0.0621602241228147,0.443862073222108,0.214208709833546,0.229653363388562,7.82493516462806,4.4286,1.86488265486508,11.7022,0.625163276635483,0.58565238481213,0.666823790094536,0.594791568176808,0.0395108918233523,0.0720322219177287,True,0.616972729262291,0.0642704860222736,0.46687642032904,104.667299796029
115,15964,1011:1372,Breast,OCUB-M,SIDM00241,909256,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.654107749163289,0.104451928855569,0.901213803436009,12.0673807687274,8.3825,0.918742512460224,0.985579890875486,0.138440194171044,0.589490932480414,0.255120038858884,0.33437089362153,8.37953171245377,0.6505,3.68784905627368,7.732,0.600956596885981,0.443419617791899,0.644675444041164,0.568763601820697,0.157536979094082,0.0759118422204673,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
116,15966,1011:1510,Breast,OCUB-M,SIDM00241,909256,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.697657675971224,0.098423094636099,0.770645451551091,10.6815481541881,32.0772,0.91328543689289,0.963883472309096,0.077084494938018,0.537646714726929,0.223319058368429,0.314327656358501,7.95479683019184,4.8458,2.72675132399626,27.2314,0.637160595401058,0.523278257436123,0.672460703198238,0.587545403479312,0.113882337964935,0.0849152997189259,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
117,15966,1012:1549,Breast,OCUB-M,SIDM00241,909256,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.924865005448421,0.0915745550563507,0.356606203081222,8.18122387231455,2.8346,0.795082264002829,0.85712091550271,0.106522844692223,0.329812597955655,0.17311697042122,0.156695627534436,6.96260330119272,1.218,1.21862057112183,1.6166,0.735343762428919,0.66410029634852,0.79272114018637,0.710251399036448,0.0712434660803994,0.0824697411499212,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
118,15966,1058:1549,Breast,OCUB-M,SIDM00241,909256,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.91484475899252,0.0915745550563507,0.356606203081222,8.18122387231455,2.8346,0.795082264002829,0.85712091550271,0.0826821917059352,0.326239315913078,0.0825946737907738,0.243644642122305,5.79470110111619,0.5421,2.38652277119836,2.2925,0.727376842190895,0.587841437261639,0.784132577370525,0.610543572236401,0.139535404929256,0.173589005134124,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
119,15966,1053:1549,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.755807252188559,0.0915745550563507,0.356606203081222,8.18122387231455,2.8346,0.795082264002829,0.85712091550271,0.120937441952172,0.269525554464214,0.0176198979749244,0.251905656489289,3.81759334522744,0.1377,4.3636305270871,2.6969,0.600928941219837,0.309182530053169,0.647818203939445,0.364849858218548,0.291746411166668,0.282968345720897,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
120,15967,1058:1558,Breast,OCUB-M,SIDM00241,909256,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.946852407156683,0.11504743890058,0.163662832960641,6.73673867845481,2.083,0.691733648479533,0.749401102220484,0.0619607034640728,0.154964547350865,0.0069829211492895,0.147981626201575,2.19827912803812,0.0896,4.53845955041669,1.9934,0.65496967017412,0.330926185387636,0.709572237563336,0.314348155796925,0.324043484786485,0.395224081766412,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
121,15967,1561:1558,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.445747102136713,0.11504743890058,0.163662832960641,6.73673867845481,2.083,0.691733648479533,0.749401102220484,0.0339387468888587,0.0729522335196905,0.0013000545145736,0.0716521790051169,0.904954532214011,0.0366,5.8317841462408,2.0464,0.308338269260207,0.0831878290066958,0.334043369652839,0.0986982329766889,0.225150440253512,0.23534513667615,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
122,15967,1012:1558,Breast,OCUB-M,SIDM00241,909256,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.557686535621312,0.11504743890058,0.163662832960641,6.73673867845481,2.083,0.691733648479533,0.749401102220484,0.03635035418112,0.0912725583237892,0.0039496617222351,0.0873228966015541,2.141690092815,0.0862,4.59504858563981,1.9968,0.385770541993241,0.181542529481892,0.417930904488135,0.182306418379269,0.20422801251135,0.235624486108866,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
123,15967,1594:1558,Breast,OCUB-M,SIDM00241,909256,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.969248325862702,0.11504743890058,0.163662832960641,6.73673867845481,2.083,0.691733648479533,0.749401102220484,0.0888862392002061,0.158629926853048,0.0182184249385892,0.140411501914459,3.51243035939634,0.2229,3.22430831905847,1.8601,0.670461680731686,0.462094747721543,0.726355763726868,0.439919065767237,0.208366933010143,0.286436697959631,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
124,15967,1053:1558,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.270495356924606,0.11504743890058,0.163662832960641,6.73673867845481,2.083,0.691733648479533,0.749401102220484,0.0489172228507718,0.0442700364169807,0.0007583273697385,0.0435117090472421,0.849923748711075,0.0352,5.88681492974374,2.0478,0.187110740142231,0.0267323669521828,0.202709518624823,0.0587150278585442,0.160378373190048,0.143994490766279,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
125,15968,1053:1561,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.242536575543062,0.0790189538810212,0.0058395587879575,1.87226752350984,0.0715,0.290164431885315,0.3028998137339,0.0475164955435219,0.0014163065911136,0.0002806618505248,0.0011356447405888,-0.380078060687169,0.015,2.25234558419701,0.0565,0.0703754876538626,0.0109138814568919,0.0734642835556515,0.0316366848431373,0.0594616061969707,0.0418275987125142,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
126,15968,1549:1594,Breast,OCUB-M,SIDM00241,909256,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.904986983681852,0.0919131978546664,0.134984831552259,6.4226709999869,0.6702,0.698040963423717,0.722805099875012,0.0632031298354166,0.122159515549282,0.0765939184792435,0.0455655970700387,5.69649332101927,0.4051,0.726177678967625,0.2651,0.631717985975203,0.592882438557085,0.654129207125747,0.595922381240478,0.0388355474181176,0.0582068258852686,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
127,15968,1561:1594,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.510512524004898,0.0919131978546664,0.134984831552259,6.4226709999869,0.6702,0.698040963423717,0.722805099875012,0.0426998768366698,0.06891144705812,0.0044124146513671,0.0644990324067529,2.42021939636713,0.0418,4.00245160361977,0.6284,0.356358654096252,0.175242924385127,0.369001055900805,0.179770145544221,0.181115729711126,0.189230910356584,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
128,15968,1053:1594,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.772489340122568,0.0919131978546664,0.134984831552259,6.4226709999869,0.6702,0.698040963423717,0.722805099875012,0.0702670091388543,0.104274343452361,0.0120008291493262,0.0922735143030347,3.24343856766934,0.074,3.17923243231756,0.5962,0.539229203213708,0.31511063796394,0.558359234639675,0.331041738182227,0.224118565249768,0.227317496457447,True,0.555386750055326,0.063085709639025,0.570398383899931,86.0068564322594
129,16617,1083:1011,Breast,EFM-19,SIDM01056,906851,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.868033047216536,0.096896502014408,0.41061012179641,7.97721646326752,4.9217,0.777881703027399,0.759738479201232,0.147944640353075,0.356423155240891,0.140526014776414,0.215897140464477,4.34729132066424,0.3976,3.62992514260327,4.5241,0.675227025052861,0.467041623398694,0.659478107188702,0.455351346328979,0.208185401654167,0.204126760859723,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
130,16617,1021:1011,Breast,EFM-19,SIDM01056,906851,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.855471105422003,0.096896502014408,0.41061012179641,7.97721646326752,4.9217,0.777881703027399,0.759738479201232,0.0728880312382196,0.351265094790638,0.154030150544268,0.197234944246369,4.71018181183413,0.5113,3.26703465143339,4.4104,0.665455320376399,0.476085856318032,0.649934316633909,0.470646625651727,0.189369464058367,0.179287690982182,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
131,16617,1594:1011,Breast,EFM-19,SIDM01056,906851,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.794750184445404,0.096896502014408,0.41061012179641,7.97721646326752,4.9217,0.777881703027399,0.759738479201232,0.100460889854215,0.326332470032846,0.275008582444055,0.0513238875887909,7.19880169371167,2.8694,0.778414769555849,2.0523,0.61822162695773,0.618687631913213,0.603802296475449,0.568165694450433,-0.0004660049554834,0.0356366020250161,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
132,16617,1053:1011,Breast,EFM-19,SIDM01056,906851,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.567912190145164,0.096896502014408,0.41061012179641,7.97721646326752,4.9217,0.777881703027399,0.759738479201232,0.0598819860447741,0.233190493565172,0.08334726893058,0.149843224634592,4.0190312874789,0.3166,3.95818517578862,4.6051,0.44176850164014,0.271328030930771,0.431464743660728,0.284721478639223,0.17044047070937,0.146743265021505,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
133,16617,1058:1011,Breast,EFM-19,SIDM01056,906851,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.764177923775685,0.096896502014408,0.41061012179641,7.97721646326752,4.9217,0.777881703027399,0.759738479201232,0.0709704292705589,0.313779190355661,0.19723712261925,0.116542067736411,6.01224824082892,1.2607,1.9649682224386,3.661,0.594440024762571,0.484362861338813,0.580575373648493,0.4887252842867,0.110077163423758,0.0918500893617938,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
134,16617,1561:1011,Breast,EFM-19,SIDM01056,906851,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.403197380091611,0.096896502014408,0.41061012179641,7.97721646326752,4.9217,0.777881703027399,0.759738479201232,0.0684620051958192,0.16555692534741,0.0697298116446063,0.0958271137028035,4.5717256941548,0.4645,3.40549076911272,4.4572,0.313639864681848,0.204226812075274,0.306324564368722,0.217895388596487,0.109413052606574,0.0884291757722345,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
135,16618,1011:1021,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.707933812535766,0.0620772839059721,0.778982652794804,12.5647292831335,118.3288,0.916038341359149,0.931657068460433,0.0925899347445853,0.55146815929225,0.237852310856985,0.313615848435265,7.07223782464582,2.6284,5.49249145848768,115.7004,0.648494515427322,0.505531046046075,0.659551540451089,0.50067469615205,0.142963469381247,0.158876844299039,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
136,16619,1058:1049,Breast,EFM-19,SIDM01056,906851,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.75721648985529,0.0804870067050773,0.760376062613108,12.2675942128794,96.3039,0.879562218028092,0.925073268172652,0.0994053170139978,0.575769293101884,0.393523586610217,0.182245706491667,9.22306990273127,11.6721,3.04452431014812,84.6318,0.666019015344565,0.54498005777841,0.700480732984657,0.622678354559065,0.121038957566155,0.0778023784255919,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
137,16619,1011:1049,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.703788014574224,0.0804870067050773,0.760376062613108,12.2675942128794,96.3039,0.879562218028092,0.925073268172652,0.0686659439304855,0.535143559436245,0.333469415785279,0.201674143650966,8.70341011057949,8.1417,3.5641841022999,88.1622,0.619025347120491,0.512541779452222,0.65105547874292,0.561389373880971,0.106483567668269,0.0896661048619488,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
138,16620,1011:1053,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.708967617810673,0.094245014389827,0.335328520649177,7.06395794912294,2.6133,0.660622854816191,0.706728920136287,0.0642726959662951,0.237737062468624,0.0642877131075359,0.173449349361088,2.47641152037445,0.1087,4.58754642874848,2.5046,0.468360211650321,0.231945062596597,0.501047918946933,0.278904818872957,0.236415149053724,0.222143100073976,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
139,16621,1011:1058,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.690177221934737,0.0668244902753144,0.327367121182287,6.9622713498608,0.9742,0.681491335538312,0.700495262160338,0.069137354680088,0.225941330250363,0.071011813592294,0.154929516658069,2.87217346778795,0.0572,4.09009788207285,0.917,0.470349796734426,0.254007578485853,0.483465874016267,0.290327853468514,0.216342218248573,0.193138020547754,True,0.647027768334058,0.0579605854386392,0.418780285727006,116.185304965541
140,16907,1011:1083,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.602675669106877,0.0487992764083061,0.71944366471202,11.6647550127905,63.412,0.927337612520093,0.910026808060811,0.0944738622967991,0.43359119201502,0.143430758896103,0.290160433118918,5.70696981210236,1.0202,5.95778520068813,62.3918,0.558883816113521,0.372199435463378,0.548451015453245,0.373098392188732,0.186684380650143,0.175352623264513,True,1.08033415175254,0.102687876423374,-0.0884941079295758,-653.448477589067
141,16911,1561:1510,Breast,EFM-19,SIDM01056,906851,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.578372570106931,0.0615947366665234,0.885452413257163,14.7870781410678,552.1844,0.946913595939708,0.966641186505412,0.0612989961711409,0.512121387962929,0.336274372153128,0.175847015809801,9.92979973573787,19.0501,4.85727840532992,533.1343,0.547668850152845,0.43437246353759,0.559078747410348,0.4930233656178,0.113296386615254,0.0660553817925482,True,1.08033415175254,0.102687876423374,-0.0884941079295758,-653.448477589067
142,16912,1510:1558,Breast,EFM-19,SIDM01056,906851,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.963202306106357,0.0724853059041825,0.748310825466503,12.0833263705208,84.7566,0.915062891494751,0.920720720021554,0.0693617061999017,0.720774712773688,0.729344295386266,-0.0085695826125782,12.218610118688,93.089,-0.135283748167183,-8.33239999999999,0.881390687320096,0.910123968032684,0.886840320804667,0.889938035788811,-0.0287332807125883,-0.0030977149841436,True,1.08033415175254,0.102687876423374,-0.0884941079295758,-653.448477589067
143,16912,1011:1558,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.654835216273866,0.0724853059041825,0.748310825466503,12.0833263705208,84.7566,0.915062891494751,0.920720720021554,0.108534500819467,0.490020281234433,0.192396953799978,0.297623327434455,6.51847292111644,1.7905,5.56485344940433,82.9661,0.599215406456154,0.437500434061739,0.602920351823144,0.44044065346102,0.161714972394415,0.162479698362124,True,1.08033415175254,0.102687876423374,-0.0884941079295758,-653.448477589067
144,16913,1011:1594,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.634658560939523,0.070534139266534,0.602534205868732,10.1772629362946,9.0459,0.835686301924352,0.862040434318125,0.0709328620990405,0.382403492013488,0.0856353218792787,0.296768170134209,3.74226413585981,0.1045,6.43499880043475,8.9414,0.530375465776181,0.281627921632233,0.547101341516023,0.305749617496763,0.248747544143947,0.24135172401926,True,1.08033415175254,0.102687876423374,-0.0884941079295758,-653.448477589067
145,14997,1558:1011,Breast,EFM-192A,SIDM01002,1290798,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.665719350905509,0.0617032627864713,0.830236986250899,13.8359538725982,285.6059,0.93889991943638,0.945648850478837,0.0359433540688668,0.552704827584695,0.323454264326629,0.229250563258065,8.82778014121776,8.8748,5.00817373138042,276.7311,0.625043844932422,0.50925758331009,0.629536738925312,0.527222386726684,0.115786261622332,0.102314352198628,True,0.643957981346452,0.0614233520202142,0.422623269778819,115.011601888654
146,14997,1561:1011,Breast,EFM-192A,SIDM01002,1290798,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.739391584128978,0.0617032627864713,0.830236986250899,13.8359538725982,285.6059,0.93889991943638,0.945648850478837,0.027538532054364,0.613870240466521,0.471000480666482,0.142869759800039,10.7134720434732,32.7949,3.12248182912499,252.811,0.694214698770635,0.634639744690871,0.699204801585295,0.642571893021912,0.0595749540797648,0.0566329085633827,True,0.643957981346452,0.0614233520202142,0.422623269778819,115.011601888654
147,14997,1549:1011,Breast,EFM-192A,SIDM01002,1290798,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.813063817352448,0.0617032627864713,0.830236986250899,13.8359538725982,285.6059,0.93889991943638,0.945648850478837,0.0396895552479749,0.675035653348348,0.520336219350736,0.154699433997612,10.7525264372985,33.6948,3.08342743529964,251.9111,0.763385552608849,0.721120907289089,0.768872864245277,0.70767894401541,0.0422646453197599,0.0611939202298668,True,0.643957981346452,0.0614233520202142,0.422623269778819,115.011601888654
148,15769,1011:1058,Breast,EFM-192A,SIDM01002,1290798,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.953070870575911,0.0961692395498355,0.546119380955805,9.56363855618902,5.912,0.865139013845141,0.82506391792982,0.108843818822283,0.520490473845927,0.317107342947139,0.203383130898787,6.87984118014634,0.9201,2.68379737604267,4.9919,0.824538793094574,0.685547737783351,0.786344386542145,0.654615462517849,0.138991055311223,0.131728924024296,True,0.796727647259104,0.0689359789599768,0.212502747806865,222.535270332721
149,16406,1558:1083,Breast,EFM-192A,SIDM01002,1290798,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.621195771484076,0.0639229852917855,0.84933022525992,14.2687283191252,385.5185,0.941017473956437,0.952268466769318,0.0524325580740061,0.527600344525081,0.284111387503635,0.243488957021445,8.47912547977878,6.9695,5.78960283934641,378.549,0.584556075714366,0.45496956976429,0.591545144874725,0.481392021683132,0.129586505950076,0.110153123191593,True,0.945435144312692,0.0867886654970215,0.0432645969770826,900.624555956825
150,16408,1011:1558,Breast,EFM-192A,SIDM01002,1290798,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.930919442786355,0.0774371372615827,0.335247689721939,6.91443882212869,2.356,0.651072616738462,0.688911958831582,0.0550556426279461,0.31208859251136,0.140422558516472,0.171666033994888,3.73539069287257,0.2601,3.17904812925612,2.0959,0.606096157587622,0.431071224225933,0.641321536844352,0.448828690690068,0.175024933361689,0.192492846154285,True,0.945435144312692,0.0867886654970215,0.0432645969770826,900.624555956825
151,16409,1012:1561,Breast,EFM-192A,SIDM01002,1290798,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.824147556114564,0.115878967452573,0.37583855606919,7.45459420711525,3.426,0.658871547344697,0.720283206510289,0.12701317012253,0.30974642747805,0.132498972387555,0.177247455090495,3.96541941948248,0.3051,3.48917478763277,3.1209,0.543007375537554,0.365271873914981,0.593619644355817,0.410148980167667,0.177735501622573,0.18347066418815,True,0.945435144312692,0.0867886654970215,0.0432645969770826,900.624555956825
152,16409,1561:1594,Breast,EFM-192A,SIDM01002,1290798,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.760238336652168,0.0840928632122752,0.551913136548355,9.63493045591574,6.2115,0.842872628261471,0.828065781586305,0.0454919596469066,0.419585524906003,0.263511142063649,0.156074382842354,7.06859740588244,1.0487,2.5663330500333,5.1628,0.640784084919142,0.522352654549086,0.629527352431751,0.530668426171068,0.118431430370056,0.0988589262606826,True,0.945435144312692,0.0867886654970215,0.0432645969770826,900.624555956825
153,16409,1053:1594,Breast,EFM-192A,SIDM01002,1290798,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.944968857354382,0.0840928632122752,0.551913136548355,9.63493045591574,6.2115,0.842872628261471,0.828065781586305,0.0567124066026318,0.521540726002972,0.299436422040247,0.222104303962725,6.65965306169617,0.7899,2.97527739421957,5.4216,0.796488384423527,0.605264337181867,0.782496375439874,0.636507790017091,0.19122404724166,0.145988585422783,True,0.945435144312692,0.0867886654970215,0.0432645969770826,900.624555956825
154,15032,1012:1558,Breast,HCC1419,SIDM00882,907045,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.959756473556875,0.110868280615993,0.3684124110789,7.05055370994245,2.5892,0.634470626846211,0.675943793376294,0.1043686215467,0.353586196471671,0.188883567049047,0.164702629422624,3.91369942366693,0.2944,3.13685428627552,2.2948,0.60893729139734,0.431771853179729,0.648741431453489,0.474918723870797,0.177165438217611,0.173822707582692,True,0.603681068257239,0.0898369406052483,0.485157943606178,100.41440238462
155,15032,1011:1558,Breast,HCC1419,SIDM00882,907045,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.866863473232057,0.110868280615993,0.3684124110789,7.05055370994245,2.5892,0.634470626846211,0.675943793376294,0.0966210037755992,0.319363262249652,0.135580608630769,0.183782653618882,2.90525397410862,0.1463,4.14529973583383,2.4429,0.549999411251627,0.345323077214327,0.585950984435826,0.376883608013016,0.204676334037299,0.20906737642281,True,0.603681068257239,0.0898369406052483,0.485157943606178,100.41440238462
156,15033,1049:1561,Breast,HCC1419,SIDM00882,907045,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.906994344922056,0.155252706557983,0.711029096331478,12.2563028517475,95.5531,0.836334198437052,0.885799513060029,0.078383072086568,0.644899369447691,0.738268188892133,-0.0933688194444426,14.338148242279,404.5226,-2.08184539053145,-308.9695,0.758550388447327,0.825195445001554,0.803415149080158,0.844165526465251,-0.066645056554227,-0.0407503773850934,True,0.603681068257239,0.0898369406052483,0.485157943606178,100.41440238462
157,15033,1012:1561,Breast,HCC1419,SIDM00882,907045,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.987565042510198,0.155252706557983,0.711029096331478,12.2563028517475,95.5531,0.836334198437052,0.885799513060029,0.141434617456566,0.702187479744584,0.423884811583019,0.278302668161565,7.96918926195781,4.8944,4.2871135897897,90.6587,0.825934418232219,0.631464060072612,0.874784633770641,0.714209311009769,0.194470358159608,0.160575322760872,True,0.603681068257239,0.0898369406052483,0.485157943606178,100.41440238462
158,15033,1011:1561,Breast,HCC1419,SIDM00882,907045,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.875197154644414,0.155252706557983,0.711029096331478,12.2563028517475,95.5531,0.836334198437052,0.885799513060029,0.0564787444076218,0.622290641978699,0.363957260194067,0.258333381784632,7.77108464221879,4.2664,4.48521820952872,91.2867,0.731957310803925,0.60369803239386,0.775249213415545,0.624306484661982,0.128259278410065,0.150942728753563,True,0.603681068257239,0.0898369406052483,0.485157943606178,100.41440238462
159,15033,1058:1594,Breast,HCC1419,SIDM00882,907045,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.981731505257208,0.117633279941261,0.712707074528197,12.2858892270966,39.0132,0.893250847818746,0.886578453167317,0.0845535351252473,0.699686989084028,0.538690040255131,0.160996948828896,9.70695377051468,6.5294,2.57893545658191,32.4838,0.876932499401374,0.727346153413503,0.870381999356557,0.786567175858016,0.149586345987871,0.0838148234985405,True,0.603681068257239,0.0898369406052483,0.485157943606178,100.41440238462
160,15033,1053:1594,Breast,HCC1419,SIDM00882,907045,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.817268833261639,0.117633279941261,0.712707074528197,12.2858892270966,39.0132,0.893250847818746,0.886578453167317,0.0878172692002601,0.582473279256975,0.41307934347324,0.169393935783735,9.07868142314042,4.2242,3.20720780395617,34.789,0.730026078206796,0.575082947952002,0.724572938014961,0.633266136273569,0.154943130254794,0.0913068017413921,True,0.603681068257239,0.0898369406052483,0.485157943606178,100.41440238462
161,15004,1012:1011,Breast,HCC1428,SIDM00881,1290905,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.428248446031216,0.100623365867936,0.215302784093326,7.19679847953904,2.8654,0.759684296658316,0.786263288011402,0.0594820889052865,0.0922030827141611,0.0045191897535428,0.0876838929606183,2.66874735601522,0.1242,4.52805112352381,2.7412,0.325333619518241,0.148769080290472,0.336716031262278,0.160631044620665,0.176564539227769,0.176084986641613,True,0.706080010294335,0.0506859132941628,0.333977805022992,145.111948393998
162,15005,1011:1021,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.661797924713124,0.0643216787315546,0.673748472691294,10.0111408218913,20.155,0.91024823332494,0.944990549868034,0.057346674028288,0.445885341005735,0.149047062977435,0.2968382780283,7.27728480250887,3.0298,2.73385601938239,17.1252,0.602400391788233,0.483136525880367,0.625392784776179,0.524486453337308,0.119263865907866,0.100906331438871,True,0.706080010294335,0.0506859132941628,0.333977805022992,145.111948393998
163,15950,1012:1561,Breast,HCC1428,SIDM00881,1290905,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.43306001620769,0.06143434207488,0.896267994905716,12.0067410271345,80.3747,0.961682081474586,0.984742436025676,0.109634507102756,0.388137832400303,0.120992159328415,0.267145673071888,7.6788936149207,4.0023,4.32784741221379,76.3724,0.416466057790029,0.260554270912161,0.426452575305679,0.356183067165998,0.155911786877868,0.0702695081396816,True,0.701959941674579,0.0572411115791267,0.340512448545019,142.625385214841
164,15950,1011:1561,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.663729368997412,0.06143434207488,0.896267994905716,12.0067410271345,80.3747,0.961682081474586,0.984742436025676,0.0239724279798911,0.594879390711347,0.295406193664398,0.299473197046949,8.69240098620849,8.0799,3.314340040926,72.2948,0.638296641113245,0.572194752979014,0.653602475688297,0.588900777314888,0.0661018881342312,0.064701698373409,True,0.701959941674579,0.0572411115791267,0.340512448545019,142.625385214841
165,15950,1011:1594,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.663729368997412,0.0940621688986724,0.615893693974803,9.65833283823001,6.313,0.875481676492579,0.932486963329587,0.0549017117914729,0.408786732871382,0.104666155144123,0.304120577727258,6.66384366969084,0.7921,2.99448916853917,5.5209,0.581082900707216,0.447935406406968,0.61891898376906,0.49316878434508,0.133147494300248,0.125750199423981,True,0.701959941674579,0.0572411115791267,0.340512448545019,142.625385214841
166,14983,1049:1012,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.92203625823457,0.0860521313780325,0.501125780617992,9.00651630290855,5.0226,0.861650136832173,0.900166419893288,0.101756869496749,0.462056139665891,0.233274350646407,0.228781789019484,7.4332956352497,1.6879,1.57322066765885,3.3347,0.794472668072042,0.749122185558928,0.829986077586816,0.739054328205399,0.0453504825131135,0.0909317493814171,True,0.928903034321778,0.0946339731956178,0.0619903676153645,684.408293042164
167,14983,1011:1012,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.0752636276274133,0.0860521313780325,0.501125780617992,9.00651630290855,5.0226,0.861650136832173,0.900166419893288,0.0325593820095824,0.0377165441469293,0.0072087476762341,0.0305077964706951,5.75132078356598,0.526,3.25519551934257,4.4966,0.0648509150436463,0.0425639556355384,0.0677497902295502,0.0498183961766978,0.0222869594081079,0.0179313940528524,True,0.928903034321778,0.0946339731956178,0.0619903676153645,684.408293042164
168,14985,1012:1049,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.873639084872516,0.113172692681433,0.808476792959345,11.083974429097,42.3974,0.875388861969526,0.969269189716455,0.0602863512182396,0.70631692554167,0.602778045511513,0.103538880030156,10.1575663200107,22.3081,0.926408109086369,20.0893,0.76477392427865,0.797235932687784,0.846791447899009,0.826778617051253,-0.0324620084091336,0.0200128308477555,True,0.928903034321778,0.0946339731956178,0.0619903676153645,684.408293042164
169,16332,1049:1053,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.942754655695705,0.0510010539671779,0.936773150304059,12.9008592464782,149.3742,0.966516168703433,0.99055838785607,0.0260600030403605,0.883147248779885,0.903769084095054,-0.0206218353151688,13.5486651872873,234.0371,-0.647805940809107,-84.6629,0.911187617850337,0.92686059058375,0.933853531889742,0.936999110919441,-0.0156729727334132,-0.0031455790296994,True,0.681270234582842,0.0650332885274441,0.37194216851201,131.321668703675
170,17720,1049:1083,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.807618467595629,0.0606313356430803,0.825768754405216,11.2515272426836,47.6187,0.962828839241241,0.97232783895188,0.0887705710863197,0.666906096021092,0.365525541818456,0.301380554202636,8.72479227927285,8.2633,2.52673496341071,39.3554,0.777598351704889,0.706225206520417,0.785269919294887,0.7151123618639,0.0713731451844725,0.0701575574309866,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
171,17720,1012:1083,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.94067997528488,0.0606313356430803,0.825768754405216,11.2515272426836,47.6187,0.962828839241241,0.97232783895188,0.0530956775605944,0.776784131484925,0.633134703030262,0.143649428454664,10.0448660020167,20.6317,1.20666124066684,26.987,0.905713808701021,0.904234301118988,0.914649327514055,0.886852458318008,0.001479507582033,0.0277968691960475,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
172,17720,1558:1083,Breast,HCC1500,SIDM00879,1303900,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.877063989616971,0.0606313356430803,0.825768754405216,11.2515272426836,47.6187,0.962828839241241,0.97232783895188,0.0817300920613156,0.724252038239676,0.621892462430266,0.10235957580941,10.2890869062457,24.4373,0.96244033643789,23.1814,0.844462503063201,0.857747382760349,0.852793733646784,0.833480399444064,-0.0132848796971479,0.0193133342027199,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
173,17725,1049:1558,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.899887487952027,0.0699797116132392,0.807195643012697,11.0720319856403,42.0478,0.947570213431995,0.969039983071222,0.0638080749992855,0.726385259476517,0.676657340012335,0.0497279194641824,10.6047349882136,30.414,0.467296997426686,11.6338,0.852706579023484,0.873346629975705,0.872026956091037,0.862804211889324,-0.0206400509522211,0.0092227442017133,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
174,17725,1012:1558,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.860972719591448,0.0699797116132392,0.807195643012697,11.0720319856403,42.0478,0.947570213431995,0.969039983071222,0.107319511987617,0.694973428007009,0.430622978734408,0.2643504492726,9.00091847701799,10.0064,2.07111350862229,32.0414,0.815832103662393,0.78696643409588,0.83431698961768,0.774778540277938,0.0288656695665134,0.059538449339742,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
175,17725,1011:1558,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.0339858114364734,0.0699797116132392,0.807195643012697,11.0720319856403,42.0478,0.947570213431995,0.969039983071222,0.0248534158385541,0.0274331989157724,0.0251573400026444,0.002275858913128,10.5153154689875,28.5861,0.556716516652809,13.4617,0.0322039425965186,0.0072375623197468,0.0329336101390619,0.0325082440993299,0.0249663802767718,0.000425366039732,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
176,17726,1012:1594,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.951917011608893,0.0831216367498525,0.708154374597486,10.2827284020407,9.7319,0.902558265972375,0.950122378826826,0.0520218254216149,0.674104196024603,0.552588145222968,0.121516050801635,9.47004535925499,5.5406,0.812683042785705,4.1913,0.859160567347328,0.840658240226379,0.904437655515564,0.877099842764291,0.0185023271209487,0.0273378127512737,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
177,17726,1021:1594,Breast,HCC1500,SIDM00879,1303900,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.867556035116611,0.0831216367498525,0.708154374597486,10.2827284020407,9.7319,0.902558265972375,0.950122378826826,0.077129277019786,0.614363601476278,0.676660534469742,-0.0622969329934636,10.8311737389701,14.2331,-0.548445336929452,-4.5012,0.783019870688717,0.796957980029457,0.824284403850563,0.836393197534784,-0.0139381093407397,-0.0121087936842209,True,0.731969844038953,0.0690028322264646,0.293892972592799,162.461350658444
178,18179,1058:1372,Breast,HCC1569,SIDM00878,907046,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.881164084821352,0.0758447073979869,0.709859484864756,10.7220316695512,3.299,0.903787784529018,0.934478212916721,0.160512047354421,0.625502683332609,0.488637061421664,0.136865621910945,9.42153727662389,1.3394,1.30049439292734,1.9596,0.79638533602723,0.650632553053297,0.823428639270255,0.781918505178179,0.145752782973933,0.0415101340920763,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
179,18179,1558:1372,Breast,HCC1569,SIDM00878,907046,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.821043156064759,0.0758447073979869,0.709859484864756,10.7220316695512,3.299,0.903787784529018,0.934478212916721,0.131306600718814,0.582825271815863,0.218465902292536,0.364359369523328,7.047227247665,0.2583,3.67480442188623,3.0407,0.742048775022481,0.539934319042341,0.7672469412069,0.614221963794329,0.20211445598014,0.153024977412571,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
180,18179,1549:1372,Breast,HCC1569,SIDM00878,907046,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.868322304700743,0.0758447073979869,0.709859484864756,10.7220316695512,3.299,0.903787784529018,0.934478212916721,0.126824501237377,0.616386823911447,0.547961540798604,0.0684252831128433,10.0330964652931,2.0464,0.688935204258085,1.2526,0.784779092022616,0.730503528896083,0.811428275532479,0.791925079468796,0.0542755631265327,0.0195031960636821,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
181,18181,1058:1510,Breast,HCC1569,SIDM00878,907046,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.882589568066454,0.0599195673866629,0.852761469080963,12.380591642204,104.1501,0.963000416731013,0.969528318400752,0.122012839461375,0.752638376659881,0.64693688829708,0.105701488362801,10.9437339588347,38.47,1.43685768336934,65.6801,0.849934121850439,0.750818197409439,0.855695579765514,0.830167887312295,0.0991159244410009,0.0255276924532192,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
182,18181,1049:1510,Breast,HCC1569,SIDM00878,907046,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.852144767852889,0.0599195673866629,0.852761469080963,12.380591642204,104.1501,0.963000416731013,0.969528318400752,0.0905606927167299,0.726676224103885,0.661828745348051,0.0648474787558342,11.3987927968746,52.7362,0.98179884532939,51.4139,0.820615766557484,0.763255033947669,0.82617848381041,0.81095185616569,0.057360732609815,0.0152266276447199,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
183,18181,1558:1510,Breast,HCC1569,SIDM00878,907046,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.938991200534533,0.0599195673866629,0.852761469080963,12.380591642204,104.1501,0.963000416731013,0.969528318400752,0.173462287069655,0.800735515621926,0.545949348722764,0.254786166899162,9.63247561231737,15.5022,2.74811602988665,88.6479,0.90424891742151,0.701799238088438,0.910378559647349,0.841705753965847,0.202449679333071,0.0686728056815019,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
184,18181,1011:1510,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.218465917689029,0.0599195673866629,0.852761469080963,12.380591642204,104.1501,0.963000416731013,0.969528318400752,0.057754210901244,0.186299316912617,0.0674425425314286,0.118856774381188,7.4483871424917,3.4113,4.93220449971232,100.7388,0.210382769776058,0.118514730316056,0.211808893804921,0.169562993318785,0.0918680394600018,0.0422459004861364,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
185,18181,1053:1510,Breast,HCC1569,SIDM00878,907046,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.745570273498158,0.0599195673866629,0.852761469080963,12.380591642204,104.1501,0.963000416731013,0.969528318400752,0.114959909257684,0.635793601731385,0.274430728115614,0.36136287361577,7.95978581061764,4.8626,4.42080583158637,99.2875,0.717984484080982,0.516971816722166,0.722851493514258,0.60350784422032,0.201012667358815,0.119343649293937,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
186,18181,1049:1549,Breast,HCC1569,SIDM00878,907046,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.67895974005918,0.0823234690284153,0.756499525411164,11.1818063473701,22.6861,0.906538951933143,0.946633575612912,0.100952749770686,0.513632721128058,0.281921097987862,0.231711623140196,8.3409707183976,3.1665,2.8408356289725,19.5196,0.615503451158049,0.504606934186765,0.642726086429436,0.565116927249244,0.110896516971283,0.0776091591801912,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
187,18181,1058:1549,Breast,HCC1569,SIDM00878,907046,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.882589568066454,0.0823234690284153,0.756499525411164,11.1818063473701,22.6861,0.906538951933143,0.946633575612912,0.192311441160356,0.667678589375117,0.250406351898091,0.417272237477026,7.21754712539386,1.4534,3.96425922197623,21.2327,0.800101822022088,0.521719601335091,0.835488918617403,0.670948871545734,0.278382220686997,0.164540047071669,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
188,18181,1021:1549,Breast,HCC1569,SIDM00878,907046,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.859063278703028,0.0823234690284153,0.756499525411164,11.1818063473701,22.6861,0.906538951933143,0.946633575612912,0.0750989683963563,0.649880962636999,0.465074758507047,0.184806204129952,9.31926216158349,6.2385,1.8625441857866,16.4476,0.778774324319692,0.706000352320074,0.813218143196399,0.758375242341108,0.0727739719996178,0.054842900855291,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
189,18181,1510:1549,Breast,HCC1569,SIDM00878,907046,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.831207332603343,0.0823234690284153,0.756499525411164,11.1818063473701,22.6861,0.906538951933143,0.946633575612912,0.161370402888326,0.628807952632709,0.422205472027214,0.206602480605494,9.06115229620423,5.2165,2.12065405116586,17.4696,0.753521824137378,0.601656369970224,0.786848769337974,0.72369371323152,0.151865454167154,0.0631550561064531,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
190,18182,1021:1558,Breast,HCC1569,SIDM00878,907046,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.877492633761309,0.118955079744646,0.613365124785611,9.88820946951783,18.5088,0.869399671650138,0.906592743999859,0.106022730096683,0.53822337880546,0.281011060342441,0.257212318463019,7.55136681346745,3.6637,2.33684265605038,14.8451,0.762891807667497,0.627747358851973,0.795528454681328,0.687155566481436,0.135144448815523,0.108372888199892,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
191,18182,1049:1558,Breast,HCC1569,SIDM00878,907046,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.824252744265171,0.118955079744646,0.613365124785611,9.88820946951783,18.5088,0.869399671650138,0.906592743999859,0.0839266163238249,0.505567887341089,0.193077003374827,0.312490883966262,6.72020292193665,2.0593,3.16800654758118,16.4495,0.716605065220865,0.557365414489958,0.747261557172775,0.596846740492129,0.159239650730907,0.150414816680646,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
192,18182,1372:1558,Breast,HCC1569,SIDM00878,907046,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.810115089632504,0.118955079744646,0.613365124785611,9.88820946951783,18.5088,0.869399671650138,0.906592743999859,0.0814165422630242,0.496896343043148,0.41041559982114,0.0864807432220077,9.05092237383982,10.3593,0.837287095678017,8.1495,0.704313792925322,0.723625933132411,0.734444462065624,0.704925771788051,-0.0193121402070895,0.0295186902775727,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
193,18182,1510:1558,Breast,HCC1569,SIDM00878,907046,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.90840113491718,0.118955079744646,0.613365124785611,9.88820946951783,18.5088,0.869399671650138,0.906592743999859,0.0313202128824702,0.557181575473867,0.330888984877487,0.22629259059638,7.92804539770908,4.7567,1.96016407180875,13.7521,0.789763648423609,0.733059409083263,0.823549877557153,0.733512450405717,0.0567042393403465,0.0900374271514361,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
194,18182,1083:1558,Breast,HCC1569,SIDM00878,907046,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.771731772515155,0.118955079744646,0.613365124785611,9.88820946951783,18.5088,0.869399671650138,0.906592743999859,0.0688851563695566,0.473353354949779,0.133849372482977,0.339503982466803,5.99469984134265,1.2454,3.89350962817518,17.2634,0.670943349626655,0.499605686596172,0.69964642527639,0.515381047600814,0.171337663030483,0.184265377675576,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
195,18182,1012:1558,Breast,HCC1569,SIDM00878,907046,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.870743569898795,0.118955079744646,0.613365124785611,9.88820946951783,18.5088,0.869399671650138,0.906592743999859,0.172130203031831,0.534083738407243,0.264827571674111,0.269256166733132,7.40699878606209,3.3148,2.48121068345574,15.194,0.757024173761482,0.618624761696248,0.789409802354782,0.673375373394187,0.138399412065234,0.116034428960595,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
196,18182,1011:1558,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.205847918998073,0.118955079744646,0.613365124785611,9.88820946951783,18.5088,0.869399671650138,0.906592743999859,0.0578627677597703,0.126259934523112,0.0466720141357899,0.0795879203873217,6.63865351272731,1.9461,3.24955595679052,16.5627,0.178964113186789,0.0981004143644054,0.186620229731124,0.147794516849695,0.0808636988223837,0.0388257128814288,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
197,18183,1083:1594,Breast,HCC1569,SIDM00878,907046,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.811745331350179,0.0762985885087926,0.647323548004228,10.168860549126,8.9934,0.881319278393362,0.916873235273433,0.0931498459027446,0.525461867965465,0.271219695346967,0.254242172618499,7.67270260667573,1.5941,2.49615794245023,7.3993,0.71540680966472,0.600963815977019,0.744267568173143,0.642185618100191,0.114442993687701,0.102081950072953,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
198,18183,1058:1594,Breast,HCC1569,SIDM00878,907046,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.846700754916501,0.0762985885087926,0.647323548004228,10.168860549126,8.9934,0.881319278393362,0.916873235273433,0.151778008405119,0.548089336770407,0.247462549034223,0.300626787736184,7.29779612588113,1.2293,2.87106442324484,7.7641,0.746213698338125,0.53555183250076,0.77631726046875,0.648412143433472,0.210661865837365,0.127905117035278,True,0.611460611184203,0.0777719836910523,0.45282365555803,104.647688810549
199,18028,1558:1011,Breast,HCC202,SIDM00870,1290906,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.687053320348345,0.146157026096771,0.445777857580214,8.53610678843586,7.2503,0.835370205371996,0.83028430094151,0.0722644193268318,0.306273157188258,0.123797819728095,0.182475337460163,5.77219899980818,1.0674,2.76390778862768,6.1829,0.573943873320909,0.406396395629703,0.570449585794969,0.442176051250532,0.167547477691206,0.128273534544437,True,1.01237943559951,0.0809399617114915,-0.022305328138984,-4097.33970093886
200,18028,1561:1011,Breast,HCC202,SIDM00870,1290906,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.550087249057207,0.146157026096771,0.445777857580214,8.53610678843586,7.2503,0.835370205371996,0.83028430094151,0.0303216724476533,0.245216715366915,0.148804493967047,0.0964122213998688,6.88652912998137,2.3109,1.64957765845449,4.9394,0.459526498217436,0.402538442497025,0.456728807040301,0.399721026490448,0.0569880557204104,0.0570077805498531,True,1.01237943559951,0.0809399617114915,-0.022305328138984,-4097.33970093886
201,16634,1549:1053,Breast,HCC202,SIDM00870,1290906,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.736076996646645,0.141466819167187,0.368127411402573,7.84900907433733,4.5032,0.707773660378433,0.790419586015972,0.143753917492681,0.270970119368509,0.110142403532056,0.160827715836454,5.29841340163512,0.7686,2.5505956727022,3.7346,0.520975910236959,0.384513765369546,0.581809674965321,0.446143947240155,0.136462144867414,0.135665727725166,True,0.94997128976248,0.102918455811318,0.0405457633931613,982.663432579057
202,16634,1372:1053,Breast,HCC202,SIDM00870,1290906,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.928010916797391,0.141466819167187,0.368127411402573,7.84900907433733,4.5032,0.707773660378433,0.790419586015972,0.109914338127141,0.341626256553952,0.13496491908187,0.206661337472081,5.22726815003846,0.7316,2.62174092429886,3.7716,0.656821683452835,0.502611682397139,0.733518004673297,0.557180386880494,0.154210001055696,0.176337617792803,True,0.94997128976248,0.102918455811318,0.0405457633931613,982.663432579057
203,15784,1021:1011,Breast,HCC2157,SIDM00774,749715,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.961391056510819,0.123369351392127,0.051242962908539,4.69286671162332,0.5052,0.535714277606743,0.56460802992338,0.077575411107643,0.0492645262493852,0.0316773101405844,0.0175872161088008,4.01297884466114,0.3153,0.679887866962185,0.1899,0.515030915336277,0.47782608402635,0.542809110402531,0.481861771310248,0.037204831309927,0.0609473390922827,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
204,15784,1549:1011,Breast,HCC2157,SIDM00774,749715,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.611020230173747,0.123369351392127,0.051242962908539,4.69286671162332,0.5052,0.535714277606743,0.56460802992338,0.0385098100591643,0.0313104869911603,0.0040286710701236,0.0272818159210367,1.59891731931347,0.0592,3.09394939230985,0.446,0.327332261210634,0.174721306511866,0.344986928401729,0.172503382994927,0.152610954698769,0.172483545406803,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
205,15784,1558:1011,Breast,HCC2157,SIDM00774,749715,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.643752662504369,0.123369351392127,0.051242962908539,4.69286671162332,0.5052,0.535714277606743,0.56460802992338,0.0556384711797882,0.0329877938069847,0.0046627655876531,0.0283250282193316,1.73858668846704,0.0652,2.95428002315628,0.44,0.344867492550945,0.194342852598579,0.363467922534523,0.189406944588021,0.150524639952366,0.174060977946502,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
206,15785,1549:1021,Breast,HCC2157,SIDM00774,749715,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.557954739004562,0.052850215706816,0.806800213920662,11.109388159027,43.1508,0.97097338255605,0.9683586747564,0.0448951918984791,0.450158002786927,0.364414802274444,0.085743200512483,9.93387793979263,19.104,1.17551021923436,24.0468,0.541759200244437,0.500818267261188,0.54030031163651,0.522928540906932,0.0409409329832493,0.0173717707295786,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
207,15785,1510:1021,Breast,HCC2157,SIDM00774,749715,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.999094532812314,0.052850215706816,0.806800213920662,11.109388159027,43.1508,0.97097338255605,0.9683586747564,0.0266878018619729,0.806069682799938,0.598016764822367,0.208052917977571,9.58951461814812,15.0474,1.51987354087886,28.1034,0.970094198018028,0.90955027425577,0.967481857750497,0.923535032671793,0.0605439237622581,0.043946825078704,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
208,15785,1083:1021,Breast,HCC2157,SIDM00774,749715,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.942947210853669,0.052850215706816,0.806800213920662,11.109388159027,43.1508,0.97097338255605,0.9683586747564,0.0578549289615071,0.760770011432631,0.443513204911504,0.317256806521127,8.82475588188934,8.8562,2.28463227713764,34.2946,0.915576642894379,0.81424134720966,0.913111111467502,0.838162154788697,0.101335295684719,0.0749489566788047,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
209,15785,1012:1021,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.0712837335876611,0.052850215706816,0.806800213920662,11.109388159027,43.1508,0.97097338255605,0.9683586747564,0.0248875620160789,0.0575117315075885,0.0457984216637909,0.0117133098437976,9.86501639460927,18.2136,1.24437176441772,24.9372,0.0692146079228356,0.0421115146920983,0.0690282217886358,0.0666362491207729,0.0271030932307373,0.0023919726678628,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
210,15785,1011:1021,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.34027016074622,0.052850215706816,0.806800213920662,11.109388159027,43.1508,0.97097338255605,0.9683586747564,0.0614779065290632,0.274530038480868,0.0498562863149548,0.224673752165913,6.39946033417516,1.6488,4.70992782485183,41.502,0.330393268962647,0.218780936244886,0.329503561919356,0.244158257310696,0.111612332717761,0.0853453046086599,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
211,15785,1594:1021,Breast,HCC2157,SIDM00774,749715,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.84469297870694,0.052850215706816,0.806800213920662,11.109388159027,43.1508,0.97097338255605,0.9683586747564,0.100558398207405,0.68149847591804,0.35073438527846,0.33076409063958,8.49466448324393,7.045,2.61472367578306,36.1058,0.820174398756423,0.664590063778776,0.817965773436688,0.735326613290106,0.155584334977647,0.0826391601465829,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
212,15785,1053:1021,Breast,HCC2157,SIDM00774,749715,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.467255218917519,0.052850215706816,0.806800213920662,11.109388159027,43.1508,0.97097338255605,0.9683586747564,0.0454913781809981,0.3769816105782,0.236201064336322,0.140780546241878,9.03251303339844,10.2279,2.07687512562854,32.9229,0.453692380429311,0.388649863495641,0.452470644563981,0.420290911601623,0.0650425169336699,0.0321797329623577,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
213,15786,1053:1049,Breast,HCC2157,SIDM00774,749715,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.406042301476728,0.0697402241749947,0.870769544452798,11.8154371882446,70.3933,0.952724472779993,0.97960363525221,0.0722238798300871,0.353569269885456,0.188662757904088,0.164906511981368,8.7909078437582,8.6508,3.02452934448641,61.7425,0.386846437600791,0.305279555546199,0.397760514592777,0.360190749359147,0.0815668820545922,0.0375697652336293,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
214,15786,1083:1049,Breast,HCC2157,SIDM00774,749715,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.95352045034291,0.0697402241749947,0.870769544452798,11.8154371882446,70.3933,0.952724472779993,0.97960363525221,0.173086689050454,0.830296568171523,0.460826600697213,0.36946996747431,8.90132119887199,9.3389,2.91411598937262,61.0544,0.90844226833789,0.699332929755163,0.934072099443239,0.851370902372751,0.209109338582727,0.0827011970704881,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
215,15786,1058:1049,Breast,HCC2157,SIDM00774,749715,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.814736049277916,0.0697402241749947,0.870769544452798,11.8154371882446,70.3933,0.952724472779993,0.97960363525221,0.141145757789512,0.709447338479004,0.124137229884045,0.585310108594959,6.46733234780103,1.7282,5.34810484044358,68.6651,0.776218973003157,0.495789919162267,0.798118395643671,0.589275438358511,0.28042905384089,0.20884295728516,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
216,15786,1021:1049,Breast,HCC2157,SIDM00774,749715,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.951516556412898,0.0697402241749947,0.870769544452798,11.8154371882446,70.3933,0.952724472779993,0.97960363525221,0.103784474534382,0.828551638366955,0.757312503773995,0.0712391345929596,11.0083207682267,40.2314,0.807116420017872,30.1619,0.906533109549913,0.848077002115968,0.93210907766474,0.919502030322483,0.0584561074339447,0.0126070473422574,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
217,15786,1558:1049,Breast,HCC2157,SIDM00774,749715,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.439697658108805,0.0697402241749947,0.870769544452798,11.8154371882446,70.3933,0.952724472779993,0.97960363525221,0.110886985469085,0.382875329448367,0.0856923432767943,0.297182986171572,6.90655425948789,2.3432,4.90888292875673,68.0501,0.418910719504309,0.259816736039901,0.430729424295269,0.333888033494951,0.159093983464409,0.0968413908003185,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
218,15786,1561:1049,Breast,HCC2157,SIDM00774,749715,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.819951204192005,0.0697402241749947,0.870769544452798,11.8154371882446,70.3933,0.952724472779993,0.97960363525221,0.034128889587028,0.713988536547796,0.657074565662335,0.0569139708854611,11.058405094225,41.6526,0.757032094019612,28.7407,0.781187578719148,0.804884059884143,0.803227180355915,0.793189042695726,-0.0236964811649946,0.0100381376601895,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
219,15786,1510:1049,Breast,HCC2157,SIDM00774,749715,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.853204105139394,0.0697402241749947,0.870769544452798,11.8154371882446,70.3933,0.952724472779993,0.97960363525221,0.0597393839305646,0.742944149957487,0.508390723656281,0.234553426301206,9.57296168866312,14.8757,2.2424754995815,55.5176,0.812868431242655,0.790051262167678,0.835801843006659,0.788110227677411,0.022817169074977,0.0476916153292477,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
220,15787,1011:1053,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.331764818966705,0.0653579111724198,0.0808192672058573,5.41201798110127,0.8316,0.613886880530598,0.630667365983052,0.0379921683586031,0.0268129895535729,0.0053262853456534,0.0214867042079194,2.92635523801219,0.1485,2.48566274308908,0.6831,0.203666069785269,0.0965369048254828,0.209233244503576,0.132778715356615,0.107129164959786,0.0764545291469608,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
221,15787,1012:1054,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.768553486290573,0.0564587488645045,0.942998899978849,13.1409916911734,70.5704,0.963097367935498,0.991348879588601,0.0374393287903563,0.72474509214692,0.68401737797229,0.0407277141746307,12.0855385391379,33.9547,1.05545315203549,36.6157,0.740191839764102,0.768553486290573,0.761904637538073,0.755352940131091,-0.0283616465264716,0.0065516974069816,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
222,15787,1558:1054,Breast,HCC2157,SIDM00774,749715,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.416406322025767,0.0564587488645045,0.942998899978849,13.1409916911734,70.5704,0.963097367935498,0.991348879588601,0.104764480734191,0.392670703614537,0.256519184119569,0.136151519494968,9.69764670351931,6.4874,3.44334498765412,64.083,0.401039832734717,0.315879858593375,0.412803940793854,0.386679160329783,0.0851599741413423,0.0261247804640706,True,0.874269559034886,0.123111625622679,0.125275004903464,374.59545871234
223,15051,1058:1083,Breast,HCC2157,SIDM00774,749715,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.88958351687985,0.0626678730137774,0.678121888880616,10.0996731929547,21.4306,0.936561636986499,0.942756958653696,0.111629431024621,0.603246054783625,0.371967105689652,0.231278949093973,8.51236404082739,7.1319,1.58730915212731,14.2987,0.833149794805199,0.790561627099144,0.838661050842107,0.775320906297665,0.0425881677060557,0.0633401445444415,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
224,15051,1549:1083,Breast,HCC2157,SIDM00774,749715,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.634544639723873,0.0626678730137774,0.678121888880616,10.0996731929547,21.4306,0.936561636986499,0.942756958653696,0.0496783281991964,0.430298609668623,0.159551636288773,0.27074697337985,7.39003882685701,3.2761,2.70963436609768,18.1545,0.594290166520799,0.487179151163056,0.598221374676084,0.505582880316067,0.107111015357742,0.0926384943600166,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
225,15051,1558:1083,Breast,HCC2157,SIDM00774,749715,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.647178378750875,0.0626678730137774,0.678121888880616,10.0996731929547,21.4306,0.936561636986499,0.942756958653696,0.0687107835143004,0.438865824641238,0.293352411063572,0.145513413577666,8.72339638693816,8.2553,1.37627680601654,13.1753,0.606122441825188,0.595215312816821,0.610131920057605,0.571738932020613,0.0109071290083664,0.0383929880369914,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
226,15051,1372:1083,Breast,HCC2157,SIDM00774,749715,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.89315466183185,0.0626678730137774,0.678121888880616,10.0996731929547,21.4306,0.936561636986499,0.942756958653696,0.0472423773810507,0.605667726343942,0.324522664202656,0.281145062141286,8.17227510981048,5.6342,1.92739808314422,15.7964,0.83649439216736,0.75591082054937,0.842027772595965,0.759974098684358,0.0805835716179902,0.0820536739116069,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
227,15051,1011:1083,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.512807422407668,0.0626678730137774,0.678121888880616,10.0996731929547,21.4306,0.936561636986499,0.942756958653696,0.071499619678768,0.347745937915088,0.112810468935152,0.234935468979936,7.13205229980401,2.7396,2.96762089315069,18.691,0.480275758988953,0.388452601479283,0.483452765924095,0.398521344651236,0.0918231575096698,0.0849314212728584,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
228,15053,1561:1372,Breast,HCC2157,SIDM00774,749715,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.891714846187038,0.0605296902763253,0.956239232050583,13.5516617886652,23.4524,0.957049823574083,0.993404069961649,0.0220227584562038,0.852692719725997,0.804692298319011,0.0480004214069863,12.2825358240289,9.7306,1.26912596463626,13.7218,0.853415536221695,0.882928442186935,0.88583315744743,0.878217927883102,-0.02951290596524,0.0076152295643273,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
229,15053,1011:1372,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.646475887552142,0.0605296902763253,0.956239232050583,13.5516617886652,23.4524,0.957049823574083,0.993404069961649,0.0819175039330134,0.618185606252079,0.493770678185232,0.124414928066848,10.7319028459554,3.3217,2.8197589427098,20.1307,0.618709634126676,0.564440136241087,0.642211777826367,0.620801332126797,0.0542694978855892,0.02141044569957,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
230,15053,1053:1372,Breast,HCC2157,SIDM00774,749715,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.757990740346839,0.0605296902763253,0.956239232050583,13.5516617886652,23.4524,0.957049823574083,0.993404069961649,0.0768433531601802,0.724820483450714,0.491286406440599,0.233534077010115,9.90152573165429,1.868,3.65013605701089,21.5844,0.725434904319731,0.65593491783548,0.752991086453794,0.709551841290608,0.0694999864842504,0.0434392451631856,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
231,15053,1058:1372,Breast,HCC2157,SIDM00774,749715,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.47942680038716,0.0605296902763253,0.956239232050583,13.5516617886652,23.4524,0.957049823574083,0.993404069961649,0.0999135116271389,0.458446715426686,0.307935504100882,0.150511211325804,9.86385127454695,1.8199,3.68781051411823,21.6325,0.458835334727218,0.376528935228243,0.476264534753296,0.448149678478409,0.0823063994989753,0.0281148562748865,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
232,15053,1012:1372,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.841298810801008,0.0605296902763253,0.956239232050583,13.5516617886652,23.4524,0.957049823574083,0.993404069961649,0.0371331887323961,0.804482928765424,0.749346998929841,0.0551359298355831,12.0960650905383,8.5508,1.45559669812693,14.9016,0.80516487845019,0.819090710202376,0.835749662703617,0.826945780329145,-0.0139258317521858,0.0088038823744716,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
233,15055,1058:1510,Breast,HCC2157,SIDM00774,749715,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.785569532196433,0.0822619382850033,0.858901723542242,11.6655256143078,63.4458,0.939838843203211,0.977581134663069,0.134133427017995,0.674727025165789,0.32648683261685,0.348240192548938,8.49699877130387,7.0564,3.16852684300394,56.3894,0.738308760395183,0.577339882183233,0.767957954641325,0.683965061424574,0.16096887821195,0.083992893216751,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
234,15055,1549:1510,Breast,HCC2157,SIDM00774,749715,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.622166976856723,0.0822619382850033,0.858901723542242,11.6655256143078,63.4458,0.939838843203211,0.977581134663069,0.150076504012267,0.534380288753305,0.148049270319002,0.386331018434304,7.28234033004949,3.0404,4.38318528425833,60.4054,0.584736691808261,0.378605928632856,0.608218699185486,0.490683038439892,0.206130763175405,0.117535660745594,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
235,15055,1558:1510,Breast,HCC2157,SIDM00774,749715,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.663808402378237,0.0822619382850033,0.858901723542242,11.6655256143078,63.4458,0.939838843203211,0.977581134663069,0.152876129299442,0.57014618090449,0.0615999774784395,0.50854620342605,5.63533869016074,0.9708,6.03018692414707,62.475,0.623872920999734,0.345835828440295,0.648926571195796,0.432005149290979,0.278037092559439,0.216921421904817,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
236,15055,1012:1510,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.190277326483829,0.0822619382850033,0.858901723542242,11.6655256143078,63.4458,0.939838843203211,0.977581134663069,0.0796370810290123,0.163429523667971,0.0702196289199696,0.0932098947480012,8.20848087815399,5.7774,3.45704473615382,57.6684,0.178830022410362,0.0898574272454093,0.186011524724717,0.16233987452924,0.0889725951649526,0.0236716501954767,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
237,15055,1011:1510,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.464339968155351,0.0822619382850033,0.858901723542242,11.6655256143078,63.4458,0.939838843203211,0.977581134663069,0.066781107432196,0.39882239895818,0.151513246804979,0.247309152153201,7.93010443117757,4.7635,3.73542118313025,58.6823,0.436404738524141,0.346222463070287,0.453929992938721,0.38775620205372,0.0901822754538534,0.0661737908850005,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
238,15055,1083:1549,Breast,HCC2157,SIDM00774,749715,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.965406726437803,0.165363149539602,0.434311595827127,8.6099828107971,3.8156,0.759530217803924,0.87714122653089,0.184619843402569,0.419287335981444,0.100384090543686,0.318903245437758,5.82156585296439,0.5523,2.78841695783271,3.2633,0.733255581200678,0.545419377180849,0.846798040128826,0.644309625664469,0.187836204019829,0.202488414464357,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
239,15055,1012:1549,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.766175238458949,0.165363149539602,0.434311595827127,8.6099828107971,3.8156,0.759530217803924,0.87714122653089,0.177632435730631,0.332758790498335,0.0688131633302015,0.263945627168134,5.58225892898671,0.4679,3.0277238818104,3.3477,0.581933245742699,0.415192325335052,0.67204388839948,0.49497539083236,0.166740920407647,0.177068497567119,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
240,15055,1058:1549,Breast,HCC2157,SIDM00774,749715,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.785569532196433,0.165363149539602,0.434311595827127,8.6099828107971,3.8156,0.759530217803924,0.87714122653089,0.140888792324092,0.341181957161402,0.0792773947405728,0.261904562420829,5.7723874595422,0.5338,2.83759535125491,3.2818,0.596663797889283,0.457997408480815,0.689055422996077,0.520857500631263,0.138666389408469,0.168197922364814,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
241,15055,1011:1549,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.464339968155351,0.165363149539602,0.434311595827127,8.6099828107971,3.8156,0.759530217803924,0.87714122653089,0.0657821926068146,0.201668232575867,0.006046597778792,0.195621634797075,2.61286391999139,0.0597,5.99711889080572,3.7559,0.3526802371481,0.148443209269698,0.407291729195099,0.172543693360279,0.204237027878403,0.23474803583482,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
242,15055,1510:1549,Breast,HCC2157,SIDM00774,749715,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.748072229310954,0.165363149539602,0.434311595827127,8.6099828107971,3.8156,0.759530217803924,0.87714122653089,0.100112248008005,0.324896443705997,0.0584962678263558,0.266400175879641,5.35911688232326,0.4008,3.25086592847384,3.4148,0.568183463261616,0.435246775806465,0.656164992751508,0.468193563832923,0.132936687455151,0.187971428918584,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
243,15055,1053:1549,Breast,HCC2157,SIDM00774,749715,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.700159565066068,0.165363149539602,0.434311595827127,8.6099828107971,3.8156,0.759530217803924,0.87714122653089,0.152730386687599,0.304087418037471,0.101690822182399,0.202396595855072,6.38429716606498,0.8158,2.22568564473213,2.9998,0.531792346952131,0.398333053475771,0.614138819669386,0.50149440713207,0.133459293476361,0.112644412537316,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
244,15056,1058:1558,Breast,HCC2157,SIDM00774,749715,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.845308182010052,0.0938916461681532,0.220506590284518,7.13652554568071,2.7481,0.732703018431804,0.777483463317165,0.127045327332483,0.186396024954641,0.0112373312097103,0.175158693744931,2.64376172555336,0.1221,4.49276382012735,2.626,0.619359856463866,0.347585148318115,0.657213132919512,0.31647895369961,0.271774708145751,0.340734179219902,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
245,15056,1012:1558,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.206513475657072,0.0938916461681532,0.220506590284518,7.13652554568071,2.7481,0.732703018431804,0.777483463317165,0.0576867090669092,0.0455375823649458,0.0045165079619764,0.0410210744029693,3.39133083941453,0.2049,3.74519470626619,2.5432,0.151313046960779,0.0558006792754766,0.160560812275525,0.091529385960403,0.0955123676853027,0.0690314263151222,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
246,15056,1011:1558,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.473113219929688,0.0938916461681532,0.220506590284518,7.13652554568071,2.7481,0.732703018431804,0.777483463317165,0.0371819594194371,0.104324582945225,0.0055667094293162,0.0987578735159086,2.46133084335406,0.1076,4.67519470232666,2.6405,0.346651484302472,0.149057356572435,0.36783770477207,0.169321532405966,0.197594127730037,0.198516172366103,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
247,15057,1054:1561,Breast,HCC2157,SIDM00774,749715,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.976781406302127,0.0614663893517765,0.0789393095741929,5.37426901495385,0.8101,0.623376670319089,0.627242953292182,0.146766685580949,0.0771064498183991,0.0066379968378301,0.0704684529805689,1.64384650865557,0.061,3.73042250629828,0.7491,0.608902740690217,0.311923859171552,0.612679254009837,0.279489071940734,0.296978881518665,0.333190182069103,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
248,15057,1558:1561,Breast,HCC2157,SIDM00774,749715,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.703131567979884,0.0614663893517765,0.0789393095741929,5.37426901495385,0.8101,0.623376670319089,0.627242953292182,0.07940899846123,0.0555047205161517,0.0006793761371927,0.054825344378959,-1.24352535907856,0.0082,6.6177943740324,0.8019,0.43831581564354,0.10771863526684,0.441034321252665,0.063615924607157,0.3305971803767,0.377418396645508,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
249,15057,1058:1561,Breast,HCC2157,SIDM00774,749715,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.430474248671854,0.0614663893517765,0.0789393095741929,5.37426901495385,0.8101,0.623376670319089,0.627242953292182,0.0784367447360872,0.0339813399796256,0.0013285572966282,0.0326527826829973,0.473461873200177,0.0271,4.90080714175367,0.783,0.268347603795172,0.105558700705827,0.270011939053167,0.0831599310948572,0.162788903089345,0.18685200795831,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
250,15057,1053:1561,Breast,HCC2157,SIDM00774,749715,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.439100445006434,0.0614663893517765,0.0789393095741929,5.37426901495385,0.8101,0.623376670319089,0.627242953292182,0.0591435032010413,0.0346622859625288,0.0017244126771537,0.0329378732853751,0.830296304620952,0.0347,4.54397271033289,0.7754,0.273724973343741,0.104479861917776,0.275422659917747,0.0965801146189356,0.169245111425965,0.178842545298812,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
251,15057,1012:1594,Breast,HCC2157,SIDM00774,749715,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.742311558977116,0.122465492444228,0.32826726002565,7.94330355534962,1.9229,0.783194954892049,0.835954463957919,0.154681578225488,0.243676581550787,0.0216269477785043,0.222049633772282,3.8255780836763,0.1108,4.11772547167332,1.8121,0.581374667948929,0.333632668549929,0.620538661374482,0.359056022499528,0.247741999399,0.261482638874954,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
252,15057,1011:1594,Breast,HCC2157,SIDM00774,749715,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.43176975801148,0.122465492444228,0.32826726002565,7.94330355534962,1.9229,0.783194954892049,0.835954463957919,0.0389889216612943,0.141735875424366,0.0260257481349317,0.115710127289435,4.94660752417035,0.2409,2.99669603117927,1.682,0.338159896149552,0.239272643339012,0.360939856611727,0.253918276923667,0.0988872528105402,0.10702157968806,True,0.907759508311934,0.122368877824174,0.089600676051625,519.232390652193
253,16335,1011:1012,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.302462459642535,0.0611928886547084,0.576086568303951,9.46608277076485,6.9068,0.898138683849771,0.916353392046759,0.040932900633015,0.17424456041624,0.0316017722373342,0.142642788178906,5.73545939041348,0.5203,3.73062338035137,6.3865,0.271653235417311,0.182005915860271,0.277162500860243,0.19919350518396,0.0896473195570406,0.0779689956762831,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
254,16336,1011:1021,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.313484350242537,0.0594559055292998,0.844311504583513,11.5690115349131,59.3403,0.958788473191661,0.974323300533341,0.050911167782367,0.264678443416661,0.0967637709499045,0.167914672466757,7.77474966028854,4.2772,3.7942618746246,55.0631,0.300565181538522,0.233298389364949,0.305435106793858,0.257638414599189,0.0672667921735728,0.0477966921946689,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
255,16337,1011:1049,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.341990414133429,0.0780442494048166,0.784843137312346,10.9664460990671,39.0804,0.910063821041805,0.963243929332643,0.0395810931598733,0.268408829559229,0.235287256939983,0.0331215726192454,10.2015763641963,22.9991,0.764869734870761,16.0813,0.311233103045938,0.308121398170767,0.329420190303982,0.322588916047488,0.003111704875171,0.0068312742564941,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
256,16337,1549:1049,Breast,HCC38,SIDM00675,749717,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.937477095655714,0.0780442494048166,0.784843137312346,10.9664460990671,39.0804,0.910063821041805,0.963243929332643,0.155845699542233,0.735772464912896,0.677865528256727,0.0579069366561691,10.4583856889239,27.4801,0.508060410143177,11.6003,0.853163987811612,0.740252576961752,0.903019121278764,0.891363514258592,0.11291141084986,0.0116556070201715,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
257,16338,1011:1053,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.348853819984005,0.090776819395893,0.799751120200913,11.1041503798456,42.9944,0.912955011068479,0.966098178349155,0.0652361646053233,0.278996233318576,0.0541112140299225,0.224885019288653,6.42430758055247,1.6774,4.67984279929318,41.317,0.318487843084778,0.185462096689839,0.337027039996691,0.250463886036893,0.133025746394939,0.0865631539597979,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
258,16338,1594:1054,Breast,HCC38,SIDM00675,749717,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.864927606869582,0.150495398945734,0.918399299192865,12.678464548611,51.2139,0.913360234738392,0.987084038355188,0.0466684105320138,0.794348908001586,0.811552891884039,-0.0172039838824527,13.1355659085063,70.3055,-0.457101359895272,-19.0916,0.789990482042117,0.827951419628298,0.853756235073715,0.85656811000076,-0.0379609375861817,-0.0028118749270446,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
259,16338,1510:1054,Breast,HCC38,SIDM00675,749717,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.888871092463579,0.150495398945734,0.918399299192865,12.678464548611,51.2139,0.913360234738392,0.987084038355188,0.0797223671576401,0.816338588391347,0.383154351058565,0.433184237332782,8.57827206228527,2.9861,4.10019248632571,48.2278,0.811859509664705,0.702406292773183,0.877390467526137,0.775457694005542,0.109453216891522,0.101932773520595,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
260,16338,1561:1054,Breast,HCC38,SIDM00675,749717,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.898976483124274,0.150495398945734,0.918399299192865,12.678464548611,51.2139,0.913360234738392,0.987084038355188,0.0701058992809681,0.8256193720922,0.758894848745384,0.0667245233468161,11.5674518187961,23.7105,1.11101272981487,27.5034,0.821089371650681,0.816374371012797,0.887365337348653,0.875871930701769,0.0047150006378844,0.0114934066468838,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
261,16339,1011:1058,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.327254216202451,0.0706217233220639,0.698386168734447,10.2758331303665,9.6855,0.899967230734171,0.945542480163692,0.0638343213223037,0.228549818255824,0.0718625703358879,0.156687247919936,7.0731738171192,1.052,3.20265931324735,8.6335,0.294518070701801,0.190467387644492,0.30943276323209,0.252113127334682,0.10405068305731,0.0573196358974079,True,0.797699660075126,0.0674135427308555,0.213696941821463,223.25402421726
262,17522,1011:1083,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.307357711382844,0.0619108502032216,0.803267199186035,11.137734004683,44.007,0.940952411985757,0.966763616729396,0.0311241797780651,0.246890367970727,0.0571800827213317,0.189710285249395,6.75722923399367,2.1128,4.38050477068929,41.8942,0.289208979868109,0.200662328565131,0.297142252686148,0.229093307879524,0.0885466513029777,0.0680489448066247,True,0.86745510200284,0.0704104497686588,0.127561946758892,355.802950364596
263,17526,1011:1510,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.241559984669916,0.082018558153635,0.886345547010316,12.1210253573644,87.0006,0.939444287850186,0.981694152568334,0.0595259937749424,0.21410561674806,0.0996401840729459,0.114465432675114,8.46254819976259,6.8899,3.65847715760184,80.1107,0.226932147771331,0.150212665518722,0.237138024444953,0.209127571341388,0.0767194822526091,0.028010453103565,True,0.86745510200284,0.0704104497686588,0.127561946758892,355.802950364596
264,17528,1049:1561,Breast,HCC38,SIDM00675,749717,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.836987568555961,0.116130090377679,0.760683136214456,10.7572252143598,33.8047,0.884991545755488,0.95850134688858,0.0423359588563025,0.63668232862166,0.454736542092334,0.181945786529326,9.26385186997604,12.0068,1.4933733443838,21.7979,0.740726922074467,0.742199939288682,0.802253711789886,0.75954275496328,-0.0014730172142148,0.0427109568266063,True,0.86745510200284,0.0704104497686588,0.127561946758892,355.802950364596
265,17528,1012:1561,Breast,HCC38,SIDM00675,749717,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.938554042196025,0.116130090377679,0.760683136214456,10.7572252143598,33.8047,0.884991545755488,0.95850134688858,0.110968672930146,0.713942232324427,0.571993816456939,0.141948415867487,9.67613723982612,15.9786,1.08108797453372,17.8261,0.830612392578121,0.763410118221192,0.899605313572611,0.868055560169896,0.0672022743569298,0.0315497534027147,True,0.86745510200284,0.0704104497686588,0.127561946758892,355.802950364596
266,17528,1011:1561,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.257963361991508,0.116130090377679,0.760683136214456,10.7572252143598,33.8047,0.884991545755488,0.95850134688858,0.0748900451564171,0.196228379228125,0.0584602512010561,0.137768128027069,7.13480573160788,2.7449,3.62241948275196,31.0598,0.228295394477147,0.123318951717915,0.247258229916767,0.199959743503092,0.104976442759233,0.047298486413675,True,0.86745510200284,0.0704104497686588,0.127561946758892,355.802950364596
267,17528,1011:1594,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.257963361991508,0.0599916168220963,0.802498491986469,11.1303533741797,17.513,0.955675092711933,0.966618383127966,0.026118050106907,0.207015208985945,0.0912644962410114,0.115750712744934,8.08459517386244,2.1208,3.04575820031724,15.3922,0.246529159887516,0.199961516323216,0.249352127874486,0.217333336882211,0.0465676435643,0.0320187909922748,True,0.86745510200284,0.0704104497686588,0.127561946758892,355.802950364596
268,16645,1372:1011,Breast,HCC70,SIDM00673,907048,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.744001400762549,0.0828015261585049,0.72346945964361,11.1754588663209,45.1729,0.90962386462042,0.927816649350247,0.0466411703377947,0.53826229138377,0.248419120092719,0.289843171291051,7.4378195248223,3.3864,3.73763934149862,41.7865,0.676761429444636,0.559595210258314,0.690296886767399,0.563384814422945,0.117166219186321,0.126912072344454,True,0.751636007345609,0.0754635152121225,0.270967850338608,177.028524620649
269,16647,1083:1049,Breast,HCC70,SIDM00673,907048,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.828588687777143,0.100963368682231,0.818039083035061,12.4000683942975,105.5656,0.915748603545482,0.955172806455881,0.0959013655712882,0.677817930362438,0.426279223253259,0.251538707109179,9.13090926106688,10.9498,3.26915913323058,94.6158,0.758778933745502,0.623925953486087,0.791445382301689,0.706133758714828,0.134852980259415,0.0853116235868604,True,0.751636007345609,0.0754635152121225,0.270967850338608,177.028524620649
270,16647,1058:1049,Breast,HCC70,SIDM00673,907048,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.865851973422593,0.100963368682231,0.818039083035061,12.4000683942975,105.5656,0.915748603545482,0.955172806455881,0.137103951168559,0.708300754382716,0.499991636692125,0.208309117690591,9.70651553806438,16.3186,2.69355285623308,89.247,0.79290273553884,0.638369361208783,0.827038259429421,0.760018384946935,0.154533374330057,0.0670198744824864,True,0.751636007345609,0.0754635152121225,0.270967850338608,177.028524620649
271,16941,1012:1372,Breast,HCC70,SIDM00673,907048,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.928677231315273,0.156540889374648,0.682745164356931,10.7336414064286,3.3257,0.785719123590034,0.914934427424871,0.152043359369293,0.634049888928885,0.651708171135266,-0.017658282206381,10.9355817588932,3.8253,-0.201940352464536,-0.4996,0.729679460287055,0.722764386390102,0.849678770895954,0.855349461624607,0.0069150738969535,-0.0056706907286534,True,0.784783808476337,0.0656455979200144,0.228492415126846,208.481482025778
272,16941,1561:1372,Breast,HCC70,SIDM00673,907048,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.881626815752567,0.156540889374648,0.682745164356931,10.7336414064286,3.3257,0.785719123590034,0.914934427424871,0.12153328724631,0.601926445222464,0.643173144916637,-0.0412466996941729,11.2444543800508,4.7386,-0.510812973622171,-1.4129,0.692711049006579,0.71686912271202,0.806630725872987,0.819624241338255,-0.0241580737054408,-0.0129935154652684,True,0.784783808476337,0.0656455979200144,0.228492415126846,208.481482025778
273,16941,1053:1372,Breast,HCC70,SIDM00673,907048,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.566456238603837,0.156540889374648,0.682745164356931,10.7336414064286,3.3257,0.785719123590034,0.914934427424871,0.111595415277239,0.386745257726586,0.247626997600231,0.139118260126355,8.4283174767202,0.6728,2.30532392970844,2.6529,0.445075499347914,0.365382849477739,0.518270314328248,0.462397731360476,0.0796926498701752,0.0558725829677721,True,0.784783808476337,0.0656455979200144,0.228492415126846,208.481482025778
274,16944,1011:1558,Breast,HCC70,SIDM00673,907048,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.912260782173776,0.0629756406174779,0.661178526609982,10.5122680295539,28.5258,0.906570152520666,0.907803058796562,0.178835056957342,0.603167239841728,0.376907167070643,0.226260072771084,8.20619605018401,5.7682,2.30607197936992,22.7576,0.827028396433903,0.789348597664519,0.828153128477499,0.733353170965268,0.0376797987693839,0.0947999575122305,True,0.784783808476337,0.0656455979200144,0.228492415126846,208.481482025778
275,14495,1011:1012,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.402196398524273,0.0681620489698752,0.733759290651926,11.6841544267692,32.1352,0.92356663813576,0.920225253672959,0.0666166081238648,0.29511534408393,0.153007136836384,0.142108207247546,7.70865735874897,2.0429,3.97549706802026,30.0923,0.371455175655373,0.312067176686007,0.370111282858349,0.303178283769126,0.0593879989693659,0.066932999089223,True,0.708189887369254,0.089418288813517,0.330370805894907,146.4465421407
276,14496,1011:1021,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.478475623569523,0.0575130063133407,0.829865024957508,13.1956841968146,183.2427,0.963441500650945,0.951862809847344,0.0553235649659142,0.397070185295082,0.134685950502599,0.262384234792483,6.51891101388432,1.7911,6.67677318293027,181.4516,0.460983272796719,0.294256631776385,0.455443151494346,0.325077518086746,0.166726641020333,0.130365633407601,True,0.708189887369254,0.089418288813517,0.330370805894907,146.4465421407
277,14638,1011:1049,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.634604092187199,0.0818888602304874,0.827574301217489,13.1529548095047,177.8951,0.918464660592083,0.951151070615146,0.0426084776513316,0.525182038141581,0.500448411350762,0.0247336267908189,12.4856657465545,112.0185,0.667289062950216,65.8766,0.582861432141063,0.569618001723858,0.603604361700607,0.595727375509437,0.0132434304172053,0.0078769861911702,True,0.426909348050011,0.0513172991523152,0.830347464497082,59.4624675532501
278,14638,1558:1049,Breast,HDQ-P1,SIDM01062,1290922,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.718403455088296,0.0818888602304874,0.827574301217489,13.1529548095047,177.8951,0.918464660592083,0.951151070615146,0.0557002561813371,0.594532237336926,0.488008422649211,0.106523814687715,10.9871743273251,39.646,2.16578048217959,138.2491,0.659828185545851,0.629329247182058,0.683310215440852,0.646894516471775,0.0304989383637931,0.0364156989690768,True,0.426909348050011,0.0513172991523152,0.830347464497082,59.4624675532501
279,14497,1372:1053,Breast,HDQ-P1,SIDM01062,1290922,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.872486265248851,0.0446997286085792,0.785532131531626,12.4372076759473,108.3185,0.941467488489994,0.937736631935568,0.0605788869132297,0.685365995672998,0.572785282872569,0.112580712800429,10.7149631696714,32.8288,1.72224450627586,75.4897,0.821417452885851,0.721554917845187,0.818162331784501,0.778021526430209,0.0998625350406633,0.0401408053542919,True,0.708189887369254,0.089418288813517,0.330370805894907,146.4465421407
280,14497,1549:1053,Breast,HDQ-P1,SIDM01062,1290922,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.7274334711629,0.0446997286085792,0.785532131531626,12.4372076759473,108.3185,0.941467488489994,0.937736631935568,0.0429666671964789,0.571422365150043,0.44010958049718,0.131312784652862,10.1290021293361,21.8707,2.30820554661124,86.4478,0.684854963139294,0.626226365845153,0.682141013205497,0.633509326762754,0.0586285972941408,0.0486316864427435,True,0.708189887369254,0.089418288813517,0.330370805894907,146.4465421407
281,14497,1011:1053,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.417746279361684,0.0446997286085792,0.785532131531626,12.4372076759473,108.3185,0.941467488489994,0.937736631935568,0.0430093545880664,0.32815312526639,0.189696765588341,0.138456359678049,8.51246897018087,7.1324,3.92473870576644,101.1861,0.393294540456683,0.298333983789161,0.39173598901224,0.33343208049307,0.0949605566675226,0.0583039085191702,True,0.708189887369254,0.089418288813517,0.330370805894907,146.4465421407
282,14497,1558:1053,Breast,HDQ-P1,SIDM01062,1290922,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.787993332654628,0.0446997286085792,0.785532131531626,12.4372076759473,108.3185,0.941467488489994,0.937736631935568,0.0438563887817173,0.6189940822329,0.325719552981897,0.293274529251003,8.07299662937077,5.2595,4.36421104657654,103.059,0.741870103841213,0.57189177887622,0.738930213751235,0.610345522901237,0.169978324964993,0.128584690849998,True,0.708189887369254,0.089418288813517,0.330370805894907,146.4465421407
283,14970,1549:1083,Breast,HDQ-P1,SIDM01062,1290922,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.448881587592194,0.128892517864098,0.59895030794983,10.0619622826869,20.8777,0.897146600471176,0.868314524077089,0.0706880441622075,0.268857765121353,0.139861818911679,0.128995946209674,6.90105955144686,2.3343,3.16090273124003,18.5434,0.402712590322441,0.336305625242254,0.389770402097084,0.316155820553826,0.0664069650801871,0.0736145815432578,True,0.351434956207464,0.0555390287068316,0.99773143132984,49.1756587478151
284,14970,1558:1083,Breast,HDQ-P1,SIDM01062,1290922,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.617602502673385,0.128892517864098,0.59895030794983,10.0619622826869,20.8777,0.897146600471176,0.868314524077089,0.134478163794726,0.36991320916681,0.166444007659745,0.203469201507065,6.35985106451236,1.6041,3.70211121817453,19.2736,0.554079985715918,0.450677486660564,0.536273223177659,0.413041189851027,0.103402499055354,0.123232033326633,True,0.351434956207464,0.0555390287068316,0.99773143132984,49.1756587478151
285,14970,1011:1083,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.264436318453093,0.128892517864098,0.59895030794983,10.0619622826869,20.8777,0.897146600471176,0.868314524077089,0.0517892694341045,0.158384214370599,0.0644837522438002,0.093900462126799,6.00372069385389,1.2532,4.058241588833,19.6245,0.237238144141305,0.157911946801697,0.229613896006295,0.170435171731821,0.0793261973396087,0.0591787242744735,True,0.351434956207464,0.0555390287068316,0.99773143132984,49.1756587478151
286,14771,1058:1372,Breast,HDQ-P1,SIDM01062,1290922,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.435226061455132,0.169119186911174,0.219463745637425,5.64065310649607,0.0974,0.551514105637392,0.619187984816202,0.111265790766834,0.0955163416459673,0.0566942926993392,0.0388220489466281,3.97306561291944,0.0307,1.66758749357663,0.0667,0.240033312033512,0.166796724520061,0.269486747931896,0.216748896929405,0.0732365875134509,0.0527378510024912,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
287,14771,1011:1372,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.528531954686299,0.169119186911174,0.219463745637425,5.64065310649607,0.0974,0.551514105637392,0.619187984816202,0.0696501235447474,0.115993602464525,0.0303847607851989,0.0856088416793259,1.59459054193386,0.0059,4.04606256456221,0.0915,0.291492828289597,0.128145173622052,0.327260635933178,0.173444178617352,0.163347654667545,0.153816457315826,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
288,14773,1549:1510,Breast,HDQ-P1,SIDM01062,1290922,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.50274044386651,0.0928409836065706,0.463679826900601,8.61466610616379,7.656,0.792126682452037,0.803430266129781,0.0934115856072016,0.233110601987955,0.0612776283237066,0.171832973664248,3.7717037240887,0.2668,4.84296238207509,7.3892,0.398234119934443,0.210136925152112,0.403916888609874,0.24291197220837,0.188097194782331,0.161004916401505,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
289,14773,1558:1510,Breast,HDQ-P1,SIDM01062,1290922,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.677140971770711,0.0928409836065706,0.463679826900601,8.61466610616379,7.656,0.792126682452037,0.803430266129781,0.0400902892569286,0.313976608577948,0.122545583918119,0.191431024659829,5.0026665386781,0.6262,3.61199956748569,7.0298,0.536381431521082,0.375234597133403,0.544035551157121,0.388347215801202,0.16114683438768,0.155688335355918,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
290,14773,1372:1510,Breast,HDQ-P1,SIDM01062,1290922,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.767255383361314,0.0928409836065706,0.463679826900601,8.61466610616379,7.656,0.792126682452037,0.803430266129781,0.133779455269938,0.355760843345528,0.165091098123595,0.190669745221933,5.5738292835074,0.9303,3.04083682265639,6.7257,0.607763461415464,0.424554338227445,0.616436196843487,0.471452964142789,0.183209123188018,0.144983232700698,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
291,14773,1011:1510,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.563455249444439,0.0928409836065706,0.463679826900601,8.61466610616379,7.656,0.792126682452037,0.803430266129781,0.0651775712975369,0.261262832528632,0.0955426505878123,0.16572018194082,4.79362504819668,0.5417,3.82104105796711,7.1143,0.446327937452609,0.304194606449359,0.452697001013368,0.314578787780931,0.14213333100325,0.138118213232437,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
292,14773,1083:1549,Breast,HDQ-P1,SIDM01062,1290922,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.970518879368068,0.127996991811922,0.243791749109282,6.00283227332928,0.6262,0.595829289949442,0.644461264776069,0.0778775403310712,0.236604495144722,0.0881259605259569,0.148478534618765,2.9001140976462,0.0729,3.10271817568308,0.5533,0.578263574776403,0.390457452279983,0.625461824486598,0.407085769787299,0.18780612249642,0.218376054699299,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
293,14773,1011:1549,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.563455249444439,0.127996991811922,0.243791749109282,6.00283227332928,0.6262,0.595829289949442,0.644461264776069,0.0449172658423607,0.137365740806867,0.0431983575894138,0.0941673832174529,2.4112221398567,0.0519,3.59161013347258,0.5743,0.335723141194766,0.19345699618628,0.363125082701679,0.216634798408878,0.142266145008485,0.1464902842928,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
294,14773,1510:1549,Breast,HDQ-P1,SIDM01062,1290922,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.444009160690545,0.127996991811922,0.243791749109282,6.00283227332928,0.6262,0.595829289949442,0.644461264776069,0.0624015267545714,0.108245769905292,0.063253213688375,0.0449925562169173,4.24740060415322,0.1855,1.75543166917606,0.4407,0.264553662945295,0.198894700579336,0.28614670527079,0.230099436122424,0.0656589623659591,0.0560472691483657,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
295,14774,1058:1558,Breast,HDQ-P1,SIDM01062,1290922,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.854687949046106,0.115874980070616,0.305272059098694,6.82277693599888,2.211,0.713408123523732,0.699287358937068,0.0697861020159335,0.260912350092145,0.0839758800734951,0.17693647001865,3.13068647226561,0.1711,3.69209046373327,2.0399,0.60974132592733,0.35439627675521,0.597672478603791,0.372797930784339,0.25534504917212,0.224874547819452,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
296,14774,1011:1558,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.57797527150629,0.115874980070616,0.305272059098694,6.82277693599888,2.211,0.713408123523732,0.699287358937068,0.0467427587227279,0.176439701240852,0.0549661292777726,0.12147357196308,3.03511477402903,0.1601,3.78766216196985,2.0509,0.412332253888422,0.224159828735938,0.404170801142569,0.24808503679514,0.188172425152484,0.156085764347428,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
297,14775,1011:1594,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.586369287572937,0.0804050064683791,0.441327998253213,8.37574800771505,2.595,0.784576976971107,0.790993423287597,0.0208531700731977,0.258781183921727,0.152679894927097,0.10610128899463,6.23587314960337,0.5888,2.13987485811168,2.0062,0.460051843032677,0.391749336629971,0.463814250088027,0.387243472206519,0.0683025064027054,0.0765707778815076,True,0.571767757671913,0.0869986500856014,0.535957339471168,90.8697484849991
298,14591,1058:1012,Breast,JIMT-1,SIDM01037,1298157,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.964952461190202,0.0738309792149694,0.523326836835715,9.19124130385939,5.7087,0.882008310796125,0.868784405868267,0.105522711159688,0.504985519211506,0.295745897276913,0.209239621934593,7.32754028900297,1.5686,1.86370101485642,4.1401,0.851096090292933,0.73617516546376,0.838335650686252,0.734597510747913,0.114920924829172,0.103738139938339,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
299,14591,1011:1012,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.820577338021919,0.0738309792149694,0.523326836835715,9.19124130385939,5.7087,0.882008310796125,0.868784405868267,0.0927048544145318,0.429430142686082,0.206229579248545,0.223200563437537,6.76435671227832,1.0616,2.42688459158107,4.6471,0.723756031786294,0.610763279827625,0.712904795082338,0.592231868140138,0.112992751958668,0.1206729269422,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
300,14591,1594:1012,Breast,JIMT-1,SIDM01037,1298157,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.900986701759338,0.0738309792149694,0.523326836835715,9.19124130385939,5.7087,0.882008310796125,0.868784405868267,0.10727581335305,0.471510520662758,0.253768728995192,0.217741791667566,7.08244936210217,1.3235,2.10879194175721,4.3852,0.794677758868526,0.701481621420205,0.782763196383197,0.670705950256236,0.093196137448321,0.11205724612696,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
301,14592,1011:1021,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.929950097187786,0.0572229533179177,0.889942166867612,13.2808304083267,194.383,0.967473887386375,0.976311272961972,0.0841989224210628,0.827601804570044,0.302783527802894,0.52481827676715,7.50858815192938,3.5566,5.77224225639728,190.8264,0.899702435601605,0.742926311948858,0.907920763176517,0.719195549064023,0.156776123652747,0.188725214112493,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
302,14592,1561:1021,Breast,JIMT-1,SIDM01037,1298157,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.852589568237815,0.0572229533179177,0.889942166867612,13.2808304083267,194.383,0.967473887386375,0.976311272961972,0.0335140423787034,0.758755407806283,0.611318848422401,0.147436559383882,10.9041135856337,37.4279,2.37671682269292,156.9551,0.82485814392811,0.799349154507232,0.832392806680359,0.795022452915796,0.0255089894208785,0.0373703537645639,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
303,14594,1549:1053,Breast,JIMT-1,SIDM01037,1298157,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.920998346790399,0.0748299892594506,0.77708733198599,11.5576072268454,58.873,0.921403011513098,0.948791178684808,0.0733179226573597,0.715696148070858,0.506364623263301,0.209331524807557,9.40933562943705,13.2807,2.14827159740837,45.5923,0.848610650331258,0.765187843885865,0.873835107018022,0.809326803092066,0.0834228064453932,0.0645083039259556,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
304,14594,1049:1053,Breast,JIMT-1,SIDM01037,1298157,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.937150506010011,0.0748299892594506,0.77708733198599,11.5576072268454,58.873,0.921403011513098,0.948791178684808,0.0667702848212189,0.728247786384639,0.671052461248841,0.0571953251357978,10.8944536130034,37.1781,0.663153613842034,21.6949,0.863493298478647,0.826102095283329,0.889160133202302,0.873619899043468,0.0373912031953183,0.015540234158834,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
305,14594,1558:1053,Breast,JIMT-1,SIDM01037,1298157,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.974636156881371,0.0748299892594506,0.77708733198599,11.5576072268454,58.873,0.921403011513098,0.948791178684808,0.0427964135933414,0.757377410808023,0.507083003834842,0.250294406973181,9.16622694569547,11.2212,2.39138028114995,47.6518,0.898032690080047,0.823574029081875,0.924726188076307,0.845599668777103,0.0744586609981724,0.0791265192992047,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
306,14594,1372:1053,Breast,JIMT-1,SIDM01037,1298157,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.960568576230317,0.0748299892594506,0.77708733198599,11.5576072268454,58.873,0.921403011513098,0.948791178684808,0.072123050845938,0.746445672092398,0.46209199363192,0.284353678460477,8.84476938056062,8.9799,2.71283784628479,49.8931,0.885070778903463,0.774976348142194,0.91137899164915,0.818208001862523,0.110094430761268,0.0931709897866275,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
307,14594,1510:1053,Breast,JIMT-1,SIDM01037,1298157,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.940634521939279,0.0748299892594506,0.77708733198599,11.5576072268454,58.873,0.921403011513098,0.948791178684808,0.0566182150065747,0.730955171027711,0.523606483750837,0.207348687276874,9.46612010900321,13.8139,2.0914871178422,45.0591,0.866703481248035,0.785443069306931,0.892465736782389,0.828935958260594,0.0812604119411042,0.0635297785217959,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
308,14594,1011:1053,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.802848571480764,0.0748299892594506,0.77708733198599,11.5576072268454,58.873,0.921403011513098,0.948791178684808,0.0568268975252476,0.62388345440075,0.314965808230211,0.308917646170539,8.10373023675623,5.3727,3.45387699008918,53.5003,0.739747091551365,0.616696069745351,0.761735642440649,0.650908770421664,0.123051021806014,0.110826872018985,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
309,14594,1594:1053,Breast,JIMT-1,SIDM01037,1298157,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.996093876730846,0.0748299892594506,0.77708733198599,11.5576072268454,58.873,0.921403011513098,0.948791178684808,0.0215795730940313,0.774051933076355,0.549780035220754,0.2242718978556,9.4270197254959,13.4445,2.13058750134951,45.4285,0.917803897769559,0.872393223667385,0.94508508338418,0.876097290880271,0.0454106741021736,0.0689877925039089,True,0.505648476069936,0.0582043536125789,0.661021359282736,74.3055738857419
310,14944,1558:1083,Breast,JIMT-1,SIDM01037,1298157,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.857401308419076,0.062211655822021,0.661770152011441,10.374667383811,25.9308,0.915010489161561,0.916238649046991,0.0433097801496992,0.5674025942073,0.377230189542044,0.190172404665257,8.50582097597382,7.0997,1.86884640783721,18.8311,0.784531190624301,0.702271537604008,0.785584216517017,0.714907109971488,0.0822596530202926,0.0706771065455291,True,0.44752476350186,0.0619279773970352,0.778495579017442,63.1728640303715
311,14944,1011:1083,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.279209907038354,0.062211655822021,0.661770152011441,10.374667383811,25.9308,0.915010489161561,0.916238649046991,0.0501554369114187,0.184772782623872,0.0596070124170667,0.125165770206805,6.3291842326445,1.5704,4.04548315116654,24.3604,0.255479993617918,0.167005737709812,0.255822908025358,0.192480066041414,0.0884742559081063,0.0633428419839432,True,0.44752476350186,0.0619279773970352,0.778495579017442,63.1728640303715
312,14946,1011:1372,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.317817346817383,0.171951456165201,0.530561530457373,9.25068438270967,1.1898,0.736107549756122,0.87155622550281,0.0811587210282936,0.168621657933332,0.0215454897267932,0.147076168206539,3.63171118316619,0.0242,5.61897319954347,1.1656,0.233947748435735,0.0898045318624683,0.276995687191475,0.149086220186113,0.144143216573267,0.127909467005363,True,0.44752476350186,0.0619279773970352,0.778495579017442,63.1728640303715
313,14946,1053:1372,Breast,JIMT-1,SIDM01037,1298157,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.912459773684126,0.171951456165201,0.530561530457373,9.25068438270967,1.1898,0.736107549756122,0.87155622550281,0.15025033555894,0.484116054006638,0.350373670501849,0.133742383504789,8.03195718210945,0.5112,1.21872720060021,0.6786,0.671668528257647,0.618360723438533,0.795259996275285,0.735846215636797,0.0533078048191137,0.0594137806384873,True,0.44752476350186,0.0619279773970352,0.778495579017442,63.1728640303715
314,14948,1011:1549,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.278108121174532,0.0928030119923708,0.49434618212687,8.95367976200317,4.842,0.800138057658645,0.857288954068634,0.0457244898543638,0.137481687921107,0.0966175490900325,0.0408641388310744,7.70879110328619,2.043,1.24488865871698,2.799,0.222524891895685,0.177517301034295,0.238419020319708,0.218693024340611,0.0450075908613906,0.0197259959790969,True,0.44752476350186,0.0619279773970352,0.778495579017442,63.1728640303715
315,14949,1011:1558,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.268091134352426,0.126119834090239,0.360913911605216,7.82971811704992,4.4433,0.813687469137553,0.794005018581217,0.0544620750501582,0.0967578199658135,0.0268102807146569,0.0699475392511566,4.4999705969477,0.4419,3.32974752010222,4.0014,0.218142396609441,0.104047236105383,0.212865706112957,0.145286170087361,0.114095160504058,0.0675795360255959,True,0.44752476350186,0.0619279773970352,0.778495579017442,63.1728640303715
316,14520,1510:1021,Breast,MDA-MB-157,SIDM00529,925338,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.879153097637823,0.0737705509230625,0.639659346201638,10.1723680058733,22.5381,0.89757974741936,0.909580431403529,0.0585898122235378,0.562358495646154,0.538310113897241,0.0240483817489137,9.93361291172717,19.1005,0.238755094146086,3.4376,0.789110015320705,0.818038115132209,0.79966045381916,0.791904591433601,-0.0289280998115037,0.007755862385559,True,0.88269461541052,0.0932134688289197,0.112250489232927,404.708980486918
317,14972,1372:1083,Breast,MDA-MB-157,SIDM00529,925338,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.909494962683179,0.0443474913710911,0.776232558445605,11.540999647674,58.1992,0.949480859956192,0.948693955922479,0.0367451628599985,0.705979601776954,0.575806009667499,0.130173592109456,10.1145052835187,21.6521,1.42649436415532,36.5471,0.86354805929425,0.845687820434241,0.862832374039473,0.825367679223975,0.0178602388600089,0.0374646948154976,True,0.635112423093796,0.0628373315311006,0.431274880766871,111.964055716369
318,14972,1594:1083,Breast,MDA-MB-157,SIDM00529,925338,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.931533065741698,0.0443474913710911,0.776232558445605,11.540999647674,58.1992,0.949480859956192,0.948693955922479,0.0729963397827556,0.723086294897356,0.606439121779689,0.116647173117667,10.2737024521682,24.1781,1.26729719550575,34.0211,0.884472816338055,0.88536499830343,0.883739789211086,0.850613359614305,-0.0008921819653747,0.0331264295967807,True,0.635112423093796,0.0628373315311006,0.431274880766871,111.964055716369
319,14973,1049:1558,Breast,MDA-MB-157,SIDM00529,925338,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.959641487337631,0.0752853326122851,0.769163767689821,11.4587756803945,54.975,0.92745349599807,0.946843155743309,0.0446762567750853,0.738121462032075,0.64498196976419,0.0931394922678849,10.4662236418662,27.6298,0.992552038528354,27.3452,0.890022852336073,0.850349754537615,0.908629974252965,0.882461364773909,0.039673097798459,0.026168609479056,True,0.635112423093796,0.0628373315311006,0.431274880766871,111.964055716369
320,16659,1021:1011,Breast,MDA-MB-175-VII,SIDM00633,908120,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.841043624429815,0.119567720704606,0.613719280904812,10.2832354745639,24.3384,0.887316882844365,0.869368950243233,0.0963834408049411,0.516164688394643,0.460165969915057,0.0559987184795859,9.52415856635236,14.3809,0.759076908211584,9.9575,0.74627220716519,0.747417818943144,0.731177212879312,0.705635521577916,-0.0011456117779532,0.0255416913013962,True,,,,
321,16659,1549:1011,Breast,MDA-MB-175-VII,SIDM00633,908120,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.210348703561651,0.119567720704606,0.613719280904812,10.2832354745639,24.3384,0.887316882844365,0.869368950243233,0.063674213322042,0.129095055089116,0.0600269406685832,0.069068114420533,6.45559734472974,1.7142,3.8276381298342,22.6242,0.186645955954678,0.0930962214223668,0.182870631600418,0.14106799300134,0.093549734532311,0.041802638599078,True,,,,
322,16659,1558:1011,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.284401402683202,0.119567720704606,0.613719280904812,10.2832354745639,24.3384,0.887316882844365,0.869368950243233,0.0553740698429556,0.174542624343055,0.0689644867979333,0.105578137545121,5.8427911542333,1.1209,4.44044432033064,23.2175,0.252354166105424,0.15693884007687,0.247249748898399,0.179125996013197,0.0954153260285539,0.0681237528852016,True,,,,
323,16659,1561:1011,Breast,MDA-MB-175-VII,SIDM00633,908120,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.710823458305557,0.119567720704606,0.613719280904812,10.2832354745639,24.3384,0.887316882844365,0.869368950243233,0.0737018293859737,0.436246061681558,0.372021411840456,0.0642246498411028,9.25925460892008,11.9686,1.02398086564386,12.3698,0.630725655276339,0.60178722734557,0.617967843755367,0.588063024116323,0.0289384279307691,0.0299048196390442,True,,,,
324,16659,1372:1011,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.764443526709663,0.119567720704606,0.613719280904812,10.2832354745639,24.3384,0.887316882844365,0.869368950243233,0.0905238548269117,0.469153731504593,0.324366330481819,0.144787401022775,8.15441089001009,5.5648,2.12882458455385,18.7736,0.678303647230572,0.617837174564968,0.664583466335815,0.590455016273068,0.0604664726656036,0.0741284500627474,True,,,,
325,16659,1510:1011,Breast,MDA-MB-175-VII,SIDM00633,908120,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.912287965827525,0.119567720704606,0.613719280904812,10.2832354745639,24.3384,0.887316882844365,0.869368950243233,0.123859127123348,0.559888714365783,0.391132935940082,0.1687557784257,8.20451418610797,5.7615,2.07872128845597,18.5769,0.809488514094507,0.756691509313132,0.793114831171011,0.707110354446597,0.0527970047813744,0.0860044767244134,True,,,,
326,16659,1053:1011,Breast,MDA-MB-175-VII,SIDM00633,908120,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.523562940344108,0.119567720704606,0.613719280904812,10.2832354745639,24.3384,0.887316882844365,0.869368950243233,0.0659466713795102,0.321320671256395,0.178299957990808,0.143020713265587,7.16833446304261,2.8094,3.11490101152133,21.529,0.464566236198964,0.354764381981431,0.455169363833218,0.374668830680915,0.109801854217533,0.0805005331523024,True,,,,
327,14642,1011:1021,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.912412069444896,0.0707767133630781,0.723507227729146,11.6661957879411,63.4753,0.898918441398167,0.913151303557714,0.0965338718845077,0.66013672691069,0.331691142764145,0.328445584146545,7.44764980912769,3.4095,4.21854597881344,60.0658,0.820184035378282,0.693114109481691,0.833170270595399,0.668237243854172,0.127069925896592,0.164933026741227,True,0.598112586962495,0.093053735965983,0.491764104536414,98.803679052796
328,14952,1549:1083,Breast,MDA-MB-175-VII,SIDM00633,908120,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.209389118972983,0.0521307976142084,0.867285593859416,14.202999378525,368.3485,0.962849266848194,0.961681675471606,0.0503900824632502,0.181600166396184,0.0933139035303874,0.0882862628657962,8.39501717868746,6.5748,5.80798219983754,361.7737,0.201610159689126,0.13209684904146,0.201365678759462,0.164407070827129,0.0695133106476663,0.0369586079323334,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
329,14952,1558:1083,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.268695386572927,0.0521307976142084,0.867285593859416,14.202999378525,368.3485,0.962849266848194,0.961681675471606,0.0593490667147374,0.233035637911186,0.100386656907854,0.132648981003333,7.56765282164416,3.7053,6.63534655688084,364.6432,0.258713155967235,0.17931142572003,0.258399429550943,0.198681470476356,0.0794017302472047,0.0597179590745875,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
330,14954,1058:1372,Breast,MDA-MB-175-VII,SIDM00633,908120,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.836068655596064,0.13222419925216,0.240768891375697,5.81675837276362,0.1101,0.583495212475629,0.628065019599045,0.059994898396013,0.201299323321834,0.118534436618618,0.0827648867032159,4.00918106882616,0.0314,1.80757730393746,0.0787,0.487842057841239,0.38997484591462,0.525105476563089,0.418584891386958,0.0978672119266192,0.106520585176131,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
331,14954,1011:1372,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.921252102170758,0.13222419925216,0.240768891375697,5.81675837276362,0.1101,0.583495212475629,0.628065019599045,0.066293428668204,0.221808847317184,0.0715431070016692,0.150265740315514,2.14110183564385,0.0086,3.67565653711977,0.1015,0.537546191099746,0.308873873075939,0.578606219605538,0.34000745603792,0.228672318023807,0.238598763567618,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
332,14954,1561:1372,Breast,MDA-MB-175-VII,SIDM00633,908120,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.694051036664958,0.13222419925216,0.240768891375697,5.81675837276362,0.1101,0.583495212475629,0.628065019599045,0.0681401492552484,0.167105898655975,0.0781053002470387,0.0890005984089365,3.27610410559322,0.0189,2.5406542671704,0.0912,0.40497545710775,0.276512262063056,0.435909177945714,0.311088536303798,0.128463195044695,0.124820641641916,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
333,14954,1053:1372,Breast,MDA-MB-175-VII,SIDM00633,908120,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.684258989651618,0.13222419925216,0.240768891375697,5.81675837276362,0.1101,0.583495212475629,0.628065019599045,0.0614391689902217,0.164748278352275,0.059538750799971,0.105209527552304,2.4845665076649,0.0109,3.33219186509872,0.0992,0.39926184455513,0.234550027512281,0.429759135746366,0.268647374913627,0.164711817042849,0.16111176083274,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
334,14956,1549:1510,Breast,MDA-MB-175-VII,SIDM00633,908120,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.23261796354563,0.0923278533244352,0.850055533751523,13.8090478738843,280.3288,0.935999531956903,0.9562945806539,0.0745453112171972,0.197738187161973,0.0243471845279301,0.173391002634043,3.05070204071213,0.1618,10.7583458331721,280.167,0.217730305003477,0.0296777420157333,0.222451297901432,0.100545299526642,0.188052562987744,0.12190599837479,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
335,14956,1558:1510,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.279232879082326,0.0923278533244352,0.850055533751523,13.8090478738843,280.3288,0.935999531956903,0.9562945806539,0.0632875839570644,0.237363454069301,0.0295334471175326,0.207830006951769,3.08309891851914,0.1655,10.7259489553651,280.1633,0.261361844128036,0.062185512061061,0.267028889006814,0.121333790758986,0.199176332066975,0.145695098247829,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
336,14956,1372:1510,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.720421187228267,0.0923278533244352,0.850055533751523,13.8090478738843,280.3288,0.935999531956903,0.9562945806539,0.0531753848531669,0.61239801683523,0.53273482148818,0.0796631953470501,11.891608203394,74.2097,1.9174396704903,206.1191,0.674313894057494,0.688015515886468,0.68893487713464,0.662053094440574,-0.0137016218289744,0.0268817826940655,True,0.492633513852012,0.0797582499680435,0.680783591662838,71.8826484127235
337,15960,1372:1561,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.76871915454381,0.118140051269836,0.204634923967386,5.23717645404359,0.7367,0.554586014142615,0.588024815368812,0.0876926788006665,0.157306785742346,0.0718023587227521,0.085504427019594,2.70056124131937,0.127,2.53661521272422,0.6097,0.426320891913532,0.285316658484277,0.452025938921094,0.313346847580676,0.141004233429255,0.138679091340417,True,0.606724998772362,0.0809637616729586,0.484316154961979,101.093913374266
338,15960,1011:1561,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.952298217961637,0.118140051269836,0.204634923967386,5.23717645404359,0.7367,0.554586014142615,0.588024815368812,0.106639250817481,0.194873473426857,0.0685323840431292,0.126341089383728,1.91301096325847,0.0736,3.32416549078512,0.6631,0.528131272974459,0.297524784027975,0.559974983792941,0.336826220680512,0.230606488946484,0.223148763112429,True,0.606724998772362,0.0809637616729586,0.484316154961979,101.093913374266
339,15960,1011:1594,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.952298217961637,0.0900233471330413,0.458314815073671,8.53676494992871,2.9014,0.772069326373995,0.792491809247465,0.126115537628286,0.436452381660074,0.210182843957661,0.226269537702413,5.5033919753765,0.3544,3.03337297455221,2.547,0.735240243648798,0.596368569287615,0.754688537695555,0.577622569255343,0.138871674361182,0.177065968440212,True,0.606724998772362,0.0809637616729586,0.484316154961979,101.093913374266
340,16349,1011:1012,Breast,MDA-MB-330,SIDM00631,1330941,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.110091064985896,0.08843951306571,0.570811823587083,9.73989755058139,8.3503,0.86888227803997,0.85862163618144,0.0369383224352804,0.0628412815652435,0.0267538633279932,0.0360874182372503,6.05193099090029,0.6479,3.6879665596811,7.7024,0.0956561753367919,0.0830555554249425,0.0945265703471473,0.0715087358866535,0.0126006199118494,0.0230178344604938,True,1.2687345046887,0.126619903169921,-0.246402683295768,-211.666710732691
341,16352,1510:1053,Breast,MDA-MB-330,SIDM00631,1330941,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.943595191796218,0.0873240448330276,0.532355225730595,9.33627021810267,12.6249,0.81467515463419,0.84120846683648,0.0637041739875055,0.50232783132698,0.27068878964351,0.23163904168347,6.63722853071976,1.9442,2.69904168738291,10.6807,0.768723558788662,0.63077499534742,0.793760264605171,0.650440798081612,0.137948563441243,0.143319466523559,True,1.2687345046887,0.126619903169921,-0.246402683295768,-211.666710732691
342,16352,1594:1053,Breast,MDA-MB-330,SIDM00631,1330941,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.862520716805121,0.0873240448330276,0.532355225730595,9.33627021810267,12.6249,0.81467515463419,0.84120846683648,0.0508050324424562,0.459167410892105,0.162806293576253,0.296361117315852,5.21673013586655,0.7263,4.11954008223612,11.8986,0.702674198338404,0.496143853391694,0.725559729798337,0.508899376992179,0.206530344946709,0.216660352806158,True,1.2687345046887,0.126619903169921,-0.246402683295768,-211.666710732691
343,16353,1510:1058,Breast,MDA-MB-330,SIDM00631,1330941,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.921342058000037,0.082941474073318,0.44188435414427,8.3941054875114,2.6283,0.79003339720849,0.794947869896303,0.0509440359106369,0.407126640245298,0.214743408248222,0.192383231997077,5.90973760119886,0.4697,2.48436788631253,2.1586,0.727890996072831,0.591032659986354,0.732418906453005,0.589299977800966,0.136858336086477,0.14311892865204,True,1.2687345046887,0.126619903169921,-0.246402683295768,-211.666710732691
344,17410,1549:1083,Breast,MDA-MB-330,SIDM00631,1330941,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.773941174326045,0.0884540340270005,0.882558296736826,14.2330795946841,376.1092,0.947097468531858,0.968315763561602,0.0861254365905093,0.683048204587693,0.474738650026258,0.208309554561435,10.1977981882757,22.9389,4.03528140640837,353.1703,0.732997726996771,0.654028660821583,0.749419439169287,0.678463549727674,0.0789690661751876,0.0709558894416128,True,0.866011726594057,0.0829583284765429,0.12999515883458,351.428580224315
345,17410,1558:1083,Breast,MDA-MB-330,SIDM00631,1330941,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.540713905129216,0.0884540340270005,0.882558296736826,14.2330795946841,376.1092,0.947097468531858,0.968315763561602,0.0403809921955633,0.477211543132759,0.223731206215699,0.25348033691706,8.09602354777814,5.3441,6.13705604690592,370.7651,0.512108770747856,0.404716465740502,0.523581797913573,0.421061186119648,0.107392305007354,0.102520611793925,True,0.866011726594057,0.0829583284765429,0.12999515883458,351.428580224315
346,17414,1549:1510,Breast,MDA-MB-330,SIDM00631,1330941,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.586139916672875,0.0604601144420831,0.823480860020199,12.9960296708747,159.5603,0.941192101686368,0.950784276009073,0.0615341339556702,0.482675002673947,0.286833647397805,0.195841355276142,8.88955941456995,9.2631,4.10647025630477,150.2972,0.551670260055616,0.443714879417365,0.557292616313838,0.480780061867929,0.107955380638251,0.0765125544459086,True,0.866011726594057,0.0829583284765429,0.12999515883458,351.428580224315
347,17414,1558:1510,Breast,MDA-MB-330,SIDM00631,1330941,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.713607151116501,0.0604601144420831,0.823480860020199,12.9960296708747,159.5603,0.941192101686368,0.950784276009073,0.122733739978501,0.58764183051798,0.207258881588602,0.380382948929378,6.68232435835746,2.0059,6.31370531251727,157.5544,0.671641414337761,0.418595174267939,0.678486458529199,0.494034451853912,0.253046240069822,0.184452006675287,True,0.866011726594057,0.0829583284765429,0.12999515883458,351.428580224315
348,17414,1561:1510,Breast,MDA-MB-330,SIDM00631,1330941,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.701112945406877,0.0604601144420831,0.823480860020199,12.9960296708747,159.5603,0.941192101686368,0.950784276009073,0.0806842560685258,0.577353091254949,0.432705864916667,0.144647226338283,10.2390779802383,23.6048,2.75695169063642,135.9555,0.659881966607018,0.584708853743642,0.666607164199266,0.615695386501455,0.0751731128633766,0.0509117776978112,True,0.866011726594057,0.0829583284765429,0.12999515883458,351.428580224315
349,17414,1053:1510,Breast,MDA-MB-330,SIDM00631,1330941,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.694164834730167,0.0604601144420831,0.823480860020199,12.9960296708747,159.5603,0.941192101686368,0.950784276009073,0.0838746252438912,0.571631455099377,0.388136505698724,0.183494949400653,9.6166919261756,15.3336,3.37933774469913,144.2267,0.653342459716457,0.552410983416839,0.66000100981988,0.592441786797492,0.100931476299617,0.0675592230223885,True,0.866011726594057,0.0829583284765429,0.12999515883458,351.428580224315
350,17415,1510:1558,Breast,MDA-MB-330,SIDM00631,1330941,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.922612471179166,0.106557222492178,0.352829316874069,7.42602637217017,3.3588,0.682658527952897,0.739593048873157,0.0736337521315205,0.325524727945642,0.100955540884068,0.224569187061573,3.5599722768393,0.2304,3.86605409533088,3.1284,0.629829271446154,0.416255283593598,0.682357770487797,0.43105895782228,0.213573987852555,0.251298812665517,True,0.866011726594057,0.0829583284765429,0.12999515883458,351.428580224315
351,14507,1058:1012,Breast,MDA-MB-361,SIDM00528,908121,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.813931320857027,0.0956659354912788,0.478818093070644,8.77236261313141,4.2702,0.83455355206835,0.80922236869248,0.138380465409212,0.389725042943232,0.253732441418002,0.135992601525231,6.87337929132206,1.145,1.89898332180935,3.1252,0.679269274960915,0.57081467827791,0.658651431416922,0.570536916378048,0.108454596683005,0.0881145150388735,True,0.722925912554769,0.0808144967118259,0.305675402240378,156.308743573886
352,14508,1558:1021,Breast,MDA-MB-361,SIDM00528,908121,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.767351168977369,0.0423110623301303,0.882323258353724,14.4094243491736,425.0098,0.9698980956263,0.967246325844199,0.0735543549899464,0.677051783713651,0.580305020995805,0.0967467627178455,12.0400526695748,82.2521,2.36937167959876,342.7577,0.744252437467765,0.697363882379432,0.742217598825611,0.711381719551485,0.0468885550883331,0.0308358792741256,True,0.722925912554769,0.0808144967118259,0.305675402240378,156.308743573886
353,14508,1561:1021,Breast,MDA-MB-361,SIDM00528,908121,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.506453372794591,0.0423110623301303,0.882323258353724,14.4094243491736,425.0098,0.9698980956263,0.967246325844199,0.0437705143998322,0.446855590088357,0.312109922369525,0.134745667718832,10.2720026987529,24.1497,4.1374216504207,400.8601,0.49120816179699,0.422770580003505,0.48986516404697,0.442653213728525,0.068437581793485,0.0472119503184454,True,0.722925912554769,0.0808144967118259,0.305675402240378,156.308743573886
354,14508,1011:1021,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.932230233932012,0.0423110623301303,0.882323258353724,14.4094243491736,425.0098,0.9698980956263,0.967246325844199,0.0998902293318013,0.822528417538748,0.369189617862605,0.453338799676143,7.86678171133053,4.559,6.54264263784304,420.4508,0.904168328575919,0.722244249160081,0.901696268611617,0.709420124449539,0.181924079415838,0.192276144162078,True,0.722925912554769,0.0808144967118259,0.305675402240378,156.308743573886
355,14745,1549:1083,Breast,MDA-MB-361,SIDM00528,908121,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.795669103263514,0.0823004870697446,0.652351172095563,10.6899680316842,32.265,0.872157024716238,0.888731396937288,0.0585153343600406,0.519055672114179,0.300467538702513,0.218588133411666,7.65846245434237,3.946,3.03150557734182,28.319,0.693948397760944,0.611197423198456,0.707136113643222,0.595945069472986,0.0827509745624877,0.111191044170236,True,0.813827197542428,0.069538610118369,0.19218275946973,245.304040617928
356,14745,1011:1083,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.876051481117895,0.0823004870697446,0.652351172095563,10.6899680316842,32.265,0.872157024716238,0.888731396937288,0.119350428782112,0.571493210523313,0.310015131644308,0.261478078879004,7.38347712736246,3.2612,3.30649090432173,29.0038,0.764054453270037,0.677513400464351,0.778574456602887,0.641838206504088,0.0865410528056864,0.136736250098799,True,0.813827197542428,0.069538610118369,0.19218275946973,245.304040617928
357,14750,1561:1558,Breast,MDA-MB-361,SIDM00528,908121,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.456220879033995,0.10017241201178,0.576612894986961,9.82938140318287,17.7692,0.790667818100688,0.856879177534946,0.0503119517080667,0.263062841813288,0.143780765628715,0.119282076184573,6.91604103322511,2.3587,2.91334036995777,15.4105,0.360719166997787,0.291456032396464,0.39092617160092,0.321033160817961,0.0692631346013228,0.0698930107829586,True,0.813827197542428,0.069538610118369,0.19218275946973,245.304040617928
358,14750,1510:1558,Breast,MDA-MB-361,SIDM00528,908121,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.904354092770866,0.10017241201178,0.576612894986961,9.82938140318287,17.7692,0.790667818100688,0.856879177534946,0.0764287550603718,0.521462231525916,0.270224717115477,0.251237514410438,6.70962230374449,2.0442,3.11975909943839,15.725,0.715043677321568,0.578457187465636,0.774922191213862,0.624402310733833,0.136586489855932,0.150519880480029,True,0.813827197542428,0.069538610118369,0.19218275946973,245.304040617928
359,14750,1012:1558,Breast,MDA-MB-361,SIDM00528,908121,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.53918519911993,0.10017241201178,0.576612894986961,9.82938140318287,17.7692,0.790667818100688,0.856879177534946,0.0596502821583691,0.310901138598664,0.151434352996902,0.159466785601762,6.47545129226967,1.7379,3.3539301109132,16.0313,0.42631638494034,0.326162634830016,0.462016569960902,0.36401299805528,0.100153750110324,0.0980035719056214,True,0.813827197542428,0.069538610118369,0.19218275946973,245.304040617928
360,14750,1011:1558,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.874661635617935,0.10017241201178,0.576612894986961,9.82938140318287,17.7692,0.790667818100688,0.856879177534946,0.0647249707431547,0.504341177847687,0.184131032771209,0.320210145076478,5.45081662222016,0.8543,4.37856478096272,16.9149,0.691566807010412,0.502062948089138,0.749479342949667,0.529059907877061,0.189503858921274,0.220419435072606,True,0.813827197542428,0.069538610118369,0.19218275946973,245.304040617928
361,14750,1053:1558,Breast,MDA-MB-361,SIDM00528,908121,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.559801956983443,0.10017241201178,0.576612894986961,9.82938140318287,17.7692,0.790667818100688,0.856879177534946,0.0444219532329377,0.322789027035589,0.156346157677086,0.166442869358503,6.45455147080223,1.7129,3.37482993238064,16.0563,0.442617391896594,0.350586758781388,0.479682640482426,0.37715775309663,0.0920306331152057,0.102524887385796,True,0.813827197542428,0.069538610118369,0.19218275946973,245.304040617928
362,14751,1011:1594,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.870344814442934,0.0742870611759776,0.424849557370943,8.18669616313041,2.2763,0.760873120623782,0.778782322238526,0.119067338319581,0.369765609176176,0.155106888344323,0.214658720831853,4.89584082693934,0.2326,3.29085533619107,2.0437,0.662221974983922,0.514102598479236,0.677809155740127,0.491929319722752,0.148119376504686,0.185879836017376,True,0.813827197542428,0.069538610118369,0.19218275946973,245.304040617928
363,17269,1011:1012,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.522458556691706,0.0677810588327861,0.704656728023604,10.6502706990504,15.6946,0.929966127591671,0.933977703788555,0.0211732612252755,0.368153937086312,0.132623784353105,0.235530152733207,6.95378444943874,1.2106,3.69648624961166,14.484,0.48586876079372,0.381346537736596,0.487964643103602,0.388007284445114,0.104522223057124,0.0999573586584882,True,0.500087383377548,0.0606704736940203,0.66984436935954,73.2329577461578
364,17271,1058:1049,Breast,MDA-MB-415,SIDM00630,924240,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.932769150961873,0.0900997437487324,0.81486041688485,11.8123560277722,70.2431,0.901334753568143,0.961366647141427,0.0559204643378281,0.760076659210119,0.537346270561852,0.222730388648266,9.58202908489394,14.9695,2.23032694287824,55.2736,0.840737252818185,0.792595509999533,0.896733151217171,0.835808938035126,0.048141742818652,0.0609242131820448,True,0.500087383377548,0.0606704736940203,0.66984436935954,73.2329577461578
365,17738,1012:1372,Breast,MDA-MB-415,SIDM00630,924240,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.962641938911368,0.0772574781738433,0.789772798775481,11.5118394733251,5.7035,0.917186888895812,0.955469984185195,0.109278724200934,0.760268418312687,0.779960504529611,-0.0196920862169242,11.7546491072031,6.7489,-0.242809633878039,-1.0454,0.88292256507075,0.830051324116642,0.919775478147651,0.924417148079857,0.0528712409541074,-0.0046416699322058,True,0.844201963167864,0.0760324142463055,0.153488688192871,299.008832805555
366,17740,1594:1549,Breast,MDA-MB-415,SIDM00630,924240,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.720359754984847,0.121698546910544,0.867127660544737,12.5598798526062,58.9659,0.922101267042331,0.973092934708459,0.184835066361914,0.62464386909059,0.228072429190668,0.396571439899922,7.53983748966798,1.8173,5.02004236293822,57.1486,0.66424464279783,0.423237157587376,0.700976988024071,0.564642334909162,0.241007485210454,0.136334653114909,True,0.844201963167864,0.0760324142463055,0.153488688192871,299.008832805555
367,17740,1058:1549,Breast,MDA-MB-415,SIDM00630,924240,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.723589892497686,0.121698546910544,0.867127660544737,12.5598798526062,58.9659,0.922101267042331,0.973092934708459,0.0990031414601622,0.627444810675336,0.414341062387866,0.213103748287471,9.55518722196508,7.3468,3.00469263064111,51.6191,0.66722315669114,0.557279522072924,0.704120212015952,0.647554266415007,0.109943634618216,0.0565659456009444,True,0.844201963167864,0.0760324142463055,0.153488688192871,299.008832805555
368,17740,1561:1549,Breast,MDA-MB-415,SIDM00630,924240,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.898298907313774,0.121698546910544,0.867127660544737,12.5598798526062,58.9659,0.922101267042331,0.973092934708459,0.185846996941792,0.778939829968886,0.471382107282392,0.307557722686494,9.18803336282772,5.696,3.37184648977848,53.2699,0.828322560616772,0.617010370709111,0.874128319963362,0.789161325560615,0.211312189907661,0.0849669944027471,True,0.844201963167864,0.0760324142463055,0.153488688192871,299.008832805555
369,16363,1594:1011,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.495712052816788,0.166529706275853,0.378208639554911,8.23358847985799,5.8788,0.894735267593244,0.850496004334105,0.0399042942375928,0.187482581106809,0.0091231537874111,0.178359427319398,2.86973262756554,0.1428,5.36385585229246,5.736,0.443531056226225,0.166863623422616,0.421601120220935,0.196377369296126,0.276667432803609,0.225223750924809,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
370,16364,1011:1021,Breast,MRK-nu-1,SIDM00562,908151,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.948031050538318,0.0875901315399937,0.534171954949906,9.2110446924178,11.5753,0.880837678601871,0.903541591059972,0.104312381906643,0.506411599619267,0.153633075063872,0.352778524555395,6.46715136547853,1.728,2.74389332693927,9.8473,0.835061469798665,0.690158130305145,0.856585483777649,0.683216645667252,0.14490333949352,0.173368838110398,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
371,16366,1594:1053,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.579667164944133,0.0161705250660063,0.959610557948424,13.883673635295,295.2108,0.998739286891231,0.993654282499855,0.075456806015299,0.55625473157642,0.379982859616691,0.176271871959729,9.99183712118182,19.8872,3.89183651411323,275.3236,0.578936370950564,0.484920798555787,0.575988760871287,0.541999221851266,0.094015572394777,0.0339895390200214,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
372,16367,1083:1058,Breast,MRK-nu-1,SIDM00562,908151,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.702912702025381,0.0488426627334458,0.595890452114295,9.59870610353989,6.0574,0.924045168018047,0.920351637757446,0.0630198916161643,0.418858967806785,0.517769057887549,-0.0989100900807638,10.5853603978182,12.0033,-0.986654294278345,-5.9459,0.649523085845063,0.624537665215177,0.646926856509572,0.66984573322093,0.0249854206298863,-0.0229188767113586,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
373,16367,1011:1058,Breast,MRK-nu-1,SIDM00562,908151,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.891816383587554,0.0488426627334458,0.595890452114295,9.59870610353989,6.0574,0.924045168018047,0.920351637757446,0.0987449600150846,0.531424868018923,0.274840872093681,0.256583995925242,7.75341843257815,1.6858,1.84528767096174,4.3716,0.824078620013409,0.766462641439216,0.820784669213729,0.730461307390945,0.0576159785741933,0.0903233618227837,True,0.244760879046097,0.0343275144163184,1.3890488223372,35.8115362683557
374,16443,1049:1083,Breast,MRK-nu-1,SIDM00562,908151,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.928411952357908,0.0720087713162289,0.713086443436441,10.4034910748954,26.4541,0.933912331474033,0.94796540711308,0.0716817439174796,0.662037977150783,0.700284254767513,-0.0382462776167302,10.7290104729229,33.15,-0.325519398027533,-6.6959,0.867055370994933,0.911659472970909,0.880102414385614,0.888123970132697,-0.0446041019759751,-0.0080215557470834,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
375,16443,1011:1083,Breast,MRK-nu-1,SIDM00562,908151,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.929533741335123,0.0720087713162289,0.713086443436441,10.4034910748954,26.4541,0.933912331474033,0.94796540711308,0.0796180117654303,0.662837909662831,0.250548311509117,0.412289598153714,7.46312151545836,3.4463,2.94036955943701,23.0078,0.868103023554066,0.734351606334342,0.881165831530094,0.742259340665142,0.133751417219723,0.138906490864952,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
376,16443,1594:1083,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.654119208215523,0.0720087713162289,0.713086443436441,10.4034910748954,26.4541,0.933912331474033,0.94796540711308,0.0493947165748706,0.466443539769868,0.259600337713256,0.206843202056612,8.35481077192808,6.3941,2.0486803029673,20.06,0.610889994806508,0.577545508475056,0.620082381516514,0.561163373815442,0.0333444863314524,0.0589190077010724,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
377,16445,1594:1372,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.265601147198077,0.0604122735440178,0.941891764483822,13.2942088548356,19.6194,0.964432065129737,0.990785811152884,0.0480968917766189,0.250167533183324,0.169910975133154,0.0802565580501702,9.88511410490184,1.8469,3.4090947499338,17.7725,0.256154262893069,0.198802488465778,0.263153848069783,0.247345426296277,0.0573517744272908,0.015808421773506,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
378,16448,1011:1558,Breast,MRK-nu-1,SIDM00562,908151,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.903207842369321,0.0620632405814131,0.855728612888131,11.7444150849036,67.0118,0.96228036830748,0.976021408534222,0.118751201568764,0.772900794100381,0.55847932244022,0.214421471660161,9.74375299022705,16.7453,2.00066209467658,50.2665,0.869139175213355,0.856373352853383,0.88155019050846,0.836402577562017,0.0127658223599723,0.0451476129464439,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
379,16448,1594:1558,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.664106287161365,0.0620632405814131,0.855728612888131,11.7444150849036,67.0118,0.96228036830748,0.976021408534222,0.0469692459775067,0.568294751922881,0.524509983956749,0.0437847679661324,11.0406091703944,41.1419,0.703805914509221,25.8699,0.639056442604951,0.640090065291931,0.648181953811667,0.639988967180582,-0.0010336226869803,0.0081929866310855,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
380,16448,1049:1558,Breast,MRK-nu-1,SIDM00562,908151,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.999969786493879,0.0620632405814131,0.855728612888131,11.7444150849036,67.0118,0.96228036830748,0.976021408534222,0.163358938041161,0.855702758326447,0.600825055795175,0.254877702531273,9.63047640338841,15.4808,2.11393868151523,51.531,0.962251294443682,0.964655238128969,0.975991919505421,0.921596542328548,-0.0024039436852864,0.0543953771768724,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
381,16449,1083:1561,Breast,MRK-nu-1,SIDM00562,908151,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.836781802334218,0.148937713018602,0.573882499991066,9.45894412947942,13.7454,0.879285240570256,0.914565420823549,0.0750352417005598,0.480214432670591,0.272037297781637,0.208177134888954,7.87397459238439,4.5818,1.58496953709503,9.1636,0.735769888370255,0.679900683417324,0.765291701189282,0.6922450672775,0.0558692049529309,0.0730466339117819,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
382,16449,1011:1561,Breast,MRK-nu-1,SIDM00562,908151,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.91010273147533,0.148937713018602,0.573882499991066,9.45894412947942,13.7454,0.879285240570256,0.914565420823549,0.105185508579514,0.52229203078776,0.293402605509513,0.228889425278248,7.85485449090958,4.5214,1.60408963856984,9.224,0.800239899188933,0.791108115717717,0.832348487604397,0.751730067384386,0.009131783471216,0.0806184202200112,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
383,16449,1594:1561,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.7323951906516,0.148937713018602,0.573882499991066,9.45894412947942,13.7454,0.879285240570256,0.914565420823549,0.0815087370449384,0.420308782992573,0.184415296629514,0.235893486363059,7.32114101070084,3.1233,2.13780311877859,10.6221,0.64398428140459,0.518417738259677,0.669823315747424,0.577194664171907,0.125566543144914,0.0926286515755173,True,0.546240230992684,0.067647548697751,0.590265691223004,83.4315535725408
384,15754,1021:1011,Breast,BT-20,SIDM00893,906801,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.955802718232384,0.115768553456179,0.522773836635193,9.21351913868378,11.5951,0.883342174324911,0.851050462821688,0.0924932935655348,0.49966865407669,0.442600243231891,0.0570684108447984,8.65333344841624,7.864,0.560185690267533,3.7311,0.844300851349054,0.798680581929149,0.813436345717897,0.787046537371289,0.0456202694199049,0.0263898083466084,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
385,15754,1549:1011,Breast,BT-20,SIDM00893,906801,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.866604286564301,0.115768553456179,0.522773836635193,9.21351913868378,11.5951,0.883342174324911,0.851050462821688,0.0466713058621356,0.453038047731724,0.117436747561585,0.335601300170139,4.65959605349066,0.4936,4.55392308519311,11.1015,0.765508114772997,0.454830228379519,0.737523979163807,0.478258265787758,0.310677886393478,0.259265713376049,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
386,15754,1558:1011,Breast,BT-20,SIDM00893,906801,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.914493753360705,0.115768553456179,0.522773836635193,9.21351913868378,11.5951,0.883342174324911,0.851050462821688,0.0849025478498882,0.478073408023294,0.295162653612848,0.182910754410446,7.26409995440036,3.0022,1.94941918428342,8.5929,0.807810900500193,0.694467559059028,0.77828033204517,0.678464017139127,0.113343341441166,0.0998163149060433,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
387,15754,1561:1011,Breast,BT-20,SIDM00893,906801,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.693154866191221,0.115768553456179,0.522773836635193,9.21351913868378,11.5951,0.883342174324911,0.851050462821688,0.0744524704781904,0.362363228781138,0.15744676917948,0.204916459601658,6.13186549874822,1.3696,3.08165363993556,10.2255,0.612292926645245,0.43580697793229,0.589909769679143,0.460065802727404,0.176485948712955,0.129843966951739,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
388,15754,1054:1012,Breast,BT-20,SIDM00893,906801,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.941938967082863,0.166247594602188,0.799315311244014,12.237088069297,47.1445,0.924348498989915,0.94835418126802,0.191587796313075,0.752906238646704,0.501968911027559,0.250937327619144,9.3087871856826,6.1933,2.92830088361436,40.9512,0.870679870363155,0.84085950886959,0.893291757932313,0.80576364114808,0.0298203614935648,0.087528116784233,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
389,15754,1058:1012,Breast,BT-20,SIDM00893,906801,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.821868770044732,0.166247594602188,0.799315311244014,12.237088069297,47.1445,0.924348498989915,0.94835418126802,0.166983122759501,0.65693229173004,0.32537619381364,0.3315560979164,8.01018134146514,2.5177,4.22690672783181,44.6268,0.759693163957535,0.609404128194267,0.779422684525526,0.64756024447027,0.150289035763268,0.131862440055256,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
390,15755,1011:1021,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.746446249507837,0.0683687910404592,0.847892457915958,13.0244371143212,162.7332,0.941725938350988,0.961939090271661,0.116911294076028,0.632906145197349,0.361248689708311,0.271657455489038,8.84964925456328,9.0103,4.17478785975788,153.7229,0.702947794746344,0.612165945973615,0.718035826188262,0.622144649089847,0.0907818487727285,0.0958911770984149,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
391,15757,1058:1053,Breast,BT-20,SIDM00893,906801,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.965027633842029,0.0644159803427253,0.529020030494554,9.27219882707906,12.0765,0.857220097559681,0.853759387508618,0.052439905338996,0.510518948283197,0.352816317851856,0.157702630431341,7.70909578403034,4.0869,1.56310304304871,7.9896,0.827241082429852,0.721783805686349,0.823901401597862,0.743009088034233,0.105457276743503,0.080892313563629,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
392,15757,1558:1053,Breast,BT-20,SIDM00893,906801,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.989699240430431,0.0644159803427253,0.529020030494554,9.27219882707906,12.0765,0.857220097559681,0.853759387508618,0.0492859030029233,0.523570722352943,0.363213501621913,0.16035722073103,7.72313719279028,4.1269,1.54906163428878,7.9496,0.848390079436516,0.729932888683124,0.844965017327629,0.762852434440037,0.118457190753392,0.0821125828875914,True,1.1926925983823,0.112043708874309,-0.185164772227284,-286.001373898576
393,17275,1561:1083,Breast,BT-20,SIDM00893,906801,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.663470377569103,0.0553049003139351,0.908318069242275,14.3714937646744,413.9813,0.963925110063115,0.977806962949411,0.059839954401337,0.602642132353011,0.491385354529336,0.111256777823676,11.4576206617278,54.931,2.91387310294653,359.0503,0.639535756721915,0.639460333327986,0.648745954897744,0.617569111590225,7.54233939288529e-05,0.031176843307519,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
394,17277,1011:1372,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.666755038518851,0.0857997971329455,0.564806370349524,9.61061513979368,1.5269,0.807409619260768,0.86870322400972,0.099021187115226,0.376587493218089,0.0819854736476258,0.294602019570463,4.39816640403446,0.0412,5.21244873575922,1.4857,0.538344431790704,0.301932395916637,0.579212251586051,0.354290296114044,0.236412035874067,0.224921955472007,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
395,17279,1058:1549,Breast,BT-20,SIDM00893,906801,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.928256821878484,0.0762976442343355,0.718440336027846,11.1941094601281,22.8804,0.867007912538662,0.923827807510033,0.0601201586340605,0.666897143030518,0.49459281131987,0.172304331710649,9.30792812451151,6.1896,1.88618133561659,16.6908,0.804806009436637,0.744347038822869,0.857549464562232,0.79402322766229,0.0604589706137678,0.0635262368999413,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
396,17279,1011:1549,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.677085760838658,0.0762976442343355,0.718440336027846,11.1941094601281,22.8804,0.867007912538662,0.923827807510033,0.0860206549489589,0.486445721536595,0.108871717219813,0.377574004316782,5.12977463271381,0.3419,6.06433482741429,22.5385,0.587038712114377,0.345533211060682,0.625510653931841,0.39841437142413,0.241505501053695,0.22709628250771,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
397,17279,1561:1549,Breast,BT-20,SIDM00893,906801,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.707794239348272,0.0762976442343355,0.718440336027846,11.1941094601281,22.8804,0.867007912538662,0.923827807510033,0.101454827667519,0.508507931155946,0.271656127241899,0.236851803914047,7.89111018311462,2.3183,3.30299927701348,20.5621,0.613663205964235,0.474475386109213,0.653880000305346,0.552717886223004,0.139187819855022,0.101162114082342,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
398,17279,1053:1549,Breast,BT-20,SIDM00893,906801,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.939881807042927,0.0762976442343355,0.718440336027846,11.1941094601281,22.8804,0.867007912538662,0.923827807510033,0.0853603034112911,0.67524900127838,0.56731182116028,0.1079371801181,9.98489447225586,9.8958,1.20921498787224,12.9846,0.814884963557354,0.763096505608989,0.868288949119036,0.830755120964161,0.0517884579483653,0.0375338281548744,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
399,17280,1011:1558,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.629703115218268,0.108457625842802,0.488038559430414,8.88791012967751,9.2525,0.867965146529528,0.835386309184831,0.0779348265301463,0.307319401219968,0.107989005531141,0.199330395688827,5.31068714744215,0.7752,3.57722298223536,8.4773,0.546560356670525,0.380405465192906,0.52604536130438,0.379285176523237,0.166154891477618,0.146760184781142,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
400,17281,1058:1594,Breast,BT-20,SIDM00893,906801,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.977097600969274,0.0597484838838319,0.679454377237569,10.7596789922766,13.5449,0.915880458718293,0.911019744302,0.0581486252838011,0.663893241966901,0.530142838341742,0.133750403625159,9.39980275231962,5.2773,1.35987623995701,8.2676,0.894904598988283,0.831377977381042,0.890155206593126,0.839844638439829,0.0635266216072405,0.0503105681532966,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
401,17281,1558:1594,Breast,BT-20,SIDM00893,906801,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.856858789352807,0.0597484838838319,0.679454377237569,10.7596789922766,13.5449,0.915880458718293,0.911019744302,0.0738035424444552,0.582196455100249,0.383293612369041,0.198902842731208,8.50463393490228,2.8375,2.25504505737435,10.7074,0.784780221049251,0.688525784308338,0.780615275179116,0.698840306357686,0.0962544367409129,0.0817749688214302,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
402,17281,1561:1594,Breast,BT-20,SIDM00893,906801,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.722571184280987,0.0597484838838319,0.679454377237569,10.7596789922766,13.5449,0.915880458718293,0.911019744302,0.0330701780935695,0.490954154025451,0.295122174412571,0.19583197961288,8.13231030102992,2.1921,2.62736869124671,11.3528,0.661788827715891,0.560093952131854,0.658276615543658,0.574418452397222,0.101694875584037,0.0838581631464366,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
403,17281,1053:1594,Breast,BT-20,SIDM00893,906801,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.976216420151807,0.0597484838838319,0.679454377237569,10.7596789922766,13.5449,0.915880458718293,0.911019744302,0.0496961475338781,0.663294519803335,0.446991787082687,0.216302732720648,8.60445161610079,3.0408,2.15522737617583,10.5041,0.894097542696967,0.811360286079078,0.889352433470113,0.801358389839545,0.0827372566178889,0.0879940436305675,True,0.802413807119885,0.06096543888917,0.205441224801666,229.724500357527
404,14513,1549:1011,Breast,BT-474,SIDM00963,946359,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.623333303365097,0.113724493127514,0.595430132144569,10.258188248195,23.9195,0.876939153244287,0.841297148210476,0.0902104843423867,0.371151431192791,0.206926726015056,0.164224705177734,6.72331252363958,2.0637,3.53487572455538,21.8558,0.546625379241952,0.438217765320779,0.524408530505672,0.417647515677532,0.108407613921173,0.106761014828139,True,0.774847864796851,0.0785104052850785,0.242224976597007,197.879738128388
405,14513,1558:1011,Breast,BT-474,SIDM00963,946359,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.66442791159315,0.113724493127514,0.595430132144569,10.258188248195,23.9195,0.876939153244287,0.841297148210476,0.0852041369545128,0.39562039920045,0.232879040916823,0.162741358283626,6.99169699356488,2.4857,3.26649125463007,21.4338,0.582662850184367,0.475912495617146,0.558981307214759,0.455464607092325,0.106750354567221,0.103516700122434,True,0.774847864796851,0.0785104052850785,0.242224976597007,197.879738128388
406,17511,1549:1053,Breast,MDA-MB-468,SIDM00628,908123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.688050355047508,0.102184616592005,0.673528122526275,10.3031441140613,24.6766,0.898540087275501,0.929217043408747,0.134196070032986,0.463421263838685,0.174111395955151,0.289309867883534,7.05224721598147,2.5922,3.25089689807984,22.0844,0.618240826074327,0.414657272023602,0.639348116633584,0.519314623665238,0.203583554050725,0.120033492968346,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
407,17511,1049:1053,Breast,MDA-MB-468,SIDM00628,908123,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.980252529082485,0.102184616592005,0.673528122526275,10.3031441140613,24.6766,0.898540087275501,0.929217043408747,0.0481805686056762,0.660227645514559,0.710256824030233,-0.0500291785156741,10.740475386016,33.4145,-0.437331271954678,-8.7379,0.880796193033807,0.937351797449043,0.910867356867974,0.923680334389366,-0.0565556044152354,-0.0128129775213922,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
408,17511,1558:1053,Breast,MDA-MB-468,SIDM00628,908123,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.849007244539672,0.102184616592005,0.673528122526275,10.3031441140613,24.6766,0.898540087275501,0.929217043408747,0.0834515872443744,0.571830255426012,0.47236209943974,0.0994681559862717,9.40747413273511,13.2636,0.895669981326208,11.413,0.76286704360621,0.704564434223663,0.788912001603762,0.759901052348527,0.0583026093825468,0.0290109492552347,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
409,17511,1510:1053,Breast,MDA-MB-468,SIDM00628,908123,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.971263242206343,0.102184616592005,0.673528122526275,10.3031441140613,24.6766,0.898540087275501,0.929217043408747,0.0803320972631615,0.654173108002021,0.440823193134912,0.213349914867109,8.66698628279068,7.9388,1.63615783127063,16.7378,0.872718958419573,0.769811718250452,0.902514358294572,0.834008884179372,0.102907240169122,0.0685054741151994,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
410,17511,1594:1053,Breast,MDA-MB-468,SIDM00628,908123,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.986039042886149,0.102184616592005,0.673528122526275,10.3031441140613,24.6766,0.898540087275501,0.929217043408747,0.0584041707513824,0.664125025292713,0.504783074818477,0.159341950474237,9.08588734982771,10.6134,1.21725676423361,14.0632,0.885995607651972,0.882117559426988,0.916244284116259,0.867886851974541,0.003878048224984,0.0483574321417177,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
411,17511,1083:1054,Breast,MDA-MB-468,SIDM00628,908123,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.709427513096934,0.076090792643215,0.909039821170753,13.1422992304463,70.6344,0.938532138810675,0.982908674845227,0.131342478100422,0.644897859639249,0.414447226914411,0.230450632724838,9.61188342580746,6.113,3.53041580463884,64.5214,0.665820521198004,0.547381851631648,0.697302456796853,0.64115954210348,0.118438669566356,0.0561429146933728,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
412,17512,1510:1058,Breast,MDA-MB-468,SIDM00628,908123,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.986082493853171,0.0762761100688281,0.545049931757746,9.32514407236054,5.0112,0.874023465695273,0.891373477359694,0.0820765147086023,0.537464195982178,0.33000673528165,0.207457460700529,7.76347684207671,1.6976,1.56166723028383,3.3136,0.861859238738986,0.778748310287913,0.87896778150942,0.793206363168254,0.0831109284510733,0.0857614183411664,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
413,17512,1549:1058,Breast,MDA-MB-468,SIDM00628,908123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.710609142013459,0.0762761100688281,0.545049931757746,9.32514407236054,5.0112,0.874023465695273,0.891373477359694,0.0630751181704504,0.387317464360866,0.194305674645525,0.193011789715341,7.24145520522542,1.1822,2.08368886713512,3.829,0.621089065057348,0.509107631800936,0.633418141960126,0.546104364435534,0.111981433256411,0.087313777524592,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
414,17512,1558:1058,Breast,MDA-MB-468,SIDM00628,908123,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.711165188534099,0.0762761100688281,0.545049931757746,9.32514407236054,5.0112,0.874023465695273,0.891373477359694,0.0514947060368032,0.387620537478995,0.101122959569156,0.286497577909839,5.76602550917897,0.4251,3.55911856318157,4.5861,0.621575062764406,0.427105573842412,0.633913787080803,0.464493778221091,0.194469488921994,0.169420008859712,True,0.660792385706973,0.0641938333175871,0.395246334080991,122.353733044505
415,16957,1053:1372,Breast,MDA-MB-468,SIDM00628,908123,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.953147436228822,0.136316677517845,0.56273727214574,9.45396549007874,1.3698,0.78993380586274,0.897080211769534,0.138691821715011,0.536371588216113,0.326466896704093,0.20990469151202,7.82655667396124,0.4434,1.6274088161175,0.9264,0.752923381848547,0.654761276906806,0.855049703939741,0.770645088841076,0.0981621049417406,0.0844046150986646,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
416,16959,1561:1549,Breast,MDA-MB-468,SIDM00628,908123,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.95513167202201,0.149232435269779,0.441490370218088,8.57691863115354,3.7291,0.742722256118899,0.853752705529329,0.122420960652363,0.421681435488018,0.426412107584244,-0.0047306720962254,8.61302256424037,3.8237,-0.036103933086828,-0.0946000000000002,0.709397550334804,0.751120920039456,0.815446249125543,0.817347088967889,-0.0417233697046528,-0.0019008398423469,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
417,16959,1594:1549,Breast,MDA-MB-468,SIDM00628,908123,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.939693647336213,0.149232435269779,0.441490370218088,8.57691863115354,3.7291,0.742722256118899,0.853752705529329,0.173785256192807,0.41486569625405,0.145852330782058,0.269013365471993,5.95119374318523,0.6042,2.62572488796831,3.1249,0.69793138581015,0.541779648716011,0.802265993782015,0.628193343929012,0.156151737094139,0.174072649853004,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
418,16959,1053:1549,Breast,MDA-MB-468,SIDM00628,908123,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.92287281904189,0.149232435269779,0.441490370218088,8.57691863115354,3.7291,0.742722256118899,0.853752705529329,0.147281046024944,0.407439462543014,0.12689061314132,0.280548849401695,5.69573777468819,0.5062,2.88118085646534,3.2229,0.685438182269601,0.538112561153366,0.787905166116493,0.597340329039328,0.147325621116235,0.190564837077165,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
419,16959,1058:1549,Breast,MDA-MB-468,SIDM00628,908123,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.819101665398845,0.149232435269779,0.441490370218088,8.57691863115354,3.7291,0.742722256118899,0.853752705529329,0.123390752031985,0.361625497503189,0.0854426502170554,0.276182847286133,5.13080152307454,0.3422,3.44611710807899,3.3869,0.608365036915778,0.445377076174664,0.699310262937843,0.49074288285439,0.162987960741115,0.208567380083453,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
420,16961,1549:1561,Breast,MDA-MB-468,SIDM00628,908123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.603916879812018,0.0685848108434161,0.521104081173359,9.15199415965345,11.111,0.881435010180067,0.883347284311061,0.0530741319432839,0.314703550759524,0.195590878079932,0.119112672679592,7.6755236050532,3.9929,1.47647055460025,7.1181,0.532313481105021,0.477853761407669,0.533468335731556,0.482270391085519,0.0544597196973516,0.0511979446460369,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
421,16961,1594:1561,Breast,MDA-MB-468,SIDM00628,908123,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.970551821399841,0.0685848108434161,0.521104081173359,9.15199415965345,11.111,0.881435010180067,0.883347284311061,0.0388558670714741,0.505758515121694,0.380494020091556,0.125264495030139,8.21048656121291,5.7854,0.941507598440534,5.3256,0.855478354575852,0.825764100810651,0.857334315716704,0.808055551784337,0.0297142537652016,0.0492787639323674,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
422,16961,1053:1594,Breast,MDA-MB-468,SIDM00628,908123,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.902725347952866,0.0807907898646119,0.449106776934351,8.63240557573862,3.1003,0.825517219731314,0.856804035919816,0.0559508249858291,0.405420071476052,0.25300980150991,0.152410269966142,7.30291709615522,1.2336,1.3294884795834,1.8667,0.745215319423033,0.717123567677681,0.773458721453136,0.697702915245515,0.0280917517453521,0.0757558062076201,True,0.447961253764776,0.072648180317143,0.773897121755163,63.4088040692738
423,17730,1012:1372,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.901830394848349,0.0643640868680808,0.909829440057579,14.7796248198466,54.9339,0.958981190532906,0.976826126875853,0.0700077412611648,0.820511843171779,0.791422124400087,0.029089718771692,13.9247461376193,30.3736,0.854878682227298,24.5603,0.86483838571043,0.853906722254758,0.880931491698634,0.872958705548656,0.0109316634556719,0.0079727861499779,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
424,17732,1011:1549,Breast,HCC1599,SIDM00877,749713,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.961330596717223,0.125830885954776,0.693681736616643,11.043733022568,20.6156,0.829093775937468,0.910567918361145,0.150570787320881,0.666857477793517,0.435153886605265,0.231703591188252,8.52509580343752,3.5976,2.51863721913048,17.018,0.797033214356502,0.661091282711962,0.875356800309679,0.776081941005665,0.13594193164454,0.099274859304014,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
425,17732,1510:1549,Breast,HCC1599,SIDM00877,749713,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.512448034663919,0.125830885954776,0.693681736616643,11.043733022568,20.6156,0.829093775937468,0.910567918361145,0.0754833833717867,0.355475842611453,0.162121168394885,0.193354674216568,7.07344699637807,1.3153,3.97028602618992,19.3003,0.424867476031243,0.310591146014604,0.466618740192184,0.36996659053432,0.114276330016639,0.0966521496578645,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
426,17732,1049:1549,Breast,HCC1599,SIDM00877,749713,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.683117004544396,0.125830885954776,0.693681736616643,11.043733022568,20.6156,0.829093775937468,0.910567918361145,0.105984227123144,0.473865790024716,0.339771017668256,0.13409477235646,8.97382981802215,4.9101,2.06990320454584,15.7055,0.566368056704806,0.481585555047451,0.622024428825091,0.566964435024397,0.0847825016573546,0.0550599938006946,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
427,17733,1012:1558,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.644532462317321,0.113751155052444,0.4537953863071,8.53657258634873,7.2526,0.812176402118682,0.807902436842742,0.0700996982233286,0.292485857724755,0.123203664529058,0.169282193195697,5.39318322595179,0.8208,3.14338936039694,6.4318,0.523474056293577,0.359650196567295,0.520719346930416,0.389908818267256,0.163823859726281,0.130810528663161,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
428,17734,1012:1561,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.58928799439285,0.173629136837521,0.265490395968206,6.45561347784427,1.7142,0.608281911076071,0.680778744046612,0.07935699449207,0.156450302970668,0.0502611610465333,0.106189141924134,3.06790928849256,0.1638,3.38770418935171,1.5504,0.358453227403468,0.229817621777708,0.401174740704512,0.253017986528386,0.12863560562576,0.148156754176126,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
429,17734,1011:1561,Breast,HCC1599,SIDM00877,749713,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.933762324893491,0.173629136837521,0.265490395968206,6.45561347784427,1.7142,0.608281911076071,0.680778744046612,0.10297945471616,0.247904929376165,0.0845762516460918,0.163328677730073,3.23270013204005,0.1836,3.22291334580422,1.5306,0.567990731477048,0.392189450257393,0.635685542779035,0.412498288609816,0.175801281219654,0.22318725416922,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
430,17734,1012:1594,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.924231692223155,0.128542137231353,0.591117317501373,9.92158347451178,7.5768,0.835985814511909,0.871697382435004,0.0552457792361568,0.546329358656706,0.422662460049371,0.123666898607335,8.57202586210374,2.9732,1.34955761240804,4.6036,0.772644584020894,0.735470076784406,0.805650346874399,0.748402801516732,0.0371745072364885,0.0572475453576666,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
431,17734,1011:1594,Breast,HCC1599,SIDM00877,749713,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.933762324893491,0.128542137231353,0.591117317501373,9.92158347451178,7.5768,0.835985814511909,0.871697382435004,0.0512982292563598,0.551963080674886,0.267560037311272,0.284403043363614,6.71908474614106,0.8231,3.20249872837072,6.7537,0.780612057736618,0.633423779432661,0.81395817442608,0.652369609201894,0.147188278303957,0.161588565224186,True,0.814920841818228,0.0980167703260647,0.195265483487689,245.928386598538
432,14584,1011:1012,Breast,HCC1937,SIDM00874,749714,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.712682705855048,0.0573192211370029,0.639316707852204,10.2737300824533,12.0893,0.875393400923105,0.901851231514387,0.0631469781206066,0.45562996125045,0.248099862306994,0.207530098943456,7.60408419968905,1.9,2.66964588276425,10.1893,0.623877737657531,0.554527593578309,0.64273377595438,0.548623354392307,0.0693501440792216,0.0941104215620732,True,0.616359485554619,0.0695836798035186,0.463787726370159,104.791341233405
433,17264,1011:1049,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.781703487475243,0.198190554797049,0.165736860692484,5.32571496666347,0.7833,0.523087557939789,0.605026968909077,0.067460345356298,0.129557082006513,0.0173496753961389,0.112207406610374,0.393825224812645,0.0257,4.93188974185083,0.7576,0.408899368296441,0.13488327572008,0.472951691612801,0.181896717673781,0.274016092576361,0.29105497393902,True,0.399757664452004,0.0545312508158561,0.891775238419063,55.3353490020201
434,17264,1561:1049,Breast,MFM-223,SIDM00332,910948,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.657702605019055,0.198190554797049,0.165736860692484,5.32571496666347,0.7833,0.523087557939789,0.605026968909077,0.145876467281746,0.109005565025127,0.0281097726212617,0.080895792403865,1.93183916222395,0.0745,3.39387580443952,0.7088,0.344036049510055,0.220008349774514,0.397927813558283,0.222669000074753,0.124027699735541,0.17525881348353,True,0.399757664452004,0.0545312508158561,0.891775238419063,55.3353490020201
435,17264,1053:1049,Breast,MFM-223,SIDM00332,910948,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.720316761347656,0.198190554797049,0.165736860692484,5.32571496666347,0.7833,0.523087557939789,0.605026968909077,0.176986456876912,0.119383038729937,0.0315521909334273,0.0878308477965102,1.99026662792909,0.0776,3.33544833873438,0.7057,0.376788735636443,0.249767192117081,0.435811066772576,0.246994274933219,0.127021543519363,0.188816791839356,True,0.399757664452004,0.0545312508158561,0.891775238419063,55.3353490020201
436,15041,1011:1561,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.62000345174137,0.118513870769036,0.367537319029073,7.76596133374901,4.2513,0.741347764588691,0.777200145053937,0.0603802131103173,0.227874406441794,0.0321395532767489,0.195734853165045,2.39232878862298,0.1025,5.37363254512603,4.1488,0.459638172985736,0.193536271871934,0.481866772627334,0.231416123449285,0.266101901113803,0.250450649178049,True,0.588351541501767,0.0776253401710523,0.512285809100232,95.4234882407677
437,15083,1558:1083,Breast,T47D,SIDM00097,905945,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.847561402787158,0.093031693658323,0.654509246857942,10.9936884734584,39.8254,0.89776955063947,0.874347546194126,0.110569980857848,0.554736775404083,0.448255312078766,0.106481463325317,9.36082705154258,12.8416,1.63286142191586,26.9838,0.760914819719586,0.735275949320061,0.741063232775803,0.68848120231602,0.0256388703995242,0.0525820304597824,True,0.638863803485452,0.0687318649181346,0.430421244441089,112.980276379217
438,15085,1012:1372,Breast,T47D,SIDM00097,905945,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.87552201718737,0.0788344449742857,0.866877207898163,14.8464695212989,57.5391,0.924432767444262,0.957360601458044,0.153808709144444,0.758970081712754,0.48840996942694,0.270560112285815,9.72530991566839,1.6533,5.12115960563053,55.8858,0.809361241306903,0.722681958484894,0.83819028496426,0.724712389411621,0.0866792828220092,0.11347789555264,True,0.638863803485452,0.0687318649181346,0.430421244441089,112.980276379217
439,15087,1372:1510,Breast,T47D,SIDM00097,905945,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.914254897541713,0.0927421562175262,0.78111030533354,12.9696180428255,156.6658,0.917660316597791,0.926441451230925,0.0725405163889983,0.714133922171492,0.706692428227768,0.0074414939437238,12.823004989624,141.527,0.146613053201525,15.1388,0.838975438729209,0.81809557791638,0.847003634073525,0.844169518842594,0.0208798608128297,0.0028341152309311,True,0.638863803485452,0.0687318649181346,0.430421244441089,112.980276379217
440,15088,1011:1558,Breast,T47D,SIDM00097,905945,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.931299642851973,0.126705748146979,0.641133045568776,10.8107249188382,35.0819,0.863444018256967,0.868299143340217,0.184215799878032,0.597086976358799,0.326294384070484,0.270792592288315,7.07334617205987,2.6304,3.73737874677832,32.4515,0.804125105825386,0.715071143672916,0.808646682081418,0.647597880886141,0.0890539621524699,0.161048801195277,True,0.638863803485452,0.0687318649181346,0.430421244441089,112.980276379217
441,15089,1049:1594,Breast,T47D,SIDM00097,905945,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.81708535885964,0.110483450156215,0.538664947893604,9.48356658255984,5.5928,0.797322490891107,0.817610712703402,0.106257472936139,0.440135242254755,0.214599935242227,0.225535307012528,5.7788438174194,0.4289,3.70472276514044,5.1639,0.651480533596622,0.449057359544491,0.668057742596746,0.503709559596826,0.202423174052131,0.164348182999919,True,0.638863803485452,0.0687318649181346,0.430421244441089,112.980276379217
442,16652,1549:1011,Breast,ZR-75-30,SIDM00971,909907,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.628515284746525,0.0622636399262511,0.892444961117567,18.0257531632874,5212.2164,0.950914719179713,0.9563641833593,0.097890129204498,0.560915298857409,0.262158399792448,0.298756899064961,7.57249335599601,3.7177,10.4532598072914,5208.4987,0.597664435494899,0.390549218902534,0.601089507025448,0.427808747991298,0.207115216592365,0.17328075903415,True,0.762816347961741,0.0805084232141152,0.2558813203898,186.752329474812
443,16652,1558:1011,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.679874218978025,0.0622636399262511,0.892444961117567,18.0257531632874,5212.2164,0.950914719179713,0.9563641833593,0.0676765119766024,0.606750320920679,0.301239829671991,0.305510491248689,8.02461963441398,5.0861,10.0011335288735,5207.1303,0.646502402017015,0.436436475406365,0.650207352219961,0.476818551811283,0.21006592661065,0.173388800408677,True,0.762816347961741,0.0805084232141152,0.2558813203898,186.752329474812
444,16656,1011:1058,Breast,ZR-75-30,SIDM00971,909907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.924303693002805,0.0896316692384461,0.779374535744231,14.3832380261748,166.946,0.884549676011447,0.905101727292725,0.106900761661523,0.72037876162074,0.464826137210971,0.255552624409769,9.04936672604532,4.1392,5.33387130012946,162.8068,0.817592532181815,0.716396148148924,0.836588869079884,0.689004823139305,0.101196384032891,0.147584045940579,True,0.762816347961741,0.0805084232141152,0.2558813203898,186.752329474812
445,17870,1011:1558,Breast,ZR-75-30,SIDM00971,909907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.969781980816459,0.0822484863737372,0.304560087646317,5.47803258922462,0.8705,0.562252710110724,0.577344822758826,0.0946111993104134,0.29535688507528,0.14458179635428,0.150775088721,1.57033884697784,0.058,3.90769374224677,0.8125,0.545262546930601,0.324434975677249,0.559898605829181,0.363078373327649,0.220827571253352,0.196820232501533,True,0.904356873847144,0.0949684076752773,0.0883337129884524,502.224815162437
446,17871,1011:1561,Breast,ZR-75-30,SIDM00971,909907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.920033579598601,0.107054673463758,0.53018488384567,9.51564818339656,14.2964,0.718500276044194,0.764131551471072,0.0850239634552272,0.4877878965336,0.266732413052308,0.221055483481292,5.17894868205917,0.7075,4.3366995013374,13.5889,0.661044380911522,0.487137257127336,0.703026686584162,0.516925796764129,0.173907123784186,0.186100889820033,True,0.904356873847144,0.0949684076752773,0.0883337129884524,502.224815162437
447,17871,1558:1594,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.487134077059966,0.0675263433676703,0.720122921291875,13.0312542466973,65.4016,0.87655092842027,0.875558287161371,0.0841523820263392,0.350796414633244,0.263164781714848,0.087631632918396,9.68791210967132,6.4438,3.34334213702597,58.9578,0.426997827512065,0.340874828563285,0.426514278128559,0.375489609622197,0.0861229989487795,0.0510246685063624,True,0.904356873847144,0.0949684076752773,0.0883337129884524,502.224815162437
448,14484,1011:1021,Breast,HCC1806,SIDM00875,907047,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.984641669118532,0.05334116648849,0.81270607395815,11.3406209960032,50.6521,0.952801530637293,0.966996339190324,0.0859648085336183,0.800224265164921,0.509866438077172,0.290357827087749,9.1137183953899,10.8201,2.22690260061326,39.832,0.938168089465396,0.801436275992187,0.952144889451871,0.88157381620585,0.136731813473209,0.0705710732460207,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
449,14484,1558:1021,Breast,HCC1806,SIDM00875,907047,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.788928166085435,0.05334116648849,0.81270607395815,11.3406209960032,50.6521,0.952801530637293,0.966996339190324,0.0917449605449171,0.641166712494297,0.428299856161499,0.212866856332798,9.27426085967075,12.0937,2.06636013633241,38.5584,0.751691964209075,0.645438584439003,0.762890648488752,0.71227374850798,0.106253379770073,0.0506168999807728,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
450,14485,1549:1053,Breast,HCC1806,SIDM00875,907047,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.712951542181967,0.0455454149806284,0.735351716701064,10.6297655028955,30.9463,0.945495892974473,0.951084422582549,0.0705531017586302,0.52427014046818,0.386922781759669,0.137347358708511,9.2730868095349,12.0839,1.35667869336055,18.8624,0.674092755022866,0.578287568976002,0.678077105825473,0.643641084471517,0.0958051860468647,0.0344360213539563,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
451,14485,1558:1053,Breast,HCC1806,SIDM00875,907047,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.798190913147188,0.0455454149806284,0.735351716701064,10.6297655028955,30.9463,0.945495892974473,0.951084422582549,0.0452126669420711,0.586951058237975,0.45538457287669,0.131566485361285,9.45287590049137,13.6877,1.17688960240408,17.2586,0.754686230190211,0.697200761348211,0.759146943741231,0.726934653222989,0.0574854688419995,0.0322122905182423,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
452,14485,1372:1053,Breast,HCC1806,SIDM00875,907047,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.778239523460783,0.0455454149806284,0.735351716701064,10.6297655028955,30.9463,0.945495892974473,0.951084422582549,0.055302808389257,0.572279769581505,0.557002389127824,0.0152773804536814,10.4725012689238,27.7503,0.157264233971677,3.196,0.735822273182582,0.713437359153405,0.740171487801617,0.73682198775244,0.0223849140291766,0.0033495000491772,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
453,14485,1012:1053,Breast,HCC1806,SIDM00875,907047,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.809691111767951,0.0455454149806284,0.735351716701064,10.6297655028955,30.9463,0.945495892974473,0.951084422582549,0.0849901971438986,0.595407749036156,0.351644457703859,0.243763291332297,8.57842319918256,7.4661,2.05134230371289,23.4802,0.765559620754532,0.650383629883859,0.770084603506043,0.702313000793996,0.115175990870674,0.0677716027120476,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
454,14485,1011:1053,Breast,HCC1806,SIDM00875,907047,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.960416670588878,0.0455454149806284,0.735351716701064,10.6297655028955,30.9463,0.945495892974473,0.951084422582549,0.0554437189227193,0.706244047465852,0.462531173042728,0.243712874423124,8.88253572666652,9.2181,1.74722977622893,21.7282,0.908070017586001,0.797738622607373,0.913437334585676,0.848818478946664,0.110331394978628,0.064618855639012,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
455,14485,1594:1053,Breast,HCC1806,SIDM00875,907047,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.958096177632855,0.0455454149806284,0.735351716701064,10.6297655028955,30.9463,0.945495892974473,0.951084422582549,0.0668450544565927,0.704537668987048,0.439554442783319,0.264983226203728,8.7364508588972,8.3304,1.89331464399825,22.6159,0.905876001026405,0.792726421079782,0.911230349882491,0.839381807520984,0.113149579946624,0.0718485423615068,True,0.31142702381149,0.0418583218870999,1.13649394755681,43.5498732511249
456,14737,1011:1083,Breast,HCC1806,SIDM00875,907047,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.872904193881294,0.0865423156623286,0.433590995555633,8.57385529048247,7.4425,0.840898857531436,0.867126412966381,0.0708025304799499,0.378483398449678,0.175960130352718,0.20252326809696,6.80488952131014,2.1838,1.76896576917233,5.2587,0.73402413936918,0.629652533005155,0.756918282503597,0.650992454223724,0.104371606364025,0.105925828279872,True,0.428017105138178,0.0447464302810151,0.827032152393697,59.674248378581
457,14741,1058:1510,Breast,HCC1806,SIDM00875,907047,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.966076596751635,0.0416235977440002,0.810669592267219,11.3193732319721,49.9115,0.967042299597207,0.966597152813209,0.0152099555335169,0.783168920787551,0.673381924071552,0.109786996715999,10.3287304620249,25.1182,0.990642769947211,24.7933,0.934236933709745,0.910183877827761,0.933806887819606,0.910595902578795,0.0240530558819835,0.0232109852408111,True,0.428017105138178,0.0447464302810151,0.827032152393697,59.674248378581
458,14741,1549:1510,Breast,HCC1806,SIDM00875,907047,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.706701896450316,0.0416235977440002,0.810669592267219,11.3193732319721,49.9115,0.967042299597207,0.966597152813209,0.119953710641052,0.572901738249849,0.270229067156373,0.302672671093476,8.23538020160497,5.8861,3.08399303036713,44.0254,0.683410627073021,0.505263406284662,0.683096040996571,0.598700503881688,0.178147220788359,0.0843955371148831,True,0.428017105138178,0.0447464302810151,0.827032152393697,59.674248378581
459,14741,1558:1510,Breast,HCC1806,SIDM00875,907047,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.830432284980462,0.0416235977440002,0.810669592267219,11.3193732319721,49.9115,0.967042299597207,0.966597152813209,0.134761514267172,0.673206201870647,0.340490044884876,0.33271615698577,8.41966247911548,6.6881,2.89971075285663,43.2234,0.803063146527269,0.608187022166196,0.802693482266282,0.71271889834636,0.194876124361073,0.0899745839199227,True,0.428017105138178,0.0447464302810151,0.827032152393697,59.674248378581
460,14741,1561:1510,Breast,HCC1806,SIDM00875,907047,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.97224054268407,0.0416235977440002,0.810669592267219,11.3193732319721,49.9115,0.967042299597207,0.966597152813209,0.0229102333463765,0.788165844323355,0.644974630273013,0.143191214050343,10.0819490238657,21.1689,1.23742420810637,28.7426,0.940197730158839,0.915645244972881,0.939764940407992,0.908758144579175,0.0245524851859584,0.0310067958288173,True,0.428017105138178,0.0447464302810151,0.827032152393697,59.674248378581
461,14741,1510:1549,Breast,HCC1806,SIDM00875,907047,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.678010524800687,0.135931796683999,0.474594159166821,8.83779493776718,4.4683,0.765156633201634,0.881476484674366,0.145857366884214,0.321779834924037,0.191209866270385,0.130569968653652,7.50971915056036,1.7797,1.32807578720682,2.6886,0.518784250431767,0.424043283586678,0.597650333973532,0.541664024443705,0.0947409668450888,0.055986309529827,True,0.428017105138178,0.0447464302810151,0.827032152393697,59.674248378581
462,14742,1510:1558,Breast,HCC1806,SIDM00875,907047,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.920910965542062,0.0859811615981186,0.432307228365106,8.56551609205293,7.3996,0.816144440884424,0.866655598474539,0.0917931865288208,0.398116467084523,0.164914171109501,0.233202295975021,6.57179189993789,1.858,1.99372419211504,5.5416,0.751596365076661,0.62199627186846,0.798112643983621,0.669582366667666,0.129600093208201,0.128530277315955,True,0.428017105138178,0.0447464302810151,0.827032152393697,59.674248378581
463,14531,1083:1011,Breast,EVSA-T,SIDM01042,906862,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.819740501721927,0.140749664967791,0.297224394682431,7.71847961961302,4.1136,0.796987653786229,0.81974803001835,0.0925660365767353,0.243646874420972,0.0268172997389966,0.216829574681975,3.95660088199561,0.3032,3.76187873761741,3.8104,0.653323059180905,0.405739639452869,0.671980661412803,0.406552101113503,0.247583419728036,0.2654285602993,True,0.666529034164887,0.0968520929255177,0.391569991468467,124.458093668511
464,14531,1053:1011,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.363921818617505,0.140749664967791,0.297224394682431,7.71847961961302,4.1136,0.796987653786229,0.81974803001835,0.0590709025391536,0.108166442250317,0.003405293496536,0.104761148753781,2.05710174361914,0.0813,5.66137787599387,4.0323,0.290041196381583,0.0936338122564074,0.298324193892395,0.117290258974779,0.196407384125175,0.181033934917615,True,0.666529034164887,0.0968520929255177,0.391569991468467,124.458093668511
465,14531,1053:1012,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.695274560827399,0.104872384210299,0.296110757457752,7.71053153131977,2.0455,0.776970671640185,0.819191293221447,0.0644544849554947,0.205878276847707,0.0598879903087112,0.145990286538996,5.48290093417903,0.4367,2.22763059714075,1.6088,0.540207942500399,0.408961139883203,0.569562866628171,0.44273692836794,0.131246802617196,0.126825938260231,True,0.666529034164887,0.0968520929255177,0.391569991468467,124.458093668511
466,14622,1012:1049,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.863338384738209,0.098783064274622,0.816576590075392,11.2238381903657,46.7135,0.907245147365761,0.969864474056408,0.0595735135176939,0.704981914290723,0.752463300507243,-0.0474813862165198,11.8517159927969,72.1858,-0.627877802431149,-25.4723,0.783259560088335,0.824182505654886,0.837321228446831,0.84568920760572,-0.0409229455665518,-0.0083679791588883,True,0.411239252531202,0.0694267259215029,0.859568603803156,57.2585134666797
467,14765,1012:1549,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.763466607907693,0.0992629452908272,0.820282857193715,11.2609807924333,23.9659,0.908184832223293,0.970537856261109,0.019012699234403,0.626258570506516,0.518409549191669,0.107849021314847,10.115809941581,10.8358,1.14517085085234,13.1301,0.693368793210734,0.721580364423586,0.740973244965673,0.719520191750614,-0.0282115712128514,0.0214530532150585,True,0.540059535548512,0.101926717214927,0.591317168673672,82.5223742080519
468,14765,1058:1549,Breast,EVSA-T,SIDM01042,906862,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.856079993695205,0.0992629452908272,0.820282857193715,11.2609807924333,23.9659,0.908184832223293,0.970537856261109,0.0839069487307242,0.70222774321468,0.451801014831104,0.250426728383576,9.16550329918507,5.6078,2.09547749324823,18.3581,0.777478865443797,0.70242448319177,0.830858041868968,0.774738920331459,0.0750543822520269,0.0561191215375094,True,0.540059535548512,0.101926717214927,0.591317168673672,82.5223742080519
469,14765,1558:1549,Breast,EVSA-T,SIDM01042,906862,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.936205156743316,0.0992629452908272,0.820282857193715,11.2609807924333,23.9659,0.908184832223293,0.970537856261109,0.110046880776791,0.767953040892897,0.564944810922248,0.20300822997065,9.62519723499116,7.7121,1.63578355744213,16.2538,0.85024732320351,0.85374875070165,0.908622545846254,0.86589501471358,-0.0035014274981397,0.0427275311326739,True,0.540059535548512,0.101926717214927,0.591317168673672,82.5223742080519
470,14765,1561:1549,Breast,EVSA-T,SIDM01042,906862,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.897358837730338,0.0992629452908272,0.820282857193715,11.2609807924333,23.9659,0.908184832223293,0.970537856261109,0.0546883280827406,0.736088071341473,0.678711962611914,0.0573761087295589,10.6868601303151,16.0978,0.574120662118178,7.8681,0.814967685488216,0.838603225739004,0.870920722667763,0.86009266169681,-0.0236355402507877,0.0108280609709527,True,0.540059535548512,0.101926717214927,0.591317168673672,82.5223742080519
471,14765,1053:1549,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.51837400623081,0.0992629452908272,0.820282857193715,11.2609807924333,23.9659,0.908184832223293,0.970537856261109,0.0385343873255463,0.425213310925962,0.13968713969758,0.285526171228382,7.51482703020073,1.786,3.74615376223256,22.1799,0.470779409877644,0.383809876654406,0.503101596748733,0.41740138992014,0.0869695332232389,0.0857002068285932,True,0.540059535548512,0.101926717214927,0.591317168673672,82.5223742080519
472,14662,1510:1011,Breast,HCC1187,SIDM00885,749711,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.783962042831936,0.0969305965476611,0.780154359751491,12.5734086367076,119.0428,0.899194159954146,0.932243752727214,0.0519072760079177,0.61161140559502,0.471210541211631,0.14040086438339,10.1564544924823,22.2909,2.41695414422532,96.7519,0.704934090540199,0.651627143449168,0.730843716805337,0.675568405340135,0.0533069470910307,0.055275311465202,True,0.82031107607249,0.0817711462283047,0.186988129075804,254.509802028371
473,15047,1012:1510,Breast,HCC1187,SIDM00885,749711,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.938756161909326,0.112653798647418,0.838867144141304,13.6547053971525,251.8871,0.900557168086835,0.951989365393632,0.0616936027892627,0.787491700585927,0.520143881409669,0.267347819176259,9.61268223518395,15.291,4.04202316196852,236.5961,0.845403590693129,0.810339475595658,0.893685882835421,0.788459243261091,0.0350641150974711,0.105226639574329,True,0.934669109050124,0.0762688209910443,0.0583235645058913,745.300579577589
474,15047,1011:1510,Breast,HCC1187,SIDM00885,749711,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.961362058222954,0.112653798647418,0.838867144141304,13.6547053971525,251.8871,0.900557168086835,0.951989365393632,0.0520449361092783,0.806455044267295,0.519008578627144,0.287446465640151,9.45088087342984,13.6687,4.20382452372262,238.2184,0.865761492659394,0.799940001592253,0.915206455721186,0.800762638822532,0.0658214910671419,0.114443816898654,True,0.934669109050124,0.0762688209910443,0.0583235645058913,745.300579577589
475,15047,1083:1549,Breast,HCC1187,SIDM00885,749711,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.993809107376524,0.107771962264507,0.897522194645664,15.1222754608284,348.3041,0.928786060828961,0.970425411300398,0.150507189109604,0.891965731111426,0.562075640576511,0.329890090534916,9.7443474640914,8.3761,5.37792799673699,339.928,0.923036046056188,0.718646822119276,0.964417611779945,0.840167087858858,0.204389223936912,0.124250523921087,True,0.934669109050124,0.0762688209910443,0.0583235645058913,745.300579577589
476,15048,1510:1558,Breast,HCC1187,SIDM00885,749711,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.838400580116028,0.0918172695153719,0.912010950418969,15.5975239236238,968.3951,0.940867393428137,0.974799727048393,0.0881752716693739,0.764630509903434,0.596642383643414,0.167988126260019,11.5487381653577,58.5122,4.04878575826607,909.8829,0.788823768462405,0.773154789387857,0.817272656654319,0.76068698946741,0.015668979074548,0.0565856671869084,True,0.934669109050124,0.0762688209910443,0.0583235645058913,745.300579577589
477,15049,1012:1561,Breast,HCC1187,SIDM00885,749711,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.964441114176167,0.111473269164314,0.833599096186697,13.546167188865,233.6322,0.884532919802641,0.95027304178414,0.093271720408141,0.803957241102544,0.314371847907842,0.489585393194702,6.95029260028247,2.4153,6.59587458858258,231.2169,0.853079914699957,0.699956249943349,0.916482391189871,0.675208940343604,0.153123664756609,0.241273450846267,True,0.934669109050124,0.0762688209910443,0.0583235645058913,745.300579577589
478,16342,1012:1011,Breast,MDA-MB-231,SIDM00146,905960,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.591027743438745,0.138940549238126,0.250615698535668,6.69925651110971,2.0296,0.755756271196107,0.714633672760134,0.0720542526173537,0.148120830775861,0.0064379523448713,0.141682878430989,-0.470524837458345,0.0141,7.16978134856805,2.0155,0.446672923554715,0.0820633064490078,0.422368326996764,0.101321461922417,0.364609617105707,0.321046865074347,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
479,16342,1011:1012,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.572331392995402,0.126784264636472,0.374090972192179,7.91885989750419,2.3633,0.841343692557617,0.796453685114936,0.097119993458708,0.214104007221754,0.0874295646849785,0.126674442536775,5.40160592870279,0.4128,2.5172539688014,1.9505,0.481527407549396,0.367651096511112,0.455835447058152,0.352030667496009,0.113876311038284,0.103804779562143,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
480,16343,1011:1021,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.679523974313059,0.0771083701105164,0.663472519265258,10.4258355300642,26.867,0.900680487288558,0.914733151399425,0.103262159896094,0.450845483138626,0.087216130190472,0.363629352948154,4.97620369961739,0.6148,5.44963183044682,26.2522,0.612033984308543,0.366039732801374,0.621583106474846,0.394555022524418,0.245994251507169,0.227028083950428,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
481,16345,1372:1053,Breast,MDA-MB-231,SIDM00146,905960,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.763615765086353,0.0839078820149806,0.799156985406627,11.9008617850543,74.6872,0.913785066174772,0.953358572781861,0.106685974876161,0.610248872835385,0.360103382464287,0.250145490371098,8.76092944797021,8.4729,3.13993233708408,66.2143,0.697780682431532,0.581341380973734,0.727999635956455,0.644580203868949,0.116439301457798,0.0834194320875062,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
482,16345,1012:1053,Breast,MDA-MB-231,SIDM00146,905960,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.649501650972239,0.0839078820149806,0.799156985406627,11.9008617850543,74.6872,0.913785066174772,0.953358572781861,0.107341279788401,0.519053781407602,0.168660855981947,0.350392925425655,6.79941876792225,2.1755,5.10144301713205,72.5117,0.593504909114291,0.441020715285421,0.619207966990357,0.468842926710688,0.15248419382887,0.150365040279669,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
483,16345,1011:1053,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.621121574062751,0.0839078820149806,0.799156985406627,11.9008617850543,74.6872,0.913785066174772,0.953358572781861,0.0617943317857153,0.496373644699007,0.355249247698127,0.14112439700088,9.60873215894245,15.2492,2.29212962611185,59.438,0.567571618657509,0.540014386558504,0.592151577372487,0.549062007230755,0.0275572320990047,0.0430895701417324,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
484,16345,1594:1054,Breast,MDA-MB-231,SIDM00146,905960,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.802484271601919,0.0844793224552544,0.746271474377774,11.2660711380729,19.2405,0.896224759827701,0.93913589763204,0.0665207322147121,0.598871120533338,0.350626128858595,0.248244991674743,8.46721277036387,2.7649,2.798858367709,16.4756,0.719206273581937,0.614491272947155,0.753641786746462,0.664765543793966,0.104715000634782,0.0888762429524954,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
485,16346,1372:1058,Breast,MDA-MB-231,SIDM00146,905960,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.56110743864395,0.0841431102941319,0.651842889137244,10.3173280947047,9.9682,0.872508752090922,0.911066784168885,0.0802081961377076,0.365753893922071,0.167696063392749,0.198057830529322,7.20889798513037,1.1558,3.10843010957436,8.8124,0.489571151080167,0.360092073119691,0.511206349698584,0.421103288410424,0.129479077960476,0.0901030612881601,True,0.175479159839648,0.0297945796611651,1.69057344824462,29.3660054974797
486,16427,1011:1083,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.466550863898367,0.110382548787159,0.570116989312411,9.59303102275616,15.0841,0.910682959261247,0.883321265992511,0.0683946069294035,0.265988573886841,0.0752426510211777,0.190745922865664,5.53674303729388,0.9067,4.05628798546228,14.1774,0.424879921380856,0.273748222009762,0.412114299748605,0.292004922835628,0.151131699371094,0.120109376912977,True,0.265815665486094,0.04582338468735,1.28256605294822,38.5674140343485
487,16429,1058:1372,Breast,MDA-MB-231,SIDM00146,905960,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.877746424396043,0.16589188496789,0.273574524223158,6.94873170676347,0.2413,0.634122140550287,0.732457447400982,0.133005831661155,0.240129060442726,0.0740052118783336,0.166123848564392,3.99000919045585,0.031,2.95872251630762,0.2103,0.55659844149838,0.410610638338492,0.642911905478464,0.43814479260631,0.145987803159888,0.204767112872154,True,0.265815665486094,0.04582338468735,1.28256605294822,38.5674140343485
488,16429,1594:1372,Breast,MDA-MB-231,SIDM00146,905960,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.857218841505508,0.16589188496789,0.273574524223158,6.94873170676347,0.2413,0.634122140550287,0.732457447400982,0.151081689542132,0.234513236719996,0.0505693760459871,0.183943860674009,3.18257438415262,0.0177,3.76615732261085,0.2236,0.54358144669551,0.360478664233841,0.627876324513151,0.370633373353764,0.18310278246167,0.257242951159387,True,0.265815665486094,0.04582338468735,1.28256605294822,38.5674140343485
489,16431,1011:1510,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.553294832534978,0.0648195343641629,0.938299842096715,14.7171058095444,526.0419,0.96307561399396,0.986741000126265,0.0610128205104732,0.519156454000498,0.302474794550304,0.216681659450195,9.39334438524814,13.1343,5.32376142429626,512.9076,0.532864760563309,0.467374057071953,0.545958696420258,0.483932567474501,0.0654907034913568,0.0620261289457569,True,0.265815665486094,0.04582338468735,1.28256605294822,38.5674140343485
490,16431,1594:1510,Breast,MDA-MB-231,SIDM00146,905960,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.916413237903308,0.0648195343641629,0.938299842096715,14.7171058095444,526.0419,0.96307561399396,0.986741000126265,0.0291503410948891,0.859870396420014,0.81652331248897,0.0433470839310435,13.4131227814173,213.0504,1.3039830281271,312.9915,0.882575241765922,0.908228573445871,0.904262514897659,0.894398741276714,-0.0256533316799489,0.0098637736209445,True,0.265815665486094,0.04582338468735,1.28256605294822,38.5674140343485
491,14791,1053:1594,Breast,MDA-MB-436,SIDM00629,1240172,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.939847309323115,0.103343024358854,0.640857257513118,10.6796886962908,12.8144,0.844653322401755,0.876066236116592,0.0514690922186739,0.602307969133894,0.444458027776199,0.157849941357695,8.6853209401095,3.2161,1.99436775618132,9.5983,0.793845152370119,0.709444727018029,0.823368494803007,0.745201486763228,0.0844004253520899,0.0781670080397796,True,0.531829920452055,0.0634298480843635,0.612309966072266,80.1680346364017
492,17494,1549:1011,Breast,HCC2218,SIDM00772,749716,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.417958908424847,0.0745685590254449,0.856426364337593,14.1607504760572,357.7179,0.948285064789162,0.956731316043079,0.0643511074426234,0.357951028384801,0.139887238706578,0.218063789678222,7.01466308716097,2.5255,7.14608738889618,355.1924,0.396344190554864,0.270854263408226,0.399874376509233,0.293078133470358,0.125489927146638,0.106796243038875,True,1.44786602651262,0.148037981229386,-0.377364988454773,-136.040892578833
493,17494,1558:1011,Breast,HCC2218,SIDM00772,749716,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.346121451308819,0.0745685590254449,0.856426364337593,14.1607504760572,357.7179,0.948285064789162,0.956731316043079,0.0618474527518427,0.296427536163663,0.0852209475691357,0.211206588594527,5.7667528687991,1.0634,8.39399760725806,356.6545,0.328221802879302,0.149977552148233,0.331145231621427,0.215125051602516,0.178244250731069,0.116020180018911,True,1.44786602651262,0.148037981229386,-0.377364988454773,-136.040892578833
494,17494,1561:1011,Breast,HCC2218,SIDM00772,749716,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.840907650708817,0.0745685590254449,0.856426364337593,14.1607504760572,357.7179,0.948285064789162,0.956731316043079,0.0739686720033257,0.720175482040218,0.634695379254834,0.0854801027853848,12.2486989460724,95.0508,1.91205152998475,262.6671,0.797420166034112,0.812957684312386,0.80452268333334,0.775011311723182,-0.0155375182782733,0.0295113716101574,True,1.44786602651262,0.148037981229386,-0.377364988454773,-136.040892578833
495,17494,1510:1011,Breast,HCC2218,SIDM00772,749716,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.850374585869629,0.0745685590254449,0.856426364337593,14.1607504760572,357.7179,0.948285064789162,0.956731316043079,0.122466680706184,0.728283214901413,0.554808417329534,0.173474797571879,10.819722896758,35.3013,3.34102757929917,322.4166,0.806397519256438,0.766155861688832,0.813579996668639,0.749511937111594,0.0402416575676064,0.0640680595570444,True,1.44786602651262,0.148037981229386,-0.377364988454773,-136.040892578833
496,17497,1372:1053,Breast,HCC2218,SIDM00772,749716,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.912273834516257,0.110488794638947,0.740049635163096,12.023267149872,81.3007,0.85479699180557,0.916180344698989,0.0766747884804402,0.675127918402595,0.354852401293061,0.320275517109534,7.69496066143817,4.0471,4.32830648843381,77.2536,0.779808929447428,0.637098727348392,0.835807356166972,0.676052036102874,0.142710202099036,0.159755320064099,True,1.44786602651262,0.148037981229386,-0.377364988454773,-136.040892578833
497,17497,1510:1053,Breast,HCC2218,SIDM00772,749716,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.905480725951912,0.110488794638947,0.740049635163096,12.023267149872,81.3007,0.85479699180557,0.916180344698989,0.0878595092997994,0.670100680887928,0.652658305908733,0.0174423749791952,11.7404818957248,66.8294,0.282785254147209,14.4713,0.774002200681618,0.804615694086271,0.829583643620913,0.822976080044899,-0.0306134934046528,0.0066075635760146,True,1.44786602651262,0.148037981229386,-0.377364988454773,-136.040892578833
498,17498,1549:1058,Breast,HCC2218,SIDM00772,749716,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.447943237920903,0.0967164710005792,0.704097488687696,11.505031361911,22.7065,0.868329397517342,0.902408363116646,0.0596537697931344,0.315395708894742,0.230160837751897,0.085234871142845,9.15974755288599,4.4684,2.34528380902501,18.2381,0.388962281905825,0.308087530374751,0.404227724101372,0.365540836881256,0.0808747515310738,0.038686887220116,True,1.44786602651262,0.148037981229386,-0.377364988454773,-136.040892578833
499,17498,1372:1058,Breast,HCC2218,SIDM00772,749716,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.916174593869156,0.0967164710005792,0.704097488687696,11.505031361911,22.7065,0.868329397517342,0.902408363116646,0.0564797996473111,0.645076230742742,0.4028364618605,0.242239768882243,8.29952811567951,2.4615,3.2055032462315,20.245,0.7955413331151,0.688513585997818,0.826763615582523,0.709029896131141,0.107027747117282,0.117733719451382,True,1.44786602651262,0.148037981229386,-0.377364988454773,-136.040892578833
500,18187,1558:1372,Breast,HCC2218,SIDM00772,749716,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.313241485337076,0.0881727677745178,0.818165499167833,13.3459957528572,20.3364,0.896166664905184,0.944016995915047,0.0798555424483765,0.256283376210882,0.219008263405062,0.0372751128058199,11.4369789156279,5.4151,1.90901683722933,14.9213,0.280716577224473,0.203742291150896,0.295705285983873,0.282063817640026,0.0769742860735772,0.0136414683438469,True,1.13793756258385,0.138313222234702,-0.148464709671008,-394.233743116163
501,18187,1561:1372,Breast,HCC2218,SIDM00772,749716,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.825410253581309,0.0881727677745178,0.818165499167833,13.3459957528572,20.3364,0.896166664905184,0.944016995915047,0.0768241397988487,0.675322192139599,0.531012619506146,0.144309572633453,10.7044946332248,3.2591,2.64150111963237,17.0773,0.739705154130504,0.668920967347785,0.779201307983304,0.724319315075677,0.0707841867827191,0.0548819929076272,True,1.13793756258385,0.138313222234702,-0.148464709671008,-394.233743116163
502,18187,1594:1372,Breast,HCC2218,SIDM00772,749716,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.78128516735459,0.0881727677745178,0.818165499167833,13.3459957528572,20.3364,0.896166664905184,0.944016995915047,0.147910454656136,0.639220568941092,0.437213363077866,0.202007205863226,9.6922850401548,1.6158,3.65371071270241,18.7206,0.700161722768052,0.541972743592414,0.737546476639065,0.655736222372955,0.158188979175638,0.0818102542661101,True,1.13793756258385,0.138313222234702,-0.148464709671008,-394.233743116163
503,18187,1053:1372,Breast,HCC2218,SIDM00772,749716,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.779388746652753,0.0881727677745178,0.818165499167833,13.3459957528572,20.3364,0.896166664905184,0.944016995915047,0.103827617213883,0.637668982950942,0.442247432901558,0.195421550049384,9.78416669574702,1.7221,3.56182905711018,18.6143,0.69846221375243,0.567696377807588,0.735756223265126,0.657100143483074,0.130765835944841,0.0786560797820517,True,1.13793756258385,0.138313222234702,-0.148464709671008,-394.233743116163
504,18191,1549:1561,Breast,HCC2218,SIDM00772,749716,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.542163215281474,0.0846425256493333,0.544705108218642,9.51811866261929,14.3209,0.784565691880252,0.831937536456346,0.0871849857093832,0.295319072852062,0.136502647579637,0.158816425272425,5.85263175290138,1.1286,3.66548690971791,13.1923,0.425362658109332,0.284741508257771,0.451045929678521,0.340064756535195,0.140621149851561,0.110981173143326,True,1.13793756258385,0.138313222234702,-0.148464709671008,-394.233743116163
505,18191,1372:1561,Breast,HCC2218,SIDM00772,749716,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.88390129412703,0.0846425256493333,0.544705108218642,9.51811866261929,14.3209,0.784565691880252,0.831937536456346,0.0896423378636242,0.481465550072062,0.294843103470349,0.186622446601712,7.00010083574645,2.5002,2.51801782687284,11.8207,0.693478630380624,0.581475558724005,0.735350665106618,0.619021642227192,0.112003071656619,0.116329022879426,True,1.13793756258385,0.138313222234702,-0.148464709671008,-394.233743116163
506,18191,1011:1561,Breast,HCC2218,SIDM00772,749716,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.923680197138304,0.0846425256493333,0.544705108218642,9.51811866261929,14.3209,0.784565691880252,0.831937536456346,0.0874919926783965,0.503133321741637,0.292526455614919,0.210606866126718,6.77784704434624,2.1432,2.74027161827306,12.1777,0.724687792943902,0.588193674712032,0.768444227680753,0.634281873137356,0.13649411823187,0.134162354543397,True,1.13793756258385,0.138313222234702,-0.148464709671008,-394.233743116163
507,14599,1011:1021,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.824522641708191,0.0982761385283321,0.746700834308523,10.9559428102123,38.7969,0.887232478397275,0.94739809962304,0.0532284700324807,0.615671744469773,0.322310119184347,0.293361625285427,8.19759138033057,5.7339,2.75835142988174,33.063,0.731543266897426,0.677944527534368,0.781151183850509,0.685325717820442,0.0535987393630581,0.0958254660300673,True,0.717069956261618,0.0796455145986675,0.317764512703512,151.963460710734
508,17712,1011:1083,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.82095688686233,0.0724610820647559,0.691493161942797,10.4602435014307,27.5155,0.920767163225173,0.933577999064105,0.0903456879496519,0.567686073515148,0.303719332870722,0.263966740644426,8.03677098603976,5.1291,2.42347251539091,22.3864,0.755910143846398,0.637828325526293,0.766427287754831,0.674266504061308,0.118081818320105,0.0921607836935231,True,0.631235615604717,0.0695455608990484,0.442469752279753,110.018627600449
509,17712,1053:1083,Breast,CAMA-1,SIDM00920,946382,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.73759599700793,0.0724610820647559,0.691493161942797,10.4602435014307,27.5155,0.920767163225173,0.933577999064105,0.0536137437033034,0.510042588207363,0.24897796177352,0.261064626433843,7.78018926472565,4.2934,2.68005423670502,23.2221,0.679154173771235,0.550453951501908,0.688603395004356,0.593704904960178,0.128700222269327,0.0948984900441781,True,0.631235615604717,0.0695455608990484,0.442469752279753,110.018627600449
510,17716,1053:1549,Breast,CAMA-1,SIDM00920,946382,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.867834452877192,0.0746878718626742,0.910788647620004,13.2033807238222,92.1115,0.948813692720436,0.98316425342854,0.0907265159846815,0.790413767694064,0.595502882843504,0.194910884850559,10.4155133503212,13.3377,2.78786737350099,78.7738,0.823413211904428,0.742796971598646,0.85322381196257,0.808990270856114,0.0806162403057821,0.0442335411064563,True,0.631235615604717,0.0695455608990484,0.442469752279753,110.018627600449
511,17717,1049:1558,Breast,CAMA-1,SIDM00920,946382,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.94726124064909,0.089610843250187,0.780260209201003,11.2926218469578,48.9946,0.912217143541507,0.955310580814976,0.0535304112063382,0.739110253796861,0.845269229552365,-0.106158975755504,12.8260812406736,141.8291,-1.53345939371583,-92.8345,0.864107943132497,0.904399982247984,0.904928685987997,0.927819783773765,-0.0402920391154865,-0.0228910977857683,True,0.631235615604717,0.0695455608990484,0.442469752279753,110.018627600449
512,17717,1053:1558,Breast,CAMA-1,SIDM00920,946382,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.752388250630076,0.089610843250187,0.780260209201003,11.2926218469578,48.9946,0.912217143541507,0.955310580814976,0.0464035135024012,0.587058613837,0.382769354376364,0.204289259460635,9.06325080526114,10.4482,2.22937104169665,38.5464,0.686341460823959,0.629184805740609,0.718764456707781,0.660914657388014,0.0571566550833501,0.0578497993197665,True,0.631235615604717,0.0695455608990484,0.442469752279753,110.018627600449
513,17718,1011:1561,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.853138207774778,0.0847113993951574,0.484282851657715,8.88621898474791,9.2416,0.83845025909076,0.86958010791352,0.105397043894069,0.413160204119322,0.174786039593612,0.23837416452571,6.54650065628644,1.8257,2.33971832846147,7.4159,0.715313951348989,0.563137458393087,0.741872014781939,0.610799051302488,0.152176492955903,0.131072963479451,True,0.631235615604717,0.0695455608990484,0.442469752279753,110.018627600449
514,14976,1021:1011,Breast,BT-483,SIDM00892,949093,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.941667904609352,0.126470568534485,0.664173908203415,11.5849096050277,59.9978,0.882265104140429,0.858349645729562,0.0715536235122244,0.625431252434114,0.511550242211117,0.113881010222998,9.6572173051211,15.7704,1.9276922999066,44.2274,0.83080073192587,0.763883248971975,0.808280312316337,0.744698335885668,0.0669174829538949,0.0635819764306688,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
515,14976,1058:1011,Breast,BT-483,SIDM00892,949093,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.894467926332458,0.126470568534485,0.664173908203415,11.5849096050277,59.9978,0.882265104140429,0.858349645729562,0.115876515457067,0.594082258394834,0.518959616098457,0.0751226422963761,10.2263876683173,23.398,1.3585219367104,36.5998,0.78915783817598,0.780315007574002,0.767766227683922,0.726990631795437,0.0088428306019781,0.040775595888485,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
516,14976,1561:1011,Breast,BT-483,SIDM00892,949093,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.81317231870179,0.126470568534485,0.664173908203415,11.5849096050277,59.9978,0.882265104140429,0.858349645729562,0.110224446360077,0.540087836955001,0.406139193409861,0.13394864354514,8.99166617328067,9.9424,2.59324343174703,50.0554,0.717433560443549,0.667925316199609,0.697986171674768,0.620513054943365,0.04950824424394,0.0774731167314026,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
517,14976,1594:1011,Breast,BT-483,SIDM00892,949093,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.941170839102575,0.126470568534485,0.664173908203415,11.5849096050277,59.9978,0.882265104140429,0.858349645729562,0.0524293577272048,0.625101114493845,0.538686583529816,0.0864145309640292,10.1048368566944,21.5075,1.48007274833329,38.4903,0.830362188374769,0.790150647029205,0.80785365631469,0.760672968433425,0.0402115413455635,0.0471806878812653,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
518,14979,1012:1053,Breast,BT-483,SIDM00892,949093,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.856261616791606,0.0881472929000871,0.776688641185803,13.7247100934569,264.411,0.881105491165398,0.911921145407969,0.0953516085615635,0.665048671645431,0.479608318073722,0.185440353571709,9.91594545440341,18.8681,3.80876463905345,245.5429,0.754456812429246,0.618690313181604,0.78084307435348,0.685871887417201,0.135766499247642,0.0949711869362795,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
519,14979,1594:1053,Breast,BT-483,SIDM00892,949093,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.93086903565627,0.0881472929000871,0.776688641185803,13.7247100934569,264.411,0.881105491165398,0.911921145407969,0.142113934982218,0.722995406425807,0.518983826722119,0.204011579703688,9.87608263208082,18.3538,3.84862746137605,246.0572,0.820193818872579,0.645936234711548,0.848879157220477,0.744194145130683,0.174257584161031,0.104685012089794,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
520,14980,1558:1058,Breast,BT-483,SIDM00892,949093,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.979700625103108,0.0798850008462557,0.736580413639032,12.8976221385207,59.6158,0.880035148355081,0.893680632723947,0.0786096714673798,0.721628291680866,0.550267185158115,0.17136110652275,9.93979717549355,7.673,2.95782496302714,51.9428,0.862170984956179,0.718900226226849,0.875539474522192,0.785649678943876,0.14327075872933,0.0898897955783162,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
521,14980,1012:1058,Breast,BT-483,SIDM00892,949093,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.822028781121742,0.0798850008462557,0.736580413639032,12.8976221385207,59.6158,0.880035148355081,0.893680632723947,0.0711723956227284,0.605490299621842,0.457804274589128,0.147686025032714,9.86677045404863,7.2943,3.03085168447205,52.3215,0.723414220346618,0.660504394127517,0.734631201230173,0.656882736967903,0.0629098262191011,0.0777484642622707,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
522,14980,1011:1058,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.909719357415662,0.0798850008462557,0.736580413639032,12.8976221385207,59.6158,0.880035148355081,0.893680632723947,0.123207437236489,0.670081460580663,0.324628171556199,0.345453289024464,6.76708550985383,0.8509,6.13053662866686,58.7649,0.800585009664781,0.614147966750322,0.812998570936451,0.596184016273379,0.186437042914459,0.216814554663072,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
523,14980,1594:1058,Breast,BT-483,SIDM00892,949093,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.922114547433916,0.0798850008462557,0.736580413639032,12.8976221385207,59.6158,0.880035148355081,0.893680632723947,0.0564915731365107,0.679211514771443,0.533811254579897,0.145400260191546,10.2063366281822,9.23,2.69128551033853,50.3858,0.811493212551385,0.707393658325503,0.824075912194698,0.748774559668361,0.104099554225882,0.0753013525263373,True,0.643614695201627,0.0677934078902963,0.424788000467702,114.720138875284
524,17709,1011:1558,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.834600167869619,0.0741025674326197,0.739751901399107,12.9598206053867,155.6054,0.906952479745828,0.895155364306428,0.111072694366451,0.617397061089565,0.359176399866772,0.258220661222793,7.93718054848788,4.787,5.02264005689878,150.8184,0.756942691845635,0.596993864729326,0.747096817319534,0.596473948773754,0.159948827116309,0.15062286854578,True,0.731107322694025,0.0632466572623584,0.295926276950934,161.729424507952
525,17710,1011:1561,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.859553450580237,0.155836768535401,0.602008295202968,10.5686461411345,29.6626,0.755300982337181,0.825144166246465,0.0553342706719653,0.517458307419637,0.145431432264022,0.372026875155615,2.96804734436855,0.1528,7.60059879676594,29.5098,0.649221565594567,0.331097506952125,0.709255515323302,0.378711509345168,0.318124058642441,0.330544005978135,True,0.731107322694025,0.0632466572623584,0.295926276950934,161.729424507952
526,17710,1083:1594,Breast,BT-483,SIDM00892,949093,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.966218317618391,0.0839525536531507,0.640506330218844,11.189230019197,18.2425,0.846727916728091,0.846048155493018,0.0806310790504506,0.618868948807981,0.408211973534924,0.210656975273057,7.81516233632341,1.7595,3.3740676828736,16.483,0.818124023181541,0.638436174450751,0.817467225424606,0.684811089688489,0.17968784873079,0.132656135736117,True,0.731107322694025,0.0632466572623584,0.295926276950934,161.729424507952
527,17710,1011:1594,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.859553450580237,0.0839525536531507,0.640506330218844,11.189230019197,18.2425,0.846727916728091,0.846048155493018,0.189525840582193,0.550549426258092,0.341506902298497,0.209042523959595,7.42052394222068,1.3384,3.76870607697633,16.9041,0.727807902526246,0.657667356923771,0.727223611411068,0.592360666076764,0.0701405456024753,0.134862945334304,True,0.731107322694025,0.0632466572623584,0.295926276950934,161.729424507952
528,16356,1561:1011,Breast,MDA-MB-453,SIDM00272,908122,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.365091756046347,0.161315930568158,0.516247497050375,9.14968867359494,11.0933,0.869429799501156,0.850556098592844,0.0349266448577723,0.188477705252653,0.0907632726040278,0.0977144326486247,6.45332948835586,1.7115,2.69635918523908,9.3818,0.3174216522589,0.253944024613722,0.310531019651191,0.251326949073952,0.0634776276451782,0.0592040705772396,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
529,16356,1012:1011,Breast,MDA-MB-453,SIDM00272,908122,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.202296168442901,0.161315930568158,0.516247497050375,9.14968867359494,11.0933,0.869429799501156,0.850556098592844,0.039213126223189,0.104434890621529,0.037770164291098,0.0666647263304307,5.61183677949146,0.9551,3.53785189410348,10.1382,0.175882317169164,0.0965762355316765,0.172064239791075,0.126693610767972,0.0793060816374872,0.0453706290231029,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
530,16356,1053:1011,Breast,MDA-MB-453,SIDM00272,908122,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.386820855216608,0.161315930568158,0.516247497050375,9.14968867359494,11.0933,0.869429799501156,0.850556098592844,0.0283846416026117,0.199695298312459,0.0708371619292951,0.128858136383164,5.5571359261152,0.9196,3.59255274747973,10.1737,0.336313578593841,0.230714095668517,0.329012837467386,0.240647297156616,0.105599482925324,0.0883655403107696,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
531,16359,1549:1054,Breast,MDA-MB-453,SIDM00272,908122,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.790601597735627,0.089940060511526,0.686214912950798,10.8016242174148,13.9445,0.866524247583761,0.914662150403267,0.138285332021977,0.542522606568915,0.32556437692617,0.216958229642745,8.17904605512966,2.2643,2.62257816228513,11.6802,0.685075454616384,0.540524118770863,0.723133357497127,0.632444677502082,0.144551335845521,0.0906886799950449,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
532,16359,1058:1054,Breast,MDA-MB-453,SIDM00272,908122,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.516924981418556,0.089940060511526,0.686214912950798,10.8016242174148,13.9445,0.866524247583761,0.914662150403267,0.0646060410227407,0.354721631126227,0.334466106340147,0.0202555247860807,10.3953073244972,10.5218,0.406316892917575,3.4227,0.447928030580964,0.42429954426436,0.472811715101465,0.465949259486383,0.0236284863166047,0.006862455615082,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
533,16359,1594:1054,Breast,MDA-MB-453,SIDM00272,908122,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.930658364920838,0.089940060511526,0.686214912950798,10.8016242174148,13.9445,0.866524247583761,0.914662150403267,0.169863090456294,0.638631648871085,0.377924355318888,0.260707293552197,8.1246493593288,2.1805,2.67697485808599,11.764,0.806438039420563,0.617915717793805,0.851237981349282,0.741584695390025,0.188522321626758,0.109653285959257,True,0.432610485048045,0.0538067672074313,0.82017465097266,60.2817438436054
534,16437,1594:1372,Breast,MDA-MB-453,SIDM00272,908122,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.596069489152148,0.092436016659668,0.774290412516257,11.8382208767756,7.1514,0.897155827065011,0.941972045247607,0.0789298022740936,0.461530890643971,0.368540276027912,0.0929906146160598,10.1104040218249,2.1591,1.7278168549507,4.9923,0.534767215528513,0.469503807584885,0.561480795806345,0.531179290543267,0.065263407943628,0.0303015052630777,True,0.537901110701962,0.0623502917795008,0.599845033657154,81.7095318851693
535,16439,1594:1549,Breast,MDA-MB-453,SIDM00272,908122,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.905729126128379,0.0932610762747561,0.68527318417552,10.7915625472131,17.3095,0.876366910696809,0.914351912937316,0.047463477190199,0.620671882262505,0.342379580737846,0.278292301524659,7.85342701287007,2.2585,2.938135534343,15.051,0.793751036193248,0.673094726696729,0.828155159078527,0.707269776067707,0.120656309496519,0.12088538301082,True,0.537901110701962,0.0623502917795008,0.599845033657154,81.7095318851693
536,16439,1012:1549,Breast,MDA-MB-453,SIDM00272,908122,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.867451018708196,0.0932610762747561,0.68527318417552,10.7915625472131,17.3095,0.876366910696809,0.914351912937316,0.0504147204795869,0.594440921706463,0.319611851886308,0.274829069820155,7.75927038473317,2.1158,3.03229216247989,15.1937,0.760205369446101,0.64384429654237,0.793155498335262,0.672434175926846,0.11636107290373,0.120721322408416,True,0.537901110701962,0.0623502917795008,0.599845033657154,81.7095318851693
537,16439,1049:1549,Breast,MDA-MB-453,SIDM00272,908122,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.710217321102984,0.0932610762747561,0.68527318417552,10.7915625472131,17.3095,0.876366910696809,0.914351912937316,0.0564154987766196,0.486692885088849,0.233085959608714,0.253606925480135,7.35056292565919,1.5938,3.44099962155387,15.7157,0.622410959618385,0.49885937885545,0.649388566151729,0.53231808712159,0.123551580762935,0.117070479030139,True,0.537901110701962,0.0623502917795008,0.599845033657154,81.7095318851693
538,16439,1058:1549,Breast,MDA-MB-453,SIDM00272,908122,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.905068369288552,0.0932610762747561,0.68527318417552,10.7915625472131,17.3095,0.876366910696809,0.914351912937316,0.111600212716334,0.620219083318911,0.250678183456435,0.369540899862476,6.79072472144436,1.0812,4.0008378257687,16.2283,0.793171970762807,0.565772572132622,0.827550994798044,0.644484290778127,0.227399398630185,0.183066704019917,True,0.537901110701962,0.0623502917795008,0.599845033657154,81.7095318851693
539,16440,1012:1558,Breast,MDA-MB-453,SIDM00272,908122,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.234358758726767,0.109585766889668,0.249670132394917,6.46645149681414,1.7271,0.680148232104261,0.689329759289651,0.0532984916191214,0.0585123823192202,0.0164670951845898,0.0420452871346304,3.05362374118741,0.1622,3.41282775562673,1.5649,0.159398695426159,0.0550048828079269,0.161550466740543,0.0996305638223519,0.104393812618232,0.0619199029181915,True,0.537901110701962,0.0623502917795008,0.599845033657154,81.7095318851693
540,15011,1021:1011,Breast,HCC1954,SIDM00872,749709,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.900231486522389,0.0568970876205071,0.79423453942864,11.6528897448285,62.8926,0.933156932836243,0.955062883844101,0.04422976044112,0.71499494007727,0.70542351684901,0.0095714232282594,11.5274622385468,57.6557,0.125427506281717,5.2369,0.840057252805844,0.857590961355035,0.859777679645335,0.857413195683058,-0.0175337085491903,0.0023644839622772,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
541,15011,1561:1011,Breast,HCC1954,SIDM00872,749709,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.663914452337295,0.0568970876205071,0.79423453942864,11.6528897448285,62.8926,0.933156932836243,0.955062883844101,0.0604323221833168,0.52730378927213,0.445912927334044,0.0813908619380855,10.4056023459239,26.4928,1.24728739890463,36.3998,0.619536374008725,0.561233248258951,0.634080051475034,0.61240130364526,0.0583031257497734,0.0216787478297739,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
542,15011,1058:1012,Breast,HCC1954,SIDM00872,749709,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.988582466256974,0.0574838828898773,0.76444245666512,11.3122039149074,24.8321,0.927281628506596,0.947612635587142,0.0458306620752279,0.755714409121544,0.656857570623631,0.0988568384979125,10.3418445435117,12.6738,0.970359371395677,12.1583,0.916694359223834,0.89321709646651,0.936793236345008,0.909805239949857,0.0234772627573243,0.0269879963951504,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
543,15011,1053:1012,Breast,HCC1954,SIDM00872,749709,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,5.0,0.972358592875529,0.0574838828898773,0.76444245666512,11.3122039149074,24.8321,0.927281628506596,0.947612635587142,0.0658715231642699,0.743312191497208,0.665080147016643,0.0782320444805644,10.5166399706193,14.3062,0.795563944288119,10.5259,0.901650259494002,0.858352841644055,0.921419288930584,0.90036014180297,0.0432974178499473,0.0210591471276141,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
544,15012,1011:1021,Breast,HCC1954,SIDM00872,749709,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.92947895663382,0.0636539580664556,0.76631761484474,11.3327144334641,50.3752,0.945659205984026,0.948089991758251,0.0639461339983818,0.712276097096006,0.418599824397106,0.2936762726989,8.60870274942266,7.6244,2.72401168404145,42.7508,0.878970332109199,0.787925327621624,0.881229696334426,0.785210204107709,0.0910450044875741,0.0960194922267172,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
545,15014,1549:1053,Breast,HCC1954,SIDM00872,749709,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.811104591403647,0.0584468392005528,0.536756908178248,9.28930914273968,12.2205,0.871846666247663,0.87882726543776,0.0614137246111738,0.435365992691002,0.204841055868449,0.230524936822553,6.86871790989117,2.2825,2.42059123284852,9.938,0.707158833993443,0.566381932654561,0.712820830047278,0.594735680285929,0.140776901338882,0.118085149761349,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
546,15014,1049:1053,Breast,HCC1954,SIDM00872,749709,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.966003177438465,0.0584468392005528,0.536756908178248,9.28930914273968,12.2205,0.871846666247663,0.87882726543776,0.0428739373843642,0.518508878812234,0.443761305354592,0.0747475734576419,8.68014671176482,8.0115,0.609162430974864,4.209,0.842206649834375,0.820387334525948,0.848949930832433,0.819777070505402,0.0218193153084277,0.0291728603270304,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
547,15014,1558:1053,Breast,HCC1954,SIDM00872,749709,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.88993860638389,0.0584468392005528,0.536756908178248,9.28930914273968,12.2205,0.871846666247663,0.87882726543776,0.0593324649486553,0.477680694831075,0.285776778855506,0.191903915975569,7.52956152957027,3.6087,1.75974761316941,8.6118,0.775890007140886,0.644377226386042,0.782102311855845,0.6936353776633,0.131512780754844,0.0884669341925454,True,0.55166784925832,0.0485019310584803,0.577495538584205,85.0076002818603
548,16421,1561:1372,Breast,HCC1954,SIDM00872,749709,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.542162599554494,0.0789790367010351,0.665041308674675,10.3471099572276,2.544,0.8665605621709,0.920487842637639,0.075303118089818,0.360560524722185,0.292568140806061,0.0679923839161236,9.31202831923825,1.2415,1.0350816379894,1.3025,0.469816727057979,0.415646204152019,0.49905408162273,0.47702963654542,0.0541705229059596,0.0220244450773101,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
549,16423,1561:1549,Breast,HCC1954,SIDM00872,749709,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.568081237286738,0.0789713414273137,0.679662604994962,10.477491077679,13.9232,0.898090984559462,0.924720429254739,0.0831725170208141,0.386103573583065,0.141207043274247,0.244896530308818,6.82711343829154,1.1088,3.65037763938748,12.8144,0.510188637704604,0.346216269571479,0.525316325595356,0.414812233455006,0.163972368133125,0.110504092140349,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
550,16423,1594:1549,Breast,HCC1954,SIDM00872,749709,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.844948824409834,0.0789713414273137,0.679662604994962,10.477491077679,13.9232,0.898090984559462,0.924720429254739,0.0830849836403556,0.574280119085818,0.365816439258881,0.208463679826938,8.46997811478094,3.4627,2.00751296289808,10.4605,0.758840921616588,0.643033386665807,0.781341439606549,0.707346027601129,0.115807534950781,0.0739954120054199,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
551,16423,1053:1549,Breast,HCC1954,SIDM00872,749709,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.970570721924356,0.0789713414273137,0.679662604994962,10.477491077679,13.9232,0.898090984559462,0.924720429254739,0.0585530572985032,0.659660625194949,0.465629855743493,0.194030769451456,8.84080344097556,4.4776,1.63668763670346,9.4456,0.871660815237633,0.801499079808788,0.897506574599973,0.831816748449756,0.0701617354288452,0.0656898261502165,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
552,16423,1058:1549,Breast,HCC1954,SIDM00872,749709,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.829002687270177,0.0789713414273137,0.679662604994962,10.477491077679,13.9232,0.898090984559462,0.924720429254739,0.106493251275514,0.563442125977872,0.257580485979747,0.305861639998126,7.43495723893425,1.6898,3.04253383874477,12.2334,0.744519839612914,0.562870822465517,0.766595720825811,0.640878638502466,0.181649017147396,0.125717082323344,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
553,16425,1049:1594,Breast,HCC1954,SIDM00872,749709,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.952125507908656,0.0833444951707476,0.604531290635854,9.83355779935862,7.1283,0.880191960056533,0.901931683642506,0.0490695136303069,0.575589662143338,0.35000598821446,0.225583673928878,7.93442674621723,1.9111,1.89913105314138,5.2172,0.838053217025942,0.764971596180704,0.85875216238703,0.766940655431343,0.0730816208452382,0.0918115069556867,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
554,16425,1058:1594,Breast,HCC1954,SIDM00872,749709,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.986608967654293,0.0833444951707476,0.604531290635854,9.83355779935862,7.1283,0.880191960056533,0.901931683642506,0.0643640639472399,0.596435992568958,0.391939589469986,0.204496403098971,8.18114184894772,2.2676,1.6524159504109,4.8607,0.868405281048985,0.777386160329154,0.889853887293231,0.809511644750615,0.0910191207198311,0.0803422425426156,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
555,16425,1053:1594,Breast,HCC1954,SIDM00872,749709,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.979916055843095,0.0833444951707476,0.604531290635854,9.83355779935862,7.1283,0.880191960056533,0.901931683642506,0.0823432336906001,0.592389917953622,0.320493262510729,0.271896655442893,7.5828444120486,1.4978,2.25071338731001,5.6305,0.862514233883401,0.741986902851264,0.883817338074886,0.767228545176093,0.120527331032136,0.116588792898793,True,0.735938825388516,0.0673460875008856,0.29436551473555,164.496524781276
556,14676,1558:1011,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.995787507128496,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.109940528732945,0.0465542603800602,0.0193057421590147,0.0272485182210455,5.3401023383858,0.7912,0.847466711385928,0.6324,0.63778776888976,0.610265810270621,0.711323595055956,0.629624666618381,0.0275219586191399,0.0816989284375748,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
557,14676,1510:1011,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.828243572771293,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.0630169305357147,0.0387213804841705,0.0023370800313067,0.0363843004528638,3.52671166551883,0.2251,2.66085738425289,1.1985,0.53047825624802,0.383844270733617,0.591641481288078,0.375304442969176,0.146633985514403,0.216337038318902,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
558,14676,1083:1011,Breast,DU-4475,SIDM01001,906844,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.430722728948199,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.0487409180328726,0.0201368042192931,5.75113061545007e-05,0.0200792929131386,0.678377675931278,0.0313,5.50919137384045,1.3923,0.275871796281265,0.0811794091575873,0.307679337041742,0.0784365616799378,0.194692387123677,0.229242775361804,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
559,14676,1012:1011,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.153279680261852,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.0594670649525019,0.0071660089073217,4.46936573226253e-05,0.0071213152499991,1.40709031910779,0.0518,4.78047873066394,1.3718,0.0981734602919932,0.0060203951622299,0.10949269039064,0.0379354638919599,0.0921530651297633,0.0715572264986804,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
560,14676,1021:1011,Breast,DU-4475,SIDM01001,906844,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.414618113634862,0.136951323355275,0.0467511994745812,6.18756904977172,1.4236,0.640485810802064,0.714332716532231,0.0224481936995704,0.019383894136318,0.0002040283023049,0.0191798658340131,1.89544380605587,0.0727,4.29212524371585,1.3509,0.265557018684647,0.11771344435958,0.29617528343626,0.121728806754436,0.147843574325067,0.174446476681824,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
561,14678,1083:1049,Breast,DU-4475,SIDM01001,906844,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.396970211416259,0.0869814439540082,0.785097530833364,10.2085600460106,23.1107,0.93573748944512,0.977431674593915,0.0549901905667506,0.311660332797304,0.142354159571802,0.169306173225501,8.457632952586,6.8664,1.7509270934246,16.2443,0.371459909015149,0.32421865789665,0.388011258508495,0.358996371705728,0.0472412511184994,0.0290148868027671,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
562,14678,1011:1049,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.434650711210396,0.0869814439540082,0.785097530833364,10.2085600460106,23.1107,0.93573748944512,0.977431674593915,0.0658083540668212,0.341243200146247,0.11115961057214,0.230083589574107,8.00357694702204,5.0124,2.20498309898856,18.0983,0.406718965293551,0.331872047404928,0.424841372521813,0.379368103825053,0.0748469178886237,0.0454732686967605,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
563,14678,1558:1049,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.75589473484641,0.0869814439540082,0.785097530833364,10.2085600460106,23.1107,0.93573748944512,0.977431674593915,0.0815896765486613,0.593451089897857,0.243769198899032,0.349681890998824,8.30753655307335,6.188,1.90102349293725,16.9227,0.707319041469964,0.630497409117798,0.73883545649765,0.67610323802524,0.076821632352166,0.0627322184724098,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
564,14678,1561:1049,Breast,DU-4475,SIDM01001,906844,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.842537439756207,0.0869814439540082,0.785097530833364,10.2085600460106,23.1107,0.93573748944512,0.977431674593915,0.0459122279725128,0.661474063587262,0.725693924559275,-0.0642198609720133,10.7035691342175,32.5706,-0.495009088206903,-9.4599,0.788393868640992,0.812862690931934,0.823522780648979,0.830804731790291,-0.0244688222909419,-0.0072819511413124,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
565,14678,1510:1049,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.176111032921097,0.0869814439540082,0.785097530833364,10.2085600460106,23.1107,0.93573748944512,0.977431674593915,0.0137961931805547,0.138264337098867,0.0785378634134399,0.0597264736854268,8.7975617660969,8.6908,1.4109982799137,14.4199,0.164793695809174,0.168976575747154,0.172136501822532,0.162845585966054,-0.0041828799379794,0.009290915856478,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
566,14678,1053:1049,Breast,DU-4475,SIDM01001,906844,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.999503469053151,0.0869814439540082,0.785097530833364,10.2085600460106,23.1107,0.93573748944512,0.977431674593915,0.0966754855691576,0.78470770561301,0.569827879360918,0.214879826252092,9.26333354822091,12.0025,0.945226497789683,11.1082,0.935272866823483,0.85749308934426,0.976946349519048,0.94711465236601,0.0777797774792234,0.0298316971530384,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
567,14679,1049:1053,Breast,DU-4475,SIDM01001,906844,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.753388145275598,0.112410123158647,0.444636957001577,8.79257855141842,8.6608,0.869681550222857,0.924399255217426,0.0887765258129674,0.334984212356404,0.126217696045004,0.2087665163114,7.50452269340132,3.5466,1.2880558580171,5.1142,0.655207770102805,0.588991665631371,0.696431440382401,0.627842375734963,0.0662161044714341,0.0685890646474381,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
568,14679,1594:1053,Breast,DU-4475,SIDM01001,906844,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.790827825114314,0.112410123158647,0.444636957001577,8.79257855141842,8.6608,0.869681550222857,0.924399255217426,0.108962315838518,0.351631277671004,0.140550406765943,0.211080870905061,7.5711035767133,3.7141,1.22147497470512,4.9467,0.687768368904787,0.589529757946234,0.731040652540889,0.663399138128063,0.098238610958553,0.0676415144128253,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
569,14679,1012:1053,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.81989202591422,0.112410123158647,0.444636957001577,8.79257855141842,8.6608,0.869681550222857,0.924399255217426,0.0835375812091419,0.364554295472357,0.218274930985013,0.146279364487344,8.05426421430036,5.1916,0.738314337118055,3.4692,0.713044968112437,0.641199247818363,0.757907578113811,0.718682164107946,0.0718457202940744,0.0392254140058654,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
570,14679,1054:1053,Breast,DU-4475,SIDM01001,906844,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.985359843487212,0.112410123158647,0.444636957001577,8.79257855141842,8.6608,0.869681550222857,0.924399255217426,0.0447265550506412,0.438127402359704,0.48998851402474,-0.0518611116650357,8.98980849532089,9.9296,-0.197229943902473,-1.2688,0.85694927621131,0.923438355844539,0.910865905440738,0.92114810486425,-0.0664890796332293,-0.0102821994235118,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
571,14679,1558:1053,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.974162653126992,0.112410123158647,0.444636957001577,8.79257855141842,8.6608,0.869681550222857,0.924399255217426,0.1330796562224,0.433148717710969,0.302867459267907,0.130281258443062,8.25757029956172,5.9773,0.535008251856699,2.6835,0.847211286340694,0.851168017793283,0.900515231011224,0.868005149800846,-0.0039567314525891,0.0325100812103781,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
572,14680,1510:1058,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.840920154830238,0.0889459413304717,0.640241326475908,9.5376778763611,5.8065,0.907497946082968,0.958406584580388,0.0977004972631354,0.538391835388837,0.252553970131699,0.285837865257138,8.21110664259688,2.3152,1.32657123376422,3.4913,0.763133313328213,0.698326104578799,0.80594341349566,0.746569511046743,0.0648072087494141,0.0593739024489168,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
573,14680,1012:1058,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.175088598822816,0.0889459413304717,0.640241326475908,9.5376778763611,5.8065,0.907497946082968,0.958406584580388,0.0626044793011413,0.112098956761128,0.0049609840393459,0.107137972721782,5.70259730537564,0.4069,3.83508057098546,5.3996,0.15889254381425,0.0579664716851238,0.167806065996741,0.11689776062281,0.100926072129127,0.0509083053739307,True,0.420815151386138,0.0667873149671643,0.849840144688778,58.2690083739384
574,15199,1558:1510,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.934372859616922,0.105773587933719,0.303656090667141,8.225823146102,5.8472,0.869216610137581,0.888827859860504,0.0838429815260177,0.283728009776752,0.229661436639095,0.0540665731376571,7.95415927538414,4.8436,0.271663870717865,1.0036,0.812172409640779,0.821256792047991,0.830496629125048,0.812071962845135,-0.0090843824072122,0.018424666279913,True,0.755252545647994,0.089812823923721,0.27319382048135,178.959809306494
575,15199,1049:1549,Breast,DU-4475,SIDM01001,906844,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.618097451064084,0.0606255768500722,0.90352652502791,11.0867124214056,21.2389,0.954222586738432,0.990536963635798,0.0492559636822655,0.55846744208854,0.356615024154829,0.201852417933711,9.28943883439074,6.1108,1.79727358701488,15.1281,0.589802548610802,0.562968233647965,0.612248372408044,0.586388070156125,0.0268343149628361,0.0258603022519186,True,0.755252545647994,0.089812823923721,0.27319382048135,178.959809306494
576,15199,1011:1549,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.364696239408464,0.0606255768500722,0.90352652502791,11.0867124214056,21.2389,0.954222586738432,0.990536963635798,0.0516998788433368,0.329512725883477,0.0987533907255447,0.230759335157932,8.07591461528239,2.6351,3.01079780612324,18.6038,0.348001388942124,0.27578623720617,0.361245105633054,0.320254604790892,0.0722151517359533,0.0409905008421625,True,0.755252545647994,0.089812823923721,0.27319382048135,178.959809306494
577,15199,1558:1549,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.625414035854077,0.0606255768500722,0.90352652502791,11.0867124214056,21.2389,0.954222586738432,0.990536963635798,0.100162409732496,0.565078170518915,0.135109502588105,0.42996866793081,7.79767344395569,2.1729,3.28903897744993,19.066,0.5967841990752,0.470946265536095,0.619495720090107,0.536024621618229,0.125837933539105,0.0834710984718782,True,0.755252545647994,0.089812823923721,0.27319382048135,178.959809306494
578,16404,1021:1561,Breast,DU-4475,SIDM01001,906844,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.72064255451911,0.0483671730142474,0.811102831670099,10.3592713343761,25.6556,0.966911975835144,0.980471301232369,0.0294973181563327,0.584515216592424,0.60628421740984,-0.021769000817416,10.5559246013073,29.4022,-0.196653266931198,-3.7466,0.696797916260958,0.694232914236586,0.706569343152771,0.709027309376915,0.0025650020243724,-0.002457966224144,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
579,16404,1049:1561,Breast,DU-4475,SIDM01001,906844,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.923504230814571,0.0483671730142474,0.811102831670099,10.3592713343761,25.6556,0.966911975835144,0.980471301232369,0.0563876684646937,0.749056896673015,0.67665843416587,0.0723984625071451,9.94063990075714,19.1938,0.418631433618989,6.4618,0.892947300509031,0.890095886312215,0.90546939488036,0.896713187522102,0.002851414196816,0.0087562073582588,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
580,16404,1558:1561,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.960481024655804,0.0483671730142474,0.811102831670099,10.3592713343761,25.6556,0.966911975835144,0.980471301232369,0.0411741715175234,0.779048878863721,0.688502913071794,0.0905459657919269,9.86638438155203,18.2309,0.492886952824099,7.4247,0.928700605302107,0.935649526971591,0.941724080053275,0.930654702076156,-0.006948921669484,0.0110693779771193,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
581,16404,1012:1561,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.325834409993935,0.0483671730142474,0.811102831670099,10.3592713343761,25.6556,0.966911975835144,0.980471301232369,0.0701247881606114,0.264285212601637,0.000206043030307,0.26407916957133,2.12951664131489,0.0855,8.22975469306124,25.5701,0.315053193162314,0.0703344812452746,0.319471287953035,0.102994163306628,0.24471871191704,0.216477124646407,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
582,16404,1011:1561,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.272879751884373,0.0483671730142474,0.811102831670099,10.3592713343761,25.6556,0.966911975835144,0.980471301232369,0.0765283595009682,0.221333539458849,0.0192220399973243,0.202111499461525,6.59343837471339,1.886,3.76583295966274,23.7696,0.263850700059923,0.135235420579375,0.267550765410037,0.205357657837136,0.128615279480548,0.0621931075729015,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
583,16404,1012:1594,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.959711178790678,0.064712549751161,0.536447335983805,9.1362342007948,4.3961,0.899310331124621,0.941908109627337,0.0969132630771563,0.514834505176136,0.299406000632586,0.21542850454355,8.26224558085987,2.3987,0.873988619934925,1.9974,0.863078177982245,0.781868888303939,0.90395974220295,0.855437427650833,0.0812092896783059,0.0485223145521171,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
584,16404,1058:1594,Breast,DU-4475,SIDM01001,906844,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.92767558247378,0.064712549751161,0.536447335983805,9.1362342007948,4.3961,0.899310331124621,0.941908109627337,0.0277322500892724,0.497649094875284,0.381774586610339,0.115874508264945,8.66642328982453,3.1743,0.469810910970271,1.2218,0.834268235250721,0.834732717526078,0.873785154235317,0.850849181934911,-0.0004644822753568,0.0229359723004062,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
585,16404,1561:1594,Breast,DU-4475,SIDM01001,906844,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.944528512608173,0.064712549751161,0.536447335983805,9.1362342007948,4.3961,0.899310331124621,0.941908109627337,0.0590439830568706,0.5066898043494,0.332212621267334,0.174477183082067,8.42961678788229,2.6938,0.706617412912513,1.7023,0.849424249430302,0.837200457949637,0.889659065799885,0.852469421437232,0.0122237914806643,0.0371896443626529,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
586,16404,1510:1594,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.278597091903812,0.064712549751161,0.536447335983805,9.1362342007948,4.3961,0.899310331124621,0.941908109627337,0.0232243639343107,0.149452667764635,0.062154900423443,0.0872977673411923,7.83614897976494,1.7853,1.30008522102986,2.6108,0.250545242970374,0.227220998929573,0.262412860182793,0.239614152468157,0.0233242440408007,0.0227987077146358,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
587,16404,1053:1594,Breast,DU-4475,SIDM01001,906844,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.968808317800857,0.064712549751161,0.536447335983805,9.1362342007948,4.3961,0.899310331124621,0.941908109627337,0.0833242985852974,0.519714641163221,0.25911725656293,0.260597384600291,8.06015644834778,2.0852,1.07607775244701,2.3109,0.871259329077776,0.787840976716198,0.912528411211045,0.849634279639248,0.0834183523615771,0.0628941315717978,True,0.80323186776311,0.0682276954276743,0.213002767823073,229.021029302879
588,17487,1021:1011,Breast,HCC1395,SIDM00884,749712,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.569602317271619,0.100355651434196,0.621966133006576,10.0567402991484,20.8023,0.901079389980407,0.900370808255033,0.085691775023172,0.354273350625014,0.144605796797969,0.209667553827045,6.71191940421525,2.0475,3.3448208949331,18.7548,0.513256908578537,0.34263900939811,0.512853298785787,0.40702127664074,0.170617899180427,0.105832022145047,True,0.854313068386799,0.0677982433116498,0.142503867884044,321.370818987034
589,16919,1049:1549,Breast,HCC1395,SIDM00884,749712,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.560068316024163,0.0962343840250969,0.840940875525046,12.5342946996473,57.9294,0.915233627615453,0.963593634851575,0.0768994338971124,0.470984340031198,0.307187417558294,0.163796922472904,9.41288788874981,6.6567,3.12140681089747,51.2727,0.512593356587273,0.456094748061601,0.539678264402924,0.489552451925977,0.0564986085256713,0.0501258124769476,True,0.694918836741811,0.0830058374282289,0.348259380045647,138.939630838179
590,16919,1021:1549,Breast,HCC1395,SIDM00884,749712,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.816216790495037,0.0962343840250969,0.840940875525046,12.5342946996473,57.9294,0.915233627615453,0.963593634851575,0.0983747190041992,0.68639006241714,0.63576332961957,0.0506267327975696,11.672835092229,31.8841,0.861459607418325,26.0453,0.747029054085415,0.719271450419532,0.78650130398,0.773375415067564,0.0277576036658833,0.0131258889124352,True,0.694918836741811,0.0830058374282289,0.348259380045647,138.939630838179
591,14991,1011:1021,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.137114388264169,0.0692058603780359,0.481857354975116,8.85147440305354,9.0217,0.848947850081698,0.852290045186461,0.0432031389606786,0.0660695764580037,0.04124605349115,0.0248235229668538,7.27458307746752,3.0241,1.57689132558603,5.9976,0.116402965132134,0.0666374708320035,0.116861228169383,0.103906027451964,0.0497654943001304,0.012955200717419,True,0.416264290666616,0.0583336833950407,0.858240951911148,57.6385354725307
592,14992,1011:1049,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.321328813029092,0.12886230503302,0.69627811897489,10.6972194056741,32.4275,0.86710908218035,0.926614323238453,0.0403706177506897,0.22373422150833,0.0964545807312303,0.1272796407771,7.26834614458328,3.0111,3.4288732610908,29.4164,0.278627132143757,0.210763432091633,0.297747880621967,0.243367984421243,0.0678637000521241,0.0543798962007241,True,0.416264290666616,0.0583336833950407,0.858240951911148,57.6385354725307
593,15182,1083:1372,Breast,COLO-824,SIDM00954,906812,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.777652947683145,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.120365075282958,0.641649197229465,0.347965990935347,0.293683206294118,8.56844710225838,0.7415,3.60522743645045,8.2819,0.708881146171324,0.561258754371658,0.747324078801329,0.65119211274839,0.147622391799667,0.0961319660529393,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
594,15182,1012:1372,Breast,COLO-824,SIDM00954,906812,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.941061954909031,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.0832856857474682,0.776479597627144,0.691580805021638,0.0848987926055063,11.0858275398787,4.2452,1.08784699883017,4.7782,0.857839064587398,0.849334284890434,0.904360049868828,0.882283835336929,0.0085047796969635,0.0220762145318989,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
595,15182,1049:1372,Breast,COLO-824,SIDM00954,906812,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.76002151112086,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.103473811477681,0.627101323206872,0.321219302188186,0.305882021018686,8.36188382682269,0.6426,3.81179071188614,8.3808,0.692808947131694,0.547502200517915,0.730380277422951,0.627710381058665,0.145306746613779,0.102669896364287,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
596,15182,1058:1372,Breast,COLO-824,SIDM00954,906812,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.833047925170008,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.106871165551097,0.687356145220707,0.463848165089366,0.223507980131342,9.46687711992672,1.3821,2.70679741878211,7.6413,0.759377264330478,0.659609903707914,0.800558623393396,0.734280389361239,0.0997673606225645,0.0662782340321567,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
597,15182,1011:1372,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.101527688871154,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.0490793796690224,0.0837715079134275,0.050864540792271,0.0329069671211565,9.00811595855797,1.0056,3.16555858015086,8.0178,0.0925490794698741,0.0381294220427832,0.097568056270492,0.0873275440784161,0.0544196574270909,0.0102405121920759,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
598,15182,1558:1372,Breast,COLO-824,SIDM00954,906812,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.800769720064806,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.0667070749111615,0.66072307650353,0.41967601077499,0.24104706572854,9.19728628276916,1.1465,2.97638825593967,7.8769,0.729953584912174,0.661411075952806,0.76953928505298,0.696046495124047,0.0685425089593679,0.0734927899289326,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
599,15182,1510:1372,Breast,COLO-824,SIDM00954,906812,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.601465344022514,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.0495112869717405,0.496275049561874,0.425728442761921,0.0705466067999531,10.8100969417989,3.5067,1.36357759690988,5.5167,0.548274707532818,0.540343030606595,0.578007883197396,0.559327466830358,0.0079316769262226,0.0186804163670374,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
600,15182,1053:1372,Breast,COLO-824,SIDM00954,906812,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.826248874469519,0.0916999473613258,0.825109966008777,12.1736745387088,9.0234,0.911564918879673,0.960999480588129,0.140357262671875,0.681746180728335,0.447586323894806,0.234159856833529,9.34209644480412,1.2676,2.83157809390471,7.7558,0.753179488230229,0.603937202285658,0.794024739201734,0.72370375079349,0.149242285944571,0.0703209884082442,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
601,15184,1011:1549,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.203831047834353,0.104528899331708,0.890319512594862,13.283793526625,97.3913,0.913806854619326,0.97642346977885,0.0770924618136429,0.181474759159581,0.0885875597991048,0.0928871993604764,8.46185689257698,3.4433,4.82193663404803,93.948,0.186262208695272,0.0936800642988534,0.199025418975078,0.169490438294823,0.0925821443964181,0.0295349806802542,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
602,15184,1054:1549,Breast,COLO-824,SIDM00954,906812,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.966491602112128,0.104528899331708,0.890319512594862,13.283793526625,97.3913,0.913806854619326,0.97642346977885,0.0998839544316949,0.860486332119497,0.786079737887764,0.0744065942317329,12.0109495719382,40.3047,1.27284395468685,57.0866,0.883186650942076,0.852590456650527,0.943705083646443,0.925981668196422,0.0305961942915497,0.017723415450021,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
603,15185,1011:1558,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.0986498311633639,0.17507237385281,0.395465958270997,8.13180257740266,5.4783,0.818907210294227,0.812561694416585,0.0505876568235007,0.0390126500142918,0.021543187386534,0.0174694626277577,6.39141854862535,1.6396,1.74038402877732,3.8387,0.0807850580339868,0.016994915012337,0.080159073964013,0.0684808881336418,0.0637901430216499,0.0116781858303712,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
604,15186,1372:1561,Breast,COLO-824,SIDM00954,906812,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.901728541544577,0.156728091815081,0.471446546103332,8.76609396978377,8.5033,0.724536644713229,0.847891724218391,0.136037221239911,0.425116806433986,0.179045607226366,0.24607119920762,6.14552041678608,1.3827,2.62057355299768,7.1206,0.653335371932862,0.522672919020275,0.764568167867167,0.609027516561739,0.130662452912587,0.155540651305428,True,0.92594235044823,0.1134648770623,0.0658912910840268,655.553106639892
605,18114,1558:1011,Breast,UACC-812,SIDM01187,910910,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.530812266379988,0.173470746555833,0.447566870208465,8.50970554045911,7.1188,0.847698024572825,0.816648896848215,0.0605075655146596,0.237573984731953,0.117327544312844,0.12024644041911,6.06612337081684,1.3086,2.44358216964227,5.8102,0.44996850962934,0.321040791495723,0.433487251772718,0.350008451827571,0.128927718133617,0.0834787999451467,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
606,18114,1561:1011,Breast,UACC-812,SIDM01187,910910,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.808919594611042,0.173470746555833,0.447566870208465,8.50970554045911,7.1188,0.847698024572825,0.816648896848215,0.130744097124833,0.362045611210365,0.28924306331204,0.0728025478983245,7.63527815464088,3.8831,0.874427385818224,3.2357,0.685719542390031,0.678427814882964,0.660603294578012,0.619723141961224,0.0072917275070665,0.0408801526167882,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
607,18115,1011:1021,Breast,UACC-812,SIDM01187,910910,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.907760203473727,0.065394550466273,0.674855010785898,10.7007845160145,32.5078,0.92331245244571,0.909933261629142,0.0940002566583653,0.61260652190627,0.333522923235812,0.279083598670458,7.73451744044552,4.1596,2.96626707556901,28.3482,0.838146299701943,0.678760243815714,0.826001202723982,0.700977928224951,0.159386055886229,0.12502327449903,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
608,18116,1054:1049,Breast,UACC-812,SIDM01187,910910,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.896855734059133,0.120160878808387,0.75434471298321,11.6130851273147,61.1811,0.95472192235617,0.93537438987796,0.135455327936431,0.676538381296183,0.432227377168179,0.244311004128005,8.83163717442507,8.8985,2.78144795288964,52.2826,0.85624783049709,0.703092267787646,0.838895885054112,0.747423555227091,0.153155562709444,0.0914723298270208,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
609,18116,1558:1049,Breast,UACC-812,SIDM01187,910910,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.504946673460378,0.120160878808387,0.75434471298321,11.6130851273147,61.1811,0.95472192235617,0.93537438987796,0.0764633095029289,0.380903853463296,0.333930562916346,0.04697329054695,10.5585886681581,29.4566,1.05449645915663,31.7245,0.482083658773446,0.40591502826072,0.472314186608907,0.457133148773098,0.0761686305127255,0.0151810378358092,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
610,18116,1058:1049,Breast,UACC-812,SIDM01187,910910,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.66789065535987,0.120160878808387,0.75434471298321,11.6130851273147,61.1811,0.95472192235617,0.93537438987796,0.128919161968615,0.503819784721609,0.287820914887275,0.215998869834335,8.3524670617363,6.3837,3.26061806557841,54.7974,0.637649850408897,0.483574345358889,0.624727814262429,0.539723199786393,0.154075505050008,0.085004614476036,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
611,18117,1012:1053,Breast,UACC-812,SIDM01187,910910,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.650663953024719,0.101524715053144,0.308144627281433,7.11619095044769,2.7097,0.706469224660999,0.732854133484483,0.112108269037305,0.200498601290266,0.0657470671701976,0.134751534120068,3.90935096934217,0.2935,3.20683998110552,2.4162,0.459674058408234,0.286304849004369,0.476841767483519,0.32066832946137,0.173369209403865,0.156173438022149,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
612,18117,1011:1053,Breast,UACC-812,SIDM01187,910910,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.933363404854636,0.101524715053144,0.308144627281433,7.11619095044769,2.7097,0.706469224660999,0.732854133484483,0.163999184524531,0.287610918507061,0.0375098468649654,0.250101071642096,1.60930259902733,0.0596,5.50688835142036,2.6501,0.659392520954604,0.323153823794916,0.684019229290871,0.295996555216085,0.336238697159688,0.388022674074786,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
613,18117,1058:1054,Breast,UACC-812,SIDM01187,910910,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.863778261020426,0.0885488242668098,0.782689916125494,11.9845589193216,31.6593,0.909852021949556,0.943813757390106,0.198663139716807,0.676070534669102,0.336185762925629,0.339884771743473,7.95035864147006,1.9324,4.03420027785157,29.7269,0.785910397305506,0.536036315628109,0.81524580608558,0.678196823247896,0.249874081677397,0.137048982837684,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
614,18118,1011:1058,Breast,UACC-812,SIDM01187,910910,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.955764234345367,0.0968547667184357,0.242813524522416,6.35105660947342,0.6377,0.688497613798397,0.68003634023029,0.0796117514508795,0.232072482353867,0.0206975901113482,0.211374892242518,0.124659389828722,0.0085,6.2263972196447,0.6292,0.658041394700637,0.2246042350725,0.649954412047229,0.209598400229805,0.433437159628137,0.440356011817424,True,0.889992549414813,0.106887110580996,0.104046112539975,433.310474375846
615,17744,1049:1083,Breast,UACC-812,SIDM01187,910910,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.982957288703319,0.102029906813588,0.736548380226209,11.3945789034826,52.5824,0.941586512772855,0.92991514537718,0.116583081432711,0.723995598825976,0.681250155631808,0.0427454431941678,10.8970037222873,37.2439,0.497575181195327,15.3385,0.925539325674818,0.940067357603362,0.914066870024106,0.900399327708386,-0.0145280319285434,0.0136675423157202,True,0.886992079529511,0.0949916432117754,0.104887287626076,422.108145690102
616,17746,1012:1372,Breast,UACC-812,SIDM01187,910910,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.902850265990181,0.100549914792418,0.830289414727201,12.6978945357161,12.9771,0.888066340275973,0.957332116666162,0.109266938641383,0.749627018935285,0.577133048608333,0.172493970326952,10.3323565866975,2.5181,2.36553794901864,10.459,0.801790931535089,0.720411635190022,0.864327556172987,0.810365954999066,0.0813792963450669,0.0539616011739206,True,0.886992079529511,0.0949916432117754,0.104887287626076,422.108145690102
617,17748,1011:1510,Breast,UACC-812,SIDM01187,910910,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.880069204764945,0.054574217820575,0.938306750386608,15.3396335418327,809.8785,0.973269372222453,0.985377609670565,0.194800157375851,0.825774875638322,0.485775293971919,0.339999581666403,9.48596957598695,14.0053,5.85366396584577,795.8732,0.856544402433891,0.63173142458871,0.867200489335957,0.760519581595388,0.224812977845182,0.106680907740569,True,0.886992079529511,0.0949916432117754,0.104887287626076,422.108145690102
618,17750,1011:1561,Breast,UACC-812,SIDM01187,910910,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.841242970015571,0.103864953499225,0.273493697026343,6.72452429246643,2.0654,0.66612413942607,0.706335465302069,0.0925491611741777,0.23007464996698,0.0694215755997808,0.160653074367199,3.39018865014216,0.2048,3.33433564232427,1.8606,0.560372249449853,0.360748492672057,0.594199744658042,0.380144053888655,0.199623756777797,0.214055690769388,True,0.886992079529511,0.0949916432117754,0.104887287626076,422.108145690102
619,17750,1011:1594,Breast,UACC-812,SIDM01187,910910,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.841242970015571,0.0655616496016224,0.698826470293689,10.9604560456544,15.5674,0.917437526556707,0.917902268417998,0.0374185605653056,0.587882855395361,0.373675084841732,0.214207770553629,8.4779096998812,2.7854,2.48254634577322,12.782,0.771787869644303,0.69857242984589,0.772178830467987,0.685562623600939,0.0732154397984128,0.0866162068670479,True,0.886992079529511,0.0949916432117754,0.104887287626076,422.108145690102
620,17750,1558:1594,Breast,UACC-812,SIDM01187,910910,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.570900270656393,0.0655616496016224,0.698826470293689,10.9604560456544,15.5674,0.917437526556707,0.917902268417998,0.0784240246814466,0.398960221032519,0.198565227807495,0.200394993225024,7.53573797591474,1.4497,3.42471806973969,14.1177,0.523765332221556,0.389608306505272,0.524030653475952,0.433834057667889,0.134157025716284,0.0901965958080634,True,0.886992079529511,0.0949916432117754,0.104887287626076,422.108145690102
621,17750,1549:1594,Breast,UACC-812,SIDM01187,910910,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.759147052085985,0.0655616496016224,0.698826470293689,10.9604560456544,15.5674,0.917437526556707,0.917902268417998,0.0826653815585286,0.530512054843108,0.39293052255489,0.137581532288218,9.16398867541464,4.4815,1.79646737023979,11.0859,0.696469993758582,0.606143749832064,0.696822801172562,0.644940169873295,0.0903262439265179,0.0518826312992667,True,0.886992079529511,0.0949916432117754,0.104887287626076,422.108145690102
622,17750,1510:1594,Breast,UACC-812,SIDM01187,910910,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.947819742751186,0.0655616496016224,0.698826470293689,10.9604560456544,15.5674,0.917437526556707,0.917902268417998,0.0540468736980343,0.662361525301484,0.352702377762288,0.309659147539196,7.78155872684247,1.719,3.17889731881195,13.8484,0.869565400411262,0.709313758753751,0.870005891922678,0.734620727323654,0.160251641657511,0.135385164599024,True,0.886992079529511,0.0949916432117754,0.104887287626076,422.108145690102
623,18291,1021:1011,Breast,MCF7,SIDM00148,905946,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.875849905810844,0.120548440720718,0.329476297869696,7.45884378947093,3.4361,0.772048428968422,0.76353896631992,0.131400913509548,0.288571784456079,0.277363725792307,0.0112080586637725,7.33191896737787,3.1467,0.126924822093056,0.2894,0.676198543793402,0.596137607489259,0.668745531734211,0.661447150076693,0.0800609363041433,0.0072983816575182,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
624,18292,1011:1021,Breast,MCF7,SIDM00148,905946,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,10.0,0.805342697898786,0.0907651192101595,0.553180290418293,9.46313289340098,13.7853,0.85016813159932,0.873318394209136,0.0524282597791019,0.445499707509902,0.244248112018115,0.201251595491787,7.1960750658227,2.8639,2.26705782757828,10.9214,0.684676696769766,0.609151541921778,0.703320591717021,0.600887588235535,0.0755251548479881,0.102433003481486,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
625,18294,1054:1053,Breast,MCF7,SIDM00148,905946,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.883805733623088,0.110172502219912,0.496439999558418,8.96911365156234,9.7882,0.775398354802027,0.850287480943907,0.130349818334264,0.438756518009573,0.243263508346161,0.195493009663412,6.90008985050365,2.3327,2.06902380105869,7.4555,0.685301511815941,0.562764428199279,0.751488950886157,0.641460174731903,0.122537083616663,0.110028776154254,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
626,18294,1558:1053,Breast,MCF7,SIDM00148,905946,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.924379017072381,0.110172502219912,0.496439999558418,8.96911365156234,9.7882,0.775398354802027,0.850287480943907,0.102781046553129,0.458898718827224,0.32561814128205,0.133280577545173,7.67881346583343,4.0021,1.29030018572891,5.7861,0.71676196905144,0.705683156390906,0.78598790586388,0.718819148203673,0.0110788126605337,0.0671687576602064,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
627,18294,1011:1053,Breast,MCF7,SIDM00148,905946,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.874993179015602,0.110172502219912,0.496439999558418,8.96911365156234,9.7882,0.775398354802027,0.850287480943907,0.105436633832038,0.434381613404124,0.224834961872638,0.209546651531486,6.6969042524462,2.0263,2.27220939911615,7.7619,0.678468271471693,0.559341891782939,0.743995746028277,0.622490278358884,0.119126379688755,0.121505467669393,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
628,18294,1058:1054,Breast,MCF7,SIDM00148,905946,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.963537512608147,0.0737522529442339,0.798684274731689,11.9890086072775,31.7571,0.931731932422435,0.951787408626514,0.190275394571325,0.769562259434214,0.454367165540961,0.315195093893253,8.7530066296252,3.3706,3.23600197765229,28.3865,0.897758668583896,0.649032421682774,0.917082872239745,0.80875782366578,0.248726246901121,0.108325048573965,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
629,18294,1561:1054,Breast,MCF7,SIDM00148,905946,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.741079926745809,0.0737522529442339,0.798684274731689,11.9890086072775,31.7571,0.931731932422435,0.951787408626514,0.0816406176908485,0.591888883811189,0.421167692900777,0.170721190910412,9.59642689472615,6.0479,2.39258171255133,25.7092,0.690487832226349,0.591578208273809,0.70535054306252,0.651461256464378,0.09890962395254,0.0538892865981415,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
630,18294,1594:1054,Breast,MCF7,SIDM00148,905946,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.79587911669903,0.0737522529442339,0.798684274731689,11.9890086072775,31.7571,0.931731932422435,0.951787408626514,0.118353198453638,0.635656135094862,0.420359417776086,0.215296717318777,9.24465556264443,4.7392,2.74435304463306,27.0179,0.741545987376648,0.606711880578841,0.757507722062928,0.687215100775917,0.134834106797807,0.0702926212870115,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
631,18294,1053:1054,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.85693268792069,0.0737522529442339,0.798684274731689,11.9890086072775,31.7571,0.931731932422435,0.951787408626514,0.116632660370584,0.684418662345813,0.54489257233396,0.139526090011854,10.209095163036,9.2477,1.77991344424153,22.5094,0.798431549272296,0.682616904802619,0.815617742403387,0.773834477297696,0.115814644469677,0.0417832651056907,True,0.350628263852705,0.0515394924053418,0.972163356290435,49.9353619849959
632,18878,1011:1083,Breast,MCF7,SIDM00148,905946,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.337243953546803,0.0625660574863289,0.916655056219922,14.200581047495,367.7315,0.949275854708542,0.981321000013448,0.0541101472613678,0.309136375198274,0.142622777646623,0.166513597551651,8.32577863845958,6.2667,5.87480240903539,361.4648,0.32013754224843,0.244729858237109,0.330944573743038,0.27527999405754,0.0754076840113207,0.055664579685498,True,0.945997151039455,0.0827786566226168,0.0300811730583094,921.490072695551
633,18197,1510:1549,Breast,MCF7,SIDM00148,905946,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.708070611221762,0.0679740642955194,0.889835604853881,13.5310694367982,115.6,0.954593250887942,0.974951274408766,0.116632857576753,0.630066440615774,0.419820084873991,0.210246355741783,9.81551643034568,8.7996,3.71555300645252,106.8004,0.675919426624394,0.529561444031292,0.690334344782051,0.628838558209942,0.146357982593102,0.061495786572109,True,0.18756449216252,0.0412732476444996,1.56103222293323,31.5237892745064
634,18199,1054:1561,Breast,MCF7,SIDM00148,905946,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.84669487370765,0.11620749451476,0.213128464184655,6.16698511768507,1.4034,0.619855819848228,0.67253313610085,0.183046942550527,0.180454778066332,0.0237261543890201,0.156728623677312,1.30817174801798,0.0484,4.85881336966709,1.355,0.524828745103347,0.297914861377017,0.569430358735118,0.244644074169964,0.226913883726329,0.324786284565154,True,0.18756449216252,0.0412732476444996,1.56103222293323,31.5237892745064
635,20577,1083:1372,Breast,BT-549,SIDM00122,905951,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.862647735405231,0.0495430992667939,0.806957527738512,11.4520572516598,5.472,0.938984380858873,0.963351170317562,0.0883304399351573,0.696120083871831,0.46140211975336,0.234717964118472,9.23948017808403,1.1806,2.21257707357578,4.2914,0.810012749728789,0.709055391624544,0.831032705474424,0.770488013389214,0.100957358104245,0.0605446920852095,True,0.602976036124412,0.0629630511061314,0.388783343819554,108.253571561522
636,20577,1561:1372,Breast,BT-549,SIDM00122,905951,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.878171361324445,0.0495430992667939,0.806957527738512,11.4520572516598,5.472,0.938984380858873,0.963351170317562,0.0942493261867427,0.708646990665138,0.634542524308067,0.0741044663570705,10.64102118941,3.1189,0.811036062249842,2.3531,0.824589192001227,0.77151995874739,0.845987408671271,0.829423052864099,0.0530692332538376,0.0165643558071719,True,0.602976036124412,0.0629630511061314,0.388783343819554,108.253571561522
637,20579,1011:1558,Breast,BT-549,SIDM00122,905951,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,10.0,0.828524845395076,0.115330587500642,0.515792175502107,9.10832568217838,10.7798,0.906110052183766,0.886975633655509,0.137871234696653,0.427346632463873,0.1943243581143,0.233022274349573,6.97227203126058,2.4524,2.1360536509178,8.3274,0.750734690896479,0.637249407413146,0.734881349743631,0.623910592063468,0.113485283483333,0.110970757680163,True,0.602976036124412,0.0629630511061314,0.388783343819554,108.253571561522
638,22535,1594:1049,Breast,HCC1143,SIDM00866,749710,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.964101214558535,0.0562144114998495,0.855148541965469,13.0622593999132,167.0559,0.948138189494584,0.964688763719776,0.0727531751843945,0.824449747936869,0.726243319267539,0.09820642866933,11.5537436657874,58.7156,1.50851573412581,108.3403,0.914101180061059,0.871290721852709,0.930057608773207,0.902521529390202,0.0428104582083502,0.0275360793830055,True,0.547198197199656,0.0707303266507497,0.55368836934093,85.9064596474616
639,22535,1372:1049,Breast,HCC1143,SIDM00866,749710,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.879147225625228,0.0562144114998495,0.855148541965469,13.0622593999132,167.0559,0.948138189494584,0.964688763719776,0.0594467102385503,0.751801468166401,0.482525164538423,0.269276303627977,9.44853453199484,13.6465,3.61372486791833,153.4094,0.83355305880349,0.728153684905311,0.848103450216072,0.760560140945337,0.105399373898179,0.0875433092707348,True,0.547198197199656,0.0707303266507497,0.55368836934093,85.9064596474616
640,22535,1011:1049,Breast,HCC1143,SIDM00866,749710,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.713624493187249,0.0562144114998495,0.855148541965469,13.0622593999132,167.0559,0.948138189494584,0.964688763719776,0.0760177379709088,0.610254944859923,0.429888252498259,0.180366692361664,9.95056339953722,19.3263,3.11169600037594,147.7296,0.676614634949549,0.581416931552454,0.688425530092959,0.632231672373869,0.0951977033970945,0.0561938577190901,True,0.547198197199656,0.0707303266507497,0.55368836934093,85.9064596474616
641,22540,1012:1372,Breast,HCC1143,SIDM00866,749710,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.867381671880672,0.095804563677992,0.534842299420461,9.31937578746172,1.2478,0.799993162930966,0.859330478424197,0.0658826315104261,0.463912407863822,0.378057239932738,0.0858551679310834,8.4097758570159,0.6642,0.909599930445825,0.5836,0.693899407156168,0.660498879565366,0.745367507073597,0.705806323490674,0.0334005275908024,0.0395611835829227,True,0.547198197199656,0.0707303266507497,0.55368836934093,85.9064596474616
642,22544,1012:1594,Breast,HCC1143,SIDM00866,749710,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.915008651391543,0.0447550188450055,0.686121602176234,10.7892244685058,13.8252,0.910160085720031,0.915135095735867,0.0255784156936043,0.627807201897881,0.57298071704609,0.0548264848517908,10.1804469510539,9.0659,0.608777517451893,4.7593,0.832804352585097,0.831928385088762,0.837356529790346,0.818593237785552,0.0008759674963345,0.0187632920047938,True,0.547198197199656,0.0707303266507497,0.55368836934093,85.9064596474616
643,22544,1021:1594,Breast,HCC1143,SIDM00866,749710,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,4.0,0.931584574428972,0.0447550188450055,0.686121602176234,10.7892244685058,13.8252,0.910160085720031,0.915135095735867,0.0592695095361224,0.639180300769872,0.647034308310903,-0.0078540075410311,10.8794583186058,14.7175,-0.0902338500999669,-0.892299999999999,0.847891096117732,0.815162173734518,0.852525738706114,0.855081299025313,0.0327289223832133,-0.0025555603191993,True,0.547198197199656,0.0707303266507497,0.55368836934093,85.9064596474616
644,22549,1058:1049,Breast,Hs-578-T,SIDM00135,905957,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.876862920246258,0.109241990906066,0.58552376126909,9.84383085128734,17.9481,0.852350737891486,0.872135121921867,0.122944432441997,0.513424075179987,0.214631725186473,0.298792349993515,6.248158795762,1.4846,3.59567205552533,16.4635,0.747394757101582,0.535457722006339,0.764742949857735,0.586179810257336,0.211937035095243,0.178563139600399,True,0.318718779162082,0.0714583106679093,1.05410383529536,46.0624684467724
645,22549,1561:1049,Breast,Hs-578-T,SIDM00135,905957,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.847493191112979,0.109241990906066,0.58552376126909,9.84383085128734,17.9481,0.852350737891486,0.872135121921867,0.154118517447257,0.496227400910415,0.349828021016601,0.146399379893815,8.13908517876894,5.506,1.70474567251839,12.4421,0.722361446803158,0.590224930119841,0.73912857755927,0.66918830499811,0.132136516683317,0.0699402725611604,True,0.318718779162082,0.0714583106679093,1.05410383529536,46.0624684467724
646,22549,1594:1049,Breast,Hs-578-T,SIDM00135,905957,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.610392578810728,0.109241990906066,0.58552376126909,9.84383085128734,17.9481,0.852350737891486,0.872135121921867,0.0878876161717366,0.357399358595997,0.257323236861464,0.100076121734533,8.22738900701172,5.8536,1.61644184427561,12.0945,0.520268564952811,0.42316238071013,0.532344806141297,0.484990302612872,0.0971061842426803,0.0473545035284251,True,0.318718779162082,0.0714583106679093,1.05410383529536,46.0624684467724
647,22549,1053:1049,Breast,Hs-578-T,SIDM00135,905957,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.723117813449632,0.109241990906066,0.58552376126909,9.84383085128734,17.9481,0.852350737891486,0.872135121921867,0.0898890256612729,0.423402661971709,0.273433244052899,0.149969417918809,7.7849283694875,4.3075,2.05890248179983,13.6406,0.616350001876272,0.531602446979847,0.630656442396769,0.55613309214154,0.084747554896424,0.0745233502552285,True,0.318718779162082,0.0714583106679093,1.05410383529536,46.0624684467724
648,22554,1561:1372,Breast,Hs-578-T,SIDM00135,905957,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.833148437906827,0.122640888172241,0.565398927246368,9.64260534427146,1.5611,0.803520555554178,0.863837196998474,0.0886742081128547,0.471061233029507,0.410706329185801,0.0603549038437061,8.93118758599848,0.9534,0.711417758272972,0.6077,0.66945189568599,0.655521101090329,0.719704611285091,0.692672810505375,0.0139307945956612,0.0270318007797161,True,0.318718779162082,0.0714583106679093,1.05410383529536,46.0624684467724
649,23695,1021:1561,Breast,Hs-578-T,SIDM00135,905957,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.758010121097612,0.107014090093794,0.389160272237563,7.89885585035935,4.6615,0.72949815046161,0.775801675501661,0.0850629846968581,0.294987425085175,0.14931685345436,0.145670571630815,5.56781870236432,0.9264,2.33103714799503,3.7351,0.552966981371889,0.429913291137527,0.588065521994744,0.469401526726954,0.123053690234362,0.118663995267791,True,0.478860993256958,0.0861055951145148,0.702045567791944,69.4481115725415
650,23695,1049:1561,Breast,Hs-578-T,SIDM00135,905957,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.962750029103495,0.107014090093794,0.389160272237563,7.89885585035935,4.6615,0.72949815046161,0.775801675501661,0.142266767173565,0.374664063422638,0.177827858850978,0.19683620457166,5.3735868645429,0.8097,2.52526898581645,3.8518,0.702324365587861,0.521779443336623,0.746903085667764,0.5822909212238,0.180544922251238,0.164612164443964,True,0.478860993256958,0.0861055951145148,0.702045567791944,69.4481115725415
651,24166,1058:1011,Breast,HCC1599,SIDM00877,749713,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.891519864028058,0.0911614751648814,0.539012624969909,9.28482297665438,12.1826,0.89004929529413,0.888071002211044,0.126411264542473,0.48054046212258,0.228034899860235,0.252505562262345,7.05463764235887,2.5965,2.23018533429551,9.5861,0.793496626718892,0.591872352385163,0.791732939138451,0.672052356117377,0.201624274333729,0.119680583021074,True,0.619539293835135,0.0799572866297131,0.461903022975487,105.646582477042
652,24166,1510:1011,Breast,HCC1599,SIDM00877,749713,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.489510844506604,0.0911614751648814,0.539012624969909,9.28482297665438,12.1826,0.89004929529413,0.888071002211044,0.0600388280665587,0.263852525248741,0.0890672161657675,0.174785309082974,6.26197330624218,1.4989,3.02284967041219,10.6837,0.435688782191937,0.319619371147449,0.434720386274154,0.339213946163298,0.116069411044488,0.0955064401108565,True,0.619539293835135,0.0799572866297131,0.461903022975487,105.646582477042
653,24166,1012:1011,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.304669578230923,0.0911614751648814,0.539012624969909,9.28482297665438,12.1826,0.89004929529413,0.888071002211044,0.0676491899088679,0.164220749110725,0.0397752071807446,0.12444554192998,5.5463005028252,0.9127,3.73852247382918,11.2699,0.271170943401993,0.15036924454576,0.270568217682752,0.193187241866237,0.120801698856233,0.0773809758165147,True,0.619539293835135,0.0799572866297131,0.461903022975487,105.646582477042
654,24166,1594:1011,Breast,HCC1599,SIDM00877,749713,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.914174751881987,0.0911614751648814,0.539012624969909,9.28482297665438,12.1826,0.89004929529413,0.888071002211044,0.0940139349359935,0.492751732693125,0.408603549367371,0.0841481833257541,8.61212604159908,7.6426,0.672696935055299,4.54,0.813660593688249,0.765314321393648,0.811852088099869,0.780931808107782,0.0483462722946008,0.030920279992087,True,0.619539293835135,0.0799572866297131,0.461903022975487,105.646582477042
655,24168,1012:1049,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.867905750083072,0.10578905253269,0.821102438196426,11.7756455691488,68.4782,0.920327753680936,0.964260871386517,0.0414098717572296,0.712639527517908,0.774242176088496,-0.0616026485705878,12.8473010731128,143.9306,-1.07165550396405,-75.4524,0.798757749380722,0.832715631175289,0.836887554856471,0.849931279412832,-0.0339578817945672,-0.0130437245563604,True,0.619539293835135,0.0799572866297131,0.461903022975487,105.646582477042
656,24168,1594:1049,Breast,HCC1599,SIDM00877,749713,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,0.791176923907422,0.10578905253269,0.821102438196426,11.7756455691488,68.4782,0.920327753680936,0.964260871386517,0.1342115624033,0.649637301265133,0.518328007644015,0.131309293621118,10.1688304080005,22.4829,1.60681516114825,45.9953,0.728142081143911,0.606242539942145,0.762900950067875,0.730542877227932,0.121899541201767,0.0323580728399427,True,0.619539293835135,0.0799572866297131,0.461903022975487,105.646582477042
657,28083,1021:1085,Breast,CAL-85-1,SIDM00928,910852,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.929030463544276,0.0856421766733781,0.702608034202195,11.9199613535783,75.6826,0.913622421912265,0.887608985044418,0.0814017018166148,0.652744267704798,0.502723560464285,0.150020707240514,9.55998482040623,14.7425,2.35997653317209,60.9401,0.848783062133596,0.795596094362176,0.824615786821881,0.749043226776372,0.0531869677714201,0.0755725600455084,True,0.424602712266287,0.0632372708380026,0.822796213546795,59.6049269528945
658,28084,1372:1096,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.916128653670643,0.0731588645349595,0.919577988677209,17.2755123872902,1549.3426,0.952881728581536,0.973085078697659,0.137813050646072,0.842451744712009,0.719513749199189,0.12293799551282,13.4061152165275,106.009,3.86939717076267,1443.3336,0.872962255112757,0.740313672875567,0.891471123054278,0.845405273628196,0.13264858223719,0.0460658494260819,True,0.424602712266287,0.0632372708380026,0.822796213546795,59.6049269528945
659,28084,1011:1096,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.860130627357678,0.0731588645349595,0.919577988677209,17.2755123872902,1549.3426,0.952881728581536,0.973085078697659,0.103844978661852,0.79095719230524,0.374086825613124,0.416870366692115,8.11081230235908,2.6996,9.16470008493111,1546.643,0.819602759002505,0.561591177232516,0.836980279212613,0.636231732065198,0.25801158176999,0.200748547147415,True,0.424602712266287,0.0632372708380026,0.822796213546795,59.6049269528945
660,28677,1372:1553,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.880273636039796,0.0615546340263253,0.870015034381329,15.4566748402586,878.3201,0.93803727815426,0.955368679907951,0.091507257689008,0.765851297724141,0.399737450665564,0.366113847058577,8.37475987483825,6.4831,7.0819149654203,871.837,0.825729485581723,0.62748148326269,0.840985861621112,0.662603863212362,0.198248002319033,0.17838199840875,True,0.455257189340288,0.0487339867599479,0.746828593354963,65.2145900521926
661,28677,1594:1553,Breast,CAL-85-1,SIDM00928,910852,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.932945611104918,0.0615546340263253,0.870015034381329,15.4566748402586,878.3201,0.93803727815426,0.955368679907951,0.0452584263318661,0.811676707921355,0.833649718384091,-0.021973010462736,16.2263351935116,1497.4201,-0.769660353253062,-619.1,0.87513776170682,0.923424441521019,0.891307016907222,0.899268911842456,-0.0482866798141994,-0.0079618949352339,True,0.455257189340288,0.0487339867599479,0.746828593354963,65.2145900521926
662,28677,1372:1560,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.880273636039796,0.0822675040139687,0.765740903961525,13.022630653256,162.5296,0.909001442351291,0.914774149688664,0.0435772152598673,0.674061529794611,0.469028467022315,0.205033062772296,9.44652463688036,13.6275,3.57610601637568,148.9021,0.80017000482399,0.701582255862908,0.805251566901652,0.705541514284432,0.0985877489610819,0.0997100526172209,True,0.455257189340288,0.0487339867599479,0.746828593354963,65.2145900521926
663,28677,1011:1560,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.598341326925462,0.0822675040139687,0.765740903961525,13.022630653256,162.5296,0.909001442351291,0.914774149688664,0.0788728000482578,0.458174428557441,0.29453945230446,0.163634976252981,8.89484107956595,9.297,4.12778957369008,153.2326,0.54389312919363,0.457265123594525,0.547347178561826,0.465056736403627,0.0866280055991054,0.0822904421581988,True,0.455257189340288,0.0487339867599479,0.746828593354963,65.2145900521926
664,28677,1053:1560,Breast,CAL-85-1,SIDM00928,910852,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.966994777161219,0.0822675040139687,0.765740903961525,13.022630653256,162.5296,0.909001442351291,0.914774149688664,0.0615496570677089,0.740467454789505,0.581969217521571,0.158498237267934,10.4030375104677,26.4458,2.61959314278834,136.0838,0.878999647185714,0.785630425669183,0.884581825031033,0.811472805602778,0.0933692215165303,0.0731090194282554,True,0.455257189340288,0.0487339867599479,0.746828593354963,65.2145900521926
665,28082,1510:2169,Breast,CAL-85-1,SIDM00928,910852,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.869397299596211,0.0784591464038889,0.815362245064451,14.0443070181476,329.9801,0.920636607852356,0.934697932543095,0.0549892320535004,0.708873734051738,0.422310300802568,0.28656343324917,8.80636734408209,8.744,5.23793967406551,321.2361,0.800398980776254,0.650425105995593,0.812623858491128,0.672203657024841,0.149973874780661,0.140420201466287,True,0.424602712266287,0.0632372708380026,0.822796213546795,59.6049269528945
666,27061,1011:1032,Breast,EFM-192A,SIDM01002,1290798,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.913144779323201,0.118653503654282,0.436844030950184,8.19839638185224,5.7371,0.693938635965094,0.755282649863362,0.177914464005759,0.398901846240663,0.224877735554331,0.174024110686332,5.46945243261254,0.8654,2.7289439492397,4.8717,0.633666442602189,0.459170429483818,0.689682408636122,0.544182319887615,0.17449601311837,0.145500088748507,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
667,27061,1558:1038,Breast,EFM-192A,SIDM01002,1290798,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.623715923980498,0.0861271505214384,0.816301065425769,13.7073703910975,261.252,0.966911866665927,0.938912755348186,0.0548877883834753,0.509139973268298,0.327663882508943,0.181476090759355,9.32020248888361,12.4851,4.3871679022139,248.7669,0.603078328325247,0.529185256042943,0.585614836739069,0.504343198674073,0.0738930722823041,0.0812716380649958,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
668,27063,1053:1050,Breast,EFM-192A,SIDM01002,1290798,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.804384828233701,0.0728850141103056,0.766542301717467,12.7523278093295,134.7607,0.929829578518117,0.920106851703141,0.0725963912685537,0.61659499770087,0.406745319283591,0.209849678417279,9.07145995608204,10.5078,3.68086785324745,124.2529,0.74794080580291,0.607363250459549,0.740119991863882,0.641501162287546,0.140577555343361,0.0986188295763368,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
669,25836,1011:1080,Breast,EFM-192A,SIDM01002,1290798,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.913668189312358,0.0854706361131964,0.753514424486718,12.5268379264925,1.1526,0.871721353232857,0.914992208377845,0.163805945028793,0.688462159841524,0.481139252532227,0.207322907309297,9.33615507856624,0.1262,3.1906828479263,1.0264,0.796464070393183,0.699013355570187,0.835999274263502,0.739439292242686,0.0974507148229957,0.0965599820208156,True,0.543369948356915,0.0638512167263975,0.581057158949269,83.6140811297661
670,25836,1053:1080,Breast,EFM-192A,SIDM01002,1290798,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.838078824804164,0.0854706361131964,0.753514424486718,12.5268379264925,1.1526,0.871721353232857,0.914992208377845,0.0923965811501823,0.631504483346815,0.440306462881455,0.19119802046536,9.3206381166071,0.1249,3.20619980988544,1.0277,0.730571207274088,0.606810073170105,0.766835594702271,0.677695266945753,0.123761134103983,0.0891403277565178,True,0.543369948356915,0.0638512167263975,0.581057158949269,83.6140811297661
671,27065,1054:1553,Breast,EFM-192A,SIDM01002,1290798,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.959627873413921,0.0675608512260923,0.662100709848895,11.1230556862398,43.5616,0.864351947439171,0.876564247833887,0.113891150812161,0.635370296178143,0.414279707939152,0.221090588238991,8.13242417738311,5.4807,2.9906315088567,38.0809,0.829456221202233,0.654744328209654,0.841175485059507,0.721537691118783,0.174711892992579,0.119637793940724,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
672,27065,1510:1553,Breast,EFM-192A,SIDM01002,1290798,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.995871815761233,0.0675608512260923,0.662100709848895,11.1230556862398,43.5616,0.864351947439171,0.876564247833887,0.0857216807001149,0.65936743613402,0.427184685993765,0.232182750140255,8.09697754142817,5.3477,3.02607814481165,38.2139,0.860783743353005,0.749625302538218,0.872945629121713,0.746964545755766,0.111158440814787,0.125981083365947,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
673,27065,1549:1553,Breast,EFM-192A,SIDM01002,1290798,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.938842170109476,0.0675608512260923,0.662100709848895,11.1230556862398,43.5616,0.864351947439171,0.876564247833887,0.116192405499448,0.621608067265561,0.219817819393749,0.401790247871812,5.25964311703768,0.7482,5.86341256920214,42.8134,0.811490058072143,0.493539888616505,0.822955480676748,0.546843799884409,0.317950169455638,0.276111680792339,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
674,27065,1594:1553,Breast,EFM-192A,SIDM01002,1290798,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.98535427779231,0.0675608512260923,0.662100709848895,11.1230556862398,43.5616,0.864351947439171,0.876564247833887,0.0780907594215516,0.652403766778933,0.546480660701167,0.105923106077767,9.69210696090198,16.1564,1.43094872533784,27.4052,0.8516928889273,0.860692076043672,0.863726331362919,0.812356465887715,-0.0089991871163718,0.0513698654752047,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
675,27065,1012:1560,Breast,EFM-192A,SIDM01002,1290798,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.78384954830166,0.0903626189935603,0.589744043429257,10.1453949243006,22.1207,0.855477968228781,0.842437941494083,0.0475492216508072,0.462270602055617,0.27159412055834,0.190676481497277,6.99736818637265,2.4954,3.14802673792798,19.6253,0.670566018978151,0.545852926704898,0.660344599912317,0.540523608144969,0.124713092273253,0.119820991767348,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
676,27065,1594:1560,Breast,EFM-192A,SIDM01002,1290798,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.971719720497535,0.0903626189935603,0.589744043429257,10.1453949243006,22.1207,0.855477968228781,0.842437941494083,0.0857796910720377,0.573065917046163,0.362157779307385,0.210908137738778,7.35671011884105,3.2013,2.78868480545958,18.9194,0.83128481217907,0.717051766864108,0.818613561045149,0.690002529048163,0.114233045314962,0.128611031996986,True,1.08530245217838,0.111643370898239,-0.0955361593230134,-618.416685395444
677,25836,1012:2169,Breast,EFM-192A,SIDM01002,1290798,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.809388878082839,0.0885423856529342,0.803095999679482,13.4368016910018,216.576,0.940165529058692,0.934030216702033,0.0896446361026017,0.650016970173392,0.368133494735662,0.28188347543773,8.42817207930559,6.7276,5.00862961169618,209.8484,0.760959522776973,0.577725703989372,0.755993669191929,0.620699373339855,0.183233818787602,0.135294295852075,True,0.543369948356915,0.0638512167263975,0.581057158949269,83.6140811297661
678,25850,1510:1085,Breast,HCC1419,SIDM00882,907045,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.963617526263217,0.10283755994789,0.562408379748713,9.96736709549515,19.5527,0.839109365941929,0.799920603575941,0.11934202835641,0.541946571643158,0.443058405488654,0.0988881661545042,8.37857635339299,6.5003,1.58879074210216,13.0524,0.808580491473258,0.759326658815844,0.770817513224827,0.706245365418004,0.0492538326574138,0.0645721478068236,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
679,25850,1011:1085,Breast,HCC1419,SIDM00882,907045,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.952310047919545,0.10283755994789,0.562408379748713,9.96736709549515,19.5527,0.839109365941929,0.799920603575941,0.146973316362877,0.53558715106885,0.346099818143244,0.189487332925607,6.83930715349174,2.2365,3.1280599420034,17.3162,0.799092280489897,0.665977716106551,0.761772428323236,0.625883694643419,0.133114564383347,0.135888733679817,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
680,25852,1049:1192,Breast,HCC1419,SIDM00882,907045,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.96196775123838,0.0814134985385179,0.755591880255038,13.3509249884956,204.0605,0.923955170234783,0.901169516849212,0.127012799217104,0.726855021902918,0.700046065008152,0.0268089568947656,12.7897945936487,138.3063,0.561130394846929,65.7542,0.888815077355829,0.904937190405103,0.866896013608013,0.8543283909906,-0.0161221130492744,0.0125676226174132,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
681,25852,1558:1192,Breast,HCC1419,SIDM00882,907045,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.633490958132591,0.0814134985385179,0.755591880255038,13.3509249884956,204.0605,0.923955170234783,0.901169516849212,0.0517908295169002,0.47866062417997,0.408532822838401,0.0701278013415696,11.3000810561523,49.2485,2.05084393234334,154.812,0.585317246063594,0.543933784861234,0.570882740668692,0.536209749388214,0.0413834612023609,0.0346729912804781,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
682,25852,1012:1192,Breast,HCC1419,SIDM00882,907045,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.975585261586483,0.0814134985385179,0.755591880255038,13.3509249884956,204.0605,0.923955170234783,0.901169516849212,0.115486177129778,0.737144302151234,0.404373179981569,0.332771122169664,7.66841709742832,3.9733,5.68250789106731,200.0872,0.901397046447684,0.638527388545837,0.879167698829103,0.682104083845689,0.262869657901847,0.197063614983413,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
683,25852,1011:1192,Breast,HCC1419,SIDM00882,907045,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.946785726402931,0.0814134985385179,0.755591880255038,13.3509249884956,204.0605,0.923955170234783,0.901169516849212,0.153547640934547,0.715383607211423,0.488661310495107,0.226722296716316,9.24875484141146,11.8818,4.10217014708418,192.1787,0.874787567014483,0.789875610707742,0.853214435622259,0.73009638410747,0.0849119563067409,0.12311805151479,True,0.689569102390084,0.0932041537937058,0.351015700715072,136.611923586837
684,26744,1510:1564,Breast,HCC1419,SIDM00882,907045,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.957353645864588,0.076971698224195,0.787800792831991,14.056602080857,166.4021,0.903456784432979,0.91573682605707,0.047624019047003,0.75420396123272,0.786501271149235,-0.0322973099165146,14.8857022985264,295.6262,-0.829100217669403,-129.2241,0.86492764645801,0.912563745360826,0.876683989078203,0.890747338618918,-0.0476360989028157,-0.0140633495407154,True,1.08146630533899,0.138387256744588,-0.101267020320404,-652.619349433064
685,27314,1011:1013,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.166133580443784,0.0988106035524395,0.48531094826537,8.91142236584608,9.4045,0.909391743197959,0.891250820730335,0.0573019314731004,0.0806264454638939,0.0140272581501243,0.0665991873137696,5.40768361389092,0.8291,3.50373875195516,8.5754,0.151080506323491,0.0458301043278791,0.148066689921392,0.104598516898417,0.105250401995612,0.0434681730229746,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
686,27314,1049:1013,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.764408444725383,0.0988106035524395,0.48531094826537,8.91142236584608,9.4045,0.909391743197959,0.891250820730335,0.0828598081246425,0.370975787171732,0.150591834254108,0.220383952917623,6.88232303656672,2.3042,2.02909932927936,7.1003,0.695146728064057,0.595653975232827,0.681279653734696,0.577869838568429,0.0994927528312292,0.103409815166267,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
687,27315,1012:1030,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.892138109099545,0.0849349965792016,0.912396304722273,12.5315405271668,115.6377,0.952664061227188,0.986201679900854,0.0608085067163535,0.813983514044341,0.758771112397748,0.0552124016465935,11.6202569275528,61.486,0.911283599613995,54.1517,0.849907914190316,0.843659992644832,0.879828101897542,0.870398059953532,0.0062479215454842,0.0094300419440098,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
688,27315,1049:1030,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.752065864429341,0.0849349965792016,0.912396304722273,12.5315405271668,115.6377,0.952664061227188,0.986201679900854,0.0795081675414564,0.686182115613093,0.300106325498905,0.386075790114188,8.38290447869023,6.5198,4.14863604847661,109.1179,0.716466120717591,0.575032878100071,0.741688618896304,0.648161510035314,0.14143324261752,0.0935271088609894,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
689,27506,1049:1038,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.860053215402476,0.101835273712556,0.598655505657011,9.60264283647529,15.185,0.923637957381325,0.922807430736586,0.0869027180599444,0.514875592558708,0.255355851196853,0.259519741361855,7.70076447201638,4.0634,1.90187836445892,11.1216,0.794377795113584,0.694015376506686,0.793663498002299,0.703053937988912,0.100362418606898,0.0906095600133864,True,1.18990599600383,0.10938205659987,-0.190979286348821,-292.434997055326
690,27322,1012:1042,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.75502625325408,0.0812778815988277,0.737617571625607,10.5577840393335,29.4401,0.938206610036748,0.95420450356751,0.109910378812595,0.556920631438855,0.374586835091686,0.182333796347169,8.97663479674459,9.8393,1.58114924258895,19.6008,0.708370621554258,0.592644140765347,0.720449451166746,0.675418627789022,0.115726480788911,0.0450308233777246,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
691,27322,1011:1042,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.133942652555674,0.0812778815988277,0.737617571625607,10.5577840393335,29.4401,0.938206610036748,0.95420450356751,0.0814643244214834,0.0987984541152086,0.0157301183663802,0.0830683357488284,5.96029675607601,1.2161,4.59748728325754,28.224,0.125665881993589,0.008520071290349,0.127808682288402,0.0909044473921599,0.11714581070324,0.0369042348962424,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
692,26765,1049:1050,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.968377292927658,0.0744754708370595,0.755501245400971,10.7002796223813,32.4964,0.95393699073725,0.957808580729746,0.13670493953446,0.731610250824867,0.571228774168341,0.160381476656525,9.54780403013299,14.6186,1.15247559224835,17.8778,0.923770920713694,0.919334877022874,0.927520080549953,0.891475925173785,0.0044360436908205,0.0360441553761685,True,1.1120462227238,0.132945306621086,-0.12825704405729,-480.978366743755
693,26765,1558:1050,Breast,HCC1500,SIDM00879,1303900,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.997758646163429,0.0744754708370595,0.755501245400971,10.7002796223813,32.4964,0.95393699073725,0.957808580729746,0.0566881029935193,0.753807899786057,0.584175911390497,0.16963198839556,9.520472725516,14.3443,1.17980689686534,18.1521,0.951798880403214,0.924006211541869,0.955661792792626,0.917402158033392,0.0277926688613449,0.0382596347592343,True,1.1120462227238,0.132945306621086,-0.12825704405729,-480.978366743755
694,26765,1012:1051,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.965693553716779,0.0713173962961293,0.932613612927114,12.9600072992806,155.6256,0.946390108370929,0.989500044389763,0.0391274888217558,0.900618954112229,0.696102225502379,0.20451672860985,10.4296297016697,26.9378,2.53037759761098,128.6878,0.91392282695513,0.894748328946876,0.95555381426966,0.918124785756879,0.019174498008254,0.0374290285127811,True,1.1120462227238,0.132945306621086,-0.12825704405729,-480.978366743755
695,26765,1011:1051,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.123887645395262,0.0713173962961293,0.932613612927114,12.9600072992806,155.6256,0.946390108370929,0.989500044389763,0.0628167225439156,0.115539304569109,0.0824657748064066,0.0330735297627023,10.0377581906991,20.5303,2.92224910858152,135.0953,0.117246042151442,0.0513218531386004,0.122586830617955,0.116300915059607,0.0659241890128413,0.0062859155583487,True,1.1120462227238,0.132945306621086,-0.12825704405729,-480.978366743755
696,26765,1594:1051,Breast,HCC1500,SIDM00879,1303900,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.773920965302543,0.0713173962961293,0.932613612927114,12.9600072992806,155.6256,0.946390108370929,0.989500044389763,0.153211885946778,0.721769227570844,0.405118794966794,0.31665043260405,9.14154784879011,11.0309,3.81845945049053,144.5947,0.732431146223208,0.566036010022334,0.765794829521034,0.698561462150461,0.166395136200874,0.0672333673705736,True,1.1120462227238,0.132945306621086,-0.12825704405729,-480.978366743755
697,27318,1011:1085,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.119895213070979,0.119148756063688,0.379903193989743,8.26157703248185,5.9939,0.873140428574535,0.854458640369874,0.0687350490349439,0.0455485743897458,0.008866117121461,0.0366824572682848,5.19069269559308,0.7133,3.07088433688878,5.2806,0.10468535772483,0.0058718866220362,0.102445500747485,0.073129993981258,0.098813471102794,0.0293155067662274,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
698,27319,1011:1096,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.150717339641952,0.0854903981411471,0.873170437556691,11.9076497150362,37.5197,0.945866133358224,0.9795886232384,0.0971231624656346,0.131601925402543,0.0231475114154905,0.108454413987053,6.42769762915135,0.8407,5.47995208588489,36.679,0.142558427277171,0.0097992225464824,0.147640991238014,0.108324582120611,0.132759204730689,0.039316409117403,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
699,27319,1012:1129,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.914835922779999,0.0770650837083649,0.650914936196669,9.93902581869177,19.1723,0.936429430677612,0.935394321483566,0.11909070688183,0.595480366306764,0.491962440305475,0.103517926001289,9.22807015447746,11.7127,0.710955664214309,7.4596,0.856679282332303,0.866063967069739,0.855732327257589,0.82946118171222,-0.0093846847374362,0.0262711455453686,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
700,27319,1049:1129,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.760100679900117,0.0770650837083649,0.650914936196669,9.93902581869177,19.1723,0.936429430677612,0.935394321483566,0.0981541310954057,0.494760885560229,0.27442060419314,0.220340281367089,8.1396080066428,5.508,1.79941781204896,13.6643,0.711780646936533,0.586325328199871,0.710993859734367,0.643658625382186,0.125455318736661,0.0673352343521808,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
701,27319,1011:1129,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.194799127553756,0.0770650837083649,0.650914936196669,9.93902581869177,19.1723,0.936429430677612,0.935394321483566,0.0806455274830798,0.126797661682819,0.0188265642809298,0.10797109740189,5.63151691258645,0.9682,4.30750890610531,18.2041,0.182415636111659,0.0485523521438206,0.182213997743736,0.126555554004837,0.133863283967838,0.0556584437388983,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
702,27319,1510:1129,Breast,HCC1500,SIDM00879,1303900,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.89016660072244,0.0770650837083649,0.650914936196669,9.93902581869177,19.1723,0.936429430677612,0.935394321483566,0.0486308592638173,0.579422736113653,0.346175101731377,0.233247634382276,8.31880240920842,6.2365,1.62022340948335,12.9358,0.83357820312274,0.760644463699975,0.832656783490099,0.763735780509101,0.072933739422765,0.0689210029809987,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
703,27319,1558:1129,Breast,HCC1500,SIDM00879,1303900,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.969225288881143,0.0770650837083649,0.650914936196669,9.93902581869177,19.1723,0.936429430677612,0.935394321483566,0.120435003194504,0.630883217072267,0.536326252148045,0.0945569649242217,9.32288070740634,12.5083,0.616145111285425,6.664,0.907611085465312,0.861640118608745,0.906607831457689,0.88294068136425,0.0459709668565674,0.0236671500934389,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
704,27319,1058:1129,Breast,HCC1500,SIDM00879,1303900,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.984979378318034,0.0770650837083649,0.650914936196669,9.93902581869177,19.1723,0.936429430677612,0.935394321483566,0.114011326968223,0.641137789192918,0.519761704490327,0.12137608470259,9.16708594925784,11.2279,0.771939869433924,7.9444,0.922363678467545,0.844486405301751,0.921344117257102,0.890258761129826,0.0778772731657942,0.031085356127276,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
705,27320,1049:1192,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.929103725735448,0.0799466233525721,0.53473220339937,9.2097189436579,11.5646,0.855541153087267,0.905828575570764,0.071681982927136,0.496821682449081,0.604450116989611,-0.107628434540531,9.93676065073855,19.1423,-0.727041707080655,-7.5777,0.794886472853382,0.85374520538702,0.841608704440431,0.869004993812393,-0.0588587325336389,-0.0273962893719626,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
706,27320,1012:1192,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.741846855986438,0.0799466233525721,0.53473220339937,9.2097189436579,11.5646,0.855541153087267,0.905828575570764,0.0819326740325678,0.396689403886524,0.189551109104979,0.207138294781544,7.38825748954531,3.272,1.82146145411258,8.2926,0.634680514584801,0.544067756955084,0.671986080849845,0.589718292137809,0.0906127576297177,0.0822677887120355,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
707,27320,1011:1192,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.0975080572506768,0.0799466233525721,0.53473220339937,9.2097189436579,11.5646,0.855541153087267,0.905828575570764,0.0729077134866175,0.0521406983028464,0.0609299070955897,-0.0087892087927432,9.76903832263752,17.0413,-0.559319378979625,-5.4767,0.0834221557355433,0.0190980192298553,0.088325584606053,0.0906096316015659,0.064324136505688,-0.0022840469955128,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
708,27507,1012:1553,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.732415995569166,0.0691064667366821,0.884814965066622,12.0727569229409,84.138,0.95022190284591,0.981582227820063,0.0559784738271208,0.648052633533767,0.424090311499973,0.223962322033794,9.48045170691559,13.9518,2.59230521602535,70.1862,0.695957720984515,0.648473111098032,0.718926524621831,0.67220769009645,0.0474846098864832,0.0467188345253818,True,1.18990599600383,0.10938205659987,-0.190979286348821,-292.434997055326
709,27507,1011:1553,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.190934447721706,0.0691064667366821,0.884814965066622,12.0727569229409,84.138,0.95022190284591,0.981582227820063,0.121278165832157,0.168941656690896,0.0457970071173736,0.123144649573522,7.26160371959205,2.997,4.81115320334888,81.141,0.181430094232952,0.034580376255143,0.187417860562265,0.149970217947568,0.146849717977809,0.0374476426146977,True,1.18990599600383,0.10938205659987,-0.190979286348821,-292.434997055326
710,27507,1049:1553,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.830082323581513,0.0691064667366821,0.884814965066622,12.0727569229409,84.138,0.95022190284591,0.981582227820063,0.106314903743857,0.734469262142197,0.452642630002576,0.281826632139621,9.27383024405598,12.0901,2.79892667888496,72.0479,0.78876240503238,0.763214490819067,0.814794056455196,0.754354256416895,0.0255479142133134,0.0604398000383013,True,1.18990599600383,0.10938205659987,-0.190979286348821,-292.434997055326
711,27507,1011:1560,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.206668488259104,0.0574753300400311,0.909264543754812,12.473421221345,111.0718,0.962976079919756,0.985684227661507,0.0859793200767024,0.187916328685411,0.05546607129856,0.132450257386851,7.48859650096865,3.5077,4.98482472037638,107.5641,0.199016810666694,0.0790486185377971,0.203709869231646,0.165810446195114,0.119968192128897,0.037899423036532,True,1.18990599600383,0.10938205659987,-0.190979286348821,-292.434997055326
712,27507,1049:1560,Breast,HCC1500,SIDM00879,1303900,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.830082323581513,0.0574753300400311,0.909264543754812,12.473421221345,111.0718,0.962976079919756,0.985684227661507,0.0641376732585608,0.754764425230278,0.547545113599278,0.207219311631,9.99715700161015,19.9606,2.47626421973488,91.1112,0.799349421973208,0.753613414952559,0.818199054014913,0.778114361109994,0.0457360070206487,0.0400846929049191,True,1.18990599600383,0.10938205659987,-0.190979286348821,-292.434997055326
713,27326,1012:1632,Breast,HCC1500,SIDM00879,1303900,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.648691201945032,0.0816611743779965,0.8927669212255,12.1940523464547,36.6071,0.946892751700164,0.982928647606842,0.0842140708832753,0.579130047186535,0.522527817032434,0.0566022301541013,11.1417565892422,17.652,1.0522957572125,18.9551,0.614240997213418,0.570552305838607,0.637617165842287,0.627577725722473,0.0436886913748116,0.0100394401198139,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
714,27326,1011:1632,Breast,HCC1500,SIDM00879,1303900,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.11850866123078,0.0816611743779965,0.8927669212255,12.1940523464547,36.6071,0.946892751700164,0.982928647606842,0.0709502242252739,0.105800612625559,0.0106565154752406,0.0951440971503184,5.51165551138764,0.3564,6.68239683506711,36.2507,0.112214992333116,0.0152571632736053,0.116485558113268,0.0757216814456482,0.0969578290595103,0.0407638766676195,True,0.872221044646994,0.129284094532565,0.108145818297196,374.934968329699
715,25055,1011:1025,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.580816559227808,0.0993084995674416,0.859156530788213,14.2717884189179,386.3371,0.936468772272849,0.957287653012845,0.0832907582942534,0.49901234005051,0.277102790112765,0.221909549937744,8.73267287576869,8.3086,5.53911554314925,378.0285,0.543916570135806,0.434701801953936,0.556008520814184,0.461412313099142,0.10921476818187,0.0945962077150422,True,0.703183336265105,0.0984298166640172,0.326794914173339,144.790142859417
716,28375,1561:1032,Breast,HDQ-P1,SIDM01062,1290922,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.868128292157876,0.106340929501804,0.326782181173185,6.89287554560527,2.3211,0.655133353217163,0.69275951934501,0.147847615644733,0.283688856849503,0.123992558017438,0.159696298832065,3.77573165839681,0.2675,3.11714388720845,2.0536,0.568739799064078,0.38549044008467,0.601404138405095,0.420536643979753,0.183249358979408,0.180867494425341,True,0.349622540569322,0.0472529798870771,1.00813396186302,48.7704804755436
717,28375,1510:1032,Breast,HDQ-P1,SIDM01062,1290922,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.85332644204046,0.106340929501804,0.326782181173185,6.89287554560527,2.3211,0.655133353217163,0.69275951934501,0.0953755016990628,0.278851875982735,0.142345615043019,0.136506260939717,4.31102750730149,0.3877,2.58184803830378,1.9334,0.559042613362838,0.412639305672581,0.591150015832337,0.445099679578704,0.146403307690256,0.146050336253633,True,0.349622540569322,0.0472529798870771,1.00813396186302,48.7704804755436
718,28375,1011:1032,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.632175655105099,0.106340929501804,0.326782181173185,6.89287554560527,2.3211,0.655133353217163,0.69275951934501,0.0668248074076183,0.206583739459832,0.0892746851850585,0.117309054274773,3.73722880790854,0.2605,3.15564673769673,2.0606,0.41415935675126,0.275533252957017,0.437945702972225,0.30454691986006,0.138626103794243,0.133398783112166,True,0.349622540569322,0.0472529798870771,1.00813396186302,48.7704804755436
719,28375,1011:1038,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.632175655105099,0.098059597730463,0.695673698778236,11.4103332822443,53.1597,0.927750724823693,0.898311061991772,0.100448106828852,0.439787976264519,0.261543443176865,0.178244533087654,7.9836889798766,4.9438,3.42664430236768,48.2159,0.586501422239649,0.514756132663529,0.567890384102806,0.477787732933608,0.0717452895761191,0.0901026511691984,True,0.349622540569322,0.0472529798870771,1.00813396186302,48.7704804755436
720,28376,1549:1050,Breast,HDQ-P1,SIDM01062,1290922,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.694549634320389,0.0942469384990128,0.701035974569456,11.4845449641691,55.9658,0.927028363870126,0.900447220334404,0.0687362594143818,0.486904279782653,0.288460496219903,0.19844378356275,8.00291639189222,5.0101,3.4816285722769,50.9557,0.643867211130625,0.531820577468353,0.625405287608071,0.525652402885399,0.112046633662272,0.0997528847226715,True,0.349622540569322,0.0472529798870771,1.00813396186302,48.7704804755436
721,28376,1558:1050,Breast,HDQ-P1,SIDM01062,1290922,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.788818308020119,0.0942469384990128,0.701035974569456,11.4845449641691,55.9658,0.927028363870126,0.900447220334404,0.0864964192912859,0.552990011321114,0.413798511498653,0.139191499822461,9.28686902938137,12.1999,2.19767593478776,43.7659,0.731256945474692,0.661142974701209,0.710289252805604,0.647105833226871,0.0701139707734837,0.0631834195787331,True,0.349622540569322,0.0472529798870771,1.00813396186302,48.7704804755436
722,28376,1011:1050,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.618312879095209,0.0942469384990128,0.701035974569456,11.4845449641691,55.9658,0.927028363870126,0.900447220334404,0.0757467271945601,0.433459571785356,0.191178288756269,0.242281283029087,6.65639128174731,1.9702,4.82815368242181,53.9956,0.573193576667459,0.433646560816416,0.556758113278243,0.419319098817257,0.139547015851043,0.137439014460987,True,0.349622540569322,0.0472529798870771,1.00813396186302,48.7704804755436
723,28376,1011:1051,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.618312879095209,0.0742340124171544,0.525535501899465,9.29803646787782,12.2947,0.806201094962749,0.820847004029234,0.081334105827405,0.324945369246204,0.0600846694989013,0.264860699747303,2.50170182563104,0.1106,6.79633464224678,12.1841,0.498484520156128,0.207271780300104,0.507540274357992,0.245498989720219,0.291212739856024,0.262041284637774,True,0.349622540569322,0.0472529798870771,1.00813396186302,48.7704804755436
724,25057,1011:1080,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.72904818290787,0.0990405994675961,0.601731022280244,10.2031049735787,0.2302,0.827624989141054,0.858099934333233,0.106425656812056,0.438690908392706,0.0908519431189723,0.347838965273734,3.3168223571339,0.0019,6.88628261644484,0.2283,0.603378494462431,0.294584426538536,0.625596197879006,0.329990704723287,0.308794067923895,0.295605493155719,True,0.703183336265105,0.0984298166640172,0.326794914173339,144.790142859417
725,25058,1011:1085,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.583813364117093,0.0741829638337519,0.662002185961124,10.9597674040515,38.8999,0.900419357638892,0.884527378304345,0.107323576348432,0.386485723238833,0.181449984181876,0.205035739056957,6.67830624126509,2.0003,4.28146116278637,36.8996,0.525676854299314,0.430533892637047,0.516398904381532,0.396719471492926,0.0951429616622668,0.119679432888607,True,0.703183336265105,0.0984298166640172,0.326794914173339,144.790142859417
726,25059,1011:1096,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.609987876601182,0.0667916377143038,0.862837545791203,14.3614591746933,205.5559,0.94908473033563,0.958487408937265,0.0641835905049559,0.526320442408951,0.141209512428959,0.385110929979992,5.50194386007174,0.4425,8.85951531462157,205.1134,0.578930179372036,0.319337451078471,0.584665699326612,0.367943629055135,0.259592728293566,0.216722070271477,True,0.703183336265105,0.0984298166640172,0.326794914173339,144.790142859417
727,27664,1561:1553,Breast,HDQ-P1,SIDM01062,1290922,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.896682604200825,0.0851370668206366,0.632579472808116,10.5838927428969,29.9778,0.874071173629174,0.8719252045986,0.0860881094211469,0.567223009041566,0.397651551335964,0.169571457705603,8.33795238032235,6.3198,2.24594036257458,23.658,0.78376441622668,0.667406320448979,0.78184016312781,0.694534674385649,0.1163580957777,0.0873054887421613,True,,,,
728,27664,1372:1553,Breast,HDQ-P1,SIDM01062,1290922,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.847135488102248,0.0851370668206366,0.632579472808116,10.5838927428969,29.9778,0.874071173629174,0.8719252045986,0.0584562765459997,0.535880520460766,0.430531643900642,0.105348876560123,9.09587067308437,10.6871,1.48802206981255,19.2907,0.740456710308455,0.650923347936535,0.738638783786288,0.687597867488513,0.0895333623719204,0.0510409162977743,True,,,,
729,27664,1011:1553,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.69722006038452,0.0851370668206366,0.632579472808116,10.5838927428969,29.9778,0.874071173629174,0.8719252045986,0.0785630574310287,0.441047098229282,0.237687852674471,0.203359245554811,7.07806963116436,2.639,3.50582311173257,27.3388,0.609419956458101,0.446829209559661,0.607923743801021,0.490823702125602,0.16259074689844,0.117100041675419,True,,,,
730,27664,1011:1560,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.69722006038452,0.0754571335451481,0.639480278657482,10.6707994690361,31.8391,0.879684636526827,0.874930193561394,0.0547277933158686,0.445858478500279,0.18756439640319,0.258294082097089,6.0858027432364,1.3266,4.58499672579973,30.5125,0.613333775398569,0.43830845159901,0.610018882387115,0.447482376466203,0.175025323799558,0.162536505920912,True,,,,
731,27665,1058:1564,Breast,HDQ-P1,SIDM01062,1290922,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.873037899521778,0.108975027893338,0.603580547943841,10.2256220371483,11.6928,0.809777439118531,0.858947566712921,0.141896641870136,0.526948693769095,0.255486464218761,0.271462229550334,6.42695457935894,0.8402,3.79866745778933,10.8526,0.706966394528166,0.497205823496992,0.749893779442391,0.579463255374568,0.209760571031174,0.170430524067823,True,,,,
732,27665,1561:1564,Breast,HDQ-P1,SIDM01062,1290922,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.829763191882652,0.108975027893338,0.603580547943841,10.2256220371483,11.6928,0.809777439118531,0.858947566712921,0.0865704788451159,0.500828922020162,0.286667964539009,0.214160957481153,7.13722366023367,1.3747,3.0883983769146,10.3181,0.671923512597552,0.548170700539627,0.712723074615551,0.587067833135615,0.123752812057925,0.125655241479936,True,,,,
733,27665,1011:1564,Breast,HDQ-P1,SIDM01062,1290922,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.65550830331431,0.108975027893338,0.603580547943841,10.2256220371483,11.6928,0.809777439118531,0.858947566712921,0.089586038349101,0.395652060896189,0.1938067355528,0.201845325343389,6.46933075348031,0.8653,3.75629128366797,10.8275,0.530815835178795,0.422788462374965,0.563047262091942,0.436842306980024,0.10802737280383,0.126204955111918,True,,,,
734,27666,1558:1632,Breast,HDQ-P1,SIDM01062,1290922,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.783730349861893,0.0551958881792292,0.932641690602184,16.6614595380849,809.8212,0.976592673355849,0.980351237301847,0.161219383031363,0.730939598471437,0.44843327135565,0.282506327115787,9.84761024678634,7.1981,6.81384929129857,802.6231,0.765385317561741,0.541045357857272,0.768331018198117,0.661633382079814,0.224339959704469,0.106697636118302,True,,,,
735,25057,1561:2169,Breast,HDQ-P1,SIDM01062,1290922,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.773428889203662,0.101641508696446,0.547204262942882,9.55210733347463,14.6623,0.840704012738881,0.831934252563428,0.154644508548793,0.423223585255421,0.213029528225516,0.210194057029906,6.1802423921494,1.4163,3.37186494132524,13.246,0.650224770721693,0.426736209566742,0.643441984850611,0.501127800557638,0.223488561154951,0.142314184292972,True,0.703183336265105,0.0984298166640172,0.326794914173339,144.790142859417
736,24299,1058:1013,Breast,JIMT-1,SIDM01037,1298157,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,1.0,0.0791179653385969,0.742124836256099,10.8768887193211,36.7282,0.95796412330224,0.947265606595329,0.152869859678515,0.742124836256099,0.563743216067776,0.178381620188323,9.45520798163825,13.7098,1.42168073768288,23.0184,0.95796412330224,0.867151076803475,0.947265606595329,0.898721549486037,0.090813046498765,0.0485440571092919,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
737,24299,1561:1013,Breast,JIMT-1,SIDM01037,1298157,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.912901614747507,0.0791179653385969,0.742124836256099,10.8768887193211,36.7282,0.95796412330224,0.947265606595329,0.13427562260169,0.677486961362422,0.522773460308593,0.154713501053829,9.51967148892776,14.3363,1.35721723039337,22.3919,0.874526995032794,0.857855863505879,0.864760301855652,0.822969468048566,0.0166711315269148,0.0417908338070861,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
738,24299,1594:1013,Breast,JIMT-1,SIDM01037,1298157,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,1.0,0.0791179653385969,0.742124836256099,10.8768887193211,36.7282,0.95796412330224,0.947265606595329,0.120677611031814,0.742124836256099,0.50199369367846,0.240131142577639,9.01416012412855,10.0986,1.86272859519258,26.6296,0.95796412330224,0.819904757409255,0.947265606595329,0.878260861514097,0.138059365892985,0.0690047450812328,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
739,24010,1012:1032,Breast,JIMT-1,SIDM01037,1298157,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.866545316444996,0.0893952952832265,0.430852878033625,8.50572081212278,7.0992,0.841943688185353,0.851334239451971,0.0652945028654979,0.373353543536884,0.160785630687404,0.21256791284948,6.37352025607704,1.6194,2.13220055604574,5.4798,0.729582359707444,0.56373651436872,0.737719697926368,0.609770179102053,0.165845845338724,0.127949518824316,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
740,24010,1011:1038,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.806825841195096,0.0609943079851531,0.684645434681104,10.3764551011569,25.963,0.931968785623448,0.93302316663461,0.0870783977269326,0.552389628756964,0.312414742308472,0.239974886448492,8.18493387558308,5.6838,2.19152122557387,20.2792,0.751936499428211,0.707506872955828,0.752787201274481,0.671713551794234,0.0444296264723827,0.0810736494802469,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
741,24012,1011:1050,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.903178859752463,0.156733737697006,0.530402018811742,9.21619459109391,11.6167,0.934206847241544,0.887967526669402,0.130380697710883,0.479047890560794,0.111153457787412,0.367894432773382,5.51327711805667,0.8921,3.70291747303724,10.7246,0.843755875064561,0.579572551887885,0.801993498234485,0.571246260339173,0.264183323176676,0.230747237895312,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
742,24012,1011:1051,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.903178859752463,0.0728622509225446,0.710526932278334,10.5943948176959,30.1968,0.915237003610452,0.939577899362885,0.09406060161503,0.641732904518561,0.007446873612248,0.634286030906313,0.495124269259332,0.0275,10.0992705484365,30.1693,0.826622713324149,0.195990884256702,0.848606895795185,0.191161863541072,0.630631829067447,0.657445032254113,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
743,24012,1561:1051,Breast,JIMT-1,SIDM01037,1298157,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.83918934306242,0.0728622509225446,0.710526932278334,10.5943948176959,30.1968,0.915237003610452,0.939577899362885,0.124001102127381,0.596266629526812,0.437247355246803,0.159019274280008,9.14949047794964,11.0918,1.44490433974622,19.105,0.768057139806273,0.651709618058797,0.788483760122308,0.742536022350569,0.116347521747476,0.0459477377717388,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
744,24302,1011:1080,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.83696484484311,0.0745579772156459,0.218037464427579,6.73230408237368,0.0208,0.713822156366858,0.731826050212694,0.0891594925193905,0.182489692584614,0.0332279060964059,0.149261786488208,3.34313237626318,0.002,3.38917170611049,0.0188,0.597444050349162,0.361311808555084,0.612512676568413,0.369832760291405,0.236132241794077,0.242679916277009,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
745,24304,1011:1096,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.812603893716409,0.0487367483364202,0.949918469458648,14.2251149339059,187.0193,0.966636806708046,0.990910625775832,0.171249561845694,0.771907446995229,0.0638339097650714,0.708073537230157,4.628199202097,0.2415,9.59691573180886,186.7778,0.785492832940553,0.423970055216294,0.805217832830404,0.451483566453805,0.36152277772426,0.3537342663766,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
746,24304,1561:1129,Breast,JIMT-1,SIDM01037,1298157,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.879666032478229,0.0498473788066508,0.899955493866432,12.9005248473916,149.3396,0.973475621917487,0.981354040821843,0.0551617330646508,0.79166027869647,0.703531549969145,0.0881287287273249,11.4589729319273,54.9825,1.44155191546434,94.3571,0.856333438046432,0.808619895442142,0.863263815546228,0.844907686110379,0.0477135426042907,0.0183561294358492,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
747,24014,1372:1553,Breast,JIMT-1,SIDM01037,1298157,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.988178822815977,0.0676266668058458,0.841267687157746,11.9611597645978,77.875,0.940093762535044,0.969429450301028,0.133844392781914,0.831322912768661,0.599223406844053,0.232099505924608,9.76736276219443,17.0216,2.19379700240341,60.8534,0.928980747598522,0.781571091116637,0.95796965300161,0.90081531936104,0.147409656481885,0.0571543336405692,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
748,24014,1594:1553,Breast,JIMT-1,SIDM01037,1298157,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.943286710095527,0.0676266668058458,0.841267687157746,11.9611597645978,77.875,0.940093762535044,0.969429450301028,0.0263454943828948,0.793556628928704,0.675669413524653,0.117887215404051,10.6444693095218,31.2633,1.31669045507603,46.6117,0.886777952443007,0.891420822524312,0.914449916844173,0.887638228832951,-0.0046428700813041,0.0268116880112221,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
749,24014,1011:1560,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.862478699342904,0.0571104064192898,0.654592884702861,10.1351259731556,21.9638,0.909921556425082,0.925095474930382,0.0388087985737134,0.564572419797643,0.329276237956805,0.235296181840839,8.14415101995617,5.5254,1.99097495319939,16.4384,0.784787960489575,0.709317429917296,0.797875141985962,0.715901750535003,0.0754705305722793,0.0819733914509587,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
750,24014,1558:1560,Breast,JIMT-1,SIDM01037,1298157,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.932918692376918,0.0571104064192898,0.654592884702861,10.1351259731556,21.9638,0.909921556425082,0.925095474930382,0.0630173849003508,0.610681938036228,0.44696361852853,0.163718319507698,8.85149022056921,9.0218,1.28363575258636,12.942,0.848882828585657,0.770981799892591,0.863038860795856,0.811670857184853,0.0779010286930659,0.0513680036110032,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
751,24014,1594:1560,Breast,JIMT-1,SIDM01037,1298157,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.936097394845585,0.0571104064192898,0.654592884702861,10.1351259731556,21.9638,0.909921556425082,0.925095474930382,0.086796896156948,0.612762694054805,0.331139549601619,0.281623144453186,7.92998694103751,4.7631,2.20513903211806,17.2007,0.851775198483358,0.694656163377845,0.86597946406577,0.764455379080064,0.157119035105513,0.101524084985705,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
752,24015,1011:1564,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.856883268887092,0.049044883145653,0.935588199466041,13.7513031044031,134.665,0.969851284025684,0.988221828101397,0.0757669583892761,0.80168987469065,0.453507104078584,0.348182770612066,9.20799683782301,5.7754,4.54330626658014,128.8896,0.831049338590271,0.701908219505325,0.846790750449103,0.760556468756614,0.129141119084946,0.086234281692489,True,0.429217451763087,0.0470851839379968,0.812888798923839,60.336039062316
753,24302,1558:2169,Breast,JIMT-1,SIDM01037,1298157,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.976413179950263,0.0461979257740768,0.902424690089536,12.9497634174082,154.5245,0.963910655387709,0.981838611262205,0.0290306929260837,0.881139361315954,0.800782721450153,0.0803566398658015,11.693961131298,64.7088,1.25580228611019,89.8157,0.941175068215055,0.953785158576493,0.95868016062048,0.942170237761917,-0.0126100903614377,0.0165099228585625,True,0.675969748037785,0.0750942135982808,0.372709379475618,129.451808920075
754,23879,1049:1050,Breast,MDA-MB-157,SIDM00529,925338,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.916325577831449,0.077269746752002,0.738428579202063,11.9926560334314,79.5938,0.895750814005985,0.915727877449131,0.0444595119558551,0.676640994524586,0.580365736570463,0.0962752579541236,10.5763721553912,29.8219,1.41628387804026,49.7719,0.820799382237025,0.81428128657932,0.839104876439941,0.8003743639611,0.0065180956577044,0.0387305124788411,True,1.24182113227034,0.117184192801437,-0.231885685731512,-234.39969331049
755,23607,1011:1080,Breast,MDA-MB-157,SIDM00529,925338,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.960770152991439,0.0621718724035621,0.597126648598311,10.1347193464403,0.2196,0.869720814950677,0.857317559870563,0.164865088348594,0.573701461529064,0.330111625880421,0.243589835648644,7.13334426450094,0.0274,3.00137508193932,0.1922,0.835601800440001,0.723941182842487,0.823685123159088,0.680830018798348,0.111660617597514,0.14285510436074,True,0.605611330841204,0.0751010466602057,0.466748670238479,102.278371455657
756,23608,1011:1085,Breast,MDA-MB-157,SIDM00529,925338,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.972500718026718,0.109937416416268,0.60340312156332,10.2101492192497,23.1362,0.892394169518476,0.860179284935611,0.1176335351045,0.586809968979892,0.290466157171158,0.296343811808734,6.53857281915252,1.8157,3.67157640009718,21.3205,0.867853970619575,0.671017442266023,0.836524972231591,0.653448751572465,0.196836528353552,0.183076220659126,True,0.605611330841204,0.0751010466602057,0.466748670238479,102.278371455657
757,23610,1011:1192,Breast,MDA-MB-157,SIDM00529,925338,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.962441329791616,0.0754431421613492,0.721242989154623,11.7412591800958,66.8654,0.910512314900773,0.909224319046692,0.0966309036774251,0.694154061584855,0.468276811556938,0.225877250027917,8.84483631158223,8.9803,2.89642286851355,57.8851,0.876314683144743,0.718598339198076,0.875075062702175,0.771490444560511,0.157716343946667,0.103584618141664,True,0.605611330841204,0.0751010466602057,0.466748670238479,102.278371455657
758,23973,1058:1032,Breast,MDA-MB-415,SIDM00630,924240,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.936230495938354,0.103765270484671,0.627441650479639,10.444694137178,27.2205,0.886710774119021,0.875241312001619,0.0680296550370603,0.587430007600932,0.539599739848216,0.0478302677527156,9.85314625167226,18.0644,0.591547885505747,9.1561,0.830165667807333,0.837964319848709,0.819427607601012,0.798365953728091,-0.0077986520413758,0.0210616538729212,True,0.520790102373951,0.0637165583821112,0.62227839021149,78.2133408496555
759,23973,1011:1032,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.575988717374095,0.103765270484671,0.627441650479639,10.444694137178,27.2205,0.886710774119021,0.875241312001619,0.0917781683276855,0.361399311486852,0.102415849599433,0.258983461887419,4.75601185944697,0.5278,5.68868227773104,26.6927,0.510735401466605,0.28473733950564,0.504129120692633,0.31913475105234,0.225998061960965,0.184994369640293,True,0.520790102373951,0.0637165583821112,0.62227839021149,78.2133408496555
760,23973,1053:1032,Breast,MDA-MB-415,SIDM00630,924240,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.546837142861147,0.103765270484671,0.627441650479639,10.444694137178,27.2205,0.886710774119021,0.875241312001619,0.053752400104394,0.343108399460368,0.12463208069828,0.218476318762088,5.61835233520347,0.9595,4.82634180197453,26.261,0.484886386263442,0.306364615051172,0.478614458369008,0.336027328787595,0.17852177121227,0.142587129581412,True,0.520790102373951,0.0637165583821112,0.62227839021149,78.2133408496555
761,23975,1011:1050,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.60889167473354,0.0762184874849695,0.807268850694964,12.9698706184313,156.6932,0.927818329790649,0.942449021348381,0.0673306317932385,0.491539282459877,0.266232828674201,0.225306453785676,8.3005581770071,6.1581,4.66931244142418,150.5351,0.564940856674705,0.430878476232842,0.573849362959802,0.475070160725347,0.134062380441863,0.0987792022344546,True,0.520790102373951,0.0637165583821112,0.62227839021149,78.2133408496555
762,23975,1011:1051,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.60889167473354,0.0681975648074282,0.727004246242008,11.7146749431661,65.6445,0.90980321040513,0.914442916115344,0.104952463774454,0.442666833032691,0.176766455378639,0.265900377654052,6.52254292055855,1.7956,5.19213202260752,63.8489,0.553971600461531,0.344724390940501,0.556796678641695,0.410996870354382,0.20924720952103,0.145799808287313,True,0.520790102373951,0.0637165583821112,0.62227839021149,78.2133408496555
763,24222,1011:1080,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.695179184298889,0.0920246248307861,0.395659785484988,7.82601619272643,0.0443,0.767040137250642,0.754263821655426,0.0596158535807786,0.275054446933328,0.127310507258305,0.147743939675023,4.85579671968534,0.0057,2.97021947304109,0.0386,0.533230336938409,0.375792773501709,0.524348508284581,0.390098617357749,0.1574375634367,0.134249890926832,True,0.767826454468379,0.10201406665302,0.248123544766186,191.591849718129
764,23625,1011:1096,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.728361362918823,0.0717508790813352,0.92692036261268,16.0406388337566,658.2843,0.962575588001202,0.979558926791765,0.0806231386297789,0.675132978629781,0.393653515633615,0.281479462996165,9.44958295366762,6.8282,6.59105588008897,651.4561,0.701102867188943,0.534642851066163,0.713472874977349,0.608745076287382,0.16646001612278,0.104727798689968,True,0.463280570456549,0.0675161722674811,0.723880865528972,66.9673715613956
765,23625,1011:1129,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.728361362918823,0.0752334032334993,0.835050869570263,13.495066944882,225.5018,0.937259195051356,0.951519062209885,0.0690330822849958,0.608218789466744,0.399991672504996,0.208227116961748,9.54683854572552,14.6088,3.94822839915643,210.893,0.682663384715804,0.567956653993833,0.693049720994432,0.611812596922889,0.114706730721971,0.0812371240715433,True,0.463280570456549,0.0675161722674811,0.723880865528972,66.9673715613956
766,24223,1011:1192,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.501562585404085,0.0616607855722289,0.622258968507365,10.3834163280847,26.0885,0.874340476791833,0.873040610885295,0.0908940301793947,0.312101817035433,0.09445543449913,0.217646382536303,4.95089680208324,0.6041,5.43251952600145,25.4844,0.438536470063152,0.224657074972167,0.437884505958391,0.284828343836745,0.213879395090985,0.153056162121646,True,0.767826454468379,0.10201406665302,0.248123544766186,191.591849718129
767,23977,1011:1553,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.58584694876577,0.0791101486548409,0.247740884895037,5.92163738214628,1.1839,0.624265428445096,0.635184433032226,0.0526378656272523,0.145138241500289,0.0478735526201138,0.0972646888801756,2.29491922798645,0.0958,3.62671815415983,1.0881,0.365723996474516,0.180246792250857,0.372120861995445,0.222360737369367,0.185477204223658,0.149760124626078,True,0.520790102373951,0.0637165583821112,0.62227839021149,78.2133408496555
768,23977,1053:1560,Breast,MDA-MB-415,SIDM00630,924240,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.815544230560033,0.0474960411121681,0.841276491556349,13.6222845271593,246.2897,0.954022906850878,0.953511475241879,0.090138104315177,0.686098188994566,0.393969358783618,0.292128830210949,8.81229828168387,8.78,4.80998624547545,237.5097,0.778047877504345,0.610027956773096,0.7776307824063,0.657549067725964,0.168019920731249,0.120081714680337,True,0.520790102373951,0.0637165583821112,0.62227839021149,78.2133408496555
769,23978,1053:1564,Breast,MDA-MB-415,SIDM00630,924240,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.587464253556104,0.095061454947473,0.761538233004856,12.2181432051438,46.5294,0.883194268181695,0.926840943561057,0.102037432607995,0.447376489606632,0.303066151376085,0.144310338230547,9.17620480022229,5.6495,3.04193840492147,40.8799,0.518845061502389,0.40059176275319,0.544485923074331,0.483789490972166,0.118253298749198,0.0606964321021648,True,0.520790102373951,0.0637165583821112,0.62227839021149,78.2133408496555
770,24222,1012:2169,Breast,MDA-MB-415,SIDM00630,924240,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.825419962569476,0.0802070992622521,0.222651056787928,5.53476635533411,0.9054,0.589783017656319,0.60872961349445,0.0447662142777926,0.183780626959946,0.0658000183682858,0.11798060859166,2.22021957508246,0.091,3.31454678025165,0.8144,0.486818676357992,0.294524271280029,0.50245757478552,0.309077986399352,0.192294405077963,0.193379588386168,True,0.767826454468379,0.10201406665302,0.248123544766186,191.591849718129
771,24222,1011:2169,Breast,MDA-MB-415,SIDM00630,924240,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.491051810663257,0.0802070992622521,0.222651056787928,5.53476635533411,0.9054,0.589783017656319,0.60872961349445,0.070401660874373,0.1093332045818,0.0215855663492281,0.0877476382325717,0.464788300019638,0.027,5.06997805531447,0.8784,0.289614018718575,0.10225705901406,0.298917778910794,0.128879717822405,0.187356959704515,0.170038061088389,True,0.767826454468379,0.10201406665302,0.248123544766186,191.591849718129
772,23901,1058:1032,Breast,MDA-MB-468,SIDM00628,908123,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,1.0,0.103530475064933,0.308288794556667,6.69485759792432,2.0234,0.688545278286492,0.682944390540914,0.0635783339841805,0.308288794556667,0.22422898070389,0.0840598138527773,5.45958771991465,0.8595,1.23526987800967,1.1639,0.688545278286492,0.586319369437915,0.682944390540914,0.601725187441989,0.102225908848577,0.0812192030989255,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
773,23657,1011:1096,Breast,MDA-MB-468,SIDM00628,908123,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.69614609091773,0.151393653332373,0.445243894468215,8.37273149079268,3.237,0.699714054466021,0.779675731589119,0.0902326591373672,0.309954796639034,0.112458917296114,0.19749587934292,4.3026756968831,0.1927,4.07005579390959,3.0443,0.487103203776716,0.335140534929708,0.542768212729187,0.362913119939383,0.151962668847008,0.179855092789804,True,0.311479619013044,0.0523649526502632,1.10505116450851,44.3782370688742
774,23905,1372:1553,Breast,MDA-MB-468,SIDM00628,908123,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.897687081484401,0.059543146191299,0.78010919243298,12.6120459638402,122.274,0.937453638047922,0.931571740126106,0.0800027709866267,0.700293944194315,0.439287182413537,0.261006761780777,8.87851888292007,9.1924,3.73352708092014,113.0816,0.841540020366173,0.680808027128311,0.836259916587149,0.722588760720455,0.160731993237862,0.113671155866694,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
775,23905,1049:1553,Breast,MDA-MB-468,SIDM00628,908123,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.986936046666113,0.059543146191299,0.78010919243298,12.6120459638402,122.274,0.937453638047922,0.931571740126106,0.0799704850178915,0.769917882347699,0.561690938668055,0.208226943679644,9.79379273484497,17.3363,2.81825322899524,104.9377,0.925206787467782,0.838179265352499,0.919401730385931,0.834585264236186,0.087027522115283,0.0848164661497455,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
776,23905,1594:1553,Breast,MDA-MB-468,SIDM00628,908123,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.947047214238366,0.059543146191299,0.78010919243298,12.6120459638402,122.274,0.937453638047922,0.931571740126106,0.102630196075114,0.738800237495395,0.370870419378611,0.367929818116784,7.74332620835837,4.1851,4.86871975548184,118.0889,0.887812856390906,0.663122836216888,0.882242421349616,0.706108175167085,0.224690020174018,0.176134246182531,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
777,23905,1549:1553,Breast,MDA-MB-468,SIDM00628,908123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.785999930867108,0.059543146191299,0.78010919243298,12.6120459638402,122.274,0.937453638047922,0.931571740126106,0.0971020184717824,0.613165771321117,0.277693093428915,0.335472677892203,7.27550716013186,3.026,5.33653880370835,119.248,0.736838494696785,0.526969056446536,0.732215323336871,0.564726571777111,0.209869438250249,0.16748875155976,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
778,23905,1558:1553,Breast,MDA-MB-468,SIDM00628,908123,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.890688951599686,0.059543146191299,0.78010919243298,12.6120459638402,122.274,0.937453638047922,0.931571740126106,0.0505923512400462,0.694834638741408,0.478484518518882,0.216350120222526,9.42531064692916,13.4286,3.18673531691105,108.8454,0.834979598046215,0.741232216210064,0.829740656552816,0.739309032338153,0.0937473818361508,0.0904316242146636,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
779,23905,1510:1553,Breast,MDA-MB-468,SIDM00628,908123,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.953191294240642,0.059543146191299,0.78010919243298,12.6120459638402,122.274,0.937453638047922,0.931571740126106,0.0552457716883982,0.743593290784214,0.529103934356762,0.214489356427452,9.63108807937997,15.4873,2.98095788446024,106.7867,0.893572646541498,0.772677034876133,0.88796607264881,0.799612970985101,0.120895611665364,0.088353101663709,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
780,23905,1083:1560,Breast,MDA-MB-468,SIDM00628,908123,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.754228710890241,0.076266514538229,0.846504030625748,13.8703628343395,292.4996,0.940206538043431,0.954015629357573,0.0829205482344831,0.638457643782252,0.438249680170966,0.200207963611286,9.93306827782504,19.0933,3.93729455651447,273.4063,0.709130765159074,0.605143628287016,0.719545978299504,0.642035788110973,0.103987136872057,0.0775101901885312,True,0.62272031493867,0.0718898044450808,0.445609142123599,107.750573305541
781,23655,1021:2169,Breast,MDA-MB-468,SIDM00628,908123,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.707736483045406,0.105451421506384,0.502124733998069,9.02424280518217,10.1695,0.761576342502145,0.811861434793262,0.0870849358944028,0.355371993289903,0.338203738552647,0.017168254737256,8.74730035202202,8.3932,0.276942453160142,1.7763,0.538995362213052,0.509475798558071,0.574583956580781,0.565181841579435,0.0295195636549814,0.0094021150013462,True,0.311479619013044,0.0523649526502632,1.10505116450851,44.3782370688742
782,23655,1549:2169,Breast,MDA-MB-468,SIDM00628,908123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.687165145038961,0.105451421506384,0.502124733998069,9.02424280518217,10.1695,0.761576342502145,0.811861434793262,0.113591013287976,0.345042615665432,0.167417807459804,0.177624808205629,5.76861865615103,1.0648,3.25562414903114,9.1047,0.523328717853728,0.373968179309657,0.557882880591251,0.427851407246332,0.149360538544071,0.130031473344919,True,0.311479619013044,0.0523649526502632,1.10505116450851,44.3782370688742
783,23655,1558:2169,Breast,MDA-MB-468,SIDM00628,908123,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.852674887842608,0.105451421506384,0.502124733998069,9.02424280518217,10.1695,0.761576342502145,0.811861434793262,0.077435728939865,0.428149151244803,0.213190215501232,0.214958935743571,5.86666373778303,1.1397,3.15757906739913,9.0298,0.649377022426601,0.510261570696514,0.692253857856084,0.536498101059958,0.139115451730086,0.155755756796126,True,0.311479619013044,0.0523649526502632,1.10505116450851,44.3782370688742
784,23655,1561:2169,Breast,MDA-MB-468,SIDM00628,908123,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.908474506653726,0.105451421506384,0.502124733998069,9.02424280518217,10.1695,0.761576342502145,0.811861434793262,0.0920614170094842,0.456167519997529,0.356840348610403,0.0993271713871259,7.75748920524475,4.2264,1.26675359993742,5.9431,0.691872692033785,0.63338610528284,0.737555416444995,0.678073616957856,0.0584865867509456,0.0594817994871392,True,0.311479619013044,0.0523649526502632,1.10505116450851,44.3782370688742
785,23655,1510:2169,Breast,MDA-MB-468,SIDM00628,908123,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.879029155631982,0.105451421506384,0.502124733998069,9.02424280518217,10.1695,0.761576342502145,0.811861434793262,0.0941284477659744,0.441382280948256,0.236066612270693,0.205315668677562,6.14193909829551,1.3792,2.88230370688665,8.7903,0.669447809298954,0.522379236539367,0.713649871516491,0.569092148364712,0.147068572759587,0.144557723151779,True,0.311479619013044,0.0523649526502632,1.10505116450851,44.3782370688742
786,26087,1011:1051,Breast,HCC1937,SIDM00874,749714,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.764765251436569,0.0696084453216742,0.693738653442282,11.6433035533902,62.4761,0.870224860921856,0.888198613077962,0.0920379226154936,0.530547215731053,0.30406159565837,0.226485620072684,7.65670004212339,3.9412,3.98660351126678,58.5349,0.665517734569256,0.50914810277969,0.679263435656179,0.553164105297554,0.156369631789566,0.126099330358625,True,0.386846446648174,0.0578389475654448,0.906641154990306,54.0389675162405
787,30673,1011:1080,Breast,HCC1937,SIDM00874,749714,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.957999809555538,0.0804148535750553,0.729445172688397,12.2063016994725,0.923,0.879150457284873,0.903407800264132,0.116388467353414,0.698808336516691,0.428471222318571,0.27033711419812,8.31541495221455,0.0622,3.89088674725799,0.8608,0.842225970649572,0.697422018511099,0.865464500604026,0.725696587645181,0.144803952138473,0.139767912958845,True,0.69197906623469,0.0712368666314907,0.343857256467682,138.335633225288
788,26089,1510:1553,Breast,HCC1937,SIDM00874,749714,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.975435178715359,0.0704717667759149,0.588335052823353,10.154383120137,22.2589,0.81941190571612,0.838613542227179,0.0615701812800439,0.573882707395257,0.451860434693765,0.122022272701492,8.52379069635137,7.1886,1.63059242378565,15.0703,0.799283198693697,0.737632182024323,0.818013150435488,0.748930264521529,0.0616510166693736,0.0690828859139595,True,0.386846446648174,0.0578389475654448,0.906641154990306,54.0389675162405
789,26089,1049:1553,Breast,HCC1937,SIDM00874,749714,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.966342448752769,0.0704717667759149,0.588335052823353,10.154383120137,22.2589,0.81941190571612,0.838613542227179,0.123046293999625,0.568533135632408,0.209902469662194,0.358630665970214,4.85564009179815,0.5655,5.29874302833886,21.6934,0.791832507506889,0.491179978754691,0.810387863953046,0.536640831877122,0.300652528752198,0.273747032075924,True,0.386846446648174,0.0578389475654448,0.906641154990306,54.0389675162405
790,30638,1011:1564,Breast,HCC1937,SIDM00874,749714,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.894979576840012,0.0990392614864018,0.755579654649644,12.6485017043161,62.7016,0.866953356928974,0.914103088212793,0.107605374618002,0.676228359587261,0.471790523303042,0.204437836284219,9.35145512176167,6.3792,3.29704658255444,56.3224,0.775905548524321,0.643400652864947,0.818103595076834,0.72126987392905,0.132504895659374,0.0968337211477838,True,0.612839905572013,0.0675552753270525,0.464699801293498,103.958011598677
791,23911,1011:1050,Breast,T47D,SIDM00097,905945,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.933428419220513,0.0681116117440316,0.782157010794588,13.5951474804651,241.7003,0.902855773047261,0.917823420807698,0.0531671267290724,0.730087582168234,0.425060597307961,0.305026984860274,8.35662840226593,6.4022,5.23851907819916,235.2981,0.842751237019619,0.655961381464968,0.856722464808093,0.693450320688288,0.186789855554651,0.163272144119805,True,0.807245427473284,0.0769782491270564,0.185379655430023,239.187907591984
792,23583,1011:1080,Breast,T47D,SIDM00097,905945,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.882412651957954,0.0649841199980097,0.562667582537733,9.90586984911351,0.1874,0.816586257393142,0.810174967695958,0.0765669824868843,0.496504993677892,0.292375966551163,0.204129027126729,6.47594132546208,0.0174,3.42992852365143,0.17,0.720566044938702,0.566612946837672,0.71490864179454,0.569372002926176,0.153953098101031,0.145536638868364,True,0.459169007859143,0.0662863316954957,0.733347304738049,66.1665895326004
793,23584,1011:1085,Breast,T47D,SIDM00097,905945,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.914813562351521,0.0688313938417665,0.798461517131786,13.9489661599809,308.8782,0.93829091101937,0.92466814357099,0.156839191956645,0.730443424887929,0.425123504616968,0.305319920270962,8.49172255498105,7.0306,5.45724360499983,301.8476,0.858361250831684,0.750914578887346,0.845898958413145,0.685456900478341,0.107446671944337,0.160442057934804,True,0.459169007859143,0.0662863316954957,0.733347304738049,66.1665895326004
794,23585,1053:1129,Breast,T47D,SIDM00097,905945,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.939708477862126,0.0664945621643243,0.834653528656646,14.8198650214556,564.8771,0.943779860132502,0.939411505311559,0.101158114418664,0.784330996956189,0.502693434588527,0.281637562367662,9.50331650227421,14.1747,5.31654851918138,550.7024,0.886877935802044,0.66457546883582,0.882772955742494,0.746094547873917,0.222302466966224,0.136678407868577,True,0.459169007859143,0.0662863316954957,0.733347304738049,66.1665895326004
795,23586,1011:1192,Breast,T47D,SIDM00097,905945,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.925787207886312,0.0759154628244572,0.787025689162359,13.6987075615159,259.688,0.91402161903964,0.919881002037255,0.0952447849357613,0.728618315304421,0.441818269896652,0.286800045407769,8.67243553259906,7.9688,5.02627202891687,251.7192,0.846189522638434,0.704626135673035,0.851614064463733,0.701441890470192,0.141563386965399,0.150172173993541,True,0.459169007859143,0.0662863316954957,0.733347304738049,66.1665895326004
796,27115,1011:1032,Breast,ZR-75-30,SIDM00971,909907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.972672296242396,0.167077852274876,0.138103797273688,3.66445551001911,0.2477,0.450993272861877,0.476685636609134,0.106787937694663,0.134329737613993,0.0346299704811119,0.0996997671328806,-0.612846306631463,0.0128,4.27730181665057,0.2349,0.438668662304435,0.214530964262252,0.463658912746374,0.205629043297726,0.224137698042182,0.258029869448648,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
797,27115,1558:1038,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.448791107242893,0.0964178074635899,0.797167223192242,12.9880673068166,158.6821,0.969398083131626,0.93633351225574,0.0426207501280401,0.357761560754188,0.15189213413814,0.205869426616048,7.04710919747208,2.583,5.94095810934454,156.0991,0.43505723908778,0.318663452531224,0.42021815371388,0.315129767688704,0.116393786556556,0.105088386025176,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
798,27115,1549:1038,Breast,ZR-75-30,SIDM00971,909907,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.6542246927757,0.0964178074635899,0.797167223192242,12.9880673068166,158.6821,0.969398083131626,0.93633351225574,0.0722649498690997,0.521526481683802,0.333085646059041,0.188440835624761,9.10642787169411,10.7656,3.88163943512251,147.9165,0.634204163114141,0.568221683924886,0.612572504391104,0.531391204783629,0.0659824791892554,0.081181299607475,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
799,27115,1053:1038,Breast,ZR-75-30,SIDM00971,909907,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.91614306217746,0.0964178074635899,0.797167223192242,12.9880673068166,158.6821,0.969398083131626,0.93633351225574,0.0594494452480059,0.730319220922843,0.495711884653434,0.234607336269409,9.47994388954762,13.9469,3.508123417269,144.7352,0.888107328349168,0.762804890139265,0.85781545113735,0.759410783418113,0.125302438209903,0.0984046677192372,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
800,27115,1058:1038,Breast,ZR-75-30,SIDM00971,909907,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.755985200975607,0.0964178074635899,0.797167223192242,12.9880673068166,158.6821,0.969398083131626,0.93633351225574,0.0688418336184742,0.602646623436153,0.433989075546161,0.168657547889992,9.8697105788665,18.273,3.11835672795012,140.4091,0.73285060470163,0.686461834200646,0.707854278442851,0.638950358415994,0.0463887705009847,0.0689039200268567,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
801,27116,1558:1042,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.596975883678825,0.050890200577764,0.841733635021542,13.869496333128,292.324,0.94547989047768,0.951563216465692,0.0742745763018776,0.502494680589174,0.391124093370732,0.111370587218442,10.8702762418036,36.5603,2.99922009132447,255.7637,0.564428693118471,0.464613383331199,0.568060292025871,0.526356509477031,0.0998153097872725,0.0417037825488406,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
802,27117,1011:1050,Breast,ZR-75-30,SIDM00971,909907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.94285758620196,0.0664288648956713,0.756966473848106,12.3104251558317,99.2058,0.93342335327568,0.921877594252835,0.07664469950066,0.713711582368235,0.427487251099833,0.286224331268402,8.45523224534089,6.855,3.85519291049077,92.3508,0.880085289774048,0.763998668810353,0.869199283290898,0.736051483653934,0.116086620963694,0.133147799636964,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
803,27119,1054:1553,Breast,ZR-75-30,SIDM00971,909907,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.994549112484859,0.060544630124711,0.711677914008007,11.6327559030029,62.021,0.892490488172701,0.904683947188573,0.123121383635917,0.707798637751739,0.401150991504256,0.306647646247483,7.85916674980077,4.535,3.77358915320218,57.486,0.887625622913338,0.670527696311458,0.899752616755694,0.744967562717375,0.217097926601879,0.15478505403832,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
804,27119,1558:1553,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.563434235987266,0.060544630124711,0.711677914008007,11.6327559030029,62.021,0.892490488172701,0.904683947188573,0.0770289520381498,0.400983701748113,0.220051494485288,0.180932207262824,7.70340532599867,4.0709,3.92935057700428,57.9501,0.502859696329488,0.368782034263365,0.509729908594138,0.417159056673601,0.134077662066123,0.0925708519205373,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
805,27119,1372:1553,Breast,ZR-75-30,SIDM00971,909907,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.952997618830361,0.060544630124711,0.711677914008007,11.6327559030029,62.021,0.892490488172701,0.904683947188573,0.0331068309509193,0.678227357423789,0.625770077322034,0.0524572801017542,10.8890958984987,37.0403,0.743660004504278,24.9807,0.85054131005733,0.855497229423596,0.862161647464762,0.840849818000578,-0.0049559193662662,0.0213118294641838,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
806,27119,1011:1553,Breast,ZR-75-30,SIDM00971,909907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.951256560172578,0.060544630124711,0.711677914008007,11.6327559030029,62.021,0.892490488172701,0.904683947188573,0.0830866104095949,0.676988284430052,0.461692853197928,0.215295431232124,8.8292083414387,8.8836,2.80354756156425,53.1374,0.848987431765908,0.733243660787123,0.860586539645952,0.76023080474878,0.115743770978785,0.100355734897173,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
807,27119,1012:1560,Breast,ZR-75-30,SIDM00971,909907,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.925445202009482,0.0745610253608665,0.54667783867532,9.54562834356361,14.5966,0.818891452026133,0.831744232360987,0.0762394723356226,0.505920382846988,0.269815390316799,0.236104992530189,6.41295841075204,1.6643,3.13266993281157,12.9323,0.757839165244163,0.568713235275152,0.769733709137534,0.613473389309878,0.189125929969011,0.156260319827657,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
808,27119,1011:1560,Breast,ZR-75-30,SIDM00971,909907,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.951256560172578,0.0745610253608665,0.54667783867532,9.54562834356361,14.5966,0.818891452026133,0.831744232360987,0.038488365184366,0.520030880340865,0.259835157226216,0.260195723114648,6.14825794932731,1.3853,3.3973703942363,13.2113,0.778975865809107,0.604808998295896,0.791202157419093,0.61442479217269,0.174166867513211,0.176777365246403,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
809,27120,1549:1564,Breast,ZR-75-30,SIDM00971,909907,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.595315691339634,0.0419817877870224,0.923978216941182,16.2777066457916,775.8504,0.983649782980494,0.977735420699524,0.0708143198706228,0.550058731001102,0.344905629955865,0.205153101045236,9.93291432117826,9.5456,6.34479232461336,766.3048,0.585582150591113,0.469116283256074,0.582061237920985,0.50465970426895,0.116465867335039,0.0774015336520341,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
810,27120,1558:1564,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.615045153955357,0.0419817877870224,0.923978216941182,16.2777066457916,775.8504,0.983649782980494,0.977735420699524,0.10393552903502,0.568288324689985,0.279713970829566,0.28857435386042,8.47157916454768,3.4666,7.80612748124394,772.3838,0.604989032211391,0.422470720526951,0.601351432351744,0.480652586331322,0.18251831168444,0.120698846020423,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
811,27120,1561:1564,Breast,ZR-75-30,SIDM00971,909907,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.842326886860441,0.0419817877870224,0.923978216941182,16.2777066457916,775.8504,0.983649782980494,0.977735420699524,0.0758586039561798,0.778291695002926,0.7166785027181,0.0616131922848262,14.07333352829,168.3432,2.20437311750167,607.5072,0.828554659458907,0.771035736258399,0.823572833091013,0.804065741260956,0.057518923200508,0.0195070918300574,True,0.749516774496127,0.0791148097907352,0.262908017978766,176.96116610254
812,27338,1558:1909,Breast,ZR-75-30,SIDM00971,909907,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.355026517537719,0.0579931767469136,0.941125900740288,17.0761085100685,269.8677,0.969063254028999,0.9829081451137,0.0982836359130222,0.334124651104374,0.221140075847077,0.112984575257296,10.4621574670874,2.7552,6.61395104298115,267.1125,0.344043152351686,0.210776365885516,0.348958455819176,0.308059741492758,0.13326678646617,0.0408987143264175,True,0.805964566386773,0.0966423949694635,0.189734085577825,236.830927586112
813,27338,1549:1909,Breast,ZR-75-30,SIDM00971,909907,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.612590565201575,0.0579931767469136,0.941125900740288,17.0761085100685,269.8677,0.969063254028999,0.9829081451137,0.0633927318728225,0.576524847460334,0.412107858801296,0.164416988659039,11.0995593128076,4.2858,5.9765491972609,265.5819,0.593639006501702,0.504938482207776,0.602120256156433,0.54461743671984,0.0887005242939257,0.0575028194365927,True,0.805964566386773,0.0966423949694635,0.189734085577825,236.830927586112
814,23628,1083:1013,Breast,HCC1806,SIDM00875,907047,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.921979365870822,0.103331100621423,0.701913971641104,11.300219861299,49.2533,0.935470120814655,0.907677774588202,0.123664918280017,0.647150198469535,0.417505487079651,0.229644711389885,8.49179207187392,7.031,2.80842778942503,42.2223,0.862484148779797,0.762936632699569,0.83686017902987,0.732926491618838,0.0995475160802277,0.103933687411031,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
815,23869,1510:1032,Breast,HCC1806,SIDM00875,907047,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.848248267606175,0.113279732820429,0.245306867272447,5.98166355906569,1.2342,0.610845511718583,0.641828154780956,0.108848792263025,0.208081125195751,0.0858675432001329,0.122213581995618,3.13511907280242,0.1716,2.84654448626327,1.0626,0.518148647090296,0.351828791874782,0.544429620393814,0.370712897558765,0.166319855215514,0.173716722835048,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
816,23869,1012:1038,Breast,HCC1806,SIDM00875,907047,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.903675012045334,0.0641377441436597,0.768917288269366,12.2289225832146,93.7568,0.955862678825753,0.931366718907734,0.0723391111934113,0.694851339738686,0.487380522306987,0.207470817431699,9.42342678627201,13.4111,2.80549579694255,80.3457,0.863789217801548,0.756427880933845,0.84165283092757,0.758775667705762,0.107361336867702,0.0828771632218085,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
817,23869,1561:1038,Breast,HCC1806,SIDM00875,907047,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.972788322145657,0.0641377441436597,0.768917288269366,12.2289225832146,93.7568,0.955862678825753,0.931366718907734,0.062358339647621,0.747993758724345,0.522581258177209,0.225412500547137,9.40038402568533,13.1986,2.82853855752922,80.5582,0.929852051536557,0.826489028545851,0.90602266778856,0.815817530134312,0.103363022990706,0.0902051376542484,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
818,23632,1011:1085,Breast,HCC1806,SIDM00875,907047,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.975340740049306,0.109452998860999,0.706765193485866,11.3627891692687,51.4364,0.945019552247699,0.909464871023438,0.156133457171981,0.689336886855595,0.46077544271385,0.228561444141746,8.70345335703765,8.142,2.65933581223106,43.2944,0.921716069450334,0.864281429357072,0.887038140352847,0.785876224527391,0.057434640093262,0.101161915825456,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
819,23634,1049:1192,Breast,HCC1806,SIDM00875,907047,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.970517015481635,0.0740250174430981,0.839705145499742,13.4478267466012,218.2374,0.937651372378984,0.954313015379957,0.0393536449667504,0.814948131694982,0.795763308198166,0.0191848234968154,13.0715109914353,168.1307,0.376315755165871,50.1067,0.91000661148351,0.921064785153271,0.926177019521835,0.9201471864312,-0.0110581736697603,0.0060298330906352,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
820,23634,1510:1192,Breast,HCC1806,SIDM00875,907047,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.914350841490371,0.0740250174430981,0.839705145499742,13.4478267466012,218.2374,0.937651372378984,0.954313015379957,0.100256987397963,0.767785106391483,0.613603739876983,0.154181366514501,10.9152089209722,37.7168,2.53261782562899,180.5206,0.857342321359325,0.770283989157441,0.872576908657877,0.819288440866278,0.0870583322018842,0.0532884677915996,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
821,23634,1011:1192,Breast,HCC1806,SIDM00875,907047,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.944018125811057,0.0740250174430981,0.839705145499742,13.4478267466012,218.2374,0.937651372378984,0.954313015379957,0.128824946241456,0.792696877688568,0.496934105745032,0.295762771943536,9.28392122787096,12.175,4.16390551873021,206.0624,0.885159891217374,0.688272837841332,0.900888784216086,0.78677120665019,0.196887053376042,0.114117577565895,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
822,23873,1012:1553,Breast,HCC1806,SIDM00875,907047,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.853461411849141,0.0651282121967328,0.684751863534222,11.0833869524944,42.3801,0.889245089549185,0.901258398426799,0.0676833242447096,0.584409292218248,0.344394441630902,0.240014850587346,7.95040021593929,4.831,3.13298673655508,37.5491,0.758936369606563,0.611059821049916,0.769189265162232,0.653478623631344,0.147876548556647,0.115710641530888,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
823,23873,1594:1553,Breast,HCC1806,SIDM00875,907047,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.956776763180294,0.0651282121967328,0.684751863534222,11.0833869524944,42.3801,0.889245089549185,0.901258398426799,0.052877298481225,0.655154671573947,0.651681483582587,0.0034731879913596,11.0383599515176,41.0778,0.0450270009767415,1.3023,0.850809038452839,0.894622822808573,0.862303093235849,0.860984945095508,-0.0438137843557341,0.0013181481403403,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
824,23873,1372:1553,Breast,HCC1806,SIDM00875,907047,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.733372085091744,0.0651282121967328,0.684751863534222,11.0833869524944,42.3801,0.889245089549185,0.901258398426799,0.0640250463185051,0.50217790193055,0.285212270623401,0.216965631307149,7.78623105143304,4.3114,3.29715590106133,38.0687,0.65214752548028,0.508220093182162,0.660957750860708,0.554686562574029,0.143927432298118,0.106271188286678,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
825,23873,1049:1553,Breast,HCC1806,SIDM00875,907047,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.871349599186213,0.0651282121967328,0.684751863534222,11.0833869524944,42.3801,0.889245089549185,0.901258398426799,0.0726927137097833,0.596658261832557,0.371376630424581,0.225281631407976,8.20140325473285,5.7491,2.88198369776151,36.631,0.77484335235699,0.625531452686772,0.7853111442324,0.679252483264963,0.149311899670218,0.106058660967437,True,0.345212458207546,0.04165304208536,1.02883802425932,47.9422281805696
826,23631,1510:2169,Breast,HCC1806,SIDM00875,907047,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.945077995503384,0.0440610505616164,0.796770358744724,12.6694580034705,127.238,0.938592951125051,0.940630738827109,0.0415413979218689,0.753010133518977,0.535770547012509,0.217239586506468,9.72313061356106,16.5076,2.94632738990942,110.7304,0.887043544842869,0.77955644908886,0.888969413159592,0.805654383484712,0.10748709575401,0.0833150296748794,True,0.285248527500019,0.0413207482711035,1.19133050935561,41.254379487671
827,29169,1012:1030,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.83171700805557,0.0936652399414415,0.734564705087957,11.0406005342356,41.1417,0.925112975113456,0.938652752232128,0.0492984265098317,0.610949958738978,0.535800933540867,0.0751490251981105,10.1901653632218,22.8179,0.850435171013727,18.3238,0.769432195774751,0.763604213150892,0.780693458689632,0.759025526677362,0.0058279826238587,0.0216679320122699,True,0.379782597692322,0.0723047189736789,0.909994462495103,53.5200840238903
828,29169,1053:1030,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.601066414892363,0.0936652399414415,0.734564705087957,11.0406005342356,41.1417,0.925112975113456,0.938652752232128,0.0695607102536409,0.441522173793684,0.200088873666241,0.241433300127443,7.60644361915292,3.8063,3.43415691508263,37.3354,0.556054339321853,0.413725144143525,0.564192644613015,0.470162754489409,0.142329195178328,0.0940298901236052,True,0.379782597692322,0.0723047189736789,0.909994462495103,53.5200840238903
829,28316,1053:1032,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.228061167716026,0.121895396377605,0.422038717472636,8.36970188458593,6.4604,0.821535091139735,0.828925639159499,0.0765077779014859,0.0962506427281835,0.0168276221808803,0.0794230205473032,3.92821798443378,0.2973,4.44148390015215,6.1631,0.18736025220502,0.068542267459476,0.189045749216469,0.112643276105361,0.118817984745544,0.0764024731111077,True,0.20306154483193,0.0395421221533299,1.53144034569159,32.3121073664987
830,30189,1558:1050,Breast,EVSA-T,SIDM01042,906862,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.949935489945758,0.101571841796186,0.576118379663522,9.61516084267289,15.3173,0.899594912767545,0.890455305309168,0.0774225414741743,0.547275295252424,0.437803013357555,0.109472281894869,8.68563406925941,8.042,0.929526773413476,7.2753,0.854557134212549,0.816385695415393,0.845875096723664,0.803933377184042,0.0381714387971562,0.0419417195396216,True,0.365571125475349,0.0608608985546088,0.97322700985884,50.6438358533132
831,30189,1012:1050,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.667256607580079,0.101571841796186,0.576118379663522,9.61516084267289,15.3173,0.899594912767545,0.890455305309168,0.11036410634625,0.384418795578814,0.1682767675783,0.216142028000514,6.8209774560617,2.2083,2.79418338661119,13.109,0.600260649689568,0.43539842975496,0.594162186222279,0.485663680893902,0.164862219934609,0.108498505328377,True,0.365571125475349,0.0608608985546088,0.97322700985884,50.6438358533132
832,30189,1011:1050,Breast,EVSA-T,SIDM01042,906862,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.928937994442011,0.101571841796186,0.576118379663522,9.61516084267289,15.3173,0.899594912767545,0.890455305309168,0.0768106674912789,0.535178252165813,0.19763251954439,0.337545732621424,6.37700350173356,1.6233,3.23815734093933,13.694,0.835667894076519,0.660812794964555,0.827177765454147,0.645370565961378,0.174855099111964,0.18180719949277,True,0.365571125475349,0.0608608985546088,0.97322700985884,50.6438358533132
833,30189,1012:1051,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.667256607580079,0.134901814491384,0.496757771201163,8.97400082070517,9.8214,0.763948414299478,0.86112022168102,0.187542902511383,0.331464905200729,0.0374433560378827,0.294021549162847,3.34153902173063,0.198,5.63246179897454,9.6234,0.50974962729165,0.277923162266401,0.574588157837482,0.296488534819754,0.231826465025249,0.278099623017728,True,0.365571125475349,0.0608608985546088,0.97322700985884,50.6438358533132
834,30189,1011:1051,Breast,EVSA-T,SIDM01042,906862,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.928937994442011,0.134901814491384,0.496757771201163,8.97400082070517,9.8214,0.763948414299478,0.86112022168102,0.175544263203413,0.461457167703092,0.0163984436105804,0.445058724092512,0.943011009218527,0.0375,8.03098981148664,9.7839,0.709660707836511,0.272176296427664,0.799927291701826,0.237072541721723,0.437484411408847,0.562854749980104,True,0.365571125475349,0.0608608985546088,0.97322700985884,50.6438358533132
835,25029,1011:1080,Breast,EVSA-T,SIDM01042,906862,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.908938231268576,0.173967947366644,0.29565486605097,7.2597665921709,0.0299,0.673984178428372,0.758944234808883,0.0913102088014417,0.268732011014316,0.0415749701227982,0.227157040891518,2.90979528593043,0.0015,4.34997130624047,0.0284,0.612609987043689,0.370830443377401,0.689833430418669,0.37107642697269,0.241779543666288,0.318757003445979,True,0.346698982789548,0.0755860240500048,1.01425062392302,48.4483271087789
836,25029,1053:1080,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.531567451971044,0.173967947366644,0.29565486605097,7.2597665921709,0.0299,0.673984178428372,0.758944234808883,0.0812491163184903,0.157160503809555,0.041756896157761,0.115403607651794,4.06411390688349,0.0033,3.19565268528741,0.0266,0.358268052395967,0.253139856412604,0.403430053085472,0.268671871620571,0.105128195983363,0.134758181464901,True,0.346698982789548,0.0755860240500048,1.01425062392302,48.4483271087789
837,23536,1058:1096,Breast,EVSA-T,SIDM01042,906862,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.868076555411494,0.100095291587771,0.761660501948393,11.3290728256843,25.1241,0.901060460632658,0.945848315971672,0.0765532606606685,0.66117962492435,0.60477707770452,0.0564025472198302,10.6670460117806,15.8782,0.662026813903667,9.2459,0.782189460883492,0.740821211990614,0.821068748070451,0.805696731358812,0.0413682488928779,0.0153720167116392,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
838,23536,1049:1096,Breast,EVSA-T,SIDM01042,906862,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.884794428293039,0.100095291587771,0.761660501948393,11.3290728256843,25.1241,0.901060460632658,0.945848315971672,0.178234648682114,0.673912968374817,0.486976808910466,0.186936159464351,9.4053966126725,6.6223,1.92367621301177,18.5018,0.797253275122935,0.649915856341514,0.836881319982089,0.779862064344872,0.147337418781422,0.0570192556372179,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
839,23536,1558:1096,Breast,EVSA-T,SIDM01042,906862,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.932307426294465,0.100095291587771,0.761660501948393,11.3290728256843,25.1241,0.901060460632658,0.945848315971672,0.0519979508659961,0.710101742281656,0.528674463652198,0.181427278629459,9.54100282126177,7.2749,1.7880700044225,17.8492,0.840065358988139,0.820779641232833,0.881821409128504,0.827251321688249,0.0192857177553057,0.0545700874402545,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
840,23536,1510:1096,Breast,EVSA-T,SIDM01042,906862,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.926923686037449,0.100095291587771,0.761660501948393,11.3290728256843,25.1241,0.901060460632658,0.945848315971672,0.0675093527205737,0.706001159975138,0.607182332746222,0.0988188272289162,10.2856491642226,12.1896,1.04342366146169,12.9345,0.835214283512225,0.81113161667462,0.876729207472776,0.848979654412896,0.0240826668376058,0.0277495530598807,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
841,23536,1011:1096,Breast,EVSA-T,SIDM01042,906862,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.866916354297506,0.100095291587771,0.761660501948393,11.3290728256843,25.1241,0.901060460632658,0.945848315971672,0.159723086983811,0.660295945561509,0.045564110408265,0.614731835153244,3.20273815790615,0.0899,8.12633466777811,25.0342,0.781144049533295,0.378100762615188,0.819971373800597,0.375103046798229,0.403043286918107,0.444868327002369,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
842,23537,1083:1192,Breast,EVSA-T,SIDM01042,906862,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.813298763673943,0.0706583274570305,0.495612143446053,8.96481371117557,9.7591,0.859406056742207,0.86066367713279,0.192284324088513,0.403080743526468,0.190202266445286,0.212878477081182,6.6211934545186,1.9227,2.34362025665697,7.8364,0.698953883442336,0.445109772580689,0.699976704551168,0.579998018437296,0.253844110861647,0.119978686113872,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
843,23537,1053:1192,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.311759164556051,0.0706583274570305,0.495612143446053,8.96481371117557,9.7591,0.859406056742207,0.86066367713279,0.0850639627207967,0.154511627784575,0.0508585556099383,0.103653072174637,5.72212888268273,1.031,3.24268482849284,8.7281,0.267927714264361,0.129131060497636,0.268319788946657,0.20058649307383,0.138796653766724,0.0677332958728275,True,0.283328311617201,0.0607107122635458,1.18237937471801,41.4047847216399
844,23857,1012:1553,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.945209338180909,0.075602995955883,0.0940040387218249,4.4579516754284,0.4292,0.540843811527924,0.538761964262674,0.070900604096146,0.0888534952265887,0.0658397328176455,0.0230137624089432,3.80384798147767,0.2728,0.654103693950723,0.1564,0.511210621153549,0.451448751471461,0.509242839677769,0.456895904914409,0.0597618696820879,0.0523469347633594,True,0.559777370681233,0.0870550572179395,0.549877491747011,88.0227815914027
845,23857,1053:1560,Breast,EVSA-T,SIDM01042,906862,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.480591293115123,0.101680639183628,0.755623207316091,11.2629713360699,47.9979,0.91263180648589,0.944267264989579,0.0384236253946384,0.363145934311837,0.107013566683043,0.256132367628794,6.49378031383266,1.7602,4.76919102223722,46.2377,0.438602900017044,0.328986488598127,0.453806625927622,0.338142357379696,0.109616411418917,0.115664268547926,True,0.559777370681233,0.0870550572179395,0.549877491747011,88.0227815914027
846,23857,1012:1560,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.945209338180909,0.101680639183628,0.755623207316091,11.2629713360699,47.9979,0.91263180648589,0.944267264989579,0.113110034609192,0.714222111701378,0.56173541456465,0.152486697136728,9.76531381683005,16.9974,1.49765751923983,31.0005,0.862628105811375,0.82565345389768,0.892530236606697,0.84748511508744,0.0369746519136951,0.0450451215192567,True,0.559777370681233,0.0870550572179395,0.549877491747011,88.0227815914027
847,23858,1561:1564,Breast,EVSA-T,SIDM01042,906862,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.930266596910428,0.101107332943536,0.886520480186876,13.1210302520179,87.0009,0.923835418608606,0.976028017297806,0.0972361076829348,0.824700390194844,0.659292232700223,0.165408157494621,10.7824663989824,17.2007,2.33856385303554,69.8002,0.859413230974349,0.796823383891893,0.907966262140862,0.866578840829836,0.0625898470824562,0.0413874213110268,True,0.559777370681233,0.0870550572179395,0.549877491747011,88.0227815914027
848,28319,1012:1909,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.838355287399067,0.0755220825088165,0.875520227091923,12.9105228117128,15.0378,0.941354340901263,0.973544303116051,0.0610998626553663,0.733997011607345,0.73090952528726,0.0030874863200856,12.8436228530485,14.3564,0.0668999586643366,0.6814,0.789189389010638,0.787438739354035,0.816176014034581,0.81547309553206,0.0017506496566025,0.0007029185025213,True,0.20306154483193,0.0395421221533299,1.53144034569159,32.3121073664987
849,25029,1549:2169,Breast,EVSA-T,SIDM01042,906862,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.912230105769152,0.125091027476556,0.127908669818762,5.15181813154314,0.6944,0.569038004103388,0.59685337403406,0.118877496808752,0.116682139397561,0.0207157907183427,0.0959663486792183,1.45825911036948,0.0537,3.69355902117366,0.6407,0.519093598669901,0.301175715130425,0.544467616523766,0.267096908629868,0.217917883539476,0.277370707893898,True,0.346698982789548,0.0755860240500048,1.01425062392302,48.4483271087789
850,25029,1561:2169,Breast,EVSA-T,SIDM01042,906862,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.915910688697841,0.125091027476556,0.127908669818762,5.15181813154314,0.6944,0.569038004103388,0.59685337403406,0.114595849356563,0.117152917864127,0.0220744431009529,0.0950784747631744,1.58039195102982,0.0584,3.57142618051332,0.636,0.521187990233579,0.307549925994549,0.546664384863166,0.276620718182562,0.213638064239031,0.270043666680604,True,0.346698982789548,0.0755860240500048,1.01425062392302,48.4483271087789
851,25029,1012:2169,Breast,EVSA-T,SIDM01042,906862,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.475326201278539,0.125091027476556,0.127908669818762,5.15181813154314,0.6944,0.569038004103388,0.59685337403406,0.0775086547615296,0.0607983421355432,0.004423739778113,0.0563746023574302,-0.357280123588196,0.0152,5.50909825513133,0.6792,0.270478672873586,0.0791897980477356,0.283700046999889,0.0816523446910968,0.19128887482585,0.202047702308792,True,0.346698982789548,0.0755860240500048,1.01425062392302,48.4483271087789
852,27497,1012:1013,Breast,HCC1187,SIDM00885,749711,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.957330029268741,0.0554227293061785,0.836553113090968,12.4643602774993,110.3764,0.954944730279237,0.962506331574331,0.0582325396602316,0.800857416240233,0.776918585916782,0.0239388303234508,12.0979244090627,85.6186,0.366435868436632,24.7578,0.914197266588252,0.933503273567828,0.921436214577403,0.915339108461046,-0.0193060069795755,0.0060971061163567,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
853,27497,1021:1013,Breast,HCC1187,SIDM00885,749711,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.956180721716407,0.0554227293061785,0.836553113090968,12.4643602774993,110.3764,0.954944730279237,0.962506331574331,0.0218548844471881,0.799895959429428,0.831275791499065,-0.0313798320696369,13.0215402777903,162.4068,-0.55718000029097,-52.0304,0.91309974139768,0.93164504128454,0.920329998781355,0.928054586916063,-0.0185452998868596,-0.0077245881347083,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
854,27524,1558:1032,Breast,HCC1187,SIDM00885,749711,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.957630152069058,0.0647532578300015,0.776985877498132,11.6483124831624,62.6934,0.926158747280073,0.947007755893421,0.101844458046022,0.744065104024047,0.664345393481798,0.0797197105422489,10.7348476013155,33.2844,0.913464881846837,29.409,0.886917541997905,0.908675379909156,0.906883181286794,0.884137955056802,-0.0217578379112507,0.0227452262299922,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
855,27524,1561:1032,Breast,HCC1187,SIDM00885,749711,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.988041106926783,0.0647532578300015,0.776985877498132,11.6483124831624,62.6934,0.926158747280073,0.947007755893421,0.10013086325659,0.767693986469732,0.606997082186931,0.160696904282801,9.98789542350557,19.8329,1.6604170596568,42.8605,0.915082913852526,0.905824648970728,0.935682591401184,0.887084676328675,0.0092582648817977,0.048597915072509,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
856,27524,1510:1032,Breast,HCC1187,SIDM00885,749711,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.736479939436144,0.0647532578300015,0.776985877498132,11.6483124831624,62.6934,0.926158747280073,0.947007755893421,0.0797481076923007,0.572234512002564,0.429533576897696,0.142700935104868,9.71295741249665,16.3916,1.93535507066572,46.3018,0.682097338105083,0.667320470262976,0.697452214705945,0.653225994251503,0.0147768678421072,0.044226220454442,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
857,27524,1012:1038,Breast,HCC1187,SIDM00885,749711,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.934294817367842,0.0498851179752172,0.845022164332187,12.598620671811,121.1414,0.946568112877426,0.964620735374921,0.0571480590355571,0.789499828696519,0.721596805143636,0.0679030235528831,11.5918874587285,60.2887,1.00673321308249,60.8527,0.884373682147038,0.853512684925734,0.901240153786346,0.883610284045781,0.0308609972213041,0.0176298697405647,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
858,27503,1594:1192,Breast,HCC1187,SIDM00885,749711,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.946733050114891,0.11288682698522,0.813068126774597,12.1190889363514,86.8839,0.907437441356708,0.956530325671424,0.0672771131023202,0.769758467612515,0.536054425090468,0.233704042522047,9.5652805801404,14.7968,2.55380835621096,72.0871,0.859101016644089,0.841173323477603,0.905578872750297,0.833858059573425,0.0179276931664863,0.0717208131768726,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
859,27528,1083:1560,Breast,HCC1187,SIDM00885,749711,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.956881300685363,0.0990398632386903,0.866189394410151,12.9627036081692,155.9167,0.928365724009361,0.969815047928462,0.170143006203512,0.828840434363052,0.528411493198909,0.300428941164143,9.4448308219626,13.6115,3.51787278620656,142.3052,0.888335801501786,0.695291533531592,0.927997884486024,0.837797176163126,0.193044267970194,0.0902007083228984,True,1.7093364876793,0.175958369561553,-0.547274162650752,-94.4739551731581
860,23564,1011:1025,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.58595988605768,0.0955764658809689,0.890376745555033,14.881245018168,589.4285,0.938546618807749,0.968378199601497,0.0896587738723358,0.521725056373835,0.201744742239574,0.319980314134261,7.19120433830882,2.8543,7.69004067985918,586.5742,0.549950669816409,0.405076913003732,0.567430779499235,0.419198761492689,0.144873756812677,0.148232018006546,True,0.376266276838739,0.0644337284002749,0.930287674904495,52.6275214634323
861,23887,1012:1050,Breast,MDA-MB-231,SIDM00146,905960,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.651104794431786,0.0934337594013969,0.707201476820101,11.4760218446332,55.6361,0.901524242609012,0.906007868569096,0.139721438850397,0.460462272186808,0.284636921997092,0.175825350189715,8.29047400148825,6.1152,3.18554784314498,49.5209,0.586986756659212,0.432731643475103,0.589906067018262,0.506395172835444,0.154255113184109,0.0835108941828178,True,0.293398464868655,0.0560186288213278,1.17469798892598,41.9350509489362
862,23887,1011:1050,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.576370768406324,0.0934337594013969,0.707201476820101,11.4760218446332,55.6361,0.901524242609012,0.906007868569096,0.0922752965340101,0.407610258612889,0.148325477923601,0.259284780689288,6.02421686102954,1.2712,5.45180498360369,54.3649,0.519612220449486,0.368926345001763,0.522196451389346,0.369452664746294,0.150685875447722,0.152743786643052,True,0.293398464868655,0.0560186288213278,1.17469798892598,41.9350509489362
863,23887,1011:1051,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.576370768406324,0.115953127610083,0.418633497643519,8.07795269026018,5.2776,0.731249341843232,0.766366402761778,0.118093164604697,0.241288110717422,0.0291585841929427,0.21212952652448,0.767228304915395,0.0332,7.31072438534479,5.2444,0.421470745054803,0.0935484634364402,0.441711192440597,0.162587236656263,0.327922281618362,0.279123955784334,True,0.293398464868655,0.0560186288213278,1.17469798892598,41.9350509489362
864,23566,1011:1080,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.567280732667102,0.10422505765766,0.515861425695443,9.17820387224206,0.1131,0.782174780328433,0.821530615561966,0.0671465678662313,0.292638247523206,0.0902228969051997,0.202415350618007,4.32398526576614,0.0039,4.85421860647591,0.1092,0.443712682458443,0.267392798149026,0.466038489504447,0.296711317199062,0.176319884309417,0.169327172305385,True,0.376266276838739,0.0644337284002749,0.930287674904495,52.6275214634323
865,24219,1012:1096,Breast,MDA-MB-231,SIDM00146,905960,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.601054403913829,0.0593454104940789,0.755293664577199,12.1645466579763,44.8326,0.91756648375838,0.923770365915781,0.102199073639538,0.45397258334234,0.305377515456254,0.148595067886086,9.09064062854188,5.3242,3.07390602943443,39.5084,0.551507375946701,0.457333029640809,0.55523624663877,0.491354774922654,0.0941743463058927,0.063881471716116,True,0.322611572785931,0.0597851502404528,1.09672195107888,45.0416296631018
866,24219,1011:1096,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.728910431676192,0.0593454104940789,0.755293664577199,12.1645466579763,44.8326,0.91756648375838,0.923770365915781,0.0856811635337124,0.550541431089259,0.065796027350442,0.484745403738817,2.51284744117956,0.0557,9.65169921679675,44.7769,0.668823781767926,0.231898374411317,0.673345856189346,0.288204307698005,0.436925407356609,0.385141548491341,True,0.322611572785931,0.0597851502404528,1.09672195107888,45.0416296631018
867,23569,1011:1192,Breast,MDA-MB-231,SIDM00146,905960,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.669385641819792,0.115759392477219,0.72199137693784,11.6796735588466,64.0711,0.879907631135921,0.911591015919864,0.15755667046459,0.483290661239891,0.116488745058537,0.366801916181354,4.62716690058908,0.4827,7.05250665825753,63.5884,0.588997534410051,0.291649021169436,0.610205937268674,0.364504748702003,0.297348513240615,0.245701188566671,True,0.376266276838739,0.0644337284002749,0.930287674904495,52.6275214634323
868,23890,1561:1564,Breast,MDA-MB-231,SIDM00146,905960,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.980364012287718,0.0832876367747304,0.42522670231601,8.15385447120639,2.7813,0.752016503042765,0.770469823243845,0.095862389650325,0.416876956014398,0.212775206185356,0.204101749829042,5.39751726493566,0.4116,2.75633720627073,2.3697,0.737249916229584,0.54373632121463,0.755340887261945,0.586685841178966,0.193513595014955,0.168655046082979,True,0.293398464868655,0.0560186288213278,1.17469798892598,41.9350509489362
869,23890,1594:1564,Breast,MDA-MB-231,SIDM00146,905960,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.951108146048704,0.0832876367747304,0.42522670231601,8.15385447120639,2.7813,0.752016503042765,0.770469823243845,0.0868032380603738,0.404436580490184,0.309697881229058,0.0947386992611264,6.9557051496075,1.2122,1.19814932159888,1.5691,0.715249022007034,0.618133235469854,0.732800125171926,0.666726868374288,0.0971157865371803,0.0660732567976381,True,0.293398464868655,0.0560186288213278,1.17469798892598,41.9350509489362
870,23566,1372:2169,Breast,MDA-MB-231,SIDM00146,905960,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.808781082585372,0.100837792210497,0.737176025983328,11.8958226814662,74.4268,0.890371880629683,0.91720996624739,0.0328374522884524,0.596214024350778,0.396142487888073,0.200071536462705,8.88544609895109,9.2367,3.01037658251507,65.1901,0.720115933519249,0.635220206106972,0.741822069459656,0.653313554875233,0.0848957274122769,0.0885085145844231,True,0.376266276838739,0.0644337284002749,0.930287674904495,52.6275214634323
871,27328,1012:1013,Breast,HCC2218,SIDM00772,749716,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.930944481890809,0.067140864366526,0.922139323804735,16.8925237937974,2376.2187,0.961163575526371,0.97529178004915,0.103430012887965,0.85846051503054,0.770114256854185,0.088346258176355,14.0009353909255,320.2075,2.89158840287189,2056.0112,0.894789926830715,0.836246643103961,0.90794250087022,0.877263491408073,0.0585432837267537,0.0306790094621471,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
872,27328,1558:1013,Breast,HCC2218,SIDM00772,749716,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.244835382830618,0.067140864366526,0.922139323804735,16.8925237937974,2376.2187,0.961163575526371,0.97529178004915,0.0979501203658413,0.225772334366899,0.14245538401018,0.0833169503567193,10.0547870095042,20.7741,6.83773678429317,2355.4446,0.235326851976844,0.123174050824248,0.238785936339888,0.20491206299345,0.112152801152596,0.0338738733464375,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
873,27328,1549:1013,Breast,HCC2218,SIDM00772,749716,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.695617967839172,0.067140864366526,0.922139323804735,16.8925237937974,2376.2187,0.961163575526371,0.97529178004915,0.0824591477996483,0.641456682489638,0.329785119195529,0.311671563294109,8.66876727230722,7.9486,8.2237565214902,2368.2701,0.668602653168687,0.476614025242361,0.678430486088039,0.540340765430769,0.191988627926325,0.13808972065727,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
874,27329,1012:1025,Breast,HCC2218,SIDM00772,749716,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.760630991320418,0.0571804736954813,0.931035092559032,17.3105714595337,3174.9091,0.97008459388451,0.978213440748931,0.107809935594176,0.708174145407274,0.480177477778328,0.227996667628946,10.7170603205691,32.8766,6.59351113896464,3142.0325,0.73787640631104,0.611182839338395,0.744059459159816,0.655023618607668,0.126693566972645,0.089035840552148,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
875,27329,1011:1025,Breast,HCC2218,SIDM00772,749716,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,1.0,0.0571804736954813,0.931035092559032,17.3105714595337,3174.9091,0.97008459388451,0.978213440748931,0.0659219337261308,0.931035092559032,0.847244648393339,0.0837904441656928,14.4701945816773,443.2948,2.84037687785641,2731.6143,0.97008459388451,0.942441282574336,0.978213440748931,0.949572492951843,0.0276433113101744,0.028640947797088,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
876,25459,1558:1038,Breast,HCC2218,SIDM00772,749716,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.33870390740259,0.084599087273691,0.727483110516954,12.135233089116,87.8616,0.89442894771143,0.903585836605178,0.0561786693659786,0.246401372101482,0.132467820876754,0.113933551224729,7.58649096577271,3.754,4.54874212334334,84.1076,0.302946579483848,0.219952596293075,0.306048053531812,0.244283011250154,0.0829939831907733,0.0617650422816579,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
877,25459,1549:1038,Breast,HCC2218,SIDM00772,749716,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.833588572337255,0.084599087273691,0.727483110516954,12.135233089116,87.8616,0.89442894771143,0.903585836605178,0.0520035343794457,0.606421607495293,0.425438833617219,0.180982773878074,9.13247065974153,10.9617,3.00276242937452,76.8999,0.745585749579885,0.668627286181487,0.753218827519874,0.665474332133862,0.0769584633983971,0.0877444953860129,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
878,25461,1549:1050,Breast,HCC2218,SIDM00772,749716,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.461698781305262,0.0710263739814044,0.835884613349321,14.198046868543,367.0862,0.937968171661327,0.945483906035097,0.0595040852942255,0.385926907295201,0.315087189307796,0.0708397179874052,11.4428896344,54.373,2.75515723414298,312.7132,0.433058761759159,0.348867066726132,0.436528767160143,0.408337348360656,0.084191695033027,0.0281914187994866,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
879,27658,1011:1080,Breast,HCC2218,SIDM00772,749716,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.931862255302105,0.096655261574625,0.699896999202238,11.7039058889894,0.6516,0.892187899117195,0.891984183940071,0.0648574278866468,0.652207596155773,0.554336600832656,0.0978709953231169,10.2265610330885,0.234,1.47734485590085,0.4176,0.831396227824596,0.78535047481039,0.831206393340202,0.786025777163233,0.0460457530142063,0.045180616176969,True,,,,
880,27333,1012:1096,Breast,HCC2218,SIDM00772,749716,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.734579470509779,0.0717748387981218,0.912174162400963,16.4732748846427,888.4846,0.949415638889021,0.971986831696831,0.126229611796979,0.670064413229201,0.506505983718109,0.163558429511091,11.5476402156002,29.2339,4.92563466904253,859.2507,0.697421237308801,0.615190273866759,0.714001572170336,0.651945013109787,0.0822309634420417,0.0620565590605487,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
881,27333,1011:1096,Breast,HCC2218,SIDM00772,749716,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.983680091384374,0.0717748387981218,0.912174162400963,16.4732748846427,888.4846,0.949415638889021,0.971986831696831,0.0980358566303436,0.897287563429044,0.721723020859401,0.175564542569643,12.236039899926,47.1102,4.23723498471671,841.3744,0.933921262424107,0.865893158706333,0.956124095427947,0.89135379319212,0.0680281037177738,0.0647703022358267,True,0.82953097681057,0.0864563625863353,0.166626733246997,272.017013557198
882,25463,1549:1553,Breast,HCC2218,SIDM00772,749716,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.483975385365221,0.0984393116698119,0.699438338064535,11.6969363343523,64.8423,0.903598060661833,0.891787681178756,0.0519070758886126,0.338510939203993,0.270511286313571,0.0679996528904226,9.75626050684948,16.8911,1.94067582750279,47.9512,0.437319219624077,0.368016556431729,0.431603286662445,0.399310665577078,0.0693026631923487,0.0322926210853676,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
883,25463,1558:1553,Breast,HCC2218,SIDM00772,749716,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.434856340357954,0.0984393116698119,0.699438338064535,11.6969363343523,64.8423,0.903598060661833,0.891787681178756,0.0545481860621874,0.304155195996793,0.249956022730942,0.0541991732658508,9.9626054800496,19.4883,1.73433085430267,45.354,0.392935345813949,0.351085386163002,0.3877995274137,0.362381144825621,0.0418499596509479,0.0254183825880785,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
884,25463,1372:1553,Breast,HCC2218,SIDM00772,749716,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.883586451947456,0.0984393116698119,0.699438338064535,11.6969363343523,64.8423,0.903598060661833,0.891787681178756,0.0626860303871218,0.618014239486468,0.395106126237149,0.222908113249318,8.32260920767058,6.253,3.37432712668169,58.5893,0.798407004406792,0.652141073712395,0.787971513103186,0.671340390565996,0.146265930694397,0.11663112253719,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
885,25463,1510:1553,Breast,HCC2218,SIDM00772,749716,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.904583589911072,0.0984393116698119,0.699438338064535,11.6969363343523,64.8423,0.903598060661833,0.891787681178756,0.112245048517833,0.632700442767851,0.378277297914464,0.254423144853387,7.94547372963701,4.8146,3.75146260471526,60.0277,0.817379977550164,0.650064570333048,0.80669650207915,0.669785778450048,0.167315407217116,0.136910723629102,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
886,25463,1372:1560,Breast,HCC2218,SIDM00772,749716,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.916076891050652,0.0803290554594401,0.750725679346842,12.5203036542896,114.7406,0.886152004703163,0.913043844549285,0.0952430850252089,0.687722446367943,0.271272241829321,0.416450204538622,6.23537147609553,1.4715,6.28493217819403,113.2691,0.811783373466776,0.558754375325656,0.836418366507643,0.588969488560757,0.25302899814112,0.247448877946887,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
887,25463,1549:1560,Breast,HCC2218,SIDM00772,749716,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.7981283796586,0.0803290554594401,0.750725679346842,12.5203036542896,114.7406,0.886152004703163,0.913043844549285,0.0420240182010234,0.599175470025196,0.430239133175739,0.168936336849457,9.49990287255552,14.1412,3.02040078173403,100.5994,0.707263063644956,0.635127630804786,0.728726204207379,0.649987713920504,0.0721354328401702,0.0787384902868754,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
888,25464,1053:1564,Breast,HCC2218,SIDM00772,749716,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.777214170806529,0.16546272796359,0.681354974817537,11.4267429197065,26.8839,0.815308538036136,0.883942301479261,0.0818169416100619,0.529558741777716,0.162957479898974,0.366601261878742,4.76305496725153,0.2652,6.66368795245497,26.6187,0.633669349341239,0.378376609546398,0.687012482885019,0.42731110355619,0.255292739794841,0.259701379328829,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
889,25464,1058:1564,Breast,HCC2218,SIDM00772,749716,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.877081886955466,0.16546272796359,0.681354974817537,11.4267429197065,26.8839,0.815308538036136,0.883942301479261,0.0641289553283695,0.59760410699946,0.690136948430251,-0.0925328414307919,13.1703771967883,90.0282,-1.7436342770818,-63.1443,0.715092350991636,0.779860457561411,0.775289781741187,0.8132404136473,-0.0647681065697747,-0.0379506319061124,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
890,25464,1561:1564,Breast,HCC2218,SIDM00772,749716,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.866418197668052,0.16546272796359,0.681354974817537,11.4267429197065,26.8839,0.815308538036136,0.883942301479261,0.0579505467249927,0.590338349253572,0.422620748467575,0.167717600785997,8.84388158039731,4.4872,2.58286133930919,22.3967,0.706398154068644,0.666014566275458,0.765863695690212,0.680207506754942,0.040383587793186,0.0856561889352692,True,0.774547172121859,0.0905464416393621,0.228806107069878,200.005956048462
891,26057,1011:1051,Breast,AU565,SIDM00898,910704,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.879952441971244,0.109530183868802,0.587411280990701,9.91162402949182,18.8116,0.799947100680758,0.866443339186816,0.110767422461368,0.516893991149224,0.314409652245582,0.202484338903642,7.48501538414634,3.499,2.42660864534548,15.3126,0.70391540469185,0.578891630865469,0.762428932147158,0.654577468828195,0.125023773826381,0.107851463318963,True,0.63530559289618,0.0841374855165565,0.428292058796561,112.281903075714
892,30662,1510:1085,Breast,AU565,SIDM00898,910704,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.981226520132083,0.0802863777712111,0.695127807562511,11.1268573558403,43.6765,0.923433336322385,0.908495374908341,0.100942896031684,0.682077839661608,0.433205195046278,0.24887264461533,8.39331712461593,6.567,2.73354023122441,37.1095,0.906097279173573,0.797574833624796,0.891439755277404,0.780768395976349,0.108522445548778,0.110671359301055,True,0.720620746220792,0.0749083539691857,0.305702222387214,155.201030412959
893,30662,1011:1085,Breast,AU565,SIDM00898,910704,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.964437310095032,0.0802863777712111,0.695127807562511,11.1268573558403,43.6765,0.923433336322385,0.908495374908341,0.105468797058284,0.670407192897845,0.3730390961737,0.297368096724145,7.81088845815565,4.3857,3.31596889768469,39.2908,0.890593562934841,0.756798759205561,0.876186835610378,0.736097328128975,0.133794803729281,0.140089507481403,True,0.720620746220792,0.0749083539691857,0.305702222387214,155.201030412959
894,26060,1012:1564,Breast,AU565,SIDM00898,910704,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.517428225440081,0.0682293572745559,0.72724442567955,11.5306632609564,28.8919,0.926178794070565,0.919813373855697,0.162180110415874,0.376296792640561,0.0439308937061815,0.332365898934379,2.86478397191388,0.0711,8.66587928904256,28.8208,0.479231049856167,0.183801348127159,0.475937401770208,0.215077696116855,0.295429701729008,0.260859705653353,True,0.63530559289618,0.0841374855165565,0.428292058796561,112.281903075714
895,26061,1558:1632,Breast,AU565,SIDM00898,910704,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.46693041883765,0.114083638737749,0.841422290151851,13.306467267811,79.1472,0.897210042871126,0.956451805213103,0.0746492601880735,0.392885662359938,0.273490998289678,0.11939466407026,9.89363884286963,7.4314,3.4128284249414,71.7158,0.41893466110316,0.339298760028552,0.44659644200618,0.404233661728317,0.0796359010746082,0.0423627802778629,True,0.63530559289618,0.0841374855165565,0.428292058796561,112.281903075714
896,23917,1012:1032,Breast,CAMA-1,SIDM00920,946382,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.821337441882371,0.0721547564994715,0.782626981216227,12.599410097959,121.2078,0.931745254649161,0.933345990840392,0.115359120258358,0.642800842700258,0.431546242312209,0.211254600388049,9.28593022095314,12.192,3.3134798770059,109.0158,0.76527726393958,0.658487168605946,0.766592008508014,0.678678385245142,0.106790095333634,0.0879136232628714,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
897,23919,1011:1050,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.758508141061842,0.0767135619118661,0.797529672331713,12.8519629967268,144.3964,0.887278378897878,0.938456452612187,0.127765394918797,0.604932749201988,0.305810343027444,0.299122406174544,7.89784708445018,4.6582,4.9541159122766,139.7382,0.673007873782194,0.602662208871138,0.71182685933836,0.573707286786895,0.0703456649110564,0.138119572551466,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
898,23919,1058:1051,Breast,CAMA-1,SIDM00920,946382,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.910473494771077,0.17661015601947,0.77041498440161,12.4016444430079,105.681,0.809166646821482,0.929087807442241,0.156515008111188,0.701442423272139,0.610640790134261,0.0908016331378777,10.9985331669897,39.9594,1.40311127601819,65.7216,0.736724784783748,0.698279507521892,0.845909822991135,0.811835389342888,0.0384452772618563,0.0340744336482468,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
899,23919,1011:1051,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.758508141061842,0.17661015601947,0.77041498440161,12.4016444430079,105.681,0.809166646821482,0.929087807442241,0.188763238686564,0.584366037664653,0.229866744262188,0.354499293402465,6.66000782230813,1.9751,5.74163662069975,103.7059,0.613759489089806,0.392197950616108,0.704720665706237,0.517586149120376,0.221561538473698,0.187134516585861,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
900,23919,1053:1051,Breast,CAMA-1,SIDM00920,946382,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.900456212450075,0.17661015601947,0.77041498440161,12.4016444430079,105.681,0.809166646821482,0.929087807442241,0.158211737773653,0.693724958869057,0.503051863258669,0.190673095610389,9.66236842917928,15.8268,2.73927601382861,89.8542,0.728619134037799,0.655194647243334,0.836602888122985,0.758780624184309,0.0734244867944654,0.0778222639386761,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
901,23766,1011:1096,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.721883648949978,0.0965683136122539,0.855999268220476,14.0082479743487,160.9173,0.899064037175092,0.957654651631728,0.154022924321879,0.617931875241509,0.257229279718826,0.360702595522683,7.33851978836569,1.5806,6.66972818598303,159.3367,0.649019627795655,0.422221519619263,0.691315234353832,0.522753136814425,0.226798108176392,0.168562097539407,True,0.742135738456837,0.0721676234634531,0.280835956229916,169.884136835809
902,23767,1011:1192,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.756249389645221,0.0764176455485304,0.602467090252272,10.1681698811289,22.4726,0.855935854222995,0.862852244745323,0.073841180291724,0.455615369284613,0.162071512035398,0.293543857249215,5.34973411346646,0.7965,4.81843576766245,21.6761,0.647300967331601,0.40090973661681,0.652531483442659,0.45004103375305,0.246391230714791,0.202490449689609,True,0.742135738456837,0.0721676234634531,0.280835956229916,169.884136835809
903,23921,1012:1553,Breast,CAMA-1,SIDM00920,946382,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.803921459365236,0.0677481523912517,0.304675171070764,6.68158005437185,2.0049,0.686603217482915,0.683743539842979,0.0499498340220659,0.244934908159562,0.0774575328729865,0.167477375286575,2.71048242217732,0.1278,3.97109763219452,1.8771,0.551975060603731,0.300846791398872,0.54967610438212,0.328861208894714,0.251128269204859,0.220814895487406,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
904,23921,1011:1553,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.855800251620109,0.0677481523912517,0.304675171070764,6.68158005437185,2.0049,0.686603217482915,0.683743539842979,0.0992752377935488,0.26074108806476,0.0847680799045865,0.175973008160173,2.79659563027788,0.1357,3.88498442409397,1.8692,0.587595206285055,0.328291055242622,0.585147893441245,0.355198668762321,0.259304151042433,0.229949224678924,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
905,23921,1053:1560,Breast,CAMA-1,SIDM00920,946382,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.931866255723782,0.0831093096359998,0.833544817516148,13.5264040331743,230.4535,0.928972876278408,0.950436150127567,0.0817118345959068,0.776752288076736,0.653713982551483,0.123038305525253,11.4009375992162,52.8146,2.12546643395802,177.6389,0.865678475886512,0.810990281310653,0.885679376523902,0.842194271639545,0.0546881945758592,0.043485104884357,True,0.613321143377006,0.0657438572075255,0.463511229988519,104.159065207725
906,23764,1561:2169,Breast,CAMA-1,SIDM00920,946382,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.909327629718881,0.0799895661302008,0.500501912996218,9.00564100868668,10.0392,0.798572235062935,0.813395678284902,0.0548002188675772,0.455120218214616,0.321994629846545,0.133125588368072,7.31117787924715,3.1018,1.69446312943954,6.9374,0.726163797669088,0.644034316661245,0.739643164158392,0.657010026960036,0.0821294810078427,0.0826331371983553,True,0.742135738456837,0.0721676234634531,0.280835956229916,169.884136835809
907,23764,1011:2169,Breast,CAMA-1,SIDM00920,946382,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.76734080827908,0.0799895661302008,0.500501912996218,9.00564100868668,10.0392,0.798572235062935,0.813395678284902,0.0751605202675627,0.384055542463743,0.180913036212661,0.203142506251082,5.69563723636616,1.0122,3.31000377232052,9.027,0.612777064322423,0.459261539255156,0.624151697225847,0.474841155025622,0.153515525067267,0.149310542200225,True,0.742135738456837,0.0721676234634531,0.280835956229916,169.884136835809
908,23764,1053:2169,Breast,CAMA-1,SIDM00920,946382,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.827641691939977,0.0799895661302008,0.500501912996218,9.00564100868668,10.0392,0.798572235062935,0.813395678284902,0.126152570960448,0.414236250091385,0.159940845438436,0.254295404652948,4.98476079778923,0.6184,4.02088021089746,9.4208,0.660931675763776,0.419552749494664,0.673200175392381,0.471499430676008,0.241378926269112,0.201700744716373,True,0.742135738456837,0.0721676234634531,0.280835956229916,169.884136835809
909,26723,1558:1032,Breast,BT-483,SIDM00892,949093,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.921602834096143,0.0630821939149173,0.729908877032725,12.7836707311145,137.7204,0.870663783932738,0.890219459223571,0.0615069868318543,0.672686089705292,0.698097494474771,-0.0254114047694783,13.3346242603068,201.7678,-0.550953529192304,-64.0474,0.802406210817283,0.848984197493279,0.820428776587978,0.832201457589858,-0.0465779866759962,-0.0117726810018799,True,0.904449885774196,0.0916894707354232,0.0771800291015912,508.057536634891
910,26723,1510:1032,Breast,BT-483,SIDM00892,949093,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.91014696087561,0.0630821939149173,0.729908877032725,12.7836707311145,137.7204,0.870663783932738,0.890219459223571,0.0594094429121777,0.664324346147463,0.611566991218843,0.0527573549286207,11.7287768111582,66.2893,1.05489391995632,71.4311,0.79243199689084,0.770770201706681,0.810230535324661,0.784437200421196,0.0216617951841594,0.0257933349034654,True,0.904449885774196,0.0916894707354232,0.0771800291015912,508.057536634891
911,26723,1011:1032,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.86964507851938,0.0630821939149173,0.729908877032725,12.7836707311145,137.7204,0.870663783932738,0.890219459223571,0.0581534005631825,0.634761662679117,0.399611075105711,0.235150587573406,8.38225254490889,6.5169,4.40141818620563,131.2035,0.757168474742167,0.638400028965546,0.774174971515962,0.639277835709397,0.118768445776621,0.134897135806566,True,0.904449885774196,0.0916894707354232,0.0771800291015912,508.057536634891
912,26723,1011:1038,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.86964507851938,0.102954126696743,0.75588973920573,13.3017110277159,197.2169,0.916709852720365,0.902267509885627,0.119303683136265,0.657355791603561,0.422764015626092,0.234591775977469,8.78885520780115,8.6385,4.51285581991478,188.5784,0.797212211848491,0.701781974676398,0.784652499479971,0.655281724437276,0.0954302371720926,0.129370775042696,True,0.904449885774196,0.0916894707354232,0.0771800291015912,508.057536634891
913,26725,1011:1050,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.848633616260123,0.0885448433264196,0.78344254969162,13.8937803999007,297.2862,0.897432464089861,0.91464105870343,0.0536561557836369,0.664855684076851,0.426122108253344,0.238733575823507,9.03238535850535,10.227,4.86139504139538,287.0592,0.761591357349812,0.606189157178616,0.776195149227479,0.648480472889763,0.155402200171196,0.127714676337716,True,0.904449885774196,0.0916894707354232,0.0771800291015912,508.057536634891
914,26725,1011:1051,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.848633616260123,0.0967882754855253,0.79521695987464,14.1633217293657,358.356,0.872678856968296,0.919808496155191,0.0957447586798631,0.674847844369797,0.453591813508584,0.221256030861213,9.52599810166037,14.3993,4.63732362770537,343.9567,0.740584614222756,0.592834127700626,0.780580410358966,0.666020352689765,0.14775048652213,0.1145600576692,True,0.904449885774196,0.0916894707354232,0.0771800291015912,508.057536634891
915,28117,1510:1085,Breast,BT-483,SIDM00892,949093,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.918625777275176,0.08857800536739,0.683866670063341,11.9366252317721,76.5618,0.886105458977799,0.867884107873493,0.0773361685672905,0.628217551339523,0.568206126043364,0.0600114252961592,10.8395905301715,35.7908,1.09703470160054,40.771,0.813999316001258,0.806470904121228,0.79726071318006,0.765913372247116,0.0075284118800296,0.0313473409329434,True,0.844134862729705,0.101581365267409,0.151887762912825,299.33131508176
916,28117,1011:1085,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.79643011687415,0.08857800536739,0.683866670063341,11.9366252317721,76.5618,0.886105458977799,0.867884107873493,0.103227877280022,0.544652011964883,0.324498366032399,0.220153645932484,7.57448689149319,3.7229,4.36213834027889,72.8389,0.705721074256511,0.552501758144681,0.691209041466903,0.554566214146063,0.15321931611183,0.136642827320841,True,0.844134862729705,0.101581365267409,0.151887762912825,299.33131508176
917,28118,1011:1096,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.868384191695435,0.0761992553660783,0.894712262607417,17.1438761040395,1414.2331,0.932956198367633,0.960880789573277,0.128966567672899,0.776953984964336,0.470409847171392,0.306544137792944,9.6364097036536,7.7723,7.50746640038594,1406.4608,0.810164414206722,0.586044948638165,0.834413687769261,0.685389571428134,0.224119465568557,0.149024116341127,True,0.844134862729705,0.101581365267409,0.151887762912825,299.33131508176
918,28119,1011:1192,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.787046988544597,0.0705171526673789,0.728849729138698,12.7632486731349,135.7847,0.906562511490268,0.889720118586901,0.0847365082498642,0.573638984420157,0.393772057656647,0.17986692676351,9.00480787820681,10.0334,3.75844079492814,125.7513,0.713507294595842,0.618450073670839,0.700251539981362,0.600482276868852,0.0950572209250029,0.0997692631125102,True,0.844134862729705,0.101581365267409,0.151887762912825,299.33131508176
919,26727,1011:1560,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.788315254806039,0.0822075566831192,0.630146385761954,11.027952123411,40.7826,0.822920731106328,0.840050823224183,0.0586880533459744,0.49675400865704,0.304732736780538,0.192021271876502,7.24248727931286,2.9576,3.78546484409818,37.825,0.648720965827257,0.526835797515478,0.662224878759994,0.535722615252531,0.121885168311778,0.126502263507463,True,0.904449885774196,0.0916894707354232,0.0771800291015912,508.057536634891
920,28116,1011:2169,Breast,BT-483,SIDM00892,949093,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.83685052524808,0.0918533529852687,0.793764416371843,14.1294632687034,350.0437,0.911312914917852,0.919174799005623,0.0593619617131359,0.664262168764013,0.408169016823074,0.256093151940939,8.81338590843515,8.7867,5.31607736026828,341.257,0.762632691514364,0.616533880040812,0.769211913342654,0.631478873716302,0.146098811473552,0.137733039626352,True,0.844134862729705,0.101581365267409,0.151887762912825,299.33131508176
921,30208,1058:1032,Breast,MDA-MB-453,SIDM00272,908122,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.927704978884557,0.113841906553368,0.367012955926237,7.88184934504986,4.6068,0.770154322902781,0.797055720259998,0.164080493302425,0.340479746527908,0.100018072060379,0.240461674467529,4.66469535424633,0.4954,3.21715399080352,4.1114,0.714475999866374,0.474300850141482,0.739432560133616,0.515470467612466,0.240175149724893,0.22396209252115,True,0.291107788233059,0.0460544685915318,1.19742347326714,41.3056000890627
922,30208,1049:1032,Breast,MDA-MB-453,SIDM00272,908122,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.789188885631924,0.113841906553368,0.367012955926237,7.88184934504986,4.6068,0.770154322902781,0.797055720259998,0.0936669931904403,0.289642545699905,0.0596955620282281,0.229946983671677,3.86502127080069,0.2846,4.01682807424917,4.3222,0.607797231856255,0.367356634830244,0.629027515658538,0.385655341637214,0.24044059702601,0.243372174021324,True,0.291107788233059,0.0460544685915318,1.19742347326714,41.3056000890627
923,30211,1558:1051,Breast,MDA-MB-453,SIDM00272,908122,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.628387532557607,0.161761236988908,0.741191645029456,11.158480982965,44.6445,0.837007828661079,0.939106182279086,0.0902512819055956,0.465755588972374,0.306466683726708,0.159288905245665,8.89907533679398,9.3244,2.25940564617099,35.3201,0.525965284183736,0.476952673289404,0.590122616691949,0.536853561825233,0.0490126108943312,0.0532690548667167,True,0.291107788233059,0.0460544685915318,1.19742347326714,41.3056000890627
924,30211,1549:1051,Breast,MDA-MB-453,SIDM00272,908122,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.93607413753412,0.161761236988908,0.741191645029456,11.158480982965,44.6445,0.837007828661079,0.939106182279086,0.188540537401762,0.693810329868444,0.461100309377783,0.232710020490661,8.93918651086546,9.5872,2.21929447209951,35.0573,0.783501381323226,0.662786356018332,0.879073009629856,0.801605797916791,0.120715025304895,0.0774672117130654,True,0.291107788233059,0.0460544685915318,1.19742347326714,41.3056000890627
925,23796,1011:1080,Breast,MDA-MB-453,SIDM00272,908122,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.935007862672247,0.123372723759078,0.331475713107706,7.56086784815047,0.0369,0.747430084903016,0.776614456099039,0.139862976907224,0.309932398040595,0.100095491714093,0.209836906326502,4.64845180726446,0.0049,2.91241604088601,0.032,0.698853006182105,0.527163757792006,0.726140622717532,0.518263258395563,0.171689248390099,0.20787736432197,True,0.360663278296778,0.0481931615832932,0.991843027077493,49.8059749745999
926,23798,1594:1096,Breast,MDA-MB-453,SIDM00272,908122,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.93178571847423,0.0828279439788429,0.852707418814189,12.6023437251766,60.7272,0.930650792521106,0.967582870500645,0.100547696149897,0.794540594888086,0.589356848326695,0.20518374656139,10.1138735630027,10.8213,2.48847016217397,49.9059,0.86716711735789,0.777128165895333,0.901579900172802,0.845071186220315,0.0900389514625565,0.0565087139524869,True,0.360663278296778,0.0481931615832932,0.991843027077493,49.8059749745999
927,24242,1549:1632,Breast,MDA-MB-453,SIDM00272,908122,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.885578814917208,0.0714938315068195,0.765571213442361,11.427834823825,21.5234,0.912856792840736,0.94567815091888,0.111452990061214,0.677973647935015,0.474447646257241,0.203526001677774,9.29384812855479,4.9036,2.13398669527021,16.6198,0.808406636793022,0.704076550324407,0.837472536183839,0.773397355222319,0.104330086468615,0.0640751809615197,True,0.62601923486366,0.0932155040377651,0.447763587028834,108.324027509349
928,24242,1372:1632,Breast,MDA-MB-453,SIDM00272,908122,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.963008517810542,0.0714938315068195,0.765571213442361,11.427834823825,21.5234,0.912856792840736,0.94567815091888,0.0719354678491283,0.737251599535546,0.753096575264283,-0.0158449757287371,11.6207432263316,24.6027,-0.192908402506591,-3.0793,0.879088867046841,0.855704355187504,0.910696114442205,0.914855633775651,0.0233845118593372,-0.0041595193334461,True,0.62601923486366,0.0932155040377651,0.447763587028834,108.324027509349
929,23941,1053:1032,Breast,HCC1954,SIDM00872,749709,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.916592906923839,0.096376783111984,0.624134285435478,10.4084874764034,26.5459,0.843859494824754,0.873608985751586,0.0955090314986126,0.572077058998138,0.327610591082989,0.244466467915149,7.3708885418243,3.2329,3.03759893457913,23.313,0.773475627396703,0.62913580854419,0.800743799764832,0.666882925553958,0.144339818852513,0.133860874210874,True,0.773479354934262,0.0653707820826554,0.238516190249404,197.469035322096
930,23941,1561:1038,Breast,HCC1954,SIDM00872,749709,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.656885477854771,0.0747416453991395,0.808112556138238,12.9932525215812,159.2534,0.952209058307284,0.942622616429399,0.0973985833865196,0.530837402599307,0.384811928828265,0.146025473771042,9.96285801658816,19.4917,3.03039450499306,139.7617,0.625492302283821,0.583246975160559,0.61919510782994,0.562813710698237,0.0422453271232626,0.0563813971317035,True,0.773479354934262,0.0653707820826554,0.238516190249404,197.469035322096
931,23941,1053:1038,Breast,HCC1954,SIDM00872,749709,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.987100963685379,0.0747416453991395,0.808112556138238,12.9932525215812,159.2534,0.952209058307284,0.942622616429399,0.126024559463421,0.79768868293031,0.57225676936533,0.22543191356498,9.89343117356997,18.5759,3.09982134801125,140.6775,0.939926479085067,0.871719423534601,0.930463693069094,0.843011567121021,0.0682070555504666,0.0874521259480729,True,0.773479354934262,0.0653707820826554,0.238516190249404,197.469035322096
932,23943,1561:1051,Breast,HCC1954,SIDM00872,749709,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.548065380843925,0.0759916997958374,0.891557786654482,14.8511897279942,577.2762,0.927948445222386,0.969041179421507,0.0724078216911925,0.488631957887156,0.211306019576665,0.277325938310491,7.70558497035236,4.077,7.1456047576418,573.1992,0.508576418034335,0.352043859666875,0.531097923053095,0.409474018631995,0.15653255836746,0.1216239044211,True,0.773479354934262,0.0653707820826554,0.238516190249404,197.469035322096
933,23791,1558:1192,Breast,HCC1954,SIDM00872,749709,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.772340443190982,0.0761474662921759,0.655964818911772,10.792399514864,34.6391,0.896504974567741,0.886843227778371,0.0556795958343687,0.50662815895601,0.381023330040262,0.125604828915748,8.92596236350122,9.4998,1.86643715136273,25.1393,0.692407049380569,0.608597820417576,0.684944891583268,0.626711359795763,0.0838092289629931,0.0582335317875048,True,0.507194069671923,0.0473566635770073,0.656318258815952,74.731104431609
934,23791,1011:1192,Breast,HCC1954,SIDM00872,749709,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.942339344693157,0.0761474662921759,0.655964818911772,10.792399514864,34.6391,0.896504974567741,0.886843227778371,0.0744856234832959,0.618141457595085,0.414017983847537,0.204123473747548,8.3228950807115,6.2542,2.46950443415245,28.3849,0.844811910248321,0.728143506128397,0.835707266110234,0.736050775998099,0.116668404119923,0.0996564901121348,True,0.507194069671923,0.0473566635770073,0.656318258815952,74.731104431609
935,23945,1372:1553,Breast,HCC1954,SIDM00872,749709,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.950048217917799,0.0677436340451969,0.622473826936761,10.3888462654456,26.1869,0.857444720250265,0.872900999395819,0.0602096718740884,0.591380149981742,0.456483761968891,0.134896388012851,8.78308805234451,8.6041,1.60575821310106,17.5828,0.81461382843679,0.732310258633443,0.829298038894663,0.76432650236927,0.0823035698033464,0.0649715365253937,True,0.773479354934262,0.0653707820826554,0.238516190249404,197.469035322096
936,23946,1561:1564,Breast,HCC1954,SIDM00872,749709,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.635770018994864,0.0768879286836624,0.808355750540589,12.9976104065091,79.8676,0.917850926817119,0.942703380311295,0.0439684791736487,0.513928350875798,0.410499171651292,0.103429179224505,10.6666056494835,15.8733,2.3310047570256,63.9943,0.583542101176974,0.554901013840158,0.599342546007035,0.561151305130904,0.0286410873368153,0.0381912408761302,True,0.773479354934262,0.0653707820826554,0.238516190249404,197.469035322096
937,26065,1558:1038,Breast,BT-474,SIDM00963,946359,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.467179313380897,0.105665500050856,0.740258236678591,12.4923889827339,112.5418,0.934703491094076,0.905490824086841,0.0629864939323945,0.345833334736058,0.146350524777128,0.199482809958929,6.38264357088852,1.6297,6.10974541184538,110.9121,0.436674135184058,0.313223311927439,0.423026581469593,0.302511697796656,0.123450823256619,0.120514883672936,True,0.539982048897851,0.0705590164079511,0.581456360127077,83.1253322750216
938,26065,1549:1038,Breast,BT-474,SIDM00963,946359,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.618156204797809,0.105665500050856,0.740258236678591,12.4923889827339,112.5418,0.934703491094076,0.905490824086841,0.102765613961348,0.457595222155556,0.334900504364204,0.122694717791352,9.55849436953273,14.7273,2.93389461320118,97.8145,0.577792762665976,0.556880218996974,0.559734771296762,0.500328395509743,0.0209125436690023,0.0594063757870182,True,0.539982048897851,0.0705590164079511,0.581456360127077,83.1253322750216
939,26065,1561:1038,Breast,BT-474,SIDM00963,946359,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.661678813754743,0.105665500050856,0.740258236678591,12.4923889827339,112.5418,0.934703491094076,0.905490824086841,0.0784665786761538,0.489813191917668,0.332774250487864,0.157038941429804,9.03900411725272,10.274,3.45338486548119,102.2678,0.618473497199545,0.569311532629431,0.599144094347585,0.520636847696392,0.0491619645701143,0.0785072466511938,True,0.539982048897851,0.0705590164079511,0.581456360127077,83.1253322750216
940,26065,1053:1038,Breast,BT-474,SIDM00963,946359,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.80378017846786,0.105665500050856,0.740258236678591,12.4923889827339,112.5418,0.934703491094076,0.905490824086841,0.131933928681309,0.595004897589821,0.386279360704584,0.208725536885238,8.74081413864943,8.3556,3.75157484408447,104.1862,0.751296138886128,0.677039515886714,0.72781557618553,0.621441092404157,0.0742566229994139,0.106374483781373,True,0.539982048897851,0.0705590164079511,0.581456360127077,83.1253322750216
941,26067,1558:1050,Breast,BT-474,SIDM00963,946359,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.556402446299615,0.077953497947596,0.767480194397334,12.9819987958201,158.016,0.938637108648028,0.916749704665557,0.0565963068978591,0.427027857649181,0.370102590497189,0.056925267151992,11.2889617304594,48.8704,1.69303706536071,109.1456,0.522259983439361,0.499923379701667,0.510081778320365,0.485353771005863,0.022336603737694,0.024728007314502,True,0.539982048897851,0.0705590164079511,0.581456360127077,83.1253322750216
942,26070,1012:1564,Breast,BT-474,SIDM00963,946359,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.627345585851217,0.0862695491765778,0.873225814137631,15.4351132117091,432.6454,0.9440186625271,0.957199865070788,0.180335926060873,0.547814359950578,0.32491298745139,0.222901372499188,9.23908913360113,5.9012,6.19602407810799,426.7442,0.592225940897546,0.43471624191621,0.600495110129539,0.49919450853577,0.157509698981335,0.101300601593769,True,0.539982048897851,0.0705590164079511,0.581456360127077,83.1253322750216
943,27340,1012:1013,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.878662759219003,0.0905251198609632,0.0679907688749274,6.13585339958292,1.3734,0.703389497638324,0.706042673377589,0.0662557889291278,0.0597409565810653,0.0583914100189891,0.0013495465620762,6.10905436625704,1.3482,0.0267990333258865,0.0251999999999999,0.618042156800559,0.614692832031702,0.620373403516314,0.618180456424842,0.0033493247688568,0.0021929470914716,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
944,27341,1011:1025,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.276950923956035,0.0439195395703778,0.920339623461739,11.6770665935799,63.9554,0.979104742522236,0.990919171126891,0.0867860238454836,0.254888909071078,0.115986035279943,0.138902873791135,8.64146735555279,7.7996,3.03559923802706,56.1558,0.271163963091269,0.183442268012447,0.27443598000934,0.250583774358832,0.0877216950788214,0.0238522056505084,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
945,27341,1011:1030,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.276950923956035,0.0631404313828805,0.769704923210837,10.3201104023396,24.9685,0.964995980555228,0.971367407404488,0.0214710837627447,0.21317048965675,0.0790620739355734,0.134108415721176,7.99625505233013,4.987,2.32385535000943,19.9815,0.26725652842863,0.226413121287073,0.269021100981451,0.238975580993895,0.0408434071415573,0.030045519987556,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
946,27341,1558:1030,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.77401754396589,0.0631404313828805,0.769704923210837,10.3201104023396,24.9685,0.964995980555228,0.971367407404488,0.0885159712379479,0.595765114242106,0.240883802399676,0.35488131184243,8.13083706434331,5.4746,2.18927333799625,19.4939,0.746923818806313,0.613795827105322,0.751855414967736,0.675192287714479,0.133127991700992,0.076663127253257,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
947,27341,1510:1030,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.169310558919349,0.0631404313828805,0.769704923210837,10.3201104023396,24.9685,0.964995980555228,0.971367407404488,0.0403898878907536,0.130319170751801,0.0340909014909563,0.0962282692608449,7.4925646362188,3.5174,2.82754576612075,21.4511,0.163384008822731,0.100739367847552,0.164462758663693,0.13963133095358,0.0626446409751782,0.0248314277101128,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
948,27341,1053:1030,Breast,DU-4475,SIDM01001,906844,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.986616163805488,0.0631404313828805,0.769704923210837,10.3201104023396,24.9685,0.964995980555228,0.971367407404488,0.0819764498653516,0.759403318600473,0.681716738681293,0.0776865799191808,9.88029430464733,18.4075,0.439816097692226,6.561,0.952080632423114,0.922038031894072,0.958366785139098,0.946719845323971,0.0300426005290422,0.0116469398151269,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
949,27347,1510:1038,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.30881421035831,0.0982444626591162,0.491905420873472,8.96457395589958,9.7574,0.943773090137241,0.92239388279185,0.0274876048012622,0.151907384118013,0.0426207905100657,0.109286593607948,6.99586159478629,2.4928,1.9687123611133,7.2646,0.291450541588154,0.2288258391243,0.284848338553701,0.241928509584376,0.0626247024638546,0.0429198289693247,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
950,27348,1558:1042,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.987670212180441,0.0591024408476848,0.953879375294383,12.3141291919147,99.4609,0.969493592436399,0.994834755712599,0.0643295538410842,0.94211824499155,0.845009635199671,0.0971086097918782,10.9461533355235,38.5346,1.3679758563912,60.9263,0.957539942149237,0.949208474054406,0.98256865425914,0.9708155955003,0.0083314680948309,0.0117530587588399,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
951,27348,1372:1042,Breast,DU-4475,SIDM01001,906844,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.0757921629772883,0.0591024408476848,0.953879375294383,12.3141291919147,99.4609,0.969493592436399,0.994834755712599,0.0308938994847187,0.0722965810729859,0.0336016074208642,0.0386949736521217,8.75097347068199,8.4146,3.56315572123276,91.0463,0.0734800163633763,0.0486902045730699,0.0754006779404401,0.0690484630647315,0.0247898117903065,0.0063522148757086,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
952,27348,1011:1042,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.350906494224917,0.0591024408476848,0.953879375294383,12.3141291919147,99.4609,0.969493592436399,0.994834755712599,0.08282020300124,0.334722467498006,0.108765474179815,0.225956993318191,8.12441652638063,5.4503,4.18971266553411,94.0106,0.340201597695377,0.248413095911267,0.34909397646021,0.30594807167299,0.0917885017841107,0.0431459047872196,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
953,27349,1558:1050,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.980594195119848,0.133671566922419,0.302484405513844,8.08594068058994,5.3069,0.864073459123727,0.869210719924494,0.121587328811521,0.296614452161153,0.26943879869424,0.0271756534669132,7.93818654037102,4.7903,0.147754140218916,0.5166,0.847305418173854,0.809463490527479,0.852342986293902,0.842038060308794,0.0378419276463744,0.0103049259851083,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
954,27349,1510:1050,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.924018595447581,0.133671566922419,0.302484405513844,8.08594068058994,5.3069,0.864073459123727,0.869210719924494,0.0455937007719388,0.279501215527699,0.0750480936328349,0.204453121894864,6.34599033787696,1.5888,1.73995034271298,3.7181,0.798419944063039,0.665857905004395,0.803166868572612,0.670342558330613,0.132562039058644,0.132824310241999,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
955,27349,1011:1050,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.30375046885946,0.133671566922419,0.302484405513844,8.08594068058994,5.3069,0.864073459123727,0.869210719924494,0.0232506130082451,0.0918797799975051,0.0054438020902071,0.086435977907298,4.61988073019422,0.4802,3.46605995039571,4.8267,0.262462718337847,0.15081821569515,0.264023163714734,0.170297871067222,0.111644502642697,0.0937252926475116,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
956,28107,1049:1080,Breast,DU-4475,SIDM01001,906844,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.908629916818014,0.132141056070688,0.268556190294282,7.90382236908377,0.0468,0.784092491475582,0.85619995553995,0.168668887995796,0.244018188848056,0.0252079992083388,0.218810189639717,5.10891654642327,0.0067,2.7949058226605,0.0401,0.712449895307087,0.545647178687227,0.777968894381852,0.552650495702313,0.16680271661986,0.225318398679539,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
957,28107,1011:1080,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.379027343942161,0.132141056070688,0.268556190294282,7.90382236908377,0.0468,0.784092491475582,0.85619995553995,0.0504730465258335,0.101790139506467,0.0030381305535482,0.0987520089529188,3.72860068760812,0.0026,4.17522168147566,0.0442,0.297192494448981,0.159781801929107,0.324523195031703,0.179439862373873,0.137410692519874,0.14508333265783,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
958,28107,1558:1080,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.903868772194298,0.132141056070688,0.268556190294282,7.90382236908377,0.0468,0.784092491475582,0.85619995553995,0.136667153585218,0.242739553986471,0.0918611275027506,0.15087842648372,6.61584834488186,0.0192,1.28797402420192,0.0276,0.708716717556802,0.654534982064986,0.773892402566707,0.677868363528111,0.0541817354918159,0.0960240390385961,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
959,28107,1053:1080,Breast,DU-4475,SIDM01001,906844,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.92195637208454,0.132141056070688,0.268556190294282,7.90382236908377,0.0468,0.784092491475582,0.85619995553995,0.0880894019085967,0.247597090904562,0.0986267230060205,0.148970367898541,6.67844605610713,0.02,1.22537631297665,0.0268,0.722899068819556,0.667939774293106,0.789379004788557,0.696597480193396,0.0549592945264498,0.0927815245951609,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
960,27344,1372:1085,Breast,DU-4475,SIDM01001,906844,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.0518148166369143,0.133531215107738,0.137366618485782,6.9898932387417,2.4825,0.794779039385551,0.782896938449072,0.0242569659704741,0.0071176261488736,0.0005437989529014,0.0065738271959722,4.0261960302776,0.3182,2.9636972084641,2.1643,0.0411813301926252,0.038201432162286,0.0405656613113402,0.0260403599548742,0.0029798980303392,0.0145253013564661,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
961,27345,1012:1096,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.209481153471866,0.0807953708212986,0.102812730606955,6.62993552215301,0.9672,0.710727619060941,0.751226643571413,0.0755152450291026,0.0215373293991371,0.0005498223464226,0.0209875070527145,2.50126229372364,0.0553,4.12867322842937,0.9119,0.148884041445199,0.0346963553853932,0.157367823814138,0.0741999702339475,0.114187686059805,0.0831678535801902,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
962,27345,1011:1096,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.27375289996543,0.0807953708212986,0.102812730606955,6.62993552215301,0.9672,0.710727619060941,0.751226643571413,0.0448581348647275,0.0281452831570184,0.0001981117297458,0.0279471714272725,1.08967481258148,0.0208,5.54026070957153,0.9464,0.194563746803458,0.0308100719970746,0.205650472208971,0.0613192812326237,0.163753674806384,0.144331190976347,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
963,27345,1053:1096,Breast,DU-4475,SIDM01001,906844,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.957642940070379,0.0807953708212986,0.102812730606955,6.62993552215301,0.9672,0.710727619060941,0.751226643571413,0.149887218429365,0.0984578856151082,0.0066340170488682,0.0918238685662399,3.56778345378255,0.1158,3.06215206837046,0.8514,0.680623286706739,0.459732973381265,0.71940689160893,0.438300555402245,0.220890313325474,0.281106336206685,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
964,27345,1049:1129,Breast,DU-4475,SIDM01001,906844,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.839109178577923,0.0619823399701994,0.651107409132852,9.68257872679013,16.0501,0.921577501263895,0.953063443212007,0.0593642973874152,0.546350203243467,0.121247402288387,0.42510280095508,7.05432352656193,2.5959,2.6282552002282,13.4542,0.773304140081442,0.620083167311769,0.799724282966274,0.661577084062579,0.153220972769672,0.138147198903695,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
965,27345,1011:1129,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.27375289996543,0.0619823399701994,0.651107409132852,9.68257872679013,16.0501,0.921577501263895,0.953063443212007,0.0373069013735815,0.178242541439096,0.0300457190922901,0.148196822346806,6.70991830445766,2.0446,2.97266042233247,14.0055,0.252284513513886,0.184559734791792,0.260903881430325,0.207605409036993,0.0677247787220944,0.0532984723933319,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
966,27345,1558:1129,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.853970909425162,0.0619823399701994,0.651107409132852,9.68257872679013,16.0501,0.921577501263895,0.953063443212007,0.0546337147088993,0.556026786310643,0.0229028541805888,0.533123932130054,5.0708347746117,0.6565,4.61174395217843,15.3936,0.787000376860097,0.488309457534115,0.813888455339634,0.516254605732379,0.298690919325982,0.297633849607254,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
967,27345,1510:1129,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.21035590893559,0.0619823399701994,0.651107409132852,9.68257872679013,16.0501,0.921577501263895,0.953063443212007,0.0449385000276854,0.136964290862838,0.0163822891337091,0.120582001729129,6.29607391466022,1.5347,3.38650481212991,14.5154,0.193859272932957,0.116293955083257,0.200482526870145,0.151640511914208,0.0775653178496996,0.0488420149559371,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
968,27346,1558:1192,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,1.0,0.0803381545859461,0.489120508077503,8.95238238841736,9.6753,0.858677623736665,0.921772873953083,0.100992153024573,0.489120508077503,0.414806113317575,0.0743143947599284,8.62350820297312,7.7031,0.328874185444242,1.9722,0.858677623736665,0.829023033740054,0.921772873953083,0.903747759061068,0.0296545899966111,0.0180251148920154,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
969,27346,1510:1192,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.951657793532415,0.0803381545859461,0.489120508077503,8.95238238841736,9.6753,0.858677623736665,0.921772873953083,0.0857588272643072,0.465475343488491,0.163287271794639,0.302188071693852,7.27749183334571,3.0302,1.67489055507165,6.6451,0.817167252760892,0.706257003203815,0.877212339364224,0.768189615086141,0.110910249557077,0.109022724278083,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
970,27346,1012:1192,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.379844388675043,0.0803381545859461,0.489120508077503,8.95238238841736,9.6753,0.858677623736665,0.921772873953083,0.132400560652398,0.185789680379125,0.0039834379705061,0.181806242408619,4.0253506736416,0.318,4.92703171477576,9.3573,0.326163877057192,0.151689832522041,0.350130253803946,0.190865385039224,0.174474044535151,0.159264868764722,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
971,27346,1011:1192,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.349161177125162,0.0803381545859461,0.489120508077503,8.95238238841736,9.6753,0.858677623736665,0.921772873953083,0.0670612582632928,0.170781892356398,0.0172017935441275,0.153580098812271,5.76166324557304,1.0597,3.19071914284432,8.6156,0.29981688987493,0.178108514596848,0.321847301711502,0.234240126311073,0.121708375278082,0.0876071754004283,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
972,27351,1021:1553,Breast,DU-4475,SIDM01001,906844,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.768814705819215,0.0977885484946193,0.525182983546551,9.11029739515626,10.7945,0.908613792387216,0.929553942613152,0.0541814968672573,0.403768400996599,0.251267266009422,0.152501134987178,8.20946919322745,5.7813,0.900828201928814,5.0132,0.698555645497459,0.669800124607886,0.714654740933221,0.674769335102929,0.0287555208895726,0.039885405830292,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
973,27351,1558:1553,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.959526244696768,0.0977885484946193,0.525182983546551,9.11029739515626,10.7945,0.908613792387216,0.929553942613152,0.113064127895936,0.503926855981066,0.417407529228857,0.0865193267522096,8.7139957125428,8.2017,0.396301682613462,2.5928,0.871838780088994,0.851634414685662,0.891931403798672,0.872161840271018,0.0202043654033317,0.0197695635276537,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
974,27351,1083:1553,Breast,DU-4475,SIDM01001,906844,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.613054178736312,0.0977885484946193,0.525182983546551,9.11029739515626,10.7945,0.908613792387216,0.929553942613152,0.0611774965601258,0.321965622664417,0.115802687234175,0.206162935430242,7.40576609998118,3.312,1.70453129517507,7.4825,0.55702948228043,0.490683190873604,0.569866928879806,0.501308246361716,0.0663462914068264,0.0685586825180899,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
975,27351,1012:1553,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.348080848752599,0.0977885484946193,0.525182983546551,9.11029739515626,10.7945,0.908613792387216,0.929553942613152,0.0517050357974986,0.182806138663306,0.0016422864747158,0.18116385218859,3.14515509242363,0.1728,5.96514230273263,10.6217,0.31627106004246,0.112155011911682,0.323559925306111,0.144956650399426,0.204116048130778,0.178603274906685,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
976,27351,1011:1553,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.308136689397066,0.0977885484946193,0.525182983546551,9.11029739515626,10.7945,0.908613792387216,0.929553942613152,0.0506789207663306,0.161828145877708,0.0113455033321737,0.150482642545534,5.42884923733551,0.8413,3.68144815782075,9.9532,0.279977245926709,0.153743920765497,0.286429674492807,0.196926202478337,0.126233325161212,0.0895034720144699,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
977,27351,1594:1553,Breast,DU-4475,SIDM01001,906844,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.97620930610548,0.0977885484946193,0.525182983546551,9.11029739515626,10.7945,0.908613792387216,0.929553942613152,0.0642650218804561,0.512688515946384,0.496164011865366,0.0165245040810185,9.03613162222007,10.2536,0.0741657729361904,0.540899999999999,0.886997239784192,0.922234131039854,0.907439209305998,0.903940943264241,-0.0352368912556619,0.0034982660417568,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
978,27351,1012:1560,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.903812101187836,0.0730558740138767,0.865265700223327,11.0346082391435,40.9711,0.947950889043366,0.984169127779389,0.0629956311116498,0.78203761060461,0.524628639926892,0.257408970677718,9.35520026902423,12.7916,1.67940797011929,28.1795,0.856769484849162,0.800677435239166,0.88950396730249,0.850035866770797,0.0560920496099959,0.039468100531693,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
979,27351,1021:1560,Breast,DU-4475,SIDM01001,906844,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.768814705819215,0.0730558740138767,0.865265700223327,11.0346082391435,40.9711,0.947950889043366,0.984169127779389,0.0204927834893669,0.665228994772654,0.585644094594154,0.0795849001785005,10.2715883313446,24.1427,0.763019907798872,16.8284,0.728798583890939,0.74201285747167,0.756643698450064,0.74592778544766,-0.0132142735807312,0.0107159130024039,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
980,27351,1011:1560,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.308136689397066,0.0730558740138767,0.865265700223327,11.0346082391435,40.9711,0.947950889043366,0.984169127779389,0.0509144846400054,0.26662010831565,0.0784634545275876,0.188156653788062,7.82498155827413,4.4288,3.20962668086939,36.5423,0.292098448660828,0.216846109592445,0.303258616840739,0.26203340171685,0.0752523390683831,0.0412252151238885,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
981,27351,1558:1560,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.907913336765286,0.0730558740138767,0.865265700223327,11.0346082391435,40.9711,0.947950889043366,0.984169127779389,0.110208511336227,0.785586269078313,0.269558799257969,0.516027469820344,8.05682612181772,5.2009,2.97778211732579,35.7702,0.860657254760982,0.694605294119451,0.893540276743566,0.787317494888156,0.166051960641531,0.10622278185541,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
982,27351,1594:1560,Breast,DU-4475,SIDM01001,906844,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.961028050698849,0.0730558740138767,0.865265700223327,11.0346082391435,40.9711,0.947950889043366,0.984169127779389,0.111911718419475,0.831544609222199,0.629419363108277,0.202125246113923,9.70110247822252,16.2575,1.333505760921,24.7136,0.911007395055588,0.840590389743198,0.945814138427813,0.916538277080282,0.0704170053123898,0.0292758613475312,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
983,27353,1021:1632,Breast,DU-4475,SIDM01001,906844,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.733753736827922,0.0801122459085411,0.910144119481131,11.5331196821283,23.1529,0.965124372510321,0.989700583201028,0.17142577354424,0.667821648721239,0.446016051184768,0.221805597536471,9.47952091812559,5.5771,2.05359876400275,17.5758,0.708163614833152,0.58386525435966,0.726196501264528,0.693796865688317,0.124298360473491,0.0323996355762112,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
984,27353,1558:1632,Breast,DU-4475,SIDM01001,906844,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.932653562086251,0.0801122459085411,0.910144119481131,11.5331196821283,23.1529,0.965124372510321,0.989700583201028,0.0659942937808153,0.848849155045931,0.859154728116984,-0.0103055730710532,11.6898766668198,25.8103,-0.156756984691416,-2.6574,0.900126683878009,0.913755648216264,0.923047774321279,0.924278945662436,-0.0136289643382554,-0.0012311713411571,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
985,27353,1372:1632,Breast,DU-4475,SIDM01001,906844,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.0641672639118107,0.0801122459085411,0.910144119481131,11.5331196821283,23.1529,0.965124372510321,0.989700583201028,0.0280968077942213,0.0584014579125283,0.0404489256679224,0.0179525322446059,9.58398562833247,5.9959,1.94913405379588,17.157,0.0619293903185905,0.0416005955784134,0.0635063785159333,0.0609282534784715,0.020328794740177,0.0025781250374618,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
986,27353,1510:1632,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.904770942534135,0.0801122459085411,0.910144119481131,11.5331196821283,23.1529,0.965124372510321,0.989700583201028,0.111945681101814,0.823471952824843,0.459923164438024,0.36354878838682,9.03646115706907,4.1024,2.49665852505928,19.0505,0.873216488178829,0.750133894537339,0.895452329489377,0.837805788905856,0.12308259364149,0.0576465405835208,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
987,27353,1012:1632,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.232060109136706,0.0801122459085411,0.910144119481131,11.5331196821283,23.1529,0.965124372510321,0.989700583201028,0.0881875705472133,0.211208143696923,0.0381315410974522,0.173076602599471,7.2206119995293,1.1652,4.31250768259905,21.9877,0.22396686721524,0.117750288785293,0.229670025350293,0.186224116106613,0.106216578429947,0.0434459092436792,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
988,27353,1011:1632,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.274041455311715,0.0801122459085411,0.910144119481131,11.5331196821283,23.1529,0.965124372510321,0.989700583201028,0.0908437558641312,0.249417219046009,0.0491251792290966,0.200292039816912,7.33558567120451,1.2619,4.19753401092383,21.891,0.264484087599534,0.141369880301726,0.271218988143263,0.222521529227717,0.123114207297808,0.0486974589155457,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
989,27353,1083:1909,Breast,DU-4475,SIDM01001,906844,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.619724569449582,0.0978457626949642,0.621898750408175,9.54440757497592,1.4584,0.87458704709717,0.948042970751617,0.147317836108828,0.385405935337939,0.110619080207151,0.274786855130788,7.32988997596694,0.3142,2.21451759900898,1.1442,0.542003081208475,0.381833889955104,0.587525521868748,0.502926388364705,0.160169191253371,0.0845991335040435,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
990,27353,1012:1909,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.881445562105416,0.0978457626949642,0.621898750408175,9.54440757497592,1.4584,0.87458704709717,0.948042970751617,0.0959329975911331,0.548169893626189,0.404292130049413,0.143877763576776,8.81871829515996,0.8819,0.725689279815962,0.5765,0.770900871338681,0.723437424484232,0.835648269254248,0.806295377278868,0.0474634468544484,0.0293528919753798,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
991,27353,1021:1909,Breast,DU-4475,SIDM01001,906844,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.733753736827922,0.0978457626949642,0.621898750408175,9.54440757497592,1.4584,0.87458704709717,0.948042970751617,0.124348011004059,0.456320532040613,0.308696683687755,0.147623848352859,8.65005797247346,0.7846,0.894349602502462,0.6738,0.641731513988846,0.550451823151011,0.695630072462443,0.664262274290476,0.091279690837835,0.0313677981719671,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
992,27353,1510:1909,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.334678767233014,0.0978457626949642,0.621898750408175,9.54440757497592,1.4584,0.87458704709717,0.948042970751617,0.0895620022876509,0.208136307130359,0.0163729272391793,0.19176337989118,5.75358433621485,0.1054,3.79082323876108,1.353,0.292705714760442,0.156329090509947,0.317289852735075,0.224267830295021,0.136376624250496,0.0930220224400544,True,0.50451629426904,0.0654298632911738,0.638628828573468,75.4039428178402
993,28107,1021:2169,Breast,DU-4475,SIDM01001,906844,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.76384608018922,0.0654225613076436,0.893077679841337,11.3221628353947,50.0081,0.962335089739995,0.987629891066685,0.129430084482937,0.682173885051289,0.594177842839864,0.0879960422114249,10.3711885005196,25.8684,0.950974334875106,24.1397,0.735075886126436,0.618411783090075,0.754397220968993,0.74285757028076,0.116664103036361,0.0115396506882334,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
994,28107,1372:2169,Breast,DU-4475,SIDM01001,906844,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.0935640492284432,0.0654225613076436,0.893077679841337,11.3221628353947,50.0081,0.962335089739995,0.987629891066685,0.0278093690644617,0.0835599640014988,0.0563826255299578,0.027177338471541,9.4555026148552,13.7126,1.86666022053948,36.2955,0.0900399677106912,0.0678233720399098,0.0924066517472453,0.0883802812950552,0.0222165956707814,0.00402637045219,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
995,28107,1510:2169,Breast,DU-4475,SIDM01001,906844,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.89697436617657,0.0654225613076436,0.893077679841337,11.3221628353947,50.0081,0.962335089739995,0.987629891066685,0.030025699673065,0.801067785822126,0.660302194534978,0.140765591287148,10.1225016241555,21.7724,1.19966121123918,28.2357,0.863189907169005,0.858429452835123,0.885878695556575,0.866917405096501,0.0047604543338821,0.0189612904600734,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
996,28107,1083:2169,Breast,DU-4475,SIDM01001,906844,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.610985331034847,0.0654225613076436,0.893077679841337,11.3221628353947,50.0081,0.962335089739995,0.987629891066685,0.0406972644710141,0.545657361857693,0.343625864312417,0.202031497545276,9.27455787317655,12.0962,2.04760496221813,37.9119,0.58797262337124,0.572430328718208,0.603427375933288,0.572520989242857,0.015542294653032,0.0309063866904312,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
997,28107,1012:2169,Breast,DU-4475,SIDM01001,906844,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.665710487474503,0.0654225613076436,0.893077679841337,11.3221628353947,50.0081,0.962335089739995,0.987629891066685,0.0927442912126917,0.594531177599775,0.208656979055988,0.385874198543787,8.14215902687057,5.5178,3.18000380852411,44.4903,0.640636561704632,0.506300830568097,0.657475576226393,0.581231828292387,0.134335731136535,0.0762437479340063,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
998,28107,1011:2169,Breast,DU-4475,SIDM01001,906844,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.379027343942161,0.0654225613076436,0.893077679841337,11.3221628353947,50.0081,0.962335089739995,0.987629891066685,0.0662550487277335,0.338500860924289,0.0625706461808713,0.275930214743418,7.22669256560741,2.9254,4.09547026978727,47.0827,0.364751313046491,0.257552806993541,0.374338734408891,0.304355098321625,0.10719850605295,0.069983636087266,True,0.612291922929542,0.0845053357199909,0.47545893654772,102.958859121377
999,23927,1011:1050,Breast,HCC1395,SIDM00884,749712,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.974971312503205,0.157311208978657,0.583596468751329,10.0144612825222,20.2015,0.90268878732431,0.845747862787408,0.116679998075009,0.568989815110719,0.3463652590133,0.222624556097419,7.20879546196454,2.8893,2.80566582055764,17.3122,0.880095671759509,0.729600835443753,0.82457990382862,0.690217975135787,0.150494836315756,0.134361928692833,True,0.667495015167967,0.0674649706669935,0.381649384184428,125.780977438173
1000,23927,1011:1051,Breast,HCC1395,SIDM00884,749712,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.974971312503205,0.0910025477718484,0.609922774171275,10.3433416719256,25.3738,0.805319871170036,0.858229381651777,0.162169780441036,0.594657207659364,0.350895461352486,0.243761746306878,7.26958502540147,3.0137,3.07375664652415,22.3601,0.785163771779562,0.598686693857051,0.836749026657848,0.693666516002322,0.186477077922511,0.143082510655526,True,0.667495015167967,0.0674649706669935,0.381649384184428,125.780977438173
1001,25841,1011:1080,Breast,HCC1395,SIDM00884,749712,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.945315547877528,0.0731624691857767,0.465303309446532,8.58222965681262,0.0749,0.765102369324519,0.782217418867008,0.147496009190406,0.439858452898675,0.208480384246942,0.231378068651733,5.20572323210951,0.0072,3.37650642470311,0.0677,0.723263165440403,0.555378229435477,0.739442287875611,0.5497759464626,0.167884936004925,0.189666341413012,True,0.44479748562928,0.0532231221514717,0.774592842687433,63.1282686288344
1002,28308,1561:1032,Breast,BT-20,SIDM00893,906801,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.622162961229422,0.11301136651222,0.615303904397837,10.2720581839246,24.1506,0.845671502148206,0.872654122040504,0.0743063328180199,0.382819299216184,0.228622813031536,0.154196486184647,7.52901446463819,3.6074,2.74304371928638,20.5432,0.526145486003861,0.457926599374387,0.542933072697781,0.460540246592014,0.0682188866294747,0.0823928261057673,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
1003,28308,1058:1032,Breast,BT-20,SIDM00893,906801,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.805902256720571,0.11301136651222,0.615303904397837,10.2720581839246,24.1506,0.845671502148206,0.872654122040504,0.111040919938788,0.495874805123195,0.277204805757698,0.218669999365497,7.2512623190803,2.9756,3.02079586484427,21.175,0.681528572025514,0.564823166139349,0.703273926288951,0.583092913098176,0.116705405886165,0.120181013190775,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
1004,28308,1012:1032,Breast,BT-20,SIDM00893,906801,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.89491506440465,0.11301136651222,0.615303904397837,10.2720581839246,24.1506,0.845671502148206,0.872654122040504,0.107913676681518,0.550644733232623,0.32392282607617,0.226721907156454,7.46465958650592,3.45,2.80739859741865,20.7006,0.756804166810139,0.646674469844821,0.780951319828861,0.659018839219376,0.110129696965317,0.121932480609485,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
1005,28308,1011:1032,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.807036634174456,0.11301136651222,0.615303904397837,10.2720581839246,24.1506,0.845671502148206,0.872654122040504,0.0947963095234148,0.496572791999632,0.0624157435939663,0.434157048405666,2.28559408285064,0.0952,7.98646410107393,24.0554,0.682487882710944,0.292250175193682,0.704263845450034,0.304454793565358,0.390237707517262,0.399809051884676,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
1006,28308,1021:1032,Breast,BT-20,SIDM00893,906801,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.793340519020705,0.11301136651222,0.615303904397837,10.2720581839246,24.1506,0.845671502148206,0.872654122040504,0.0366386665165634,0.488145518870446,0.277595275879971,0.210550242990476,7.32225357905476,3.1257,2.94980460486981,21.0249,0.670905468435277,0.552530096783824,0.692311874105171,0.577429879303478,0.118375371651452,0.114881994801693,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
1007,28308,1011:1038,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.807036634174456,0.131642796824512,0.569663431634062,9.75966114386885,16.9309,0.881781162638132,0.852643860263548,0.116455954848566,0.459739258478224,0.244209948328478,0.215529310149746,6.73859670818907,2.0857,3.02106443567979,14.8452,0.711629701573917,0.601920294085223,0.688114831136609,0.557962512795877,0.109709407488694,0.130152318340732,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
1008,28310,1549:1050,Breast,BT-20,SIDM00893,906801,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.877426827978906,0.065322094454503,0.640469625761041,10.5638677506799,29.5645,0.885854274730533,0.883086348177509,0.0610279630328271,0.561965232148347,0.284010258767244,0.277954973381103,7.00417973859148,2.5073,3.55968801208841,27.0572,0.777272306328366,0.604127588752012,0.774843653312868,0.621427040243161,0.173144717576354,0.153416613069707,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
1009,28310,1558:1050,Breast,BT-20,SIDM00893,906801,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.881253754294711,0.065322094454503,0.640469625761041,10.5638677506799,29.5645,0.885854274730533,0.883086348177509,0.0677598832834849,0.564416262213646,0.42843104525936,0.135985216954286,8.85003070737574,9.0127,1.71383704330415,20.5518,0.780662405364301,0.723406636623817,0.778223159697836,0.715316490851402,0.0572557687404832,0.0629066688464344,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
1010,28310,1011:1050,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.764187259652383,0.065322094454503,0.640469625761041,10.5638677506799,29.5645,0.885854274730533,0.883086348177509,0.13623641458825,0.489438728200917,0.181597078171632,0.307841650029285,5.84277611137881,1.1209,4.72109163930108,28.4436,0.676958550657675,0.511218152551525,0.674843336450201,0.482675570711907,0.16574039810615,0.192167765738294,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
1011,28310,1011:1051,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.764187259652383,0.151943083976931,0.579178194733823,9.86508114395179,18.2144,0.755821813330187,0.856939166525253,0.141374518097598,0.442600597484055,0.0948627353262952,0.347737862157759,3.70812555796987,0.2553,6.15695558598192,17.9591,0.57758940031429,0.325585876642967,0.65486199335573,0.365878144464357,0.252003523671323,0.288983848891373,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
1012,28310,1558:1051,Breast,BT-20,SIDM00893,906801,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.881248369114554,0.151943083976931,0.579178194733823,9.86508114395179,18.2144,0.755821813330187,0.856939166525253,0.177423963828188,0.510399839535894,0.297403394532426,0.212996445003468,7.1730251752084,2.8186,2.69205596874339,15.3958,0.666066740338432,0.517525814068591,0.755176242930764,0.63337959492704,0.148540926269841,0.121796648003724,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
1013,28310,1549:1051,Breast,BT-20,SIDM00893,906801,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.856029570442636,0.151943083976931,0.579178194733823,9.86508114395179,18.2144,0.755821813330187,0.856939166525253,0.179521022913022,0.495793661247736,0.312451949341416,0.18334171190632,7.50027165799714,3.5362,2.36480948595465,14.6782,0.647005822196214,0.512385659609409,0.733565266616082,0.63219638072447,0.134620162586804,0.101368885891612,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
1014,28310,1561:1051,Breast,BT-20,SIDM00893,906801,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.665369203784412,0.151943083976931,0.579178194733823,9.86508114395179,18.2144,0.755821813330187,0.856939166525253,0.0778075199115515,0.385367334279337,0.20177184656552,0.183595487713817,6.74689707215855,2.0977,3.11818407179324,16.1167,0.502900558138397,0.417692651741158,0.570180930922585,0.460372651863384,0.0852079063972382,0.109808279059201,True,0.526253313397235,0.0544055226357989,0.619330977615164,79.0524314471407
1015,27486,1549:1096,Breast,BT-20,SIDM00893,906801,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.886195416605757,0.0631606370966427,0.824459774901272,13.1895946805515,91.2355,0.92046686924406,0.949152780896984,0.100478938064312,0.730632473693322,0.591999150876633,0.138633322816689,10.8939061719637,18.582,2.29568850858788,72.6535,0.815713520661537,0.738973010925768,0.841134844089516,0.792316934046416,0.0767405097357685,0.0488179100430994,True,1.25334280311119,0.110750657810219,-0.239897217854411,-224.523668877531
1016,27486,1561:1096,Breast,BT-20,SIDM00893,906801,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.588041744513053,0.0631606370966427,0.824459774901272,13.1895946805515,91.2355,0.92046686924406,0.949152780896984,0.0288928686715492,0.484816764313783,0.4567182927158,0.0280984715979838,12.3758223655825,51.9032,0.81377231496907,39.3323,0.541272943556746,0.538719485404489,0.558141457088078,0.548926786065308,0.0025534581522568,0.0092146710227701,True,1.25334280311119,0.110750657810219,-0.239897217854411,-224.523668877531
1017,27486,1011:1096,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.847085942206233,0.0631606370966427,0.824459774901272,13.1895946805515,91.2355,0.92046686924406,0.949152780896984,0.176490631055877,0.698388285233383,0.30807099926482,0.390317285968563,7.48485731630821,1.7493,5.70473736424334,89.4862,0.779714545203226,0.520513775578801,0.804013977703788,0.624815722673665,0.259200769624426,0.179198255030123,True,1.25334280311119,0.110750657810219,-0.239897217854411,-224.523668877531
1018,27487,1011:1192,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.888701923520543,0.0673101737212491,0.657187740084802,10.7626240253927,33.9315,0.914410440861386,0.889800996857055,0.153345622736023,0.584044008727482,0.27737098470209,0.306673024025392,6.85955855868613,2.2681,3.90306546670658,31.6634,0.812638317680781,0.617373138625245,0.790767857457361,0.62129796300814,0.195265179055537,0.169469894449221,True,1.25334280311119,0.110750657810219,-0.239897217854411,-224.523668877531
1019,28701,1561:1564,Breast,BT-20,SIDM00893,906801,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.620705159634988,0.0665946380658255,0.730711262690471,11.7036683321721,32.5728,0.899390535015731,0.917501773999729,0.0586581270187275,0.453556250955372,0.375164761807007,0.0783914891483655,10.1481226370395,11.0813,1.55554569513263,21.4915,0.558256345611136,0.492007689518264,0.569498085095886,0.538780450559334,0.0662486560928724,0.0307176345365519,True,1.02859151306523,0.0847988514123996,-0.0368532270813195,-1785.96185254479
1020,28701,1011:1564,Breast,BT-20,SIDM00893,906801,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.760464948989309,0.0665946380658255,0.730711262690471,11.7036683321721,32.5728,0.899390535015731,0.917501773999729,0.12737783987551,0.555680303107823,0.207379004871031,0.348301298236792,6.34310355973343,0.7928,5.36056477243868,31.78,0.683954977332205,0.430261016697023,0.697727939762304,0.506086216024971,0.253693960635182,0.191641723737333,True,1.02859151306523,0.0847988514123996,-0.0368532270813195,-1785.96185254479
1021,29178,1011:1030,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.278289561642279,0.0411179332367868,0.881811728479941,12.8477832877844,143.9787,0.968391819287551,0.976057007695686,0.0627353896709102,0.245398999369703,0.196334820407075,0.0490641789626288,10.6727038654196,31.8812,2.17507942236481,112.0975,0.269493334887502,0.19667066187045,0.271626476809507,0.259822578528555,0.0728226730170518,0.0118038982809522,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
1022,28367,1011:1038,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.782040745129411,0.0988773376850667,0.515318515840604,9.11735242095803,10.8474,0.868906906943032,0.874035705922819,0.0549146741276196,0.403000076106968,0.167526886232475,0.235473189874494,6.51161014794874,1.7821,2.60574227300928,9.0653,0.679520604953821,0.523281985888976,0.683531534729592,0.554274373582862,0.156238619064845,0.12925716114673,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
1023,28367,1012:1038,Breast,HCC1428,SIDM00881,1290905,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.877298454764726,0.0988773376850667,0.515318515840604,9.11735242095803,10.8474,0.868906906943032,0.874035705922819,0.0691414574145752,0.452088137658614,0.346645497565443,0.105442640093171,8.18474999240805,5.6831,0.932602428549973,5.1643,0.76229068679552,0.720093291549626,0.766790174215286,0.722713104763132,0.0421973952458939,0.0440770694521532,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
1024,30193,1011:1050,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.600669241425642,0.05904479652145,0.826919694234219,11.9943518424807,79.6874,0.943019972611937,0.963829274334037,0.0434902957728735,0.496705225455592,0.276995215079633,0.219710010375959,8.70182559244448,8.1328,3.29252625003625,71.5546,0.566443091598042,0.480340892907032,0.578942599078052,0.512372885047852,0.0861021986910092,0.0665697140302007,True,0.768000060532699,0.0777395877736317,0.250621367036338,191.296964465036
1025,30193,1049:1050,Breast,HCC1428,SIDM00881,1290905,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.973145742819465,0.05904479652145,0.826919694234219,11.9943518424807,79.6874,0.943019972611937,0.963829274334037,0.0874404668509302,0.804713380097603,0.521307716777129,0.283405663320474,9.27382069963569,12.0901,2.72053114284504,67.5973,0.917695871741035,0.862902265341175,0.937946355122942,0.857715192695999,0.0547936063998599,0.0802311624269423,True,0.768000060532699,0.0777395877736317,0.250621367036338,191.296964465036
1026,30193,1011:1051,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.600669241425642,0.150776537283023,0.732472712744762,10.9283999072153,38.0633,0.808870881794366,0.940769345657739,0.150939556526597,0.439973828729378,0.250679472591456,0.189294356137923,8.36104080495581,6.4218,2.56735910225953,31.6415,0.485863858978712,0.367564741299501,0.565091209212731,0.501032719802652,0.11829911767921,0.0640584894100793,True,0.768000060532699,0.0777395877736317,0.250621367036338,191.296964465036
1027,29180,1011:1080,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.266661434775163,0.077717319645014,0.821194649047461,11.9187449599461,0.7562,0.922522183400384,0.962507809912885,0.0747152457780849,0.218980943344683,0.148806434966373,0.0701745083783095,9.44646950957881,0.1363,2.47227545036733,0.6199,0.246001089037463,0.160733232635659,0.25666371357367,0.237096780793011,0.085267856401804,0.0195669327806593,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
1028,29181,1011:1085,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.740411991324534,0.0713295178826422,0.540103194902976,9.30778842885722,12.3781,0.864259663968979,0.882938101619011,0.186914860670442,0.399898882058855,0.345771874958834,0.0541270071000215,8.74689861869003,8.3909,0.560889810167186,3.9872,0.639908218820744,0.597377348489538,0.653737958036035,0.633341806804271,0.0425308703312062,0.0203961512317641,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
1029,29182,1011:1096,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.24579587206276,0.0704266525776884,0.869613292051256,12.633049129781,62.0336,0.933980865838574,0.973406377395633,0.0784669354739724,0.213747357477106,0.117013166695566,0.0967341907815403,8.81650402721749,4.4028,3.81654510256346,57.6308,0.229568641408724,0.129928467444566,0.239259269403412,0.211145467919959,0.0996401739641578,0.0281138014834528,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
1030,29182,1011:1129,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.24579587206276,0.0553058697797603,0.768819249995061,11.300697944975,49.2696,0.919622805125108,0.94997524576123,0.0620097463425607,0.188972598011173,0.107950242991804,0.0810223550193696,8.53194769568366,7.2294,2.76875024929137,42.0402,0.226039489354528,0.14388639635863,0.233499993969917,0.207396115092861,0.0821530929958983,0.0261038788770558,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
1031,29183,1011:1192,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.260377733563885,0.0832303328683097,0.81971358520452,11.8994951915649,74.6165,0.922980874438072,0.962164458127663,0.0800374647402247,0.213435165487079,0.104241342674859,0.10919382281222,8.2264587165617,5.8498,3.6730364750032,68.7667,0.240323668208998,0.140232822001943,0.250526200923004,0.215142852134232,0.100090846207055,0.0353833487887724,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
1032,28371,1011:1560,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.568281796452205,0.046803043998758,0.949907191500604,14.6337032149189,496.4936,0.975809475933723,0.99021507312249,0.115964014729536,0.539814965248832,0.271035232010287,0.268779733238544,8.82325666557403,8.847,5.81044654934487,487.6466,0.554534761978701,0.386274261898325,0.5627212006281,0.488368445939792,0.168260500080375,0.0743527546883074,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
1033,28372,1011:1564,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.597390796080047,0.0470437447968922,0.850512275168808,12.3287811812742,50.2381,0.956872377130198,0.969180713401667,0.0427846160037174,0.508088205138946,0.313470830716229,0.194617374422717,9.18957266486114,5.7021,3.13920851641302,44.536,0.571626751120816,0.495536592473523,0.578979637924449,0.524190304754122,0.0760901586472934,0.0547893331703275,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
1034,28373,1549:1909,Breast,HCC1428,SIDM00881,1290905,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.999855549861155,0.0633653837642667,0.906308775253849,13.344960210496,20.3219,0.952740957113031,0.981271694476122,0.0962479025497422,0.906177858825428,0.563174330327072,0.343003528498356,9.48704854774022,1.4016,3.85791166275578,18.9203,0.952603333549493,0.805041240640468,0.981129949643611,0.890767464677728,0.147562092909025,0.0903624849658825,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
1035,28373,1561:1909,Breast,HCC1428,SIDM00881,1290905,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.968851089145239,0.0633653837642667,0.906308775253849,13.344960210496,20.3219,0.952740957113031,0.981271694476122,0.0297595758118982,0.878078244006579,0.524149839677276,0.353928404329303,9.31471316549636,1.2438,4.03024704499963,19.0781,0.923064113972237,0.857648105117423,0.950706149940585,0.855740726405814,0.0654160088548142,0.094965423534771,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
1036,28373,1510:1909,Breast,HCC1428,SIDM00881,1290905,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.944808948962922,0.0633653837642667,0.906308775253849,13.344960210496,20.3219,0.952740957113031,0.981271694476122,0.0802334451310969,0.856288641383462,0.404352644391096,0.451935996992367,8.44452220435234,0.6804,4.90043800614365,19.6415,0.900158182323891,0.731987608744971,0.927114278305051,0.792584103817091,0.16817057357892,0.134530174487959,True,0.529839606693131,0.0464284488132228,0.610266617538589,80.0369465272855
1037,29180,1012:2169,Breast,HCC1428,SIDM00881,1290905,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.283718671163062,0.0438758973198862,0.921591943624623,13.7179261261406,263.1705,0.968199421446613,0.984454515275012,0.077926518918168,0.261472841599762,0.131617139338022,0.12985570226174,8.72305027230995,8.2533,4.99487585383061,254.9172,0.274696253273679,0.167748755333011,0.279308126894303,0.242332893051173,0.106947497940667,0.0369752338431299,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
1038,29180,1011:2169,Breast,HCC1428,SIDM00881,1290905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.266661434775163,0.0438758973198862,0.921591943624623,13.7179261261406,263.1705,0.968199421446613,0.984454515275012,0.0752471241721918,0.245753029964173,0.150854627771118,0.094898402193055,9.50620901773857,14.2031,4.21171710840199,248.9674,0.258181446871437,0.160186157194453,0.262516053514122,0.237788050161116,0.0979952896769833,0.0247280033530068,True,1.09371466975938,0.117913895939682,-0.102377456500339,-564.625261646695
1039,24002,1011:1038,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.128492178804365,0.101127236617676,0.642887971896542,11.1351903294162,43.9295,0.860582674090317,0.852183820190114,0.0402002399405824,0.0826060762361062,0.0571426395616851,0.0254634366744211,8.19360196919002,5.7181,2.94158836022618,38.2114,0.110578142835152,0.055895811489991,0.109498955798055,0.094250160827422,0.0546823313451608,0.0152487949706331,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
1040,24003,1011:1042,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.154588698479263,0.0710959058628726,0.746202177925533,12.9167075172778,151.0242,0.909250621897217,0.901462028989748,0.0511113006497757,0.1153544234879,0.0896127009320546,0.0257417225558453,10.1675364373827,22.4628,2.74917107989503,128.5614,0.140559870230552,0.0742501736250377,0.139355841790001,0.126510775872298,0.0663096966055139,0.012845065917703,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
1041,24004,1011:1051,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.118110956081537,0.132813878126938,0.569808823119777,10.0207843614992,20.2902,0.737829071141921,0.812790147113907,0.0436620525559202,0.0673006648823724,0.0593587192502535,0.0079419456321189,9.03729748129136,10.2619,0.983486880207799,10.0283,0.0871456970173248,0.0466156452471685,0.0959994213692768,0.0912209132246808,0.0405300517701563,0.0047785081445959,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
1042,23773,1012:1085,Breast,COLO-824,SIDM00954,906812,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.771316082736451,0.0959892504412896,0.684929087986472,11.8201288674562,70.6225,0.911771983685902,0.8730494118571,0.116618721772238,0.528296821097975,0.37528745094734,0.153009370150636,8.804631986185,8.7335,3.01549688127117,61.889,0.703264394805452,0.625451436417437,0.67339705238898,0.587738951571789,0.0778129583880154,0.0856581008171908,True,0.62116469445567,0.0716828660669558,0.459323519276856,106.226187185512
1043,23773,1011:1085,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.17702265278358,0.0959892504412896,0.684929087986472,11.8201288674562,70.6225,0.911771983685902,0.8730494118571,0.0347540345101908,0.121247964124003,0.0517885106864218,0.0694594534375815,5.79309106928985,1.083,6.02703779816631,69.5395,0.161404295285825,0.080037292979603,0.154549522898088,0.10721413061068,0.0813670023062222,0.0473353922874082,True,0.62116469445567,0.0716828660669558,0.459323519276856,106.226187185512
1044,23774,1372:1096,Breast,COLO-824,SIDM00954,906812,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.942350728400443,0.142665676861343,0.691555882540549,11.9322984387556,38.1663,0.8084724207238,0.876231702316605,0.117072328686686,0.651688189641697,0.460383086173328,0.191305103468369,8.83359967367558,4.4553,3.09869876508004,33.711,0.761864574560742,0.665030568589544,0.825717582925613,0.719294042813139,0.0968340059711986,0.106423540112473,True,0.62116469445567,0.0716828660669558,0.459323519276856,106.226187185512
1045,23774,1011:1096,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.218589896319167,0.142665676861343,0.691555882540549,11.9322984387556,38.1663,0.8084724207238,0.876231702316605,0.0980015095497688,0.151167128663449,0.0947131392851647,0.0564539893782843,8.02510937209786,2.5439,3.90718906665776,35.6224,0.176723902622922,0.0539167213024407,0.191535396960954,0.15854871982029,0.122807181320481,0.032986677140664,True,0.62116469445567,0.0716828660669558,0.459323519276856,106.226187185512
1046,24006,1011:1560,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.16466952826961,0.106188831566647,0.607978878564591,10.5937068942997,30.1824,0.795153198315271,0.833897848271777,0.0543415076210134,0.100115595131118,0.0753513721249118,0.0247642230062058,8.38244517076328,6.5177,2.21126172353641,23.6647,0.130937502068647,0.0671016140624645,0.137317565299956,0.122269624248779,0.0638358880061829,0.0150479410511777,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
1047,24007,1011:1564,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.200011797311372,0.0871932194805664,0.676263791191845,11.6753544978617,31.9398,0.850619023988854,0.868845681007224,0.0816421215050176,0.135260736332883,0.0778652764355653,0.057395459897318,7.36483003596265,1.6097,4.31052446189908,30.3301,0.170133839815256,0.0546252866096266,0.173779386244478,0.138402856304446,0.115508553205629,0.0353765299400319,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
1048,24008,1011:1632,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.201782176861376,0.0974260018113913,0.877332948138366,16.1451795797957,566.2046,0.92565175664426,0.955692129975677,0.0625222698695959,0.177030152107568,0.0958730961651052,0.0811570559424628,8.63843754005925,3.1133,7.50674203973642,563.0913,0.186780026471235,0.0930466668226238,0.192841638395777,0.152231828652264,0.0937333596486114,0.0406098097435132,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
1049,24008,1510:1909,Breast,COLO-824,SIDM00954,906812,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.601272067670247,0.100492686673153,0.353333157737576,6.80488959590683,0.2184,0.652166813770467,0.662223597363319,0.0708074157014995,0.21244935832933,0.122413374844757,0.090035983484573,4.04626647561022,0.0323,2.75862312029661,0.1861,0.392129688581685,0.260979909054567,0.398176551646672,0.302296615244198,0.131149779527118,0.0958799364024736,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
1050,24008,1021:1909,Breast,COLO-824,SIDM00954,906812,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.639385190987864,0.100492686673153,0.353333157737576,6.80488959590683,0.2184,0.652166813770467,0.662223597363319,0.0516518281183317,0.225915988542385,0.0988337712577758,0.127082217284609,2.82908613064498,0.0139,3.97580346526186,0.2045,0.416985802778577,0.228723678834902,0.423415961276816,0.275250192221614,0.188262123943675,0.148165769055202,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
1051,24008,1083:1909,Breast,COLO-824,SIDM00954,906812,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.653185125770195,0.100492686673153,0.353333157737576,6.80488959590683,0.2184,0.652166813770467,0.662223597363319,0.0743303524494679,0.230791963075599,0.107658472647809,0.123133490427789,3.10641734473563,0.0168,3.69847225117121,0.2016,0.425985662275809,0.248598472800186,0.43255460373175,0.291863829248435,0.177387189475623,0.140690774483316,True,0.565928555038378,0.0610135507893322,0.548003044388525,89.1023628595486
1052,23772,1011:2169,Breast,COLO-824,SIDM00954,906812,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.169032360679055,0.0950957469157578,0.743383041401528,12.862842278938,145.4894,0.870117409311307,0.900202427965327,0.0660009715037335,0.125655790376876,0.0843557711959149,0.0413000191809608,8.98621402655667,9.9049,3.8766282523813,135.5845,0.147077999763833,0.0612133630175979,0.152163341487996,0.130169679611605,0.0858646367462355,0.0219936618763907,True,0.62116469445567,0.0716828660669558,0.459323519276856,106.226187185512
1053,25003,1049:1013,Breast,CAL-148,SIDM00938,924106,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.99483026580583,0.113204002582084,0.7213806560262,11.3278742980883,50.2065,0.899565730020046,0.921666288193826,0.121772332816166,0.717651309781729,0.385409772985588,0.332241536796141,7.87878453271989,4.5971,3.44908976536844,45.6094,0.894915214305658,0.798996927016981,0.916901518468136,0.7703707049564,0.0959182872886769,0.146530813511736,True,0.532529058290825,0.0951136991230921,0.58840538390151,81.7022787053045
1054,25003,1561:1013,Breast,CAL-148,SIDM00938,924106,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.566736366338332,0.113204002582084,0.7213806560262,11.3278742980883,50.2065,0.899565730020046,0.921666288193826,0.0386812235048584,0.408832651743051,0.285996518624013,0.122836133119038,9.04539466814852,10.3197,2.28247962993982,39.8868,0.50981661311405,0.486060257701115,0.522341803147507,0.47415883975524,0.0237563554129342,0.0481829633922666,True,0.532529058290825,0.0951136991230921,0.58840538390151,81.7022787053045
1055,25441,1054:1042,Breast,CAL-148,SIDM00938,924106,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.90544692475043,0.121393626577099,0.792373171744402,12.2772331603269,96.9495,0.885626181372593,0.944127435868645,0.0638671687143236,0.717451851610713,0.772338826168838,-0.0548869745581244,13.3024538702311,197.3184,-1.02522070990413,-100.3689,0.80188750240228,0.860331760501,0.854857283379773,0.870857762478829,-0.0584442580987199,-0.0160004790990563,True,0.392728619687363,0.0747674562514498,0.88826692499863,55.0399055266655
1056,25441,1012:1042,Breast,CAL-148,SIDM00938,924106,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.374571726442875,0.121393626577099,0.792373171744402,12.2772331603269,96.9495,0.885626181372593,0.944127435868645,0.0975501749084984,0.296800586927317,0.123877245580772,0.172923341346545,7.27500744316645,3.025,5.00222571716048,93.9245,0.331730527739743,0.207497182168512,0.353643443635403,0.276217106101488,0.12423334557123,0.0774263375339145,True,0.392728619687363,0.0747674562514498,0.88826692499863,55.0399055266655
1057,29162,1011:1096,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.281871340001267,0.198386166315835,0.414774399477503,8.15759176250337,2.7886,0.685964130509473,0.790390731342839,0.081794376013192,0.116913015778945,0.0868081409657726,0.0301048748131719,7.01885788680247,1.2664,1.13873387570089,1.5222,0.193353628659509,0.139198578455669,0.222788494568187,0.203192700175412,0.05415505020384,0.0195957943927755,True,0.506210556802888,0.0758872663076725,0.653588914111242,74.7712202968833
1058,29162,1011:1129,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.281871340001267,0.0779069631230616,0.574235201748533,9.73202276956406,16.6097,0.865992937954338,0.867289746106231,0.0466484806781943,0.161860445792757,0.0736384649702367,0.0882219808225201,6.45637661982046,1.7151,3.2756461497436,14.8946,0.244098589852823,0.155509703427802,0.244464122904322,0.192489484249026,0.0885888864250213,0.0519746386552953,True,0.506210556802888,0.0758872663076725,0.653588914111242,74.7712202968833
1059,29162,1558:1129,Breast,CAL-148,SIDM00938,924106,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.994794952077488,0.0779069631230616,0.574235201748533,9.73202276956406,16.6097,0.865992937954338,0.867289746106231,0.104554327247811,0.571246280004639,0.346566561164334,0.224679718840305,7.46777095390448,3.4574,2.26425181565958,13.1523,0.861485403211729,0.765101688527219,0.862775461415045,0.745641438189812,0.0963837146845101,0.117134023225233,True,0.506210556802888,0.0758872663076725,0.653588914111242,74.7712202968833
1060,30667,1053:1560,Breast,CAL-148,SIDM00938,924106,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.78900785800848,0.0749572925297236,0.327659966652019,7.24113137009836,2.9548,0.760341817949629,0.73526078745793,0.0732583330128498,0.25852628844324,0.0548730702008311,0.203653218242409,2.65330838625799,0.1229,4.58782298384038,2.8319,0.599915669134711,0.310202581678016,0.580126538989809,0.313466534591967,0.289713087456695,0.266660004397843,True,0.474910258884972,0.0624969254260594,0.715510620813386,68.4171977900929
1061,30668,1012:1564,Breast,CAL-148,SIDM00938,924106,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.277263127431314,0.0497128065074787,0.93141347613742,15.3832430448604,417.3665,0.969621459940451,0.982916080426342,0.105780522396379,0.258246613325533,0.0730550760469428,0.18519153727859,6.48467321125923,0.8745,8.89856983360122,416.492,0.268840278407606,0.109799260336074,0.272526386461537,0.18988588467948,0.159041018071532,0.0826405017820565,True,0.474910258884972,0.0624969254260594,0.715510620813386,68.4171977900929
1062,30668,1011:1564,Breast,CAL-148,SIDM00938,924106,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.327813322180072,0.0497128065074787,0.93141347613742,15.3832430448604,417.3665,0.969621459940451,0.982916080426342,0.0752626204546044,0.305329745935897,0.145641660593189,0.159688085342707,8.45236249598093,3.4207,6.93088054887952,413.9458,0.317854832040171,0.208588097088121,0.322212985748774,0.264402452739332,0.10926673495205,0.0578105330094419,True,0.474910258884972,0.0624969254260594,0.715510620813386,68.4171977900929
1063,23753,1011:1013,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.407010449058274,0.110632761923569,0.76636826980744,12.6847898678446,128.5974,0.946132800513818,0.921202126898849,0.0579481830668074,0.311919893638339,0.161892401302006,0.150027492336333,7.71331025258835,4.0989,4.97147961525629,124.4985,0.385085936005892,0.254005547435426,0.374938891342538,0.298007291094076,0.131080388570465,0.0769316002484615,True,0.736730507296901,0.0706013932544102,0.288990505344406,165.690121335531
1064,24308,1011:1032,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.295931781289953,0.0763222254830528,0.706161646176403,11.7197837838716,65.8774,0.863009823706813,0.897176952809321,0.0740066132654221,0.208975673831629,0.139242962851875,0.0697327109797535,8.63384813426269,7.7585,3.08593564960895,58.1189,0.255392034400286,0.165903323266957,0.265503173777155,0.230748820748718,0.0894887111333292,0.0347543530284364,True,0.835536134961899,0.0932482516360093,0.163052550286689,282.012793113546
1065,24309,1011:1042,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.348106724597721,0.0809494601213323,0.858538978700826,14.5933566786154,482.801,0.940239575670921,0.95471657328842,0.123043657959683,0.298863191815017,0.180034393807343,0.118828798007674,9.21326589953702,11.5931,5.38009077907839,471.2079,0.327303719023955,0.186002368759304,0.332343259246592,0.280849062206824,0.141301350264651,0.0514941970397676,True,0.835536134961899,0.0932482516360093,0.163052550286689,282.012793113546
1066,24310,1011:1050,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.298540555291034,0.0609012460063724,0.728330097988092,12.0589827532316,83.3385,0.902982664247901,0.906241042730268,0.0759095422086109,0.217436071888538,0.0902968637045855,0.127139208183953,6.40803934436883,1.6586,5.65094340886273,81.6799,0.269576946002746,0.119322431230983,0.27054970412422,0.195936837739682,0.150254514771763,0.0746128663845376,True,0.835536134961899,0.0932482516360093,0.163052550286689,282.012793113546
1067,24310,1011:1051,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.298540555291034,0.0802521925062826,0.785138277904344,13.0196342854202,162.1924,0.884822982152515,0.928327033783249,0.0911353149423648,0.234395617465809,0.112468057456746,0.121927560009062,7.43829918761115,3.3875,5.58133509780903,158.8049,0.26415554442608,0.126715516560543,0.277143268157329,0.214042710082704,0.137440027865537,0.0631005580746258,True,0.835536134961899,0.0932482516360093,0.163052550286689,282.012793113546
1068,23757,1011:1085,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.463170168384529,0.0596497443915987,0.891103659809969,15.5203772669614,917.9714,0.981752015511787,0.965741971907444,0.07442296872491,0.412732632162253,0.236535590929821,0.176197041232432,9.13263616373888,10.963,6.38774110322255,907.0084,0.454718246336445,0.356624667823247,0.447302871744378,0.372001372238078,0.0980935785131979,0.0753014995063005,True,0.736730507296901,0.0706013932544102,0.288990505344406,165.690121335531
1069,23758,1011:1096,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.491714502384009,0.0785340274392974,0.840201042810825,14.1482873051648,177.3205,0.938351076956946,0.948330974307928,0.128444548193573,0.41313903766825,0.16467224292616,0.24846679474209,6.87169146227451,1.1436,7.27659584289027,176.1769,0.461400832867383,0.233739552794092,0.466308093127165,0.336465494144248,0.227661280073291,0.129842598982918,True,0.736730507296901,0.0706013932544102,0.288990505344406,165.690121335531
1070,23759,1011:1192,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.4498949048784,0.0860335555767862,0.797411618985631,13.2501966427028,190.2991,0.890069299789595,0.932898914012007,0.058721588180743,0.358751424472471,0.188235387663324,0.170516036809148,7.97838907771307,4.9257,5.27180756498976,185.3734,0.400437642964024,0.280749846017238,0.419706468180594,0.335814911671418,0.119687796946786,0.0838915565091764,True,0.736730507296901,0.0706013932544102,0.288990505344406,165.690121335531
1071,24312,1011:1553,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.239777185595395,0.069451516281356,0.767117934433524,12.6977918528253,129.7616,0.907999954783926,0.921489851923651,0.0855718106498387,0.183937379338223,0.11922100931749,0.0647163700207327,8.96545470362978,9.7634,3.73233714919547,119.9982,0.217717673678836,0.103349268475483,0.22095224324897,0.190742956191764,0.114368405203352,0.0302092870572061,True,0.835536134961899,0.0932482516360093,0.163052550286689,282.012793113546
1072,23756,1011:2169,Breast,HCC38,SIDM00675,749717,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.430251450309792,0.0661336601115262,0.798720713277555,13.2753937620208,193.6519,0.915489962835865,0.933382604689106,0.0413664863922079,0.343650745280139,0.217959074344245,0.125691670935894,9.08171270423559,10.5827,4.19368105778518,183.0692,0.393890884254188,0.312725443381391,0.401589219361419,0.34456681393362,0.0811654408727973,0.0570224054277986,True,0.736730507296901,0.0706013932544102,0.288990505344406,165.690121335531
1073,25068,1049:1013,Breast,MRK-nu-1,SIDM00562,908151,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.824880359062618,0.111320857656754,0.729031706914571,11.033211901723,40.9315,0.945262268088293,0.935661435077829,0.159979966010548,0.601363936167725,0.319830578764538,0.281533357403186,8.06144277920773,5.2175,2.97176912251527,35.714,0.779728279109016,0.681882490779185,0.771808740528044,0.666373046418186,0.0978457883298315,0.105435694109859,True,0.467811078910659,0.0676782117312176,0.737813918168036,66.7104404815887
1074,25069,1012:1030,Breast,MRK-nu-1,SIDM00562,908151,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.861696424885913,0.197991976433969,0.593777831729,9.7798377277611,17.1694,0.817478646507104,0.893995567257894,0.0444877295927004,0.511656234777388,0.46951538952926,0.0421408452481279,9.36973500562409,12.9212,0.41010272213701,4.2482,0.704418427115747,0.717130475814056,0.770352784169981,0.755342021767327,-0.0127120486983091,0.0150107624026538,True,0.467811078910659,0.0676782117312176,0.737813918168036,66.7104404815887
1075,25496,1021:1038,Breast,MRK-nu-1,SIDM00562,908151,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.787473764015529,0.123051342161273,0.286581199753291,7.12634601229304,2.7288,0.739448320919187,0.747158206800768,0.0746711764964982,0.22567517606581,0.18022271067164,0.0454524653941706,6.50449274000695,1.7733,0.621853272286086,0.9555,0.582296152569195,0.56446730362895,0.588367485424494,0.553054781962525,0.0178288489402444,0.0353127034619688,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
1076,25496,1594:1038,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.26665006173926,0.123051342161273,0.286581199753291,7.12634601229304,2.7288,0.739448320919187,0.747158206800768,0.0341128158176896,0.0764168946075262,0.0172351286103177,0.0591817659972085,3.51045803360652,0.2226,3.61588797868651,2.5062,0.197173940426093,0.0880430899573365,0.199229781972419,0.122391683519936,0.109130850468757,0.0768380984524833,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
1077,25498,1011:1050,Breast,MRK-nu-1,SIDM00562,908151,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.954254952507654,0.12742948910122,0.352255544853968,7.74862066568078,4.2005,0.734703796917381,0.788535403450693,0.107838816882482,0.336141598225181,0.119099711270968,0.217041886954212,4.99885130288067,0.6245,2.74976936280011,3.576,0.701094736834588,0.559776499158912,0.752463813970444,0.556605933218282,0.141318237675676,0.195857880752162,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
1078,25073,1594:1096,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.833681870067712,0.18011428802034,0.677075933976539,10.5209639061711,14.3491,0.789283359037132,0.92063867763658,0.181511089747212,0.564465930815404,0.259494908042477,0.304971022772927,7.36840627692902,1.6137,3.15255762924203,12.7354,0.658011226775401,0.534566411849754,0.767519774428729,0.636684062813596,0.123444814925647,0.130835711615134,True,0.467811078910659,0.0676782117312176,0.737813918168036,66.7104404815887
1079,25073,1049:1096,Breast,MRK-nu-1,SIDM00562,908151,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.861577939926596,0.18011428802034,0.677075933976539,10.5209639061711,14.3491,0.789283359037132,0.92063867763658,0.130720830814511,0.583353688369382,0.345773212188245,0.237580476181138,8.17837669191572,2.829,2.34258721425534,11.5201,0.680029130497556,0.611636344218087,0.79320197529487,0.702001478772411,0.0683927862794693,0.091200496522459,True,0.467811078910659,0.0676782117312176,0.737813918168036,66.7104404815887
1080,25500,1021:1560,Breast,MRK-nu-1,SIDM00562,908151,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.831225365004297,0.0673814432828828,0.896916832895422,13.4444145672121,217.7219,0.957716849317771,0.977831898673976,0.0117413147743976,0.745540021801995,0.65252588171658,0.0930141400854151,11.6606686692389,63.2326,1.78374589797318,154.4893,0.79607853764493,0.795232539266685,0.812798676888121,0.790251683636905,0.0008459983782455,0.0225469932512159,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
1081,25501,1510:1564,Breast,MRK-nu-1,SIDM00562,908151,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.990717095832567,0.0895730410607589,0.832277139658594,12.2907495960848,48.931,0.914817538104433,0.962602561203812,0.0717142140149137,0.824551190730398,0.624768718253883,0.199782472476515,10.0988443562193,10.7092,2.19190523986553,38.2218,0.906325374567522,0.83179253827274,0.953666813876832,0.89779626723415,0.0745328362947824,0.0558705466426819,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
1082,25502,1594:1909,Breast,MRK-nu-1,SIDM00562,908151,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.367798484916436,0.060269048410773,0.920321481277445,14.0264008390461,32.591,0.953307711941635,0.98307909645064,0.0380166558089478,0.338492846449894,0.20458401712114,0.133908829328754,9.46410342188319,1.3795,4.56229741716288,31.2115,0.350625132111287,0.294595159103835,0.361575002227564,0.323941443590339,0.0560299730074517,0.037633558637225,True,0.320451994521816,0.0452146751194436,1.09103231884115,45.1099532283496
1083,25071,1021:2169,Breast,MRK-nu-1,SIDM00562,908151,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.84917104799255,0.0868135699596218,0.7824948129935,11.6300986977245,61.9068,0.938429356782616,0.950052312873689,0.0623105430312031,0.664471940398425,0.627243641835733,0.0372282985626918,11.1344278114618,43.9063,0.495670886262674,18.0005,0.796887040366068,0.792105807088688,0.806756918170697,0.796800146316822,0.00478123327738,0.0099567718538742,True,0.467811078910659,0.0676782117312176,0.737813918168036,66.7104404815887
1084,25071,1012:2169,Breast,MRK-nu-1,SIDM00562,908151,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.896496706806776,0.0868135699596218,0.7824948129935,11.6300986977245,61.9068,0.938429356782616,0.950052312873689,0.0403255299474602,0.701504022942057,0.443299709409197,0.25820431353286,8.95463849446604,9.6905,2.67546020325848,52.2163,0.841298827926415,0.791278006891195,0.851718769785423,0.768236984318688,0.0500208210352208,0.083481785466735,True,0.467811078910659,0.0676782117312176,0.737813918168036,66.7104404815887
1085,29204,1049:1013,Breast,MCF7,SIDM00148,905946,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.979922067457235,0.135216813849994,0.523505959361381,9.25986537161124,11.9737,0.855161278935771,0.827901507690351,0.197032565935981,0.512995042023588,0.31294622785329,0.200048814170297,6.91009377737944,2.349,2.34977159423179,9.6247,0.837991408464115,0.739090924522374,0.811278957066891,0.686020591915049,0.0989004839417406,0.125258365151842,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1086,28334,1053:1025,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.763612971535716,0.0743482756706858,0.791774644365921,12.688797069251,128.9551,0.957497800679013,0.937455024909103,0.0695771077952042,0.604609388970896,0.496242216280798,0.108367172690098,10.7079660246507,32.67,1.98083104460035,96.2851,0.731157740815413,0.626728197352734,0.715852817251928,0.675737430616269,0.104429543462679,0.0401153866356591,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1087,28334,1561:1030,Breast,MCF7,SIDM00148,905946,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.668535683984527,0.041970143800195,0.878862531372301,14.4730402144876,444.1701,0.976737455101915,0.965354731712416,0.105797158043032,0.587550963539355,0.355610542805682,0.231940420733672,9.35315565755101,12.7735,5.11988455693663,431.3966,0.652983842619865,0.475522295588498,0.64537408585306,0.556281354478303,0.177461547031367,0.0890927313747569,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1088,29212,1510:1032,Breast,MCF7,SIDM00148,905946,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.824569698353262,0.121817457753569,0.701592311571629,11.3610292143226,51.3737,0.910517294986086,0.9052471640299,0.10416002603554,0.578511760719586,0.392875916871031,0.185635843848555,8.73977705588433,8.3496,2.62125215843828,43.0241,0.750784971272105,0.587950552887208,0.746439380979281,0.662338639315366,0.162834418384897,0.084100741663915,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1089,29212,1053:1032,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.913929144537864,0.121817457753569,0.701592311571629,11.3610292143226,51.3737,0.910517294986086,0.9052471640299,0.0847298342507952,0.641205661129001,0.431426104508043,0.209779556620958,8.69098094884243,8.0719,2.67004826548018,43.3018,0.832148292493563,0.738160699246024,0.827331766217174,0.73190082199644,0.0939875932475389,0.0954309442207338,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1090,29213,1021:1042,Breast,MCF7,SIDM00148,905946,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.818589412369067,0.0827396154882723,0.778781272568477,12.4759252093628,111.2648,0.914841588725094,0.933039812644713,0.0573207530564334,0.637502104275864,0.442593645538917,0.194908458736946,9.4503761691997,13.664,3.02554904016311,97.6008,0.748879638525258,0.654218272763126,0.763776511949779,0.684649738672367,0.0946613657621321,0.0791267732774127,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1091,29213,1053:1042,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.914066417385372,0.0827396154882723,0.778781272568477,12.4759252093628,111.2648,0.914841588725094,0.933039812644713,0.0679266767785399,0.711857807743489,0.501057276199127,0.210800531544362,9.53371725313331,14.4765,2.9422079562295,96.7883,0.836225973481088,0.75289576509867,0.852860358822071,0.767808254436657,0.0833302083824183,0.0850521043854142,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1092,29214,1058:1050,Breast,MCF7,SIDM00148,905946,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.944840232049887,0.085495506073784,0.770291103544719,12.3416398401727,101.3757,0.922101625273148,0.930116206627368,0.0983548789966695,0.727802025019156,0.695400562490065,0.0324014625290909,11.8315799982712,71.1853,0.510059841901487,30.1904,0.871238713596659,0.805351981241098,0.878811212503163,0.867346224487031,0.0658867323555611,0.0114649880161316,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1093,29214,1549:1050,Breast,MCF7,SIDM00148,905946,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.987144547255066,0.085495506073784,0.770291103544719,12.3416398401727,101.3757,0.922101625273148,0.930116206627368,0.0648223365597307,0.760388662663257,0.600034021872303,0.160354640790954,10.2104252705377,23.1406,2.13121456963496,78.2351,0.910247591403422,0.835531102860037,0.918159141685772,0.856088510231049,0.0747164885433848,0.0620706314547235,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1094,29214,1558:1050,Breast,MCF7,SIDM00148,905946,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.998225366934004,0.085495506073784,0.770291103544719,12.3416398401727,101.3757,0.922101625273148,0.930116206627368,0.110175548021968,0.768924119481926,0.487507805036234,0.281416314445693,8.87154812476305,9.1481,3.47009171540964,92.2276,0.920465233238729,0.822770564737429,0.928465591651868,0.808269196016215,0.0976946685013005,0.120196395635653,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1095,29214,1561:1050,Breast,MCF7,SIDM00148,905946,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.932435588185803,0.085495506073784,0.770291103544719,12.3416398401727,101.3757,0.922101625273148,0.930116206627368,0.092791614954528,0.718246838208011,0.525368569942697,0.192878268265314,9.7045932318767,16.2969,2.63704660829599,85.0788,0.859800371328652,0.733879178808608,0.867273452207737,0.789981888230003,0.125921192520044,0.0772915639777338,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1096,29214,1510:1050,Breast,MCF7,SIDM00148,905946,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.816958929605378,0.085495506073784,0.770291103544719,12.3416398401727,101.3757,0.922101625273148,0.930116206627368,0.105327543845797,0.629296195436439,0.206778798166566,0.422517397269873,6.01145756708437,1.26,6.33018227308832,100.1157,0.75331915677053,0.477607564018454,0.759866740574909,0.524109936122778,0.275711592752076,0.235756804452131,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1097,29214,1083:1050,Breast,MCF7,SIDM00148,905946,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.855942086833869,0.085495506073784,0.770291103544719,12.3416398401727,101.3757,0.922101625273148,0.930116206627368,0.0774153188505538,0.659324574637631,0.456741126045522,0.202583448592109,9.37187963625728,12.9404,2.96976020391541,88.4353,0.789265589409201,0.733633439586279,0.796125606898631,0.712932273182796,0.0556321498229218,0.0831933337158354,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1098,29214,1594:1050,Breast,MCF7,SIDM00148,905946,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.990990225918248,0.085495506073784,0.770291103544719,12.3416398401727,101.3757,0.922101625273148,0.930116206627368,0.0642701654970925,0.763350954724598,0.676372399526241,0.0869785551983567,11.1138307980031,43.2839,1.22780904216959,58.0918,0.91379369794902,0.893538522931085,0.921736069735879,0.88983696130538,0.0202551750179352,0.0318991084304988,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1099,29214,1053:1050,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.877430216585349,0.085495506073784,0.770291103544719,12.3416398401727,101.3757,0.922101625273148,0.930116206627368,0.127728129545639,0.675876689817011,0.264903712549881,0.41097297726713,6.68499885739391,2.0096,5.65664098277879,99.3661,0.809079828777121,0.535811786072524,0.816112064630595,0.601759962687794,0.273268042704596,0.214352101942801,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1100,29214,1012:1051,Breast,MCF7,SIDM00148,905946,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.947944096730787,0.0716021704055906,0.79466107903826,12.7373988411699,133.3734,0.928100928456706,0.938426341179264,0.103411213300204,0.753294278776036,0.507675136347511,0.245619142428526,9.39343294944464,13.1352,3.34396589172528,120.2382,0.879787796300897,0.717212128438044,0.889575710337555,0.790467085751662,0.162575667862852,0.0991086245858931,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1101,29214,1372:1051,Breast,MCF7,SIDM00148,905946,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.955538120321512,0.0716021704055906,0.79466107903826,12.7373988411699,133.3734,0.928100928456706,0.938426341179264,0.0840779806830192,0.759328953756884,0.48616464294605,0.273164310810834,9.09707283534992,10.696,3.64032600582,122.6774,0.886835816646171,0.729092251615635,0.896702142110628,0.783945641090982,0.157743565030536,0.112756501019646,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1102,29214,1021:1051,Breast,MCF7,SIDM00148,905946,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.881265080389016,0.0716021704055906,0.79466107903826,12.7373988411699,133.3734,0.928100928456706,0.938426341179264,0.0710946340639349,0.700307059700675,0.486346965076507,0.213960094624168,9.57512515880039,14.8981,3.16227368236953,118.4753,0.817902939325519,0.69408319950707,0.827002364998514,0.741819264459634,0.123819739818449,0.0851831005388807,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1103,29214,1011:1051,Breast,MCF7,SIDM00148,905946,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.947424983474051,0.0716021704055906,0.79466107903826,12.7373988411699,133.3734,0.928100928456706,0.938426341179264,0.114615204181008,0.752881759675296,0.330351669760273,0.422530089915022,7.27435237523046,3.0236,5.46304646593946,130.3498,0.879306006805346,0.606355762833587,0.889088560783379,0.684506951831038,0.272950243971759,0.204581608952341,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1104,29214,1561:1051,Breast,MCF7,SIDM00148,905946,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.932435588185803,0.0716021704055906,0.79466107903826,12.7373988411699,133.3734,0.928100928456706,0.938426341179264,0.0990619061627171,0.740970270641405,0.528962112263119,0.212008158378286,9.74790865471114,16.7936,2.98949018645878,116.5798,0.865394335121318,0.7236618402815,0.875022117406538,0.791655915609682,0.141732494839819,0.0833662017968558,True,0.315129368312542,0.0607799338606985,1.10129995646435,44.6207699056795
1105,28338,1058:1096,Breast,MCF7,SIDM00148,905946,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.852874745137688,0.0981430458388702,0.754351160746687,12.0986006389356,42.8294,0.889934379698219,0.924542229213482,0.0915005475466975,0.643367053966149,0.457653925773776,0.185713128192374,9.40506752678606,6.6208,2.69353311214958,36.2086,0.759002557274385,0.649297642995921,0.788518718109478,0.711628993017814,0.109704914278464,0.0768897250916648,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1106,28338,1054:1096,Breast,MCF7,SIDM00148,905946,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.966126732036028,0.0981430458388702,0.754351160746687,12.0986006389356,42.8294,0.889934379698219,0.924542229213482,0.111413541822863,0.728798821739781,0.501365138428062,0.227433683311719,9.20937130243176,5.7809,2.88922933650388,37.0485,0.85978939398435,0.731829372528146,0.893224962539325,0.797639176026382,0.127960021456204,0.0955857865129431,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1107,28338,1558:1096,Breast,MCF7,SIDM00148,905946,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.942034137867742,0.0981430458388702,0.754351160746687,12.0986006389356,42.8294,0.889934379698219,0.924542229213482,0.0606359463093301,0.710624545363535,0.567460766642454,0.143163778721081,10.1472018966617,11.0742,1.95139874227392,31.7552,0.838348566137876,0.772780947109337,0.870950341819443,0.814717430513587,0.0655676190285387,0.0562329113058559,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1108,28338,1561:1096,Breast,MCF7,SIDM00148,905946,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.754315594640164,0.0981430458388702,0.754351160746687,12.0986006389356,42.8294,0.889934379698219,0.924542229213482,0.111034844542746,0.569018844386135,0.382795952179705,0.18622289220643,9.08257839622098,5.2945,3.01602224271466,37.5349,0.671291380812788,0.535007326791474,0.697396621399111,0.618347839580426,0.136284054021314,0.0790487818186851,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1109,28338,1011:1096,Breast,MCF7,SIDM00148,905946,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.937869792917525,0.0981430458388702,0.754351160746687,12.0986006389356,42.8294,0.889934379698219,0.924542229213482,0.0771381066337831,0.70748316691659,0.383175691908767,0.324307475007823,7.9783509543581,2.4628,4.12024968457753,40.3666,0.834642572397755,0.676433544864916,0.867100229055956,0.71586132041881,0.158209027532839,0.151238908637145,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1110,28338,1510:1096,Breast,MCF7,SIDM00148,905946,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.731899214791462,0.0981430458388702,0.754351160746687,12.0986006389356,42.8294,0.889934379698219,0.924542229213482,0.118532097029937,0.552109022227528,0.323880997621251,0.228228024606277,8.36220487379387,3.2135,3.73639576514176,39.6159,0.651342273717054,0.48120477576014,0.676671731602896,0.573807291555177,0.170137497956914,0.102864440047719,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1111,28338,1053:1096,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.773612506556943,0.0981430458388702,0.754351160746687,12.0986006389356,42.8294,0.889934379698219,0.924542229213482,0.165313456692484,0.583575492289384,0.237365495051316,0.346209997238067,6.74916078029976,1.0505,5.34943985863588,41.7789,0.688464366149538,0.427795087459958,0.715237431359586,0.533726406718509,0.26066927868958,0.181511024641077,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1112,28338,1011:1129,Breast,MCF7,SIDM00148,905946,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.995221778314322,0.0612291970727675,0.792704550160268,12.7044001515571,130.3574,0.926386484209224,0.937768321347239,0.0755655552381933,0.788916832088356,0.574500197754278,0.214416634334078,9.86037717858759,18.1551,2.84402297296955,112.2023,0.921960004221056,0.824091002368582,0.933287456418036,0.849530643858299,0.0978690018524747,0.0837568125597369,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1113,28338,1053:1129,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.891145318759122,0.0612291970727675,0.792704550160268,12.7044001515571,130.3574,0.926386484209224,0.937768321347239,0.0329749445972512,0.706414949034378,0.483884762899722,0.222530186134656,9.47611445745858,13.9099,3.22828569409856,116.4475,0.825544978764771,0.737731043778348,0.835687849649192,0.746333983622984,0.0878139349864226,0.0893538660262079,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1114,28338,1021:1129,Breast,MCF7,SIDM00148,905946,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.791134184366344,0.0612291970727675,0.792704550160268,12.7044001515571,130.3574,0.926386484209224,0.937768321347239,0.105802634717772,0.627135667734533,0.405713868454747,0.221421799279786,9.141717469907,11.0322,3.56268268165014,119.3252,0.73289601559287,0.600709253435272,0.741900576033644,0.650704409661554,0.132186762157598,0.0911961663720903,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1115,28339,1558:1192,Breast,MCF7,SIDM00148,905946,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.972242069066553,0.076379374585718,0.578425487206261,9.87358967149196,18.3222,0.873772370480352,0.854141819082696,0.11658049479767,0.562369592482244,0.307027519591904,0.25534207289034,6.86466295397203,2.2761,3.00892671751993,16.0461,0.849518257369003,0.639427118738182,0.83043260946123,0.677869930546852,0.210091138630821,0.152562678914377,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1116,28345,1021:1564,Breast,MCF7,SIDM00148,905946,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.875194210605137,0.0551438904142998,0.895912446481613,14.9450511535411,308.0411,0.963699995282971,0.970501791890064,0.0616442172214864,0.784097386369792,0.729004730027109,0.0550926563426838,13.4375748388728,108.3461,1.50747631466823,199.695,0.843424656631853,0.796651704515816,0.849377549644096,0.83231155339122,0.0467729521160369,0.017065996252876,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1117,28346,1058:1632,Breast,MCF7,SIDM00148,905946,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.819071106723066,0.116798087564922,0.736032326021154,11.8320672949439,28.4838,0.873572905992545,0.917994293301499,0.126783718914682,0.602862811858099,0.376091222163242,0.226771589694857,8.54791580333714,2.9239,3.28415149160674,25.5599,0.715518326914599,0.567022529283193,0.751902601779917,0.65002295350198,0.148495797631406,0.101879648277937,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1118,28346,1012:1632,Breast,MCF7,SIDM00148,905946,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.822977648035081,0.116798087564922,0.736032326021154,11.8320672949439,28.4838,0.873572905992545,0.917994293301499,0.186967554181454,0.605738152546679,0.358823650135075,0.246914502411604,8.28915648988788,2.4439,3.542910805056,26.0399,0.718930975560916,0.530896401108449,0.755488784410894,0.642040159857768,0.188034574452467,0.113448624553126,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1119,28346,1011:1632,Breast,MCF7,SIDM00148,905946,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.926050216024247,0.116798087564922,0.736032326021154,11.8320672949439,28.4838,0.873572905992545,0.917994293301499,0.150999925102031,0.681602894512719,0.439841308249035,0.241761586263684,8.72320159654516,3.3017,3.10886569839873,25.1821,0.808972378307326,0.65131207091341,0.850108813620879,0.743092446369358,0.157660307393915,0.107016367251521,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1120,28346,1053:1632,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.740361231561774,0.116798087564922,0.736032326021154,11.8320672949439,28.4838,0.873572905992545,0.917994293301499,0.105135015892812,0.544929799362298,0.186940742779527,0.357989056582772,6.0025596140055,0.5009,5.82950768093838,27.9829,0.646759512539638,0.414262899431769,0.679647385555378,0.474525681301521,0.232496613107869,0.205121704253857,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1121,28346,1054:1909,Breast,MCF7,SIDM00148,905946,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.839053302333125,0.084789087286831,0.881376185349345,14.5388391831043,46.4897,0.94014765438328,0.966119613253681,0.17479453809482,0.73952159891514,0.264378813091826,0.475142785823314,6.85569110484942,0.2262,7.68314807825491,46.2635,0.788833994091032,0.486091471394704,0.810625851949303,0.584533596576023,0.302742522696328,0.226092255373279,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1122,28346,1058:1909,Breast,MCF7,SIDM00148,905946,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.819071106723066,0.084789087286831,0.881376185349345,14.5388391831043,46.4897,0.94014765438328,0.966119613253681,0.0813413433702043,0.721909767573442,0.58937157141645,0.132538196156992,11.6023897923139,6.0729,2.93644939079041,40.4168,0.770047779758807,0.679365360011541,0.791320660854553,0.746969227041299,0.0906824197472667,0.0443514338132532,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1123,28346,1558:1909,Breast,MCF7,SIDM00148,905946,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.8133223256329,0.084789087286831,0.881376185349345,14.5388391831043,46.4897,0.94014765438328,0.966119613253681,0.114180695969523,0.716842928825783,0.400004674689318,0.316838254136464,8.90957855659506,0.9392,5.62926062650926,45.5505,0.764643076701325,0.608650029988251,0.785766650691041,0.660045472409141,0.155993046713074,0.125721178281901,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1124,28346,1053:1909,Breast,MCF7,SIDM00148,905946,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.855421628874283,0.084789087286831,0.881376185349345,14.5388391831043,46.4897,0.94014765438328,0.966119613253681,0.0740829787224894,0.753948252122538,0.578158850175497,0.175789401947042,11.0295901726241,4.0829,3.50924901048019,42.4068,0.804222637894881,0.732953890963365,0.826439613256856,0.765884500707941,0.0712687469315164,0.060555112548915,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1125,28336,1054:2169,Breast,MCF7,SIDM00148,905946,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,1.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.899350697623081,0.100542325897339,0.538509319796986,9.42626234040903,13.4375,0.867172532546611,0.835321081128846,0.0807912544577774,0.484308732435951,0.261794316438438,0.222514415997513,6.54177874610086,1.8197,2.88448359430817,11.6178,0.779892222105369,0.597347984034273,0.751246597052494,0.608500975726362,0.182544238071095,0.142745621326132,True,0.13778728057532,0.0320565199110076,1.88104235225034,26.3278766532713
1126,24316,1049:1032,Breast,HCC1569,SIDM00878,907046,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.834374458426088,0.139760203552006,0.450724923123093,8.49037745695939,7.0241,0.73553879997657,0.801027318877183,0.146506363892007,0.376073363629971,0.125253557507731,0.25081980612224,4.53193156722213,0.4518,3.95844588973726,6.5723,0.613714787881825,0.401414940606132,0.668356735372651,0.450366000080151,0.212299847275693,0.217990735292499,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
1127,24316,1011:1032,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.163703599136669,0.139760203552006,0.450724923123093,8.49037745695939,7.0241,0.73553879997657,0.801027318877183,0.0588577536760813,0.0737852921358486,0.045046239477062,0.0287390526587866,6.50384429629333,1.7725,1.98653316066606,5.2516,0.120410348860831,0.058432201174075,0.131131055106991,0.11149759249688,0.0619781476867556,0.0196334626101109,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
1128,24317,1372:1042,Breast,HCC1569,SIDM00878,907046,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.947892462289355,0.0802899601877595,0.803863337928067,12.6354543927635,124.2742,0.926057539729396,0.945027942791654,0.0726792555034867,0.761975998732775,0.689753799552363,0.072222199180412,11.5329771074425,57.8765,1.10247728532103,66.3977,0.877802961555719,0.86071274852536,0.895784863625025,0.872111063789353,0.0170902130303593,0.0236737998356717,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
1129,24317,1011:1042,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.147297654516326,0.0802899601877595,0.803863337928067,12.6354543927635,124.2742,0.926057539729396,0.945027942791654,0.0472690180927376,0.118407184228469,0.0687784607306696,0.0496287234977998,8.65864247263173,7.893,3.97681192013181,116.3812,0.1364061035493,0.0784789741394218,0.1392003994256,0.119271819809425,0.0579271294098779,0.0199285796161747,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
1130,23750,1558:1096,Breast,HCC1569,SIDM00878,907046,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.805369717385001,0.0985476844823735,0.624072178611078,10.3063063017211,12.3654,0.822540048293046,0.881673071183442,0.0528673986745531,0.502608834115846,0.414731665279025,0.087877168836821,9.15424661646242,5.5642,1.1520596852587,6.8012,0.662448846231615,0.669760525287926,0.710072792164975,0.671615955416815,-0.0073116790563102,0.0384568367481596,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
1131,23750,1011:1096,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.218051038452907,0.0985476844823735,0.624072178611078,10.3063063017211,12.3654,0.822540048293046,0.881673071183442,0.0716509246448562,0.136079586615714,0.0938097614852584,0.0422698251304553,8.27591667539275,3.0269,2.03038962632837,9.3385,0.179355711699403,0.0993748771954917,0.192249728747514,0.172167777938392,0.0799808345039114,0.0200819508091217,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
1132,23750,1011:1129,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.218051038452907,0.0725602532828324,0.812604019450179,12.7808150951185,137.4481,0.959590330036905,0.947744247612733,0.0763564718332443,0.177189150292118,0.0965052801901135,0.0806838701020045,8.40545604620363,6.6225,4.3753590489149,130.8256,0.209239667953915,0.100309916998487,0.206656617379726,0.173686377773781,0.108929750955428,0.0329702396059445,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
1133,23751,1372:1192,Breast,HCC1569,SIDM00878,907046,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.958823736949957,0.0626031000963483,0.589701853132735,9.93483822006569,19.1168,0.841949919345631,0.86756385670135,0.0555495656315054,0.565420134507044,0.531146685168159,0.034273449338885,9.55840322608173,14.7264,0.376434993983967,4.3904,0.807281567991693,0.812809684397187,0.831840819125105,0.816938677615978,-0.0055281164054944,0.0149021415091266,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
1134,23751,1049:1192,Breast,HCC1569,SIDM00878,907046,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.721573800007407,0.0626031000963483,0.589701853132735,9.93483822006569,19.1168,0.841949919345631,0.86756385670135,0.0538127114701969,0.425513407036398,0.208811313771859,0.216702093264538,6.68468384507679,2.0092,3.2501543749889,17.1076,0.607529002718157,0.490420198194333,0.626011348829074,0.50017464514083,0.117108804523824,0.125836703688245,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
1135,24320,1083:1560,Breast,HCC1569,SIDM00878,907046,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.84628587039552,0.0549774825989829,0.529481664914374,9.30427443035751,12.348,0.858388418934675,0.840812332857722,0.0978220860882127,0.44809285165053,0.241134865267247,0.206957986383283,6.62865553421621,1.9327,2.6756188961413,10.4153,0.726441990255566,0.590431400443329,0.711567596951785,0.583472707407586,0.136010589812237,0.1280948895442,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
1136,24320,1011:1560,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.146633439834351,0.0549774825989829,0.529481664914374,9.30427443035751,12.348,0.858388418934675,0.840812332857722,0.0352714057596092,0.0776397178556141,0.0377869460315898,0.0398527718240242,6.27337912423189,1.5108,3.03089530612562,10.8372,0.125868446582362,0.0672936546739701,0.123291204622073,0.0975738990766902,0.0585747919083915,0.0257173055453831,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
1137,24320,1053:1560,Breast,HCC1569,SIDM00878,907046,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.949292709437247,0.0549774825989829,0.529481664914374,9.30427443035751,12.348,0.858388418934675,0.840812332857722,0.090172838536069,0.502633084283911,0.270841866673298,0.231791217610612,6.63340982303451,1.939,2.670864607323,10.409,0.814861867960053,0.632544454178774,0.79817701758676,0.654791309516797,0.182317413781279,0.143385708069963,True,0.769620794974068,0.10024655109279,0.246634271457924,193.158839126199
1138,23748,1510:2169,Breast,HCC1569,SIDM00878,907046,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.82958439088036,0.0790902289099556,0.753561566935814,11.8805411166134,73.6426,0.903522487347066,0.928813681857749,0.0645411260292303,0.625142913497297,0.404487645704186,0.220655267793111,8.87192416178888,9.1505,3.00861695482453,64.4921,0.749548152312524,0.631947922379398,0.770529332505306,0.680599993738759,0.117600229933125,0.0899293387665473,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
1139,23748,1011:2169,Breast,HCC1569,SIDM00878,907046,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.219553665424202,0.0790902289099556,0.753561566935814,11.8805411166134,73.6426,0.903522487347066,0.928813681857749,0.0744142643470538,0.165447204143563,0.0836330899559681,0.081814114187595,7.74842692629091,4.1999,4.1321141903225,69.4427,0.19837167389024,0.0921163590077684,0.203924448348018,0.166809203815299,0.106255314882472,0.0371152445327189,True,0.651986154406439,0.0772730352432496,0.407258196959781,118.640417855539
1140,26755,1058:1032,Breast,UACC-893,SIDM01186,909778,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.960757140061125,0.0979958685195143,0.0344988638953333,1.49858410209854,0.0552,0.315342474518601,0.306102338811245,0.0691519994444594,0.0331450298114384,0.0071739423400941,0.0259710874713442,-2.00938814664655,0.0049,3.5079722487451,0.0503,0.302967533958289,0.0827769079056322,0.294090007602313,0.105218225666332,0.220190626052657,0.188871781935981,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1141,26755,1012:1032,Breast,UACC-893,SIDM01186,909778,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.740937354150043,0.0979958685195143,0.0344988638953333,1.49858410209854,0.0552,0.315342474518601,0.306102338811245,0.0752769919080021,0.0255614969357907,0.0056285770444076,0.019932919891383,-1.97035256110752,0.005,3.46893666320607,0.0502,0.23364901872094,0.0912870176600774,0.226802657017944,0.0822559455136572,0.142362001060862,0.144546711504287,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1142,26755,1011:1032,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.77989077249665,0.0979958685195143,0.0344988638953333,1.49858410209854,0.0552,0.315342474518601,0.306102338811245,0.0521869700438494,0.0269053456135883,0.0045778772659288,0.0223274683476594,-2.55483976415086,0.0033,4.05342386624941,0.0519,0.245932686053317,0.0357585515123229,0.238726389478533,0.070313949229542,0.210174134540994,0.168412440248991,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1143,26755,1053:1032,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.544790051339185,0.0979958685195143,0.0344988638953333,1.49858410209854,0.0552,0.315342474518601,0.306102338811245,0.0839069565146364,0.0187946378326822,0.0035938917863599,0.0152007460463223,-2.29032031474224,0.004,3.78890441684079,0.0512,0.171795442882414,0.0256036306288674,0.166761508876023,0.0540303214194246,0.146191812253547,0.112731187456598,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1144,26755,1012:1038,Breast,UACC-893,SIDM01186,909778,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.962802426943286,0.0847867577776621,0.809029966538313,12.2505543811307,95.1731,0.978441659076196,0.952911203092049,0.124880701099415,0.778936015252933,0.680350873950762,0.0985851413021708,10.9793095071861,39.4304,1.27124487394457,55.7427,0.942046003980976,0.929718104966803,0.917465218998472,0.888586574272104,0.0123278990141739,0.0288786447263681,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1145,26755,1372:1038,Breast,UACC-893,SIDM01186,909778,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.755969497598651,0.0847867577776621,0.809029966538313,12.2505543811307,95.1731,0.978441659076196,0.952911203092049,0.103252632518742,0.611601977346222,0.238497372448423,0.373104604897799,7.25598326061504,2.9854,4.99457112051568,92.1877,0.739672049441422,0.607839952725794,0.720371803457623,0.563906031495953,0.131832096715628,0.15646577196167,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1146,26755,1011:1038,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.77989077249665,0.0847867577776621,0.809029966538313,12.2505543811307,95.1731,0.978441659076196,0.952911203092049,0.132657886630238,0.630955005576504,0.38933072898709,0.241624276589414,8.99290202902887,9.9509,3.25765235210184,85.2222,0.763077621339838,0.713603096159347,0.743166654300171,0.659964283256629,0.0494745251804911,0.083202371043542,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1147,26755,1558:1038,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.277586907755077,0.0847867577776621,0.809029966538313,12.2505543811307,95.1731,0.978441659076196,0.952911203092049,0.0457410624828784,0.224576126692564,0.0603117456760756,0.164264381016488,6.11437488476601,1.3531,6.1361794963647,93.82,0.271602594561709,0.1899824791858,0.264515674231493,0.184772691759531,0.0816201153759092,0.0797429824719611,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1148,26755,1549:1038,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.710851613194622,0.0847867577776621,0.809029966538313,12.2505543811307,95.1731,0.978441659076196,0.952911203092049,0.136652317425742,0.575100256836551,0.294066238600756,0.281034018235794,8.21474769856391,5.8025,4.0358066825668,89.3706,0.695526831771136,0.627612012767046,0.677378465949212,0.572232622229961,0.0679148190040898,0.10514584371925,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1149,26755,1561:1038,Breast,UACC-893,SIDM01186,909778,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.367107541289652,0.0847867577776621,0.809029966538313,12.2505543811307,95.1731,0.978441659076196,0.952911203092049,0.0511681116042051,0.29700100184553,0.255144541369202,0.0418564604763281,10.8544858926023,36.1623,1.39606848852842,59.0108,0.359193311758831,0.363350220562774,0.349820888834487,0.337461824172195,-0.0041569088039433,0.0123590646622923,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1150,26756,1558:1042,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.236995726311291,0.083491380811227,0.819763193402743,12.4104670227232,106.3293,0.933169133854744,0.955835793278371,0.0767328599078204,0.194280373423747,0.118076755933022,0.076203617490725,8.98399747079297,9.8897,3.42646955193023,96.4396,0.221157096649184,0.137103727396098,0.226528998062337,0.200448759016979,0.0840533692530861,0.0260802390453578,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1151,26756,1053:1042,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.443748697939561,0.083491380811227,0.819763193402743,12.4104670227232,106.3293,0.933169133854744,0.955835793278371,0.0706091532552391,0.363768849691244,0.231155599074259,0.132613250616984,9.18847663373639,11.3956,3.22199038898681,94.9337,0.41409258810543,0.317995367728509,0.424150888711304,0.379666746632452,0.0960972203769218,0.0444841420788522,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1152,26756,1049:1042,Breast,UACC-893,SIDM01186,909778,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.93269385182379,0.083491380811227,0.819763193402743,12.4104670227232,106.3293,0.933169133854744,0.955835793278371,0.137118232455952,0.764588090438175,0.549827118640717,0.214760971797458,9.81486098998635,17.5913,2.59560603273685,88.738,0.870361113858051,0.828226102162526,0.891502167743852,0.823431295489061,0.042135011695525,0.0680708722547911,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1153,26756,1561:1042,Breast,UACC-893,SIDM01186,909778,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.399642909092072,0.083491380811227,0.819763193402743,12.4104670227232,106.3293,0.933169133854744,0.955835793278371,0.0575116780925956,0.327612547378079,0.244309597904531,0.0833029494735472,10.019627480592,20.274,2.39083954213116,86.0553,0.372934427328638,0.317169295296918,0.381992997040096,0.356031861900014,0.0557651320317207,0.0259611351400824,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1154,26757,1058:1050,Breast,UACC-893,SIDM01186,909778,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.992294822840439,0.0649149197172569,0.791115273428704,11.998253563223,79.9032,0.942455802447936,0.947943564574353,0.027181404421037,0.785019590093302,0.755224726891969,0.0297948632013323,11.6087379641497,60.997,0.389515599073388,18.9062,0.935194013525019,0.939398205527754,0.940639491472042,0.932125551032907,-0.0042041920027354,0.0085139404391344,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1155,26757,1549:1050,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.454972638919991,0.0649149197172569,0.791115273428704,11.998253563223,79.9032,0.942455802447936,0.947943564574353,0.0537974312502359,0.359935803641767,0.196401084117097,0.16353471952467,8.38080317394975,6.5103,3.61745038927328,73.3929,0.428791603505195,0.320570165535598,0.431288385121616,0.370493268932134,0.108221437969597,0.0607951161894814,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1156,26757,1558:1050,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.459688529617997,0.0649149197172569,0.791115273428704,11.998253563223,79.9032,0.942455802447936,0.947943564574353,0.0485929580414175,0.363666616800781,0.210700882192277,0.152965734608503,8.62407873071746,7.7061,3.37417483250557,72.1971,0.433236122057241,0.384579945830902,0.435758783360027,0.380378250123076,0.0486561762263393,0.0553805332369508,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1157,26757,1561:1050,Breast,UACC-893,SIDM01186,909778,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.392044715225477,0.0649149197172569,0.791115273428704,11.998253563223,79.9032,0.942455802447936,0.947943564574353,0.0501803620512096,0.310152562081882,0.199629108994261,0.110523453087621,9.08286368535202,10.5912,2.91538987787102,69.312,0.369484816683299,0.342496176719819,0.371636264823376,0.333466880224796,0.0269886399634808,0.03816938459858,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1158,26757,1011:1050,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.809513882040078,0.0649149197172569,0.791115273428704,11.998253563223,79.9032,0.942455802447936,0.947943564574353,0.0709429833145795,0.640418796134468,0.416087773272628,0.22433102286184,9.12609144472592,10.9133,2.87216211849712,68.9899,0.762931055290825,0.698341989327844,0.767373474913494,0.690229560659002,0.064589065962981,0.0771439142544917,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1159,26757,1053:1050,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.443952433606499,0.0649149197172569,0.791115273428704,11.998253563223,79.9032,0.942455802447936,0.947943564574353,0.0446248886185746,0.351217550901944,0.162484854061535,0.188732696840409,7.76294513441642,4.2424,4.23530842880662,75.6608,0.418405547063327,0.30671013808363,0.420841852414404,0.345501871576261,0.111695408979697,0.0753399808381431,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1160,27096,1011:1080,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.805906192690569,0.0994855009616376,0.617970776481281,10.0828522427073,0.2118,0.850813222775624,0.893264988612287,0.0848475011486485,0.498026475668064,0.2947403741369,0.203286101531164,7.76031834806185,0.0423,2.32253389464541,0.1695,0.685675645057896,0.586074449135227,0.719887786036313,0.627059025579509,0.0996011959226688,0.092828760456804,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
1161,27096,1558:1080,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.254839404025676,0.0994855009616376,0.617970776481281,10.0828522427073,0.2118,0.850813222775624,0.893264988612287,0.02432748356091,0.157483304383774,0.141069246798657,0.0164140575851169,9.48423452129677,0.1399,0.598617721410502,0.0719,0.216820734629305,0.227084137352419,0.227639117334957,0.221449855090114,-0.010263402723114,0.0061892622448432,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
1162,27096,1058:1080,Breast,UACC-893,SIDM01186,909778,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.611692832681841,0.0994855009616376,0.617970776481281,10.0828522427073,0.2118,0.850813222775624,0.893264988612287,0.114875819884657,0.378008294780432,0.212906471237294,0.165101823543138,7.58701095430882,0.0376,2.49584128839845,0.1742,0.520436350322788,0.393328196461324,0.546403791219763,0.469348057627728,0.127108153861464,0.0770557335920344,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
1163,27096,1561:1080,Breast,UACC-893,SIDM01186,909778,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.231559398453341,0.0994855009616376,0.617970776481281,10.0828522427073,0.2118,0.850813222775624,0.893264988612287,0.0528692578112351,0.14309694126375,0.0579242483431768,0.0851726929205728,6.52824263347659,0.018,3.55460960923068,0.1938,0.197013798062072,0.117120270020912,0.206843903422492,0.161123716410331,0.0798935280411603,0.0457201870121608,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
1164,27098,1011:1129,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.657008404768725,0.074221812427024,0.525289764478902,9.22795555023535,11.7117,0.854100346459755,0.857430339075302,0.0468168436938438,0.345119790201623,0.194842775729331,0.150277014472292,7.05529904874536,2.5977,2.17265650148999,9.114,0.561151106139939,0.482348034686639,0.563338939276171,0.481279606269315,0.0788030714532997,0.0820593330068568,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
1165,27098,1058:1129,Breast,UACC-893,SIDM01186,909778,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.543372893320658,0.074221812427024,0.525289764478902,9.22795555023535,11.7117,0.854100346459755,0.857430339075302,0.142435516663771,0.285428219156628,0.289752480142079,-0.004324260985451,9.29987537423293,12.3104,-0.0719198239975825,-0.598699999999999,0.464094976442013,0.364005116198751,0.46590440416426,0.467703466362779,0.100089860243262,-0.0017990621985193,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
1166,27099,1011:1192,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.793163712106229,0.0996808592207224,0.56729212175613,9.60973590877211,15.2598,0.885443058890093,0.874379789863137,0.0580984123575731,0.449955525140711,0.124036500895401,0.325919024245309,5.20530227371983,0.7206,4.40443363505227,14.5392,0.702301303447961,0.439306727685579,0.693526319918511,0.472814704086404,0.262994575762382,0.220711615832106,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
1167,26759,1549:1553,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.369182846781486,0.0744263110590437,0.126642659458093,4.65238208074764,0.4912,0.556894528226654,0.552334342458035,0.0505060419788098,0.0467542975427169,0.0110396482095672,0.0357146493331497,1.16599307653861,0.0438,3.48638900420903,0.4474,0.205595907287748,0.0768196235160635,0.203912364923837,0.104341165587029,0.128776283771685,0.0995711993368082,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1168,26759,1558:1560,Breast,UACC-893,SIDM01186,909778,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.256374448871674,0.104780975545705,0.224943228419579,6.21467865411682,1.4506,0.698945582215939,0.673052126585912,0.0556110651457669,0.0576696962134845,0.0179041774857636,0.0397655187277209,3.17035635748619,0.1758,3.04432229663063,1.2748,0.179191788431903,0.0857839058936308,0.172553368015371,0.111150471429792,0.0934078825382717,0.0614028965855791,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1169,26759,1549:1560,Breast,UACC-893,SIDM01186,909778,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.639927886655244,0.104780975545705,0.224943228419579,6.21467865411682,1.4506,0.698945582215939,0.673052126585912,0.0770566223751939,0.143947444779949,0.0583674793248492,0.0855799654550996,3.82386865871805,0.2766,2.39080999539877,1.174,0.447274769314465,0.308119683789059,0.43070482497494,0.310901430129184,0.139155085525406,0.119803394845756,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1170,26760,1053:1564,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.797533886406168,0.111302175414479,0.590750102315213,9.82645673113497,8.8666,0.840380770101823,0.883318579149196,0.0914930874059945,0.471143224994293,0.276781627144892,0.1943615978494,7.57694060452525,1.8646,2.24951612660972,7.002,0.670232141640315,0.562804719805563,0.704476499363632,0.611436093788501,0.107427421834752,0.0930404055751313,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1171,26760,1561:1564,Breast,UACC-893,SIDM01186,909778,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.40771003046301,0.111302175414479,0.590750102315213,9.82645673113497,8.8666,0.840380770101823,0.883318579149196,0.0573644717515499,0.240854742210962,0.151049239195697,0.0898055030152642,7.80636111133475,2.186,2.02009561980022,6.6806,0.342631669378742,0.28779142092343,0.360137844813461,0.318379785592094,0.0548402484553123,0.0417580592213677,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1172,26760,1510:1564,Breast,UACC-893,SIDM01186,909778,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.927341924214814,0.111302175414479,0.590750102315213,9.82645673113497,8.8666,0.840380770101823,0.883318579149196,0.120189539761645,0.547827336611087,0.294729874515031,0.253097462096056,7.28029795505095,1.5181,2.54615877608402,7.3485,0.779320320419352,0.619891696347226,0.81913835088291,0.693224077533545,0.159428624072126,0.125914273349365,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1173,26760,1011:1564,Breast,UACC-893,SIDM01186,909778,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.798256867612161,0.111302175414479,0.590750102315213,9.82645673113497,8.8666,0.840380770101823,0.883318579149196,0.0701571756053538,0.471570326215705,0.143271565297827,0.328298760917878,5.57798951669219,0.4665,4.24846721444278,8.4001,0.670839721142977,0.474260450474703,0.705115122095262,0.498965528493527,0.196579270668274,0.206149593601735,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1174,26760,1594:1564,Breast,UACC-893,SIDM01186,909778,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.876777566620832,0.111302175414479,0.590750102315213,9.82645673113497,8.8666,0.840380770101823,0.883318579149196,0.0492510678556574,0.51795643718894,0.507656776083751,0.0102996611051887,9.7175161557539,8.2217,0.108940575381068,0.6449,0.736827006644818,0.789490563609913,0.774473914377403,0.770588065395555,-0.0526635569650949,0.0038858489818482,True,0.845567190608253,0.0948709381444209,0.145801217251947,303.587155424171
1175,27523,1053:1909,Breast,UACC-893,SIDM01186,909778,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.769898880423952,0.0664687716040618,0.918271730829021,14.4466224158972,43.6111,0.954383289390446,0.981039069196327,0.126191961834174,0.706976377490228,0.590106166429179,0.116870211061049,11.6759194687526,6.3905,2.77070294714467,37.2206,0.734778625997033,0.608545896287829,0.755300881026409,0.724417903728483,0.126232729709205,0.030882977297926,True,1.18067733215172,0.113658977316676,-0.180505218992649,-305.228865526021
1176,27096,1012:2169,Breast,UACC-893,SIDM01186,909778,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.726259516865457,0.105392649496166,0.259281020256053,6.6365660080599,1.9433,0.731669124792043,0.703532645167825,0.0724620675757767,0.188305308503544,0.0611547966113313,0.127150511892212,3.62668055640686,0.2413,3.00988545165305,1.702,0.531381665076841,0.321419182220849,0.510947278978661,0.341343630427678,0.209962482855992,0.169603648550983,True,0.759942519724141,0.0720124927544811,0.256498819929855,184.690351758114
1177,29164,1011:1013,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.399791982835201,0.167189577673611,0.374046243423469,7.83487370955993,4.4593,0.832169599538118,0.781993642776085,0.0471101032841535,0.149540689330327,0.0524800488699581,0.0970606404603688,4.72371943495095,0.5161,3.11115427460898,3.9432,0.332694734254519,0.205079187072901,0.312634789009972,0.223036703414401,0.127615547181618,0.0895980855955709,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
1178,28726,1561:1030,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.801044395541848,0.0819917949551204,0.8896983617352,13.7240352509153,264.2873,0.93607985489056,0.973891244834089,0.0657612610423667,0.712687886390746,0.57533898739624,0.137348898994506,11.1173983421746,43.3911,2.60663690874071,220.8962,0.74984152153971,0.746562868490066,0.780130123541621,0.741908525596961,0.003278653049644,0.0382215979446602,True,0.209215131890064,0.0424920144814723,1.50958538614663,32.8051673366155
1179,29166,1049:1032,Breast,CAL-51,SIDM00933,910927,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.925823373202073,0.0971714834035144,0.707494171684332,10.9986358688766,39.9622,0.938593638039068,0.922824022684189,0.0648584360529591,0.655014640549595,0.621307426651366,0.0337072138982291,10.6136323087724,30.6021,0.385003560104217,9.3601,0.868971928035336,0.84981330308696,0.854372049553382,0.843496345611385,0.0191586249483765,0.0108757039419968,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
1180,29166,1561:1032,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.948056801804104,0.0971714834035144,0.707494171684332,10.9986358688766,39.9622,0.938593638039068,0.922824022684189,0.127130791197283,0.670744661702092,0.450478752932974,0.220265908769118,8.7749804170602,8.5558,2.22365545181644,31.4064,0.889840082672998,0.825409232718563,0.87488959157397,0.791259658215005,0.064430849954435,0.0836299333589651,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
1181,29166,1012:1032,Breast,CAL-51,SIDM00933,910927,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.832173776875914,0.0971714834035144,0.707494171684332,10.9986358688766,39.9622,0.938593638039068,0.922824022684189,0.119929820517846,0.588758096968247,0.359421477199952,0.229336619768295,8.37981202157254,6.5059,2.6188238473041,33.4563,0.781073012718676,0.720867087307429,0.767949952348925,0.677040984375234,0.0602059254112468,0.0909089679736911,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
1182,29166,1011:1032,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.762167920113632,0.0971714834035144,0.707494171684332,10.9986358688766,39.9622,0.938593638039068,0.922824022684189,0.110357310759336,0.539229361325165,0.320287481453764,0.218941879871401,8.27177409849822,6.0365,2.72686177037842,33.9257,0.715365960936124,0.648782630125766,0.703346866000103,0.615491025687552,0.0665833308103584,0.0878558403125512,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
1183,29166,1011:1038,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.762167920113632,0.0697585741724306,0.627018746064749,10.1754249332583,22.5859,0.896431786299474,0.895991038131437,0.104852298545238,0.477893573560428,0.27047953521877,0.207414038341658,7.64762050868657,3.9165,2.52780442457172,18.6694,0.683231550087618,0.580919456333589,0.682895625973091,0.5872333900769,0.102312093754029,0.0956622358961909,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
1184,29166,1561:1038,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.948056801804104,0.0697585741724306,0.627018746064749,10.1754249332583,22.5859,0.896431786299474,0.895991038131437,0.0887138991495479,0.594449387065366,0.422604458862465,0.171844928202901,8.50710319086101,7.106,1.66832174239728,15.4799,0.849868252354619,0.825655418579447,0.849450398056029,0.777910394329552,0.024212833775172,0.0715400037264775,True,0.350958335207378,0.0449826280107119,0.991316499570475,49.3515852834387
1185,23847,1058:1050,Breast,CAL-51,SIDM00933,910927,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.942691125648322,0.0568679101556498,0.785099858035723,11.9318117571702,76.3068,0.9345939063717,0.945996750614978,0.0544590800978844,0.740106668918033,0.640514039667743,0.0995926292502903,10.6999713138844,32.4894,1.23184044328576,43.8174,0.881033381621601,0.856200284085534,0.891782741696889,0.861460238146798,0.0248330975360669,0.030322503550091,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
1186,23847,1049:1050,Breast,CAL-51,SIDM00933,910927,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.942412873421143,0.0568679101556498,0.785099858035723,11.9318117571702,76.3068,0.9345939063717,0.945996750614978,0.0301186694345347,0.739888213133977,0.611097237876584,0.128790975257392,10.3852717610262,26.1221,1.54653999614401,50.1847,0.880773328785645,0.858534057400787,0.891519515994125,0.851422560034333,0.0222392713848579,0.0400969559597926,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
1187,23847,1558:1050,Breast,CAL-51,SIDM00933,910927,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.96310427629708,0.0568679101556498,0.785099858035723,11.9318117571702,76.3068,0.9345939063717,0.945996750614978,0.0821449900337695,0.756133030594435,0.616047712566398,0.140085318028037,10.2984967423474,24.5972,1.63331501482284,51.7096,0.900111387827777,0.861140239157428,0.911093515880427,0.867196679854341,0.0389711486703486,0.0438968360260857,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
1188,23847,1561:1050,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.874037645553958,0.0568679101556498,0.785099858035723,11.9318117571702,76.3068,0.9345939063717,0.945996750614978,0.0511196058028679,0.686206831442289,0.429930663774982,0.256276167667307,8.92659021035998,9.5039,3.00522154681022,66.8029,0.816870257474197,0.736756187744222,0.82683677260921,0.73615802845595,0.0801140697299744,0.0906787441532597,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
1189,23847,1011:1050,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.923551219373611,0.0568679101556498,0.785099858035723,11.9318117571702,76.3068,0.9345939063717,0.945996750614978,0.109979952734548,0.725079931218941,0.142405697991783,0.582674233227158,5.14847318063556,0.6927,6.78333857653464,75.6141,0.86314534184873,0.56088482997337,0.873676452553936,0.546214579027702,0.30226051187536,0.327461873526234,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
1190,23847,1510:1050,Breast,CAL-51,SIDM00933,910927,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.977524653143835,0.0568679101556498,0.785099858035723,11.9318117571702,76.3068,0.9345939063717,0.945996750614978,0.0549794270315867,0.767454466409644,0.560957361010387,0.206497105399257,9.67341217898327,15.9484,2.25839957818693,60.3584,0.913588584156338,0.845138617009119,0.924735145520101,0.856645738506968,0.0684499671472188,0.0680894070131332,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
1191,23847,1053:1050,Breast,CAL-51,SIDM00933,910927,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.95176896192929,0.0568679101556498,0.785099858035723,11.9318117571702,76.3068,0.9345939063717,0.945996750614978,0.045633031003746,0.747233676893493,0.528651452692907,0.218582224200586,9.50388638182326,14.1803,2.42792537534694,62.1265,0.889517472092833,0.814682419234171,0.900370345321299,0.827199275379338,0.0748350528586624,0.0731710699419609,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
1192,23847,1058:1051,Breast,CAL-51,SIDM00933,910927,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.942691125648322,0.118792547279117,0.575330176590918,9.68706890436125,16.1001,0.79328916912695,0.876910722681429,0.16384220880391,0.54235865178994,0.420629165867962,0.121729485921978,8.51114951649836,7.1259,1.17591938786289,8.9742,0.747826659808907,0.644954151780431,0.82665595625764,0.773713393337336,0.102872508028476,0.0529425629203045,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
1193,23847,1594:1051,Breast,CAL-51,SIDM00933,910927,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.884685561185945,0.118792547279117,0.575330176590918,9.68706890436125,16.1001,0.79328916912695,0.876910722681429,0.125187675889002,0.508986300144545,0.306950437783776,0.202035862360769,7.56891804428987,3.7085,2.11815086007139,12.3916,0.701811473771808,0.59576700678183,0.775790254805393,0.677262849616078,0.106044466989977,0.0985274051893145,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
1194,23847,1011:1051,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.916248035697975,0.118792547279117,0.575330176590918,9.68706890436125,16.1001,0.79328916912695,0.876910722681429,0.123339547498862,0.527145144179197,0.0535717505719586,0.473573393607238,2.71154597420571,0.1279,6.97552293015555,15.9722,0.726849642953046,0.356875073098262,0.803467727139351,0.364329316081959,0.369974569854784,0.439138411057392,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
1195,23847,1561:1051,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.874037645553958,0.118792547279117,0.575330176590918,9.68706890436125,16.1001,0.79328916912695,0.876910722681429,0.0897851906728452,0.502860232963668,0.273528672130067,0.229331560833601,7.22057310003783,2.913,2.46649580432342,13.1871,0.693364597627175,0.587633801765722,0.766452983413496,0.649434493277082,0.105730795861453,0.117018490136414,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
1196,23550,1011:1080,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.71174886085315,0.0709368848961427,0.688688180856109,10.7966751734383,0.3474,0.898350363420463,0.91683240982217,0.0794233389551666,0.490173028207364,0.174760141880623,0.315412886326741,6.45982764807907,0.0172,4.33684752535922,0.3302,0.639399847811528,0.483330754184854,0.652554423284179,0.491427352218671,0.156069093626674,0.161127071065508,True,0.712052186993795,0.0594619573924292,0.310434235108037,150.6425287284
1197,23550,1561:1080,Breast,CAL-51,SIDM00933,910927,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.924786910587501,0.0709368848961427,0.688688180856109,10.7966751734383,0.3474,0.898350363420463,0.91683240982217,0.064476298640437,0.636889815132047,0.59962873063306,0.0372610844989867,10.3848515996454,0.2611,0.411823573792923,0.0863,0.830782657212769,0.826428966617506,0.847874611805938,0.835484981486314,0.0043536905952625,0.0123896303196239,True,0.712052186993795,0.0594619573924292,0.310434235108037,150.6425287284
1198,25015,1011:1096,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.874186728695784,0.140966738287399,0.502059753863198,9.01864362515612,5.065,0.757131628623728,0.846769444866781,0.0859436244805392,0.43889397383948,0.0388291952218841,0.400064778617595,2.05607153126065,0.0406,6.96257209389546,5.0244,0.661874421618688,0.282726162081925,0.740234610967636,0.303745576920174,0.379148259536763,0.436489034047462,True,0.135415023081001,0.0304704527633978,1.89014286052259,26.1886554136554
1199,25015,1049:1096,Breast,CAL-51,SIDM00933,910927,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.861919687457297,0.140966738287399,0.502059753863198,9.01864362515612,5.065,0.757131628623728,0.846769444866781,0.16031354693578,0.432735186134655,0.19158289891379,0.241152287220865,6.1658924239645,0.7012,2.85275120119161,4.3638,0.652586656707398,0.485082455867449,0.729847255267964,0.576663631978838,0.167504200839949,0.153183623289127,True,0.135415023081001,0.0304704527633978,1.89014286052259,26.1886554136554
1200,25016,1011:1192,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.909719520769137,0.0858121757060902,0.584394694113401,9.77126545064595,17.0677,0.870873542440895,0.880375261527799,0.112461210976293,0.53163526106887,0.196001974887355,0.335633286181515,6.07559879198038,1.3172,3.69566665866557,15.7505,0.792250661679852,0.609499648804428,0.800894561014074,0.602565979680184,0.182751012875424,0.19832858133389,True,0.135415023081001,0.0304704527633978,1.89014286052259,26.1886554136554
1201,23849,1011:1553,Breast,CAL-51,SIDM00933,910927,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.860689541485231,0.0867283176812034,0.59233420258821,9.84544728027052,17.9682,0.818383973608264,0.883366837158531,0.0533367405560844,0.509815853231667,0.304682078298492,0.205133774933175,7.63887660648082,3.8928,2.20657067378971,14.0754,0.704374527003758,0.647791807715686,0.760304598037235,0.662672421693966,0.0565827192880723,0.0976321763432687,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
1202,23849,1594:1553,Breast,CAL-51,SIDM00933,910927,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.999135331042764,0.0867283176812034,0.59233420258821,9.84544728027052,17.9682,0.818383973608264,0.883366837158531,0.0935623392858224,0.591822029590923,0.338252802152483,0.253569227438441,7.48439363475504,3.4975,2.36105364551548,14.4707,0.817676342391185,0.723748673874668,0.882603017276588,0.759518851866266,0.093927668516517,0.123084165410322,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
1203,23849,1083:1560,Breast,CAL-51,SIDM00933,910927,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.910101176671378,0.0551639691087999,0.713686951429103,11.0667784639075,41.895,0.909590442577674,0.924762828375212,0.0613385092413264,0.649527334270635,0.361574762085224,0.287952572185411,8.05692658782699,5.2012,3.00985187608051,36.6938,0.82781933207898,0.741899358060101,0.841627738246232,0.723728635678435,0.085919974018879,0.117899102567797,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
1204,23849,1021:1560,Breast,CAL-51,SIDM00933,910927,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.812672320568609,0.0551639691087999,0.713686951429103,11.0667784639075,41.895,0.909590442577674,0.924762828375212,0.0824941233402252,0.579993630977425,0.480037068614505,0.0999565623629203,9.8300452699933,17.7774,1.23673319391419,24.1176,0.739198975736627,0.666575641932617,0.751529153711274,0.717386806112849,0.0726233338040091,0.0341423475984258,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
1205,23849,1510:1560,Breast,CAL-51,SIDM00933,910927,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.911253959881742,0.0551639691087999,0.713686951429103,11.0667784639075,41.895,0.909590442577674,0.924762828375212,0.0472224830623939,0.650350060605698,0.42339160732115,0.226958453284548,8.67927557053865,8.0067,2.38750289336885,33.8883,0.828867892669491,0.746482576520337,0.842693789308351,0.756037314252307,0.082385316149154,0.0866564750560448,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
1206,23849,1053:1560,Breast,CAL-51,SIDM00933,910927,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.952958844607207,0.0551639691087999,0.713686951429103,11.0667784639075,41.895,0.909590442577674,0.924762828375212,0.057249465950778,0.680114292645117,0.559188690680705,0.120925601964412,9.79362002414173,17.3342,1.27315843976577,24.5608,0.866802257224578,0.822996286878196,0.881260916464135,0.839826198664562,0.0438059703463813,0.0414347177995725,True,0.260785824546488,0.0393796232250331,1.28727706727948,38.3190151167901
1207,25434,1011:1051,Breast,BT-549,SIDM00122,905951,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.767133698976271,0.143589212112984,0.550191767345068,9.62236014105678,15.3939,0.740578900682727,0.825175338253242,0.146748969905273,0.422070645629714,0.301249757922028,0.120820887707686,7.6530003675246,3.9311,1.96935977353217,11.4628,0.56812303146452,0.462555696886195,0.633019809538205,0.559581332193417,0.105567334578325,0.0734384773447875,True,0.48007583420443,0.0691850781264327,0.685633043817425,70.3849554459059
1208,25820,1011:1096,Breast,BT-549,SIDM00122,905951,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.749244494442054,0.0661670683798372,0.699713739450885,11.6134918229426,30.5992,0.86685078354703,0.89484576084017,0.105634479035463,0.524256666969038,0.32504709591389,0.199209571055148,8.17749378878301,2.8273,3.4359980341596,27.7719,0.649483177075393,0.493553145149478,0.670458259684309,0.567513710037465,0.155930031925915,0.102944549646844,True,0.439260134971284,0.057859028021508,0.790167407202078,62.0287632637178
1209,25820,1011:1129,Breast,BT-549,SIDM00122,905951,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.749244494442054,0.0697770664749921,0.772494938626431,12.7767328667245,137.0597,0.91739212941428,0.923805846142441,0.0490895023181182,0.578787579750206,0.417200920481529,0.161586659268677,9.70533152490853,16.3052,3.07140134181602,120.7545,0.687351002208122,0.602268903083157,0.692156444155608,0.620842738221404,0.0850820991249646,0.0713137059342035,True,0.439260134971284,0.057859028021508,0.790167407202078,62.0287632637178
1210,25821,1011:1192,Breast,BT-549,SIDM00122,905951,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.61508693601468,0.0795748210144357,0.355175542755858,7.15754470713406,2.7885,0.667832522206211,0.701482350502756,0.0747212078072444,0.218463836341051,0.0734082202487035,0.145055616092348,2.82526877374702,0.1384,4.33227593338705,2.6501,0.410775059854774,0.217641993562136,0.431472629639116,0.259513505738899,0.193133066292638,0.171959123900217,True,0.439260134971284,0.057859028021508,0.790167407202078,62.0287632637178
1211,23863,1049:1050,Breast,HCC1143,SIDM00866,749710,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.90284298145202,0.076894057780015,0.730528569218744,12.4913029159708,112.4571,0.923128566530212,0.897424810866889,0.0752404861685796,0.659552591469329,0.608476568223646,0.0510760232456831,11.5419988811323,58.2395,0.949304034838484,54.2176,0.833440147269667,0.810994375094243,0.810233691872077,0.786795220572671,0.0224457721754231,0.0234384712994056,True,0.847673427917615,0.0918835434609086,0.141300080327203,308.738200919289
1212,23866,1049:1564,Breast,HCC1143,SIDM00866,749710,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.850816990713152,0.0791645367192591,0.650238779557799,11.1707664992594,22.5131,0.842609765409259,0.859980287078269,0.0472375003691937,0.553234201668359,0.548489110275371,0.0047450913929876,11.0852307767354,21.2171,0.0855357225240105,1.296,0.716906704951021,0.710340332167927,0.731685839924565,0.729340993173095,0.0065663727830932,0.0023448467514696,True,0.847673427917615,0.0918835434609086,0.141300080327203,308.738200919289
1213,23866,1012:1564,Breast,HCC1143,SIDM00866,749710,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.640994602744477,0.0791645367192591,0.650238779557799,11.1707664992594,22.5131,0.842609765409259,0.859980287078269,0.113735018024015,0.416799548191705,0.230944872405538,0.185854675786167,6.99023065804686,1.2416,4.18053584121257,21.2715,0.540108311847125,0.374934503635062,0.551242722483816,0.433724384036652,0.165173808212063,0.117518338447164,True,0.847673427917615,0.0918835434609086,0.141300080327203,308.738200919289
1214,25085,1011:1025,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.752739731467924,0.120724013973701,0.736487785830934,11.2852749304554,48.7457,0.892152545918138,0.932876384514609,0.113459423899151,0.554383618135783,0.359427106624668,0.194956511511115,8.79967934337061,8.7036,2.48559558708478,40.0421,0.671558667842844,0.616695217947326,0.702213119172294,0.631045901574551,0.0548634498955176,0.0711672175977436,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
1215,25085,1053:1025,Breast,Hs-578-T,SIDM00135,905957,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.705853850980849,0.120724013973701,0.736487785830934,11.2852749304554,48.7457,0.892152545918138,0.932876384514609,0.0421286665058914,0.519852739829123,0.384800811727737,0.135051928101386,9.40271518860077,13.2199,1.88255974185463,35.5258,0.629729310198686,0.594122584283645,0.658474388498728,0.612089689486709,0.035606725915041,0.0463846990120192,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
1216,26772,1011:1042,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.827332173834478,0.130569947883041,0.625039145652219,10.1361808923523,21.9798,0.898774871501426,0.896990273767775,0.171849234768403,0.517114995104095,0.274217333457263,0.242897661646832,7.43990854432666,3.3913,2.69627234802563,18.5885,0.743585368227078,0.640108201070152,0.742108913104677,0.628279591498086,0.103477167156926,0.113829321606591,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
1217,26773,1011:1050,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.82383710854052,0.136034089430592,0.390497115499369,8.01005625207837,5.035,0.826545292755736,0.794750618403388,0.0526864051623423,0.321706014526414,0.0565179678451702,0.265188046681244,3.20040415390562,0.1795,4.80965209817274,4.8555,0.680938684061664,0.347134687237726,0.654745051476238,0.35881969897011,0.333803996823937,0.295925352506128,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
1218,26773,1011:1051,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.82383710854052,0.199978364511154,0.310274077516982,7.22380069713128,2.9195,0.648555188145882,0.745224313340452,0.148109626331529,0.255615298876668,0.0156742089308408,0.239941089945827,0.233388878839388,0.023,6.9904118182919,2.8965,0.534303830931056,0.223743389192578,0.613943443516493,0.181213526354666,0.310560441738478,0.432729917161827,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
1219,26773,1561:1051,Breast,Hs-578-T,SIDM00135,905957,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.914132727498124,0.199978364511154,0.310274077516982,7.22380069713128,2.9195,0.648555188145882,0.745224313340452,0.179594020079659,0.283631688752563,0.0864770098191281,0.197154678933435,3.97778881426932,0.3077,3.24601188286196,2.6118,0.592865523072854,0.423328976824076,0.681233934151824,0.455423611187393,0.169536546248778,0.225810322964431,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
1220,25856,1011:1085,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.964679061781894,0.123511045505695,0.479465923505854,8.81726895668408,8.8103,0.891341016719987,0.839228368192228,0.161022768062437,0.462530737244016,0.25350752106203,0.209023216181986,6.70643762274455,2.0397,2.11083133393953,6.7706,0.859858015737157,0.698023080012068,0.809586034848428,0.684627532728869,0.161834935725089,0.124958502119559,True,0.267097541031162,0.0635120476940969,1.2666714972128,38.9519367860063
1221,25089,1011:1096,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.869035276830005,0.118549345391759,0.649553003543763,10.3720525892893,12.9419,0.83862247642194,0.905395450807786,0.121050705226093,0.564484474250415,0.103401596902737,0.461082877347678,4.54841162987612,0.2285,5.8236409594132,12.7134,0.728792515953205,0.427155719224635,0.786820586233371,0.473010079927624,0.30163679672857,0.313810506305746,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
1222,25089,1058:1129,Breast,Hs-578-T,SIDM00135,905957,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.69141589500502,0.0978982500476824,0.835258516359628,12.6095136265453,122.0596,0.937571042302476,0.960462167837388,0.0513672005318098,0.577511014649357,0.481708170072214,0.0958028445771432,10.8490969664782,36.0275,1.76041666006711,86.0321,0.648251521344356,0.63398615937338,0.664078809393749,0.636599255114424,0.0142653619709762,0.0274795542793246,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
1223,27077,1049:1192,Breast,Hs-578-T,SIDM00135,905957,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.844154652572654,0.120953862935701,0.526751459751899,9.2381525405697,11.7948,0.790504930851237,0.859682943628311,0.0893780562844754,0.444659695499002,0.282929720909501,0.161729974589501,7.47708826662957,3.4798,1.76106427394012,8.315,0.667308415259696,0.640847377181946,0.725705356601193,0.643078712652425,0.02646103807775,0.0826266439487675,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
1224,27077,1011:1192,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.785325700143283,0.120953862935701,0.526751459751899,9.2381525405697,11.7948,0.790504930851237,0.859682943628311,0.115860052787428,0.413671458931156,0.161885087185222,0.251786371745934,6.00193620972098,1.2517,3.23621633084872,10.5431,0.620803838287465,0.453954418440929,0.675131109606142,0.516904217064483,0.166849419846536,0.158226892541659,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
1225,26775,1049:1560,Breast,Hs-578-T,SIDM00135,905957,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.619971365136852,0.1072228457132,0.498925823273003,8.99044635218944,9.934,0.825513955462705,0.847875259956889,0.0703623858964001,0.309319723756592,0.126930336934019,0.182389386822573,5.98284272275435,1.2352,3.00760362943509,8.6988,0.511795013907736,0.428923278732161,0.525658382381236,0.407175722004226,0.0828717351755749,0.11848266037701,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
1226,26776,1561:1564,Breast,Hs-578-T,SIDM00135,905957,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.867436187164528,0.137681426396964,0.622424420457146,10.1114086796666,10.8028,0.817057276219375,0.896074708010054,0.116086045659964,0.539913466079438,0.327759156478795,0.212154309600643,7.89116975214062,2.3183,2.22023892752603,8.4845,0.708745048378769,0.627769420496103,0.777287628130809,0.683225419822306,0.0809756278826655,0.0940622083085025,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
1227,26776,1011:1564,Breast,Hs-578-T,SIDM00135,905957,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.703616027524183,0.137681426396964,0.622424420457146,10.1114086796666,10.8028,0.817057276219375,0.896074708010054,0.0541270293403209,0.437947798156099,0.223934737068161,0.214013061087938,7.30622731278806,1.5456,2.80518136687859,9.2572,0.574894594953206,0.523620856578812,0.630492526414927,0.528191227939739,0.051273738374394,0.102301298475188,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
1228,26776,1053:1564,Breast,Hs-578-T,SIDM00135,905957,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.652641897853152,0.137681426396964,0.622424420457146,10.1114086796666,10.8028,0.817057276219375,0.896074708010054,0.0725840686130515,0.4062202550373,0.205894523470173,0.200325731567127,7.27762891018891,1.5153,2.83377976947774,9.2875,0.533245811406539,0.44808195030154,0.58481589805389,0.488694648216962,0.0851638611049989,0.0961212498369288,True,0.475170786745362,0.083764377779771,0.702567472245077,69.0740616224605
1229,27078,1049:1632,Breast,Hs-578-T,SIDM00135,905957,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.665472666647804,0.0850842804174838,0.894714726016267,13.7578678779333,108.2233,0.935440857359884,0.975554941607511,0.152268974986235,0.595408194611105,0.361131262396283,0.234276932214822,9.38041793137842,5.2069,4.3774499465549,103.0164,0.62251032183859,0.487191842762217,0.649205148452993,0.576409635114761,0.135318479076373,0.0727955133382319,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
1230,27078,1561:1632,Breast,Hs-578-T,SIDM00135,905957,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.92131080819315,0.0850842804174838,0.894714726016267,13.7578678779333,108.2233,0.935440857359884,0.975554941607511,0.168347832350096,0.82431034732836,0.706143381332236,0.118166965996124,11.64238532592,24.9745,2.11548255201332,83.2488,0.861831772311127,0.719459220340532,0.898789311689237,0.867518610785224,0.142372551970595,0.031270700904013,True,0.365803862566113,0.0690380380611123,0.965328189521898,50.911055800263
1231,25087,1021:2169,Breast,Hs-578-T,SIDM00135,905957,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.734826726995058,0.108455492900088,0.389047070466104,7.99650086578741,4.9879,0.760134773759731,0.793946661556034,0.0739651982911166,0.285882185437623,0.204924836307555,0.0809573491300674,6.88758783705137,2.3126,1.10891302873604,2.6753,0.558567347876992,0.53469947414091,0.583413226719874,0.530821715232423,0.0238678737360822,0.0525915114874509,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
1232,25087,1049:2169,Breast,Hs-578-T,SIDM00135,905957,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.806271985844106,0.108455492900088,0.389047070466104,7.99650086578741,4.9879,0.760134773759731,0.793946661556034,0.0695988310126715,0.313677754091537,0.227526241203434,0.0861515128881033,6.92416614566556,2.372,1.07233472012185,2.6159,0.612875373548418,0.579837333941937,0.640136951467081,0.584472062205392,0.0330380396064817,0.0556648892616891,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
1233,25087,1012:2169,Breast,Hs-578-T,SIDM00135,905957,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.69370122544001,0.108455492900088,0.389047070466104,7.99650086578741,4.9879,0.760134773759731,0.793946661556034,0.162070426276191,0.269882429536182,0.0862046586454926,0.183677770890689,4.65838734413599,0.4932,3.33811352165142,4.4947,0.52730642405669,0.345515612376786,0.550761772055426,0.383710088144755,0.181790811679905,0.167051683910671,True,0.532116710634315,0.107457460561628,0.588859162781535,81.6206801907577
1234,23596,1053:1013,Breast,MDA-MB-361,SIDM00528,908121,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1013,Nilotinib,ABL,ABL signaling,Targeted,FDA approved,10.0,0.573462894007447,0.0765745949788281,0.858795524032739,13.7402430584615,267.2732,0.956327594097672,0.96098623188681,0.0275778566443876,0.492487366572457,0.447366145142811,0.045121221429646,12.3250038920346,100.2134,1.41523916642693,167.0598,0.54841838973043,0.523824735199838,0.551089945639122,0.537011353815456,0.0245936545305925,0.014078591823666,True,0.616140688182289,0.0701054918648606,0.453927077406696,105.569384254758
1235,25483,1561:1032,Breast,MDA-MB-361,SIDM00528,908121,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.431051333916104,0.192065937036644,0.305262358113954,6.84071796190257,2.2387,0.613562431287046,0.701369467516364,0.0648964299119472,0.131583746659395,0.0198907185607511,0.111693028098644,1.0474457856398,0.0404,5.79327217626278,2.1983,0.264476904447089,0.0846987648492333,0.302326244540956,0.125624876161799,0.179778139597856,0.176701368379158,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1236,25483,1058:1032,Breast,MDA-MB-361,SIDM00528,908121,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.479467096061974,0.192065937036644,0.305262358113954,6.84071796190257,2.2387,0.613562431287046,0.701369467516364,0.0500887023280757,0.146363256381928,0.0241709422363392,0.122192314145588,1.29146253843882,0.0478,5.54925542346375,2.1909,0.294182997181924,0.107458247454853,0.336283581856604,0.147308134754793,0.186724749727071,0.188975447101812,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1237,25483,1510:1032,Breast,MDA-MB-361,SIDM00528,908121,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.928146430029684,0.192065937036644,0.305262358113954,6.84071796190257,2.2387,0.613562431287046,0.701369467516364,0.101280419013336,0.283328167905909,0.0594747299401007,0.223853437965808,1.95939776829128,0.076,4.88132019361129,2.1627,0.569475780199405,0.298659267082742,0.650973567407134,0.326929181353281,0.270816513116662,0.324044386053853,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1238,25483,1012:1032,Breast,MDA-MB-361,SIDM00528,908121,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.382412970564966,0.192065937036644,0.305262358113954,6.84071796190257,2.2387,0.613562431287046,0.701369467516364,0.159541527518239,0.116736285168023,0.0320063232967124,0.0847299618713109,2.71626494215493,0.1284,4.12445301974764,2.1103,0.234634231975542,0.120403700047665,0.268212781536501,0.155167619344197,0.114230531927876,0.113045162192304,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1239,25483,1011:1032,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.673575347055991,0.192065937036644,0.305262358113954,6.84071796190257,2.2387,0.613562431287046,0.701369467516364,0.0621149069439039,0.205617198809736,0.016215561879125,0.189401636930611,-0.721043875803908,0.0118,7.56176183770648,2.2269,0.413280527594689,0.107280862119405,0.472425182496811,0.127925221773432,0.305999665475285,0.344499960723378,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1240,25483,1021:1032,Breast,MDA-MB-361,SIDM00528,908121,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.990011991314927,0.192065937036644,0.305262358113954,6.84071796190257,2.2387,0.613562431287046,0.701369467516364,0.176539376821766,0.302213395029885,0.112073844550778,0.190139550479107,3.59520056447174,0.236,3.24551739743083,2.0027,0.607434164394516,0.435068590042432,0.694364183183366,0.465346752019701,0.172365574352084,0.229017431163665,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1241,25483,1594:1032,Breast,MDA-MB-361,SIDM00528,908121,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.89625880737499,0.192065937036644,0.305262358113954,6.84071796190257,2.2387,0.613562431287046,0.701369467516364,0.124857490821305,0.273594077019689,0.174903673762895,0.0986904032567945,5.27964820464164,0.7587,1.56106975726094,1.48,0.549910732915427,0.495748287341056,0.628608562485448,0.532329376970215,0.054162445574371,0.0962791855152332,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1242,25483,1053:1032,Breast,MDA-MB-361,SIDM00528,908121,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.599392274998963,0.192065937036644,0.305262358113954,6.84071796190257,2.2387,0.613562431287046,0.701369467516364,0.0682360592366487,0.182971899301471,0.015547299947652,0.167424599353819,-0.52014699352653,0.0136,7.3608649554291,2.2251,0.367764581543037,0.0952097155104991,0.420395440749445,0.119990403124494,0.272554866032538,0.300405037624951,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1243,25483,1058:1038,Breast,MDA-MB-361,SIDM00528,908121,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.813883669251709,0.102421690264968,0.54814127755713,9.50719039391484,14.2128,0.876245781334066,0.84689454836738,0.0738023480231237,0.446123234246517,0.243803219326556,0.202320014919961,6.76968374314146,2.1311,2.73750665077337,12.0817,0.713162131678501,0.551722056034553,0.689273642494512,0.567081537655791,0.161440075643947,0.122192104838721,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1244,25483,1011:1038,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.673575347055991,0.102421690264968,0.54814127755713,9.50719039391484,14.2128,0.876245781334066,0.84689454836738,0.0766672557485883,0.369214451266258,0.142162976169402,0.227051475096856,5.53783903618536,0.9074,3.96935135772948,13.3054,0.590217556268442,0.406328687555986,0.570447289336384,0.412533935781197,0.183888868712456,0.157913353555188,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1245,25483,1561:1038,Breast,MDA-MB-361,SIDM00528,908121,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.431051333916104,0.102421690264968,0.54814127755713,9.50719039391484,14.2128,0.876245781334066,0.84689454836738,0.0386332368238506,0.236277028865478,0.0924261478398498,0.143850881025628,5.59056390150536,0.9411,3.91662649240947,13.2717,0.377706912882408,0.250271330087531,0.365055024760035,0.265615942388972,0.127435582794877,0.0994390823710638,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1246,25483,1053:1038,Breast,MDA-MB-361,SIDM00528,908121,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.637653077555808,0.102421690264968,0.54814127755713,9.50719039391484,14.2128,0.876245781334066,0.84689454836738,0.0579849599999652,0.349523972569676,0.153508852476988,0.196015120092688,5.98405029385434,1.2363,3.5231401000605,12.9765,0.558740819162961,0.420641249425976,0.540024915131696,0.410549536020227,0.138099569736985,0.129475379111469,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1247,25484,1561:1042,Breast,MDA-MB-361,SIDM00528,908121,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.400239231752748,0.0844929428788114,0.813320804152199,12.8643397620389,145.6405,0.909878255113932,0.947078559766717,0.0848478512325568,0.325522893822403,0.218618695399637,0.106904198422766,9.48683083409499,14.0136,3.37750892794387,131.6269,0.364168973815331,0.270780571665667,0.37905799517053,0.338606123196975,0.0933884021496637,0.0404518719735548,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1248,25484,1011:1042,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.591263363164089,0.0844929428788114,0.813320804152199,12.8643397620389,145.6405,0.909878255113932,0.947078559766717,0.0968281092592387,0.480886793994351,0.320838037953847,0.160048756040504,9.44883922357007,13.6494,3.41550053846879,131.9911,0.537977677188537,0.432860169675464,0.559972854428271,0.499231897178333,0.105117507513072,0.0607409572499381,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1249,25484,1053:1042,Breast,MDA-MB-361,SIDM00528,908121,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.412110164783795,0.0844929428788114,0.813320804152199,12.8643397620389,145.6405,0.909878255113932,0.947078559766717,0.138043944992874,0.335177770621252,0.192566648414657,0.142611122206595,8.65574864957849,7.8772,4.20859111246037,137.7633,0.374970077648195,0.213830425349702,0.390300701328661,0.332482720501035,0.161139652298492,0.0578179808276266,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1250,25485,1058:1050,Breast,MDA-MB-361,SIDM00528,908121,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.777018189324341,0.0750848822973631,0.758381254330325,12.0033478140406,80.1859,0.913583532342182,0.929230167607891,0.111817513909132,0.589276029057272,0.442288278738347,0.146987750318925,9.73162104217476,16.605,2.2717267718658,63.5809,0.709871022097058,0.610813766881579,0.722028742300237,0.665447896498291,0.0990572552154786,0.0565808458019464,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1251,25485,1561:1050,Breast,MDA-MB-361,SIDM00528,908121,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.405995118734907,0.0750848822973631,0.758381254330325,12.0033478140406,80.1859,0.913583532342182,0.929230167607891,0.0553488843702358,0.307899087398168,0.184377688450666,0.123521398947502,8.51695871534661,7.1547,3.48638909869395,73.0312,0.37091045468752,0.294046220429159,0.377262912230023,0.32465298873501,0.0768642342583615,0.0526099234950137,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1252,25485,1012:1050,Breast,MDA-MB-361,SIDM00528,908121,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.321442392179286,0.0750848822973631,0.758381254330325,12.0033478140406,80.1859,0.913583532342182,0.929230167607891,0.0778678447292041,0.243775884575868,0.138103045835442,0.105672838740426,8.25603615387583,5.971,3.74731166016474,74.2149,0.293664476091674,0.227202649908609,0.29869396796104,0.252588114627302,0.0664618261830647,0.0461058533337381,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1253,25485,1011:1050,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.613986884076635,0.0750848822973631,0.758381254330325,12.0033478140406,80.1859,0.913583532342182,0.929230167607891,0.0938277606967598,0.465636143288407,0.179104449623239,0.286531693665168,6.67071958132208,1.9898,5.33262823271848,78.1961,0.560928306366502,0.385078283162216,0.570535135199578,0.423826513418752,0.175850023204287,0.146708621780826,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1254,25485,1053:1050,Breast,MDA-MB-361,SIDM00528,908121,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.391934863631903,0.0750848822973631,0.758381254330325,12.0033478140406,80.1859,0.913583532342182,0.929230167607891,0.0451840940738006,0.297236053496947,0.170145277377795,0.127090776119152,8.30398729297679,6.1728,3.69936052106377,74.0131,0.358065237164885,0.269056176016742,0.364197699024049,0.308995243630196,0.0890090611481432,0.0552024553938524,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1255,25485,1011:1051,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.613986884076635,0.126672608075352,0.775445126397463,12.2540814982586,95.4061,0.878824317307112,0.934904758385257,0.178529403348992,0.476113136929191,0.128096324914378,0.348016812014813,5.49940737979009,0.8835,6.75467411846856,94.5226,0.53958660423417,0.278816728630873,0.574019259509384,0.374356139725404,0.260769875603297,0.19966311978398,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1256,25485,1558:1051,Breast,MDA-MB-361,SIDM00528,908121,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.698304292555218,0.126672608075352,0.775445126397463,12.2540814982586,95.4061,0.878824317307112,0.934904758385257,0.106862653343804,0.541496660404372,0.281046985751918,0.260449674652454,7.96237061159058,4.8713,4.29171088666807,90.5348,0.613686793177466,0.45484568078996,0.652848005910725,0.537368505338474,0.158841112387506,0.115479500572251,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1257,25485,1561:1051,Breast,MDA-MB-361,SIDM00528,908121,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.405995118734907,0.126672608075352,0.775445126397463,12.2540814982586,95.4061,0.878824317307112,0.934904758385257,0.0687956326102861,0.314826936164143,0.302149874826542,0.0126770613376009,11.8043094719945,69.8524,0.449772026264151,25.5537,0.356798383052225,0.319203193602474,0.379566768386452,0.375312467432061,0.0375951894497507,0.0042543009543913,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1258,25867,1011:1080,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.641774037367772,0.0772825835907859,0.644021673654293,10.5566822805304,0.2942,0.853819504321094,0.887662656393671,0.102406793410606,0.413316389653465,0.146106483173135,0.26720990648033,5.79251784451355,0.0108,4.7641644360169,0.2834,0.547959190471499,0.360765973294417,0.569678846814368,0.404620696109258,0.187193217177082,0.16505815070511,True,0.515683554896602,0.0592523699019833,0.644583472804719,76.3402472101585
1259,23600,1011:1085,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.715514304829782,0.1325631550124,0.562118156187598,9.65580392012805,15.7549,0.904264480288444,0.853246234912593,0.165568190712213,0.402203581756768,0.170735259293594,0.231468322463173,5.9534831089139,1.2103,3.70232081121415,14.5446,0.64701417099585,0.48938975577354,0.610509886622113,0.459160934950436,0.157624415222311,0.151348951671677,True,0.616140688182289,0.0701054918648606,0.453927077406696,105.569384254758
1260,23601,1011:1129,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.767381284341832,0.0725007104491622,0.743306792400865,11.7917213835743,69.2456,0.916718523785211,0.924113052829429,0.128799878561181,0.570399721012584,0.318450450538227,0.251949270474357,8.09832771537289,5.3527,3.69339366820136,63.8929,0.703472638162244,0.633261142997749,0.709147061357299,0.596370048136985,0.0702114951644955,0.112777013220314,True,0.616140688182289,0.0701054918648606,0.453927077406696,105.569384254758
1261,23602,1510:1192,Breast,MDA-MB-361,SIDM00528,908121,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.83129944565825,0.0639266096098773,0.697225885014939,11.1901596086667,45.6356,0.915949005023611,0.907822112425253,0.0712923767533552,0.579603491711501,0.452502392626191,0.12710109908531,9.4668306247447,13.8207,1.72332898392203,31.8149,0.761427900127353,0.724840750939229,0.754672018815414,0.70256124927443,0.0365871491881239,0.052110769540984,True,0.616140688182289,0.0701054918648606,0.453927077406696,105.569384254758
1262,23602,1011:1192,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.730673659301597,0.0639266096098773,0.697225885014939,11.1901596086667,45.6356,0.915949005023611,0.907822112425253,0.0495786019929643,0.50944458876366,0.17327120629921,0.336173382464449,5.93204854066679,1.1925,5.25811106799994,44.4431,0.669259811234258,0.462129085570064,0.663321704880665,0.467799325055519,0.207130725664194,0.195522379825146,True,0.616140688182289,0.0701054918648606,0.453927077406696,105.569384254758
1263,25487,1012:1560,Breast,MDA-MB-361,SIDM00528,908121,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.471022816357278,0.0895599087498145,0.203873760412817,5.42311516924246,0.838,0.624269019761853,0.604257935818701,0.0632601972759985,0.096029192810994,0.0232878937688282,0.0727412990421658,1.23771223831535,0.0461,4.18540293092711,0.7919,0.294044951852825,0.122891051077297,0.28461927473556,0.143059900936636,0.171153900775529,0.141559373798924,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1264,25487,1011:1560,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.679278760853154,0.0895599087498145,0.203873760412817,5.42311516924246,0.838,0.624269019761853,0.604257935818701,0.0313209095305953,0.138487115343691,0.0462332837107674,0.0922538316329239,2.12894336520675,0.0854,3.29417180403571,0.7526,0.424052686182845,0.231014163314801,0.410459581878612,0.247274288165121,0.193038522868044,0.163185293713491,True,0.820198666823576,0.098964081801492,0.165148084338625,259.464809493856
1265,26114,1561:1564,Breast,MDA-MB-361,SIDM00528,908121,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.425740291318785,0.0756200311246341,0.902602436899929,14.84608290464,287.6182,0.943835509913962,0.973721308519064,0.037391411201031,0.384274224430821,0.338932142723586,0.0453420817072351,12.5764716455089,59.6479,2.26961125913113,227.9703,0.401828804947784,0.416765130011351,0.414552393552215,0.400882861980346,-0.0149363250635671,0.0136695315718683,True,0.565658653598617,0.0705282839333344,0.540834861214288,89.5503927675915
1266,26114,1510:1564,Breast,MDA-MB-361,SIDM00528,908121,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.925114547904223,0.0756200311246341,0.902602436899929,14.84608290464,287.6182,0.943835509913962,0.973721308519064,0.075396852898397,0.835010645349928,0.767595391888043,0.0674152534618847,13.1583706322526,89.2821,1.68771227238745,198.3361,0.873155961050007,0.849235840061107,0.900803748115322,0.880877814073556,0.0239201209889004,0.0199259340417665,True,0.565658653598617,0.0705282839333344,0.540834861214288,89.5503927675915
1267,26114,1012:1564,Breast,MDA-MB-361,SIDM00528,908121,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.453345752750342,0.0756200311246341,0.902602436899929,14.84608290464,287.6182,0.943835509913962,0.973721308519064,0.107945075271608,0.409190981190692,0.109943438292936,0.299247542897756,6.00948802089186,0.6291,8.83659488374819,286.9891,0.427883819714448,0.231587748909942,0.441432419579623,0.292683749263249,0.196296070804507,0.148748670316374,True,0.565658653598617,0.0705282839333344,0.540834861214288,89.5503927675915
1268,26114,1011:1564,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.55084531672696,0.0756200311246341,0.902602436899929,14.84608290464,287.6182,0.943835509913962,0.973721308519064,0.121163957359256,0.497194325232668,0.222071480657425,0.275122844575243,7.9697499954094,2.4481,6.87633290923065,285.1701,0.519907370396709,0.334166826152916,0.536369822594974,0.424123702458269,0.185740544243793,0.112246120136705,True,0.565658653598617,0.0705282839333344,0.540834861214288,89.5503927675915
1269,26114,1053:1564,Breast,MDA-MB-361,SIDM00528,908121,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.424873387721327,0.0756200311246341,0.902602436899929,14.84608290464,287.6182,0.943835509913962,0.973721308519064,0.0669616991817864,0.383491755131198,0.222816522935087,0.160675232196111,9.25679266092649,5.9741,5.58929024371356,281.6441,0.401010590548831,0.303644595325745,0.413708271046938,0.355090033936079,0.0973659952230868,0.0586182371108587,True,0.565658653598617,0.0705282839333344,0.540834861214288,89.5503927675915
1270,25867,1558:2169,Breast,MDA-MB-361,SIDM00528,908121,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.664589885396157,0.0716319542871653,0.60919850604338,10.1656672219288,22.4337,0.891178495938423,0.873577017851271,0.0682274948824452,0.40486716531488,0.216349924151018,0.188517241163862,7.08735330103955,2.656,3.07831392088926,19.7777,0.592268214483236,0.467828908205107,0.580570450178493,0.476591919954025,0.124439306278129,0.103978530224467,True,0.515683554896602,0.0592523699019833,0.644583472804719,76.3402472101585
1271,25867,1012:2169,Breast,MDA-MB-361,SIDM00528,908121,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.469589669646893,0.0716319542871653,0.60919850604338,10.1656672219288,22.4337,0.891178495938423,0.873577017851271,0.0528790053178888,0.286073325202292,0.129122516264724,0.156950808937568,6.45422916460076,1.7126,3.71143805732805,20.7211,0.41848821550414,0.308971612191395,0.410222743223897,0.317405321703357,0.109516603312744,0.0928174215205398,True,0.515683554896602,0.0592523699019833,0.644583472804719,76.3402472101585
1272,25867,1011:2169,Breast,MDA-MB-361,SIDM00528,908121,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.641774037367772,0.0716319542871653,0.60919850604338,10.1656672219288,22.4337,0.891178495938423,0.873577017851271,0.080447113284643,0.390967784781875,0.169510384948717,0.221457399833159,6.30964139709365,1.5492,3.85602582483516,20.8845,0.571935221353741,0.432517824832941,0.560639049698109,0.427536299239663,0.1394173965208,0.133102750458446,True,0.515683554896602,0.0592523699019833,0.644583472804719,76.3402472101585
1273,26095,1011:1038,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.81633346741934,0.0751806187498558,0.71730912574788,11.8350446837967,71.3565,0.922643901311504,0.903303790818542,0.112284516150889,0.585563445833302,0.353184763765492,0.23237868206781,8.17472386067776,5.6437,3.66032082311899,65.7128,0.753185095150928,0.664543723834191,0.737397115691935,0.620013356086253,0.0886413713167369,0.117383759605682,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
1274,26096,1012:1042,Breast,MFM-223,SIDM00332,910948,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.941733359249244,0.178502689021711,0.585191427330546,10.047734368143,20.6728,0.892877897376769,0.844841557436985,0.186272110569171,0.551094288663854,0.530558102656575,0.0205361860072795,9.77611427969848,17.1251,0.271620088444532,3.5477,0.840852901696026,0.841333071658121,0.795615477918495,0.785417902892638,-0.0004801699620952,0.0101975750258566,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
1275,30690,1012:1050,Breast,MFM-223,SIDM00332,910948,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.666743491235853,0.126288528376136,0.700582869409301,11.5881898948993,60.1344,0.91468639889222,0.896494024744262,0.150909109910257,0.467109068249989,0.276730706615643,0.190378361634346,7.95527135791202,4.8474,3.63291853698732,55.287,0.609861202983349,0.497322024413992,0.597731555930071,0.498677071367998,0.112539178569356,0.0990544845620723,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
1276,30690,1011:1050,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.694471084022068,0.126288528376136,0.700582869409301,11.5881898948993,60.1344,0.91468639889222,0.896494024744262,0.0623356250730777,0.486534544765968,0.123016563654428,0.36351798111154,4.3238094206206,0.3911,7.26438047427874,59.7433,0.635223254978921,0.355698938084834,0.622589177183454,0.362422051723822,0.279524316894087,0.260167125459632,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
1277,30690,1011:1051,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.694471084022068,0.0768811856693239,0.206706851091338,4.9052625240862,0.5853,0.551213259144612,0.560921966383347,0.0681188505415534,0.14355193095219,0.0241061543326581,0.119445776619532,-1.12457800191933,0.009,6.02984052600553,0.5763,0.382801669605495,0.101364005713054,0.389544086046033,0.134809578987954,0.281437663892441,0.254734507058079,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
1278,30687,1012:1080,Breast,MFM-223,SIDM00332,910948,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.966190246705211,0.0839682302831792,0.405824082660128,7.839205857209,0.0447,0.737009779282835,0.741679272731787,0.0586723871858596,0.392103270544305,0.34597408269794,0.046129187846365,7.22281873170004,0.0292,0.616387125508966,0.0155,0.712091660469435,0.680514125945957,0.716603279496867,0.683196774164401,0.0315775345234782,0.0334065053324663,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
1279,30687,1011:1080,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.899606868842057,0.0839682302831792,0.405824082660128,7.839205857209,0.0447,0.737009779282835,0.741679272731787,0.122506913325405,0.365082132302578,0.184316314051635,0.180765818250943,4.87133210052355,0.0057,2.96787375668545,0.039,0.663019059846607,0.496051464041892,0.667219768227297,0.502570573930301,0.166967595804714,0.164649194296996,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
1280,28104,1011:1096,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.71770786622787,0.0898038939700817,0.507337760099629,9.08937037668701,5.3195,0.800196272682543,0.804275089397844,0.0502170496988794,0.364120301257932,0.0688060561798678,0.295314245078064,2.16781282865376,0.0439,6.92155754803325,5.2756,0.574307159430483,0.22459222245465,0.577234558271956,0.271444991795973,0.349714936975833,0.305789566475983,True,0.510180859930454,0.0724218129580126,0.647018430485456,75.5756476517284
1281,30689,1021:1192,Breast,MFM-223,SIDM00332,910948,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.444329778233951,0.0943020185728289,0.788566837907504,13.0077120165038,160.8576,0.96532563280022,0.930720607041845,0.056081271896425,0.350383728210089,0.265198864283314,0.0851848639267758,10.1946124487268,22.8883,2.813099567777,137.9693,0.42892292434567,0.323952762913859,0.413546880924671,0.37789238413596,0.104970161431812,0.0356544967887111,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
1282,30689,1561:1192,Breast,MFM-223,SIDM00332,910948,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.78829907618994,0.0943020185728289,0.788566837907504,13.0077120165038,160.8576,0.96532563280022,0.930720607041845,0.122246016993233,0.621626509836508,0.577550506494187,0.0440760033423208,12.0694140928254,83.9432,0.938297923678398,76.9144,0.760965304558883,0.758971344173843,0.733686194722026,0.716894930127643,0.0019939603850397,0.0167912645943831,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
1283,30689,1510:1192,Breast,MFM-223,SIDM00332,910948,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.909318577502408,0.0943020185728289,0.788566837907504,13.0077120165038,160.8576,0.96532563280022,0.930720607041845,0.0596946537085063,0.717058475311624,0.703882699449001,0.0131757758626224,12.7494320064634,134.4905,0.258280010040419,26.3671,0.877788531244508,0.870889946709722,0.846321538447467,0.841430685426194,0.0068985845347862,0.0048908530212733,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
1284,30689,1011:1192,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.652292449903449,0.0943020185728289,0.788566837907504,13.0077120165038,160.8576,0.96532563280022,0.930720607041845,0.0728803081185338,0.514376194611302,0.183819949714401,0.330556244896901,6.15165698066473,1.3886,6.85605503583904,159.469,0.629674621973853,0.372466658322176,0.60710202494295,0.418866752516274,0.257207963651677,0.188235272426676,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
1285,26099,1049:1560,Breast,MFM-223,SIDM00332,910948,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,10.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.549875345486925,0.0938347748102038,0.605433217288,10.3035893164632,24.6842,0.850621963088872,0.854559550395842,0.0599526778131493,0.3329127995255,0.134588193922949,0.198324605602551,5.5694269537167,0.9275,4.7341623627465,23.7567,0.46773604583226,0.333290939894084,0.469901228013065,0.332551777758858,0.134445105938177,0.137349450254207,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
1286,26099,1021:1560,Breast,MFM-223,SIDM00332,910948,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.523790789574281,0.0938347748102038,0.605433217288,10.3035893164632,24.6842,0.850621963088872,0.854559550395842,0.0465781157780618,0.317120342917779,0.0955521539918852,0.221568188925894,4.432983355419,0.4219,5.87060596104419,24.2623,0.445547949675546,0.260986016005943,0.447610421640081,0.277205145843905,0.184561933669603,0.170405275796176,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
1287,26099,1510:1560,Breast,MFM-223,SIDM00332,910948,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.957485842916549,0.0938347748102038,0.605433217288,10.3035893164632,24.6842,0.850621963088872,0.854559550395842,0.0773567210752791,0.579693734384679,0.37287277816048,0.206820956224199,7.63077673872704,3.871,2.67281257773615,20.8132,0.814458487331479,0.679928258687398,0.81822867143315,0.699197631268539,0.134530228644081,0.119031040164611,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
1288,26099,1053:1560,Breast,MFM-223,SIDM00332,910948,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.901225584506886,0.0938347748102038,0.605433217288,10.3035893164632,24.6842,0.850621963088872,0.854559550395842,0.0336185284718073,0.545631905130262,0.309939012597154,0.235692892533108,7.03337675443402,2.5585,3.27021256202918,22.1257,0.766602275879164,0.623651116580713,0.770150930301435,0.627285475462157,0.142951159298451,0.142865454839277,True,0.653753468716616,0.103293154734791,0.398371306841104,120.003434048815
1289,30691,1372:1564,Breast,MFM-223,SIDM00332,910948,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.924797835533682,0.0888645498102905,0.724963816660842,11.9509432840948,38.6627,0.879504541243187,0.90637016108196,0.12468513413818,0.670444968488183,0.427564141742582,0.242880826745602,8.5403907774376,3.6359,3.41055250665723,35.0268,0.813363896083743,0.649528473079996,0.838209163160911,0.719582243351412,0.163835423003748,0.118626919809499,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
1290,30691,1012:1564,Breast,MFM-223,SIDM00332,910948,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.41422286864219,0.0888645498102905,0.724963816660842,11.9509432840948,38.6627,0.879504541243187,0.90637016108196,0.103730628513035,0.300296591799045,0.17238760403396,0.127908987765085,7.96934788503582,2.4474,3.98159539905901,36.2153,0.364310894057586,0.2183323423848,0.375439248175053,0.310121039613107,0.145978551672786,0.0653182085619465,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
1291,30691,1011:1564,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.596526473973953,0.0888645498102905,0.724963816660842,11.9509432840948,38.6627,0.879504541243187,0.90637016108196,0.120127759561619,0.432460109311392,0.180457804556845,0.252002304754546,6.45663249142256,0.8577,5.49431079267227,37.805,0.524647742831878,0.393604804825025,0.540673796305426,0.394420628705813,0.131042938006853,0.146253167599613,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
1292,30687,1021:2169,Breast,MFM-223,SIDM00332,910948,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.453000916962686,0.0706104374614104,0.610480596011694,10.3680660193612,25.8124,0.88516103389457,0.856935217656835,0.0253447080938047,0.276548269781225,0.152871532865321,0.123676736915904,6.94602391780047,2.4082,3.42204210156076,23.4042,0.400978760013879,0.29964356277267,0.388192439376165,0.312963477508005,0.101335197241209,0.0752289618681598,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
1293,30687,1011:2169,Breast,MFM-223,SIDM00332,910948,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.722662440570523,0.0706104374614104,0.610480596011694,10.3680660193612,25.8124,0.88516103389457,0.856935217656835,0.0522152325775503,0.441171397434758,0.187604243363548,0.25356715407121,5.80907112309813,1.0951,4.55899489626309,24.7173,0.639672633052177,0.449214103984461,0.619274895802721,0.448268652850492,0.190458529067716,0.171006242952229,True,0.6071989498949,0.0824661982717897,0.477339150063199,101.749386895928
1294,28353,1012:1030,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.877497912262984,0.0606045591338237,0.859846569149973,12.6713879325311,127.4084,0.944844744790839,0.969674501746649,0.0815026668822023,0.754513569295591,0.709324988860258,0.045188580435333,11.9130422762202,75.3205,0.75834565631083,52.0879,0.829099290966613,0.836957488545062,0.850887350857334,0.840012983595038,-0.0078581975784485,0.010874367262296,True,0.429713227651758,0.0557296793840869,0.813583656083833,60.3431862324098
1295,27649,1021:1032,Breast,HCC1599,SIDM00877,749713,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.937646449678319,0.0856589440838811,0.526214035934185,9.21241314292572,11.5862,0.86000050950297,0.871354372879339,0.0700843788810662,0.493402722564588,0.433390330845333,0.0600123917192548,8.69348934277025,8.086,0.518923800155473,3.5002,0.806376424457006,0.79008404983174,0.81702233414199,0.792765933925177,0.0162923746252652,0.0242564002168129,True,,,,
1296,27649,1083:1038,Breast,HCC1599,SIDM00877,749713,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.839424445668703,0.0575121565212725,0.619568731387298,9.98709283484889,19.8219,0.889679714439073,0.903995819194103,0.0514804021256624,0.520081138898444,0.302674349427763,0.217406789470681,7.84055783135097,4.4769,2.14653500349792,15.345,0.746818901115709,0.670211485085037,0.758836189413835,0.668265392285525,0.076607416030672,0.0905707971283096,True,,,,
1297,27649,1012:1038,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.868288333697315,0.0575121565212725,0.619568731387298,9.98709283484889,19.8219,0.889679714439073,0.903995819194103,0.0927385567822607,0.537964301387236,0.406325263039198,0.131639038348038,8.74027090250368,8.3524,1.24682193234521,11.4695,0.772498516774606,0.727863764978838,0.784929023517387,0.7362643882872,0.0446347517957677,0.0486646352301874,True,,,,
1298,27649,1011:1038,Breast,HCC1599,SIDM00877,749713,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.831036595466666,0.0575121565212725,0.619568731387298,9.98709283484889,19.8219,0.889679714439073,0.903995819194103,0.0736377324609857,0.514884289189701,0.276912028839005,0.237972260350696,7.59604133409206,3.7789,2.39105150075683,16.043,0.739356400943203,0.664091771205059,0.751253607899167,0.64858497492526,0.0752646297381437,0.102668632973907,True,,,,
1299,27649,1561:1038,Breast,HCC1599,SIDM00877,749713,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.627611435425664,0.0575121565212725,0.619568731387298,9.98709283484889,19.8219,0.889679714439073,0.903995819194103,0.0455958655239472,0.388848420850839,0.182494180835131,0.206354240015709,7.19545112668195,2.8627,2.79164170816694,16.9592,0.558373162648201,0.4776078647849,0.56735811370321,0.472908538176674,0.0807652978633009,0.0944495755265354,True,,,,
1300,27649,1510:1038,Breast,HCC1599,SIDM00877,749713,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.5191453668281,0.0575121565212725,0.619568731387298,9.98709283484889,19.8219,0.889679714439073,0.903995819194103,0.0380696260650812,0.32164623633128,0.156901754833119,0.16474448149816,7.30660848993325,3.092,2.68048434491564,16.7299,0.461873101711992,0.395056219586228,0.469305241166592,0.395142301371398,0.0668168821257641,0.0741629397951939,True,,,,
1301,27649,1053:1038,Breast,HCC1599,SIDM00877,749713,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.801252611298093,0.0575121565212725,0.619568731387298,9.98709283484889,19.8219,0.889679714439073,0.903995819194103,0.0727184234278036,0.496431063902719,0.255560067129139,0.24087099677358,7.46467281549726,3.45,2.52242001935163,16.3719,0.712858194413249,0.620516013743976,0.724329010731834,0.618399355909919,0.0923421806692732,0.105929654821915,True,,,,
1302,27650,1372:1042,Breast,HCC1599,SIDM00877,749713,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.984961932012572,0.0605065310777451,0.76032851117277,11.3365552466094,50.5095,0.931621507682,0.944999680774806,0.0675397864069106,0.748894639328974,0.699197336701048,0.0496973026279253,10.810914408998,35.0865,0.525640837611359,15.423,0.917611720110928,0.901730151252042,0.930788711327217,0.917233386208206,0.015881568858886,0.0135553251190101,True,,,,
1303,27650,1012:1042,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.416691532023641,0.0605065310777451,0.76032851117277,11.3365552466094,50.5095,0.931621507682,0.944999680774806,0.093056077281378,0.316822452161836,0.159764757894698,0.157057694267138,8.03846794572606,5.1351,3.29808730088333,45.3744,0.388198793302187,0.264536981016109,0.393773364743906,0.336808937933642,0.123661812286078,0.0569644268102643,True,,,,
1304,27650,1011:1042,Breast,HCC1599,SIDM00877,749713,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.845055634050981,0.0605065310777451,0.76032851117277,11.3365552466094,50.5095,0.931621507682,0.944999680774806,0.0549198852655565,0.642519892096143,0.396822688517594,0.245697203578549,8.75344135756917,8.429,2.58311388904022,42.0805,0.787272003869743,0.72081707927537,0.798577304415128,0.717146541701698,0.0664549245943732,0.0814307627134301,True,,,,
1305,27651,1012:1050,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.457109322609258,0.0839849233668799,0.713937351823938,10.8510275923411,36.0757,0.917791673680275,0.932381457733558,0.0578844089954997,0.326347419277688,0.144334961900056,0.182012457377632,7.43482619029618,3.3794,3.41620140204492,32.6963,0.419531130252407,0.323445530949726,0.426200256558019,0.351882059132862,0.0960855993026813,0.0743181974251576,True,,,,
1306,27651,1011:1050,Breast,HCC1599,SIDM00877,749713,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.847891267262059,0.0839849233668799,0.713937351823938,10.8510275923411,36.0757,0.917791673680275,0.932381457733558,0.0589160367470532,0.605341245983718,0.358068186129332,0.247273059854386,8.36586987136484,6.4433,2.48515772097626,29.6324,0.778187545279334,0.678671181176218,0.790558095769353,0.701632788918064,0.0995163641031162,0.0889253068512887,True,,,,
1307,27651,1012:1051,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.457109322609258,0.0834002264379571,0.768496232013754,11.4283555342785,53.828,0.896248080317378,0.947142054858696,0.131370449364987,0.351286792043574,0.0671710000059715,0.284115792037603,5.44047148955133,0.8482,5.98788404472719,52.9798,0.409683352883724,0.200618792696748,0.432947463111199,0.283457556419719,0.209064560186976,0.14948990669148,True,,,,
1308,27651,1011:1051,Breast,HCC1599,SIDM00877,749713,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.847891267262059,0.0834002264379571,0.768496232013754,11.4283555342785,53.828,0.896248080317378,0.947142054858696,0.110843908202979,0.651601244048259,0.417670206130138,0.233931037918121,8.94007831996247,9.5932,2.48827721431605,44.2348,0.759920920601489,0.655322701223624,0.80307347717133,0.727643592336492,0.104598219377865,0.0754298848348379,True,,,,
1309,28357,1012:1096,Breast,HCC1599,SIDM00877,749713,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.46804548159757,0.096329030221859,0.690114881749921,10.6204487952348,15.3735,0.875359730828409,0.925582654169875,0.0838027311908078,0.323005152186292,0.0887962346789025,0.234208917507389,6.06160160515115,0.6523,4.55884719008361,14.7212,0.409708166786702,0.262732962790271,0.433214779129296,0.313435624530437,0.146975203996431,0.119779154598859,True,0.429713227651758,0.0557296793840869,0.813583656083833,60.3431862324098
1310,28357,1011:1096,Breast,HCC1599,SIDM00877,749713,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.864060492178291,0.096329030221859,0.690114881749921,10.6204487952348,15.3735,0.875359730828409,0.925582654169875,0.127514278645507,0.5963010043844,0.372383445623494,0.223917558760906,8.43756215615745,3.3858,2.18288663907731,11.9877,0.756363759852651,0.626611250154258,0.799759403713711,0.718505737461681,0.129752509698393,0.0812536662520302,True,0.429713227651758,0.0557296793840869,0.813583656083833,60.3431862324098
1311,27655,1510:1909,Breast,HCC1599,SIDM00877,749713,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.535851505771859,0.0700379860807973,0.887147286480269,13.1731356081909,18.0401,0.952633123275911,0.975948896684319,0.100830647580864,0.475379209301871,0.222977859266184,0.252401350035687,8.31445044128722,0.6218,4.85868516690364,17.4183,0.510469893555546,0.352572381150491,0.522963685844677,0.44184562469646,0.157897512405054,0.0811180611482171,True,,,,
1312,27655,1561:1909,Breast,HCC1599,SIDM00877,749713,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.476263895033107,0.0700379860807973,0.887147286480269,13.1731356081909,18.0401,0.952633123275911,0.975948896684319,0.0529290157812809,0.422516222127144,0.27610684212551,0.146409380001634,9.6510595331189,1.5703,3.52207607507196,16.4698,0.453704761828939,0.375110808713256,0.464809222888137,0.424211180803963,0.0785939531156828,0.0405980420841737,True,,,,
1313,27072,1011:1032,Breast,HCC70,SIDM00673,907048,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.947299909255044,0.119141426607221,0.644329729205051,10.7339075998351,33.2628,0.909212884039212,0.876926044939287,0.140475951310128,0.610373494006272,0.358665336315264,0.251708157691008,7.55436574785883,3.6713,3.17954185197626,29.5915,0.861297282543862,0.748515294296827,0.830711962794371,0.693187308335404,0.112781988247035,0.137524654458968,True,0.897710429713034,0.0931134865295216,0.0924821916336861,469.308377553025
1314,27072,1053:1032,Breast,HCC70,SIDM00673,907048,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.654069310776944,0.119141426607221,0.644329729205051,10.7339075998351,33.2628,0.909212884039212,0.876926044939287,0.080838218429711,0.421436301894242,0.214992236644179,0.206444065250063,6.91631919217393,2.3591,3.81758840766116,30.9037,0.594688244413044,0.456396833245895,0.573570413815791,0.453977523911979,0.138291411167149,0.119592889903812,True,0.897710429713034,0.0931134865295216,0.0924821916336861,469.308377553025
1315,27072,1011:1038,Breast,HCC70,SIDM00673,907048,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.964693126067321,0.0682499902255591,0.653108371432981,10.846321921141,35.9582,0.908422338570266,0.880680525906149,0.144972704858209,0.630049156498419,0.481682788294575,0.148366368203844,8.99196880162334,9.9445,1.85435311951764,26.0137,0.876348785584736,0.839677782303415,0.849586449603015,0.778208357687803,0.0366710032813208,0.0713780919152118,True,0.897710429713034,0.0931134865295216,0.0924821916336861,469.308377553025
1316,27072,1558:1038,Breast,HCC70,SIDM00673,907048,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.97495011359489,0.0682499902255591,0.653108371432981,10.846321921141,35.9582,0.908422338570266,0.880680525906149,0.0706366421364454,0.636748080918358,0.528171568722774,0.108576512195584,9.48835467921168,14.0284,1.3579672419293,21.9298,0.885666462181216,0.837548981153088,0.858619578773008,0.808278140866677,0.0481174810281283,0.0503414379063302,True,0.897710429713034,0.0931134865295216,0.0924821916336861,469.308377553025
1317,27072,1561:1038,Breast,HCC70,SIDM00673,907048,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.913010433651821,0.0682499902255591,0.653108371432981,10.846321921141,35.9582,0.908422338570266,0.880680525906149,0.101795238595425,0.59629475742366,0.384869130634982,0.211425626788679,8.07656128882553,5.2725,2.76976063231545,30.6857,0.82939907327704,0.742670006867986,0.804070508866288,0.694485728802156,0.0867290664090543,0.109584780064131,True,0.897710429713034,0.0931134865295216,0.0924821916336861,469.308377553025
1318,25469,1053:1051,Breast,HCC70,SIDM00673,907048,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.6227583331486,0.124976989208274,0.758022589210398,12.3319982222992,100.7004,0.841559312687763,0.922168887711551,0.108251250839808,0.472064884145654,0.402937685398561,0.0691271987470924,10.7682335929322,34.0637,1.56376462936705,66.6367,0.524088074815113,0.461031111124032,0.574288359392744,0.546832992879808,0.0630569636910803,0.0274553665129366,True,0.61999503388235,0.0705374589707875,0.442922827892318,107.362367348008
1319,25469,1594:1051,Breast,HCC70,SIDM00673,907048,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.962175466878676,0.124976989208274,0.758022589210398,12.3319982222992,100.7004,0.841559312687763,0.922168887711551,0.095335811525116,0.729350738678098,0.618702651214264,0.110648087463834,10.7173049814527,32.8822,1.61469324084654,67.8182,0.809727724591446,0.77537538773847,0.887288280074852,0.84321573390251,0.0343523368529759,0.0440725461723411,True,0.61999503388235,0.0705374589707875,0.442922827892318,107.362367348008
1320,23740,1011:1080,Breast,HCC70,SIDM00673,907048,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.967549826488848,0.0785843578458385,0.529929873306479,9.34976226123641,0.1274,0.809186600756098,0.822992073401422,0.0932266140627241,0.512733556968941,0.287924559876636,0.224808997092306,6.49387709777869,0.0176,2.85588516345771,0.1098,0.782928355158663,0.661941200808063,0.796285837821244,0.646201686786175,0.120987154350601,0.150084151035069,True,0.680872585130312,0.0825361768624602,0.368612997774341,131.54939790493
1321,23743,1561:1192,Breast,HCC70,SIDM00673,907048,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.945344937737361,0.0782485077275298,0.613736899447901,10.3511830183092,25.5121,0.859292589936037,0.863451066669609,0.0793430492366384,0.580193070995697,0.372353850931183,0.207839220064514,7.74225800220931,4.182,2.6089250160999,21.3301,0.812327899931258,0.668924921818151,0.816259094860039,0.701786613273396,0.143402978113107,0.114472481586643,True,0.680872585130312,0.0825361768624602,0.368612997774341,131.54939790493
1322,25471,1372:1553,Breast,HCC70,SIDM00673,907048,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.871512595113719,0.0780073479392853,0.294724890840987,6.45389279188445,1.7122,0.657777395059971,0.665346613195364,0.0834535443678346,0.256856454461436,0.156736850502682,0.100119603958754,4.57219188570149,0.4646,1.88170090618297,1.2476,0.573261284575858,0.461723057411191,0.579857953516016,0.470335542212184,0.111538227164666,0.109522411303832,True,0.61999503388235,0.0705374589707875,0.442922827892318,107.362367348008
1323,28762,1561:1030,Breast,MDA-MB-330,SIDM00631,1330941,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.6049237405524,0.0408631593142973,0.904552345409361,14.3627182975435,411.4708,0.980346655262921,0.976457977019034,0.0632122967160616,0.547185188310477,0.451262814055379,0.095922374255098,11.5689722163412,59.3387,2.79374608120236,352.1321,0.59303496573968,0.522940272264418,0.590682611950583,0.563389717814879,0.0700946934752623,0.0272928941357039,True,0.955223667874901,0.115953398274562,0.0291781763160902,1107.28982924016
1324,28762,1053:1030,Breast,MDA-MB-330,SIDM00631,1330941,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.703126646648136,0.0408631593142973,0.904552345409361,14.3627182975435,411.4708,0.980346655262921,0.976457977019034,0.0566742333036408,0.63601485734539,0.618900881529876,0.0171139758155138,13.7560240622267,270.2128,0.606694235316802,141.258,0.689307856267734,0.651225236984081,0.686573622974216,0.682077342109342,0.0380826192836526,0.0044962808648735,True,0.955223667874901,0.115953398274562,0.0291781763160902,1107.28982924016
1325,30697,1011:1085,Breast,MDA-MB-330,SIDM00631,1330941,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.215887300843363,0.105131731080599,0.598214601226299,9.94916020242389,19.3075,0.890738506337769,0.879881208608409,0.0471975554375133,0.129146935583834,0.0553827993198635,0.0737641362639707,6.46262083242799,1.7226,3.4865393699959,17.5849,0.192299131890509,0.11266618512763,0.189955179189265,0.148051688242995,0.0796329467628795,0.0419034909462695,True,0.945378612019343,0.0939934088263652,0.0386979291183321,903.723751361501
1326,28767,1011:1192,Breast,MDA-MB-330,SIDM00631,1330941,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.400397176903575,0.074855495876019,0.569847561545968,9.67062942648722,15.9177,0.877775435668953,0.868592800456875,0.0682739024156576,0.228165354908392,0.0893895827445679,0.138775772163824,6.02680410727196,1.2734,3.64382531921526,14.6443,0.351458806397154,0.203962501994223,0.347782105181703,0.262115892986221,0.147496304402931,0.0856662121954814,True,0.955223667874901,0.115953398274562,0.0291781763160902,1107.28982924016
1327,23837,1011:1032,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.346759232320249,0.0898052009465085,0.68326699610348,11.0099526628012,40.2769,0.901482003539022,0.903059397381104,0.0776306375529191,0.236929139038605,0.201504992950425,0.0354241460881802,9.85573912028365,18.0969,1.15421354251755,22.18,0.312597207497711,0.242807655251679,0.313144183375459,0.298965455905231,0.0697895522460325,0.0141787274702276,True,0.59639014242596,0.0746576032925633,0.487314599745485,98.8170824196229
1328,23837,1083:1038,Breast,CAL-120,SIDM00940,906826,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.969520889470456,0.080238878311414,0.76194838185917,12.0414681071109,82.3328,0.915413555660241,0.930698860073665,0.0624873085918138,0.738724872910677,0.517870659268504,0.220854213642173,9.35768357925958,12.8137,2.6837845278513,69.5191,0.88751256471703,0.803675845240611,0.902331986647759,0.815357420107836,0.0838367194764184,0.0869745665399233,True,0.59639014242596,0.0746576032925633,0.487314599745485,98.8170824196229
1329,23837,1561:1038,Breast,CAL-120,SIDM00940,906826,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.972112382755851,0.080238878311414,0.76194838185917,12.0414681071109,82.3328,0.915413555660241,0.930698860073665,0.0607568787901686,0.740699457026082,0.575254826110895,0.165444630915187,9.97052605253349,19.5955,2.0709420545774,62.7373,0.889884852799882,0.867179842028276,0.904743886494364,0.84257192654948,0.0227050107716066,0.0621719599448842,True,0.59639014242596,0.0746576032925633,0.487314599745485,98.8170824196229
1330,23837,1510:1038,Breast,CAL-120,SIDM00940,906826,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.938936980660275,0.080238878311414,0.76194838185917,12.0414681071109,82.3328,0.915413555660241,0.930698860073665,0.0493972554765123,0.715421513081831,0.502774025673403,0.212647487408428,9.37155885152645,12.9375,2.66990925558444,69.3953,0.859515640007113,0.778639739308666,0.873867577581526,0.79021844333946,0.0808759006984467,0.0836491342420658,True,0.59639014242596,0.0746576032925633,0.487314599745485,98.8170824196229
1331,23838,1011:1042,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.375966371225263,0.0556923658428604,0.942626199199798,16.317674548151,1595.2896,0.966976952973076,0.984900129139156,0.0792680149570045,0.35439575153501,0.214115127054005,0.140280624481005,9.73157916043295,16.6046,6.58609538771801,1578.685,0.36355081606775,0.250856511266417,0.370289327571742,0.322238537819438,0.112694304801333,0.0480507897523033,True,0.59639014242596,0.0746576032925633,0.487314599745485,98.8170824196229
1332,23839,1011:1050,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.313699373478003,0.0584041639967337,0.878531163035453,14.1726616354882,360.6835,0.951966665842333,0.96693103075728,0.0654070144731869,0.275594675425123,0.120579955639922,0.1550147197852,7.76867021707064,4.2592,6.40399141841758,356.4243,0.298631346646683,0.198841282515343,0.303325658544998,0.238103619655758,0.09979006413134,0.0652220388892398,True,0.59639014242596,0.0746576032925633,0.487314599745485,98.8170824196229
1333,23839,1011:1051,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.313699373478003,0.0732000200319805,0.684318488348691,11.0226662327421,40.6334,0.889110599897915,0.903448711455643,0.0909405404634801,0.214670281054398,0.108143821078197,0.106526459976201,7.32094667839115,3.1229,3.70171955435098,37.5105,0.278913438140627,0.146568171113473,0.283411294753144,0.229692233409639,0.132345267027154,0.0537190613435049,True,0.59639014242596,0.0746576032925633,0.487314599745485,98.8170824196229
1334,23615,1011:1080,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.315388508073791,0.0782171909511638,0.4585895622191,8.56596652630948,0.074,0.786958871969453,0.80283655037492,0.0644862176177697,0.144633877846495,0.0720956074496429,0.072538270396852,5.82028269244513,0.011,2.74568383386435,0.063,0.24819778454588,0.162268482311267,0.253205421849855,0.199561426108904,0.085929302234613,0.0536439957409511,True,0.236419811525149,0.0428531842744916,1.36363887219313,36.0919245180187
1335,23618,1011:1192,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.362112554401572,0.0726327692157239,0.727688842520796,11.5696811802431,59.3678,0.899592212490559,0.919021436424602,0.0816119456813924,0.263505265574729,0.118931177910679,0.14457408766405,7.13008025180845,2.7359,4.4396009284347,56.6319,0.325753633984718,0.181451098045925,0.332789199893515,0.260840250246589,0.144302535938794,0.0719489496469258,True,0.236419811525149,0.0428531842744916,1.36363887219313,36.0919245180187
1336,23618,1594:1192,Breast,CAL-120,SIDM00940,906826,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.927716656999912,0.0726327692157239,0.727688842520796,11.5696811802431,59.3678,0.899592212490559,0.919021436424602,0.0310024755002355,0.675089060319529,0.623743807319866,0.0513452529996625,10.8791711468402,36.7864,0.690510033402948,22.5814,0.834566680034896,0.828836642979641,0.852591494711089,0.833998837623086,0.0057300370552551,0.0185926570880033,True,0.236419811525149,0.0428531842744916,1.36363887219313,36.0919245180187
1337,24186,1049:1553,Breast,CAL-120,SIDM00940,906826,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.92431333983968,0.0504246204827619,0.840930451273343,13.3532676802947,204.3921,0.958560754389887,0.955784643077465,0.0407254414483687,0.777283233989353,0.609525470757747,0.167757763231606,10.7274898607191,33.1151,2.62577781957553,171.277,0.88601049232936,0.821421962351218,0.883444495610408,0.826407156303622,0.064588529978142,0.0570373393067851,True,0.565411235593296,0.0827652068016045,0.549244766441732,88.9365855972975
1338,24186,1011:1553,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.334955420043103,0.0504246204827619,0.840930451273343,13.3532676802947,204.3921,0.958560754389887,0.955784643077465,0.100218183611895,0.281674212533299,0.147639460490411,0.134034752042888,8.37773200522111,6.4965,4.97553567507356,197.8956,0.321075120123499,0.186031544936666,0.32014524659276,0.26560861998243,0.135043575186833,0.05453662661033,True,0.565411235593296,0.0827652068016045,0.549244766441732,88.9365855972975
1339,24186,1594:1553,Breast,CAL-120,SIDM00940,906826,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.969718028188824,0.0504246204827619,0.840930451273343,13.3532676802947,204.3921,0.958560754389887,0.955784643077465,0.0741712629783575,0.815465419052724,0.53670953292584,0.278755886126884,9.56129204550572,14.7559,3.79197563478895,189.6362,0.929533644646154,0.841442498354664,0.926841599458238,0.824175218942193,0.0880911462914893,0.102666380516045,True,0.565411235593296,0.0827652068016045,0.549244766441732,88.9365855972975
1340,24186,1372:1560,Breast,CAL-120,SIDM00940,906826,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.990742920427197,0.0598055000083392,0.840006334749982,13.3352492439437,201.8553,0.946661085038442,0.955504623388566,0.0808462389902428,0.832230329267543,0.572575185433611,0.259655143833932,9.82157749699818,17.6734,3.51367174694552,184.1819,0.937897768045766,0.804429074547891,0.946659441057677,0.852818564331695,0.133468693497874,0.0938408767259821,True,0.565411235593296,0.0827652068016045,0.549244766441732,88.9365855972975
1341,24186,1011:1560,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.334955420043103,0.0598055000083392,0.840006334749982,13.3352492439437,201.8553,0.946661085038442,0.955504623388566,0.0714053627178011,0.281364674695048,0.183081093314615,0.0982835813804328,9.48855171544969,14.0304,3.84669752849401,187.8249,0.317089261377511,0.231627971648924,0.320051452480245,0.283629088654141,0.0854612897285872,0.0364223638261032,True,0.565411235593296,0.0827652068016045,0.549244766441732,88.9365855972975
1342,24186,1594:1560,Breast,CAL-120,SIDM00940,906826,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.821334404381974,0.0598055000083392,0.840006334749982,13.3352492439437,201.8553,0.946661085038442,0.955504623388566,0.086998339770969,0.689926102628962,0.332669211339853,0.357256891289109,7.99472126773201,4.9817,5.34052797621169,196.8736,0.777525318431642,0.596819517804405,0.784788820735071,0.634045308321705,0.180705800627237,0.150743512413366,True,0.565411235593296,0.0827652068016045,0.549244766441732,88.9365855972975
1343,23615,1510:2169,Breast,CAL-120,SIDM00940,906826,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.957280213460919,0.0834361191819881,0.736193578310993,11.683009908329,64.2194,0.924194346045913,0.921969324433488,0.0843452969097454,0.704743545794106,0.59837903096938,0.106364514824725,10.3363770688092,25.2516,1.34663283951984,38.9678,0.884712960862206,0.782925426691816,0.882582991698108,0.842942217862461,0.10178753417039,0.0396407738356475,True,0.236419811525149,0.0428531842744916,1.36363887219313,36.0919245180187
1344,23615,1011:2169,Breast,CAL-120,SIDM00940,906826,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.315388508073791,0.0834361191819881,0.736193578310993,11.683009908329,64.2194,0.924194346045913,0.921969324433488,0.0717074880259454,0.23218699431701,0.110200875743231,0.121986118573779,7.37489121061335,3.2419,4.30811869771565,60.9775,0.291480275969654,0.179074849335235,0.290778529722879,0.231972808241336,0.112405426634419,0.0588057214815431,True,0.236419811525149,0.0428531842744916,1.36363887219313,36.0919245180187
1345,30681,1011:1025,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.823071475142499,0.0516539669639515,0.899567513011257,14.1947576393097,366.2502,0.970356175489744,0.975310236092495,0.120398125768356,0.740408359924445,0.443060055310821,0.297348304613624,9.36371367779336,12.8673,4.83104396151636,353.3829,0.798672488773978,0.736384344874971,0.802750034742229,0.704730824915029,0.0622881438990066,0.0980192098271997,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
1346,30201,1372:1038,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.800085629591559,0.0746777910878659,0.813499364199284,12.4899261197128,112.3498,0.96480238213816,0.951889740337198,0.106571618823827,0.650869150977718,0.444355539643805,0.206513611333912,9.52708132793104,14.4101,2.96284479178175,97.9397,0.771924521344446,0.709628447498916,0.761593302199433,0.690815637011504,0.0622960738455303,0.0707776651879288,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
1347,30201,1011:1038,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.880141175109815,0.0746777910878659,0.813499364199284,12.4899261197128,112.3498,0.96480238213816,0.951889740337198,0.113475138853497,0.715994286357446,0.444638369499366,0.27135591685808,9.04918905615008,10.3468,3.44073706356271,102.003,0.849162302363829,0.78160344871668,0.837797354635358,0.740724265214849,0.0675588536471498,0.0970730894205096,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
1348,30201,1558:1038,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.276346056216469,0.0746777910878659,0.813499364199284,12.4899261197128,112.3498,0.96480238213816,0.951889740337198,0.0466223965725343,0.224807341031077,0.0770153638392583,0.147791977191819,6.74678696319236,2.0976,5.74313915652043,110.2522,0.266619333332135,0.201607204102363,0.263050975695103,0.195132229691767,0.0650121292297726,0.0679187460033364,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
1349,30201,1549:1038,Breast,MDA-MB-175-VII,SIDM00633,908120,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.367945236449714,0.0746777910878659,0.813499364199284,12.4899261197128,112.3498,0.96480238213816,0.951889740337198,0.0570747111213563,0.299323215911998,0.115185116751528,0.18413809916047,7.13788131309138,2.7507,5.35204480662141,109.5991,0.354994440623073,0.278331689029573,0.350243295582428,0.26945982362781,0.0766627515935003,0.0807834719546179,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
1350,30201,1561:1038,Breast,MDA-MB-175-VII,SIDM00633,908120,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.729180428937224,0.0746777910878659,0.813499364199284,12.4899261197128,112.3498,0.96480238213816,0.951889740337198,0.0531620211261503,0.593187815326993,0.427690884200627,0.165496931126366,9.82849995803356,17.7584,2.66142616167923,94.5914,0.703515014847159,0.661328268369568,0.69409936916002,0.638782841583005,0.0421867464775906,0.0553165275770154,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
1351,30201,1053:1038,Breast,MDA-MB-175-VII,SIDM00633,908120,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.845063523525982,0.0746777910878659,0.813499364199284,12.4899261197128,112.3498,0.96480238213816,0.951889740337198,0.093363645859587,0.687458639096393,0.420696049673405,0.266762589422988,8.97941182686644,9.8583,3.51051429284635,102.4915,0.815319300555934,0.69716020513813,0.804407297977584,0.708348477015199,0.118159095417804,0.0960588209623847,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
1352,30202,1558:1042,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.340242588184392,0.13118927231565,0.660644927837398,10.5784275575722,29.8644,0.925543369945201,0.903560278588523,0.0674586845150197,0.224779540118287,0.107278334253815,0.117501205864473,7.16262276053389,2.7983,3.41580479703835,27.0661,0.314909271667059,0.208090418376597,0.307429687767569,0.249723331430708,0.106818853290462,0.0577063563368616,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
1353,30202,1372:1042,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.890234406216632,0.13118927231565,0.660644927837398,10.5784275575722,29.8644,0.925543369945201,0.903560278588523,0.139439475927162,0.588128845053356,0.487670676757437,0.100458168295919,9.45442148201682,13.7023,1.12400607555542,16.1621,0.823950552370906,0.788741603397224,0.804380448090188,0.765828403451875,0.0352089489736825,0.0385520446383139,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
1354,30202,1011:1042,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.73753971728369,0.13118927231565,0.660644927837398,10.5784275575722,29.8644,0.925543369945201,0.903560278588523,0.0893801286576209,0.487251873302099,0.259850590906312,0.227401282395787,7.55737793537922,3.679,3.02104962219301,26.1854,0.682624995403177,0.563032636949218,0.666411592418952,0.559892003661076,0.119592358453959,0.106519588757876,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
1355,28755,1011:1050,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.879850239067369,0.108237767244637,0.589217888379342,9.85472397332696,18.0841,0.873754204760199,0.877082522038059,0.0895227399335796,0.518423499953334,0.23775689746318,0.280666602490154,6.64602861968971,1.9561,3.20869535363724,16.128,0.768772845944379,0.635212756648616,0.771701266696997,0.615175160116205,0.133560089295763,0.156526106580792,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
1356,28755,1011:1051,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.879850239067369,0.119115428231446,0.680456330626569,10.7909638258194,34.6046,0.849837654277023,0.910408885655056,0.171964657978488,0.598699665176691,0.21898955312257,0.379710112054121,6.38294362267711,1.63,4.40802020314233,32.9746,0.747729863284091,0.500397392381612,0.801023475692657,0.59896578152802,0.247332470902479,0.202057694164637,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
1357,28755,1549:1051,Breast,MDA-MB-175-VII,SIDM00633,908120,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.314040983491784,0.119115428231446,0.680456330626569,10.7909638258194,34.6046,0.849837654277023,0.910408885655056,0.0482851618233263,0.213691175293178,0.135192331112371,0.0784988441808069,8.33694129282542,6.3154,2.45402253299402,28.2892,0.266883852757507,0.228922994371818,0.285905701830772,0.252759457470149,0.0379608583856883,0.0331462443606239,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
1358,28755,1510:1051,Breast,MDA-MB-175-VII,SIDM00633,908120,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.942693719248,0.119115428231446,0.680456330626569,10.7909638258194,34.6046,0.849837654277023,0.910408885655056,0.11098115557812,0.641461909104208,0.372739911622696,0.268721997481511,7.99377294965039,4.9785,2.79719087616905,29.6261,0.801136619067403,0.667161958450869,0.858236738454592,0.740406706327212,0.133974660616534,0.11783003212738,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
1359,28749,1011:1080,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.858270244033976,0.0735042046850449,0.825903087834182,12.6888493820389,1.2896,0.919434041034507,0.955411139509982,0.108530186617503,0.708848044743858,0.220137381197409,0.488710663546449,6.4782514772282,0.0174,6.21059790481073,1.2722,0.789122878771831,0.543527620014434,0.820000951860012,0.590047416624785,0.245595258757397,0.229953535235226,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
1360,28749,1558:1080,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.242679466091412,0.0735042046850449,0.825903087834182,12.6888493820389,1.2896,0.919434041034507,0.955411139509982,0.0637448839496555,0.200429720398847,0.121646139319124,0.0787835810797232,9.01196645225884,0.1008,3.67688292978009,1.1888,0.223127762184523,0.157009952018019,0.23185866523407,0.203802506447623,0.0661178101665043,0.0280561587864462,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
1361,28749,1549:1080,Breast,MDA-MB-175-VII,SIDM00633,908120,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.331330802845609,0.0735042046850449,0.825903087834182,12.6888493820389,1.2896,0.919434041034507,0.955411139509982,0.0461313391404966,0.273647133164767,0.167200984753388,0.106446148411379,9.04392622500363,0.1031,3.6449231570353,1.1865,0.304636818979546,0.258269733918105,0.316557139901481,0.278763190574033,0.0463670850614406,0.0377939493274472,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
1362,30682,1011:1096,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.889753771505829,0.0546724883029285,0.938007113404726,15.4370608602791,433.2299,0.958755848162811,0.985066275857956,0.186579728450566,0.834595366851151,0.193952757966047,0.640642608885103,5.97320169173542,0.6135,9.46385916854367,432.6164,0.853056631856131,0.498666145954425,0.876466434127818,0.579435488232871,0.354390485901706,0.297030945894947,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
1363,30682,1011:1129,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.889753771505829,0.0718195582234152,0.683011771068559,10.8188701239181,35.2805,0.917938684841784,0.911278035444764,0.0556327716805134,0.607712299291127,0.230904276545513,0.376808022745613,6.51569478889916,1.7871,4.30317533501894,33.4934,0.816739406849078,0.585550224966652,0.810813068927402,0.614028784447523,0.231189181882426,0.196784284479879,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
1364,30683,1021:1192,Breast,MDA-MB-175-VII,SIDM00633,908120,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,1.0,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.933982384127976,0.0795553921713483,0.652379317126875,10.4915762444314,28.1196,0.925909639088542,0.900643361559403,0.057693558773269,0.609310789965939,0.593464022014959,0.0158467679509797,10.3162240893834,24.9014,0.175352155048,3.2182,0.86478329220299,0.857833451970028,0.841185034078286,0.835485405973991,0.0069498402329625,0.0056996281042944,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
1365,30683,1011:1192,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.802961440217169,0.0795553921713483,0.652379317126875,10.4915762444314,28.1196,0.925909639088542,0.900643361559403,0.157766011450121,0.523835436048088,0.254635093867306,0.269200342180782,7.18257127454227,2.8373,3.30900496988918,25.2823,0.743469737313495,0.63741278190501,0.72318189071977,0.590384904223002,0.106056955408485,0.132796986496768,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
1366,30204,1372:1553,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.918084528160435,0.0772092263849426,0.230477484017915,6.1434011751388,1.3806,0.663744260144316,0.663611835009392,0.064911784334342,0.211597812166192,0.0782310677839269,0.133366744382265,3.37606626697523,0.2028,2.76733490816357,1.1778,0.609373335893792,0.399162215350014,0.609251758426278,0.414245056055828,0.210211120543777,0.195006702370449,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
1367,30204,1372:1560,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.918084528160435,0.0762036427389428,0.410999227890163,8.1474012769013,5.5379,0.792062599568925,0.794257718430205,0.0468528501208515,0.377332032211843,0.184234878506573,0.19309715370527,5.72525827553722,1.0332,2.42214300136409,4.5047,0.727180417998764,0.569607347015275,0.729195722662778,0.581083249192087,0.157573070983489,0.148112473470691,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
1368,30204,1558:1560,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.257602848842658,0.0762036427389428,0.410999227890163,8.1474012769013,5.5379,0.792062599568925,0.794257718430205,0.068290694974237,0.105874571976639,0.0281556415941895,0.0777189303824491,4.02915890139716,0.3189,4.11824237550414,5.219,0.204037582110676,0.0925386561709306,0.20460305098289,0.129390156836035,0.111498925939746,0.0752128941468557,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
1369,30204,1549:1560,Breast,MDA-MB-175-VII,SIDM00633,908120,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.328531534064286,0.0762036427389428,0.410999227890163,8.1474012769013,5.5379,0.792062599568925,0.794257718430205,0.0224022500047506,0.135026206837992,0.0555400328810725,0.07948617395692,5.22710472420671,0.7316,2.92029655269459,4.8063,0.260217540911326,0.183107487583169,0.260938706678275,0.195591794924632,0.0771100533281562,0.0653469117536432,True,0.837711561026985,0.0973970778679042,0.161464736200137,285.893578219592
1370,30684,1058:1564,Breast,MDA-MB-175-VII,SIDM00633,908120,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.908389944143887,0.0911246495770854,0.571012392854978,9.67761016937584,7.9974,0.836872312295478,0.869832483975334,0.0711074777858327,0.518701915651,0.271585881731079,0.247116033919922,6.98082923863395,1.2335,2.69678093074189,6.7639,0.760206393021654,0.644589174749578,0.790147081532891,0.655806363646518,0.115617218272077,0.134340717886373,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
1371,30684,1549:1564,Breast,MDA-MB-175-VII,SIDM00633,908120,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.254118313141124,0.0911246495770854,0.571012392854978,9.67761016937584,7.9974,0.836872312295478,0.869832483975334,0.0677337570458289,0.145104706054984,0.054209313931246,0.0908953921237378,5.90789981770033,0.5863,3.76971035167551,7.4111,0.212664580315039,0.107201463268579,0.221040363543166,0.164272390087669,0.10546311704646,0.0567679734554962,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
1372,30684,1558:1564,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.404784875763419,0.0911246495770854,0.571012392854978,9.67761016937584,7.9974,0.836872312295478,0.869832483975334,0.068979182214522,0.231137180501175,0.0574616965780517,0.173675483923123,4.73710986601763,0.2604,4.94050030335821,7.737,0.33875325496237,0.176387339690431,0.352095033960941,0.225705688132875,0.162365915271939,0.126389345828067,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
1373,30684,1561:1564,Breast,MDA-MB-175-VII,SIDM00633,908120,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.752176564151993,0.0911246495770854,0.571012392854978,9.67761016937584,7.9974,0.836872312295478,0.869832483975334,0.0663664307185092,0.429502139745865,0.119095963438581,0.310406176307284,5.04150525958226,0.3216,4.63610490979358,7.6758,0.629475740496346,0.432201076173353,0.65426760918436,0.437109160259693,0.197274664322993,0.217158448924666,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
1374,30684,1510:1564,Breast,MDA-MB-175-VII,SIDM00633,908120,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.914312549719343,0.0911246495770854,0.571012392854978,9.67761016937584,7.9974,0.836872312295478,0.869832483975334,0.0707933329517519,0.522083796832578,0.245737876128129,0.276345920704449,6.62850045560719,0.9662,3.04910971376865,7.0312,0.7651628576444,0.634582194238984,0.795298756252196,0.638161232702823,0.130580663405416,0.157137523549373,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
1375,30684,1012:1564,Breast,MDA-MB-175-VII,SIDM00633,908120,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.69596355014104,0.0911246495770854,0.571012392854978,9.67761016937584,7.9974,0.836872312295478,0.869832483975334,0.0731894032684426,0.39740381210588,0.0409044837368426,0.356499328369038,2.42848034812967,0.0526,7.24912982124618,7.9448,0.582432625479901,0.226863894221988,0.605371703575472,0.263464790173718,0.355568731257914,0.341906913401754,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
1376,30684,1011:1564,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.834939831837644,0.0911246495770854,0.571012392854978,9.67761016937584,7.9974,0.836872312295478,0.869832483975334,0.0776933286559305,0.476760991267546,0.0447000629931804,0.432060928274366,2.19420329868314,0.0447,7.4834068706927,7.9527,0.698738027697567,0.264536224217634,0.726257787897285,0.301490616611323,0.434201803479932,0.424767171285962,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
1377,30684,1053:1564,Breast,MDA-MB-175-VII,SIDM00633,908120,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.702997325037629,0.0911246495770854,0.571012392854978,9.67761016937584,7.9974,0.836872312295478,0.869832483975334,0.0517647820629875,0.401420184740385,0.0420472652014401,0.359372919538945,2.4725555768488,0.0542,7.20505459252704,7.9432,0.588318996941776,0.232524787594771,0.611489909465496,0.268456537044935,0.355794209347004,0.343033372420561,True,1.05980494238137,0.109157373625576,-0.0731324150120437,-872.61358169783
1378,28749,1558:2169,Breast,MDA-MB-175-VII,SIDM00633,908120,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.34164600559922,0.0605117976924761,0.553792864587961,9.51180981683708,14.2584,0.848891824029059,0.862764727333725,0.0753906012762041,0.189201120115827,0.0932534615536502,0.0959476585621764,6.67871654309017,2.0009,2.83309327374691,12.2575,0.290020500865364,0.180710615517611,0.294760122865467,0.239643756434364,0.109309885347753,0.0551163664311032,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
1379,28749,1372:2169,Breast,MDA-MB-175-VII,SIDM00633,908120,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.919882724107575,0.0605117976924761,0.553792864587961,9.51180981683708,14.2584,0.848891824029059,0.862764727333725,0.0365659966474949,0.509424488868511,0.328225242230009,0.181199246638502,7.60387884838836,3.7995,1.90793096844872,10.4589,0.780880923560499,0.687922568979054,0.793642367643676,0.700964363701987,0.0929583545814442,0.0926780039416891,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
1380,28749,1011:2169,Breast,MDA-MB-175-VII,SIDM00633,908120,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.858270244033976,0.0605117976924761,0.553792864587961,9.51180981683708,14.2584,0.848891824029059,0.862764727333725,0.110804618131432,0.475303937034184,0.251900943985631,0.223402993048553,6.91858565870776,2.3628,2.59322415812932,11.8956,0.728578592967867,0.577920180190183,0.740485293072623,0.616043287467574,0.150658412777684,0.124442005605049,True,0.550432533300249,0.0756485778333503,0.577003870657841,84.8624514962054
1381,25077,1053:1030,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1030,KU-55933,ATM,Genome integrity,Targeted,Experimental only,10.0,0.706977985141752,0.0880865073678181,0.738845575887891,11.2176433805601,46.5133,0.898885815541852,0.936151139293417,0.125508816976523,0.522347556572119,0.318145947723068,0.204201608849051,8.57216186100897,7.4337,2.64548151955113,39.0796,0.635492482744279,0.506637232750308,0.661838246245816,0.588285103723879,0.128855249993971,0.0735531425219367,True,0.696813824939661,0.0921391971612566,0.336642508283271,141.041246137303
1382,27336,1058:1032,Breast,OCUB-M,SIDM00241,909256,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.892714149570672,0.0718010772084429,0.095175294380483,4.19779869715214,0.3584,0.514696522541966,0.516315383845192,0.0518050861522311,0.0849643319830112,0.0085795419303087,0.0763847900527025,-0.884145579618229,0.0106,5.08194427677037,0.3478,0.459476868408033,0.0991988241508913,0.460922048799616,0.135352047087687,0.360278044257142,0.325570001711929,True,0.49621423654552,0.0626877082544931,0.663764931189795,73.1460280545743
1383,27336,1561:1032,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.25648335096175,0.0718010772084429,0.095175294380483,4.19779869715214,0.3584,0.514696522541966,0.516315383845192,0.059462080731132,0.0244108784314774,0.0040561322198609,0.0203547462116165,0.191298088063042,0.0223,4.0065006090891,0.3361,0.132011088829923,0.0094977507409289,0.132426299801717,0.0544220211548487,0.122513338088995,0.0780042786468685,True,0.49621423654552,0.0626877082544931,0.663764931189795,73.1460280545743
1384,27336,1012:1032,Breast,OCUB-M,SIDM00241,909256,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.430364640529019,0.0718010772084429,0.095175294380483,4.19779869715214,0.3584,0.514696522541966,0.516315383845192,0.0932901363950849,0.0409600813533002,0.0049247554987549,0.0360353258545453,-0.50803398007784,0.0137,4.70583267722998,0.3447,0.221507183905309,0.0693712752781383,0.222203884568139,0.0737499448910197,0.152135908627171,0.148453939677119,True,0.49621423654552,0.0626877082544931,0.663764931189795,73.1460280545743
1385,27336,1594:1032,Breast,OCUB-M,SIDM00241,909256,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.949021533636566,0.0718010772084429,0.095175294380483,4.19779869715214,0.3584,0.514696522541966,0.516315383845192,0.0551508631009017,0.0903234038372777,0.0250640964347248,0.0652593074025528,1.30795628106956,0.0484,2.88984241608258,0.31,0.488458083180184,0.266185399982629,0.489994417416916,0.272660265797416,0.222272683197555,0.217334151619501,True,0.49621423654552,0.0626877082544931,0.663764931189795,73.1460280545743
1386,27336,1053:1032,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.273873853508452,0.0718010772084429,0.095175294380483,4.19779869715214,0.3584,0.514696522541966,0.516315383845192,0.0680895174183412,0.0260660246307842,0.0033966685835341,0.0226693560472501,-0.334336637094061,0.0155,4.5321353342462,0.3429,0.140961920015968,0.0120547287980116,0.141405283799378,0.0495753917630488,0.128907191217956,0.0918298920363292,True,0.49621423654552,0.0626877082544931,0.663764931189795,73.1460280545743
1387,27336,1561:1038,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.25648335096175,0.164805236334982,0.465222557040134,8.70288305336718,8.1388,0.895495179797953,0.83906164935354,0.0319833576809445,0.119321840372647,0.0751987408628443,0.0441230995098031,7.12363238724303,2.7237,1.57925066612415,5.4151,0.229679604484674,0.214308613097696,0.215205343489689,0.190578182339746,0.0153709913869784,0.0246271611499425,True,0.49621423654552,0.0626877082544931,0.663764931189795,73.1460280545743
1388,25505,1058:1042,Breast,OCUB-M,SIDM00241,909256,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.922893471466843,0.120728503139718,0.659321586828633,10.4079626388902,26.5362,0.900233654533887,0.912186598778399,0.0608949988308106,0.608483588081304,0.534602343194125,0.0738812448871796,9.68187172712497,16.0422,0.726090911765231,10.494,0.830819762564062,0.847277814069621,0.84185105677213,0.816753227911949,-0.0164580515055588,0.0250978288601805,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
1389,25505,1561:1042,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.0761397800895721,0.120728503139718,0.659321586828633,10.4079626388902,26.5362,0.900233654533887,0.912186598778399,0.0315828812970812,0.0502006006294398,0.0283353466851985,0.0218652539442412,7.88473881453085,4.6161,2.52322382435935,21.9201,0.068543592485442,0.0299334899074633,0.0694536870316421,0.0603409283884965,0.0386101025779787,0.0091127586431456,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
1390,25505,1011:1042,Breast,OCUB-M,SIDM00241,909256,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.582189647368686,0.120728503139718,0.659321586828633,10.4079626388902,26.5362,0.900233654533887,0.912186598778399,0.0895580963231353,0.383850202138324,0.0958880281331598,0.287962174005165,5.53773890969095,0.9073,4.87022372919926,25.6289,0.524106713882508,0.335031890158827,0.531065594277238,0.363933993649804,0.18907482372368,0.167131600627434,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
1391,27081,1011:1096,Breast,OCUB-M,SIDM00241,909256,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.199600514645895,0.179774188281564,0.471368926752728,8.75552135518398,4.2206,0.718098594452588,0.841806091131047,0.077839977485462,0.094085480367928,0.0177319631672221,0.0763535172007058,4.0359615161048,0.1602,4.71955983907917,4.0604,0.143332849019231,0.0402970753830347,0.168024929021807,0.100392459062165,0.103035773636196,0.0676324699596419,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
1392,25508,1012:1560,Breast,OCUB-M,SIDM00241,909256,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,0.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.910193989452031,0.120768641086762,0.153407907563388,5.35761401116479,0.8008,0.632535294996408,0.610799369059789,0.1303685554218,0.139630955398608,0.138009950884762,0.0016210045138463,5.32823263332307,0.7847,0.0293813778417196,0.0161,0.575729823621998,0.593959092754532,0.555945914479313,0.553809449872357,-0.018229269132534,0.0021364646069553,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
1393,25508,1558:1560,Breast,OCUB-M,SIDM00241,909256,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.470280830271115,0.120768641086762,0.153407907563388,5.35761401116479,0.8008,0.632535294996408,0.610799369059789,0.0632264224156738,0.0721447981390646,0.0166093117151348,0.0555354864239298,1.94729071557444,0.0753,3.41032329559035,0.7255,0.297469223706696,0.137822244068135,0.287247234410511,0.157460279064713,0.159646979638561,0.129786955345798,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
1394,25508,1549:1560,Breast,OCUB-M,SIDM00241,909256,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.832083958856039,0.120768641086762,0.153407907563388,5.35761401116479,0.8008,0.632535294996408,0.610799369059789,0.112719974500357,0.127648259045165,0.0583446265872054,0.0693036324579597,3.48803705875232,0.2191,1.86957695241246,0.5817,0.526322472376784,0.381714453717022,0.50823635707404,0.380949644402952,0.144608018659762,0.127286712671088,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
1395,25508,1053:1560,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.694790286861547,0.120768641086762,0.153407907563388,5.35761401116479,0.8008,0.632535294996408,0.610799369059789,0.0643809171059178,0.106586324102796,0.0289606907924974,0.0776256333102985,2.31473582752317,0.0972,3.04287818364161,0.7036,0.439479379060608,0.232772562629684,0.424377468843902,0.252397751523925,0.206706816430924,0.171979717319977,True,0.580978458229836,0.0841587442812999,0.506517911403239,94.5380765593994
1396,27083,1011:1632,Breast,OCUB-M,SIDM00241,909256,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.34831358287374,0.0895791588034211,0.895806084959749,13.5877875607154,96.1882,0.939220811278269,0.976764793529109,0.13074840024599,0.312021427012428,0.0642955312751217,0.247725895737306,5.83222338122697,0.4451,7.75556417948841,95.7431,0.327143365885914,0.13172258590869,0.340220444859052,0.225774671245066,0.195420779977224,0.114445773613986,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
1397,27083,1558:1632,Breast,OCUB-M,SIDM00241,909256,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.532264783474203,0.0895791588034211,0.895806084959749,13.5877875607154,96.1882,0.939220811278269,0.976764793529109,0.143471010848254,0.476806031845974,0.244269609040619,0.232536422805355,8.64885581021207,3.1358,4.93893175050331,93.0524,0.499914161749493,0.336761424142545,0.519897501332996,0.445086504039009,0.163152737606948,0.0748109972939872,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
1398,27083,1594:1909,Breast,OCUB-M,SIDM00241,909256,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.393697212413928,0.0619333709568286,0.829564448001762,12.3746103413754,10.3719,0.939329127043697,0.960557487814257,0.0454705918762729,0.326597210695993,0.207770588013749,0.118826622682244,9.23687177298911,1.1784,3.13773856838634,9.1935,0.369811258856312,0.312120429984009,0.378168805315799,0.340727222061413,0.0576908288723026,0.0374415832543856,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
1399,27083,1011:1909,Breast,OCUB-M,SIDM00241,909256,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.575265064125575,0.0619333709568286,0.829564448001762,12.3746103413754,10.3719,0.939329127043697,0.960557487814257,0.0719020154830563,0.477219445376031,0.317164842401363,0.160054602974668,9.43943079122434,1.3561,2.9351795501511,9.0158,0.540363230503813,0.434901648010965,0.55257516482377,0.503140665110471,0.105461582492848,0.0494344997132985,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
1400,27083,1053:1909,Breast,OCUB-M,SIDM00241,909256,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.556148272688705,0.0619333709568286,0.829564448001762,12.3746103413754,10.3719,0.939329127043697,0.960557487814257,0.0794842624643461,0.46136083484014,0.239129155779667,0.222231679060473,8.39875317491942,0.6592,3.97585716645603,9.7127,0.522406271491542,0.387332587540384,0.534212387666101,0.457488452744865,0.135073683951157,0.0767239349212357,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
1401,27083,1021:1909,Breast,OCUB-M,SIDM00241,909256,1021,Axitinib,"PDGFR, KIT, VEGFR",RTK signaling,Targeted,FDA approved,4.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.64214883399145,0.0619333709568286,0.829564448001762,12.3746103413754,10.3719,0.939329127043697,0.960557487814257,0.0988757522772345,0.532703843005093,0.347834707776915,0.184869135228177,9.35628024079059,1.2801,3.01833010058486,9.0918,0.603189103665317,0.486674902587867,0.616820870781681,0.559257812457762,0.11651420107745,0.0575630583239193,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
1402,27083,1561:1909,Breast,OCUB-M,SIDM00241,909256,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1909,Venetoclax,BCL2,Apoptosis regulation,Targeted,Advanced clinical trials,1.0,0.140120557386679,0.0619333709568286,0.829564448001762,12.3746103413754,10.3719,0.939329127043697,0.960557487814257,0.0674919831214728,0.11623903284218,0.0775287001703387,0.0387103326718408,9.45636056679926,1.3721,2.91824977457619,8.9998,0.131619320850905,0.0525949861306008,0.134593850594482,0.122657255880111,0.0790243347203045,0.0119365947143712,True,0.597231696755248,0.0818589810846161,0.483725397765941,99.2586921991921
1403,25079,1058:2169,Breast,OCUB-M,SIDM00241,909256,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.898478178654717,0.125546794289599,0.138276602184987,5.09840044761176,0.6691,0.604638403201402,0.589981982481955,0.101482190565804,0.12423850968173,0.0816400917032042,0.0425984179785259,4.08883409023713,0.3323,1.00956635737463,0.3368,0.543254411253092,0.462000659011322,0.530085937059486,0.455823856930039,0.0812537522417709,0.0742620801294471,True,0.696813824939661,0.0921391971612566,0.336642508283271,141.041246137303
1404,25079,1549:2169,Breast,OCUB-M,SIDM00241,909256,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.555253909400608,0.125546794289599,0.138276602184987,5.09840044761176,0.6691,0.604638403201402,0.589981982481955,0.0705815705723885,0.0767786239418468,0.0172571896676914,0.0595214342741553,1.66535870812925,0.062,3.43304173948251,0.6071,0.33572783715132,0.146001992995486,0.327589802249027,0.174087405680442,0.189725844155834,0.153502396568585,True,0.696813824939661,0.0921391971612566,0.336642508283271,141.041246137303
1405,25079,1558:2169,Breast,OCUB-M,SIDM00241,909256,1558,Lapatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved in breast,0.625,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.586014474905346,0.125546794289599,0.138276602184987,5.09840044761176,0.6691,0.604638403201402,0.589981982481955,0.050761040021261,0.0810320904211306,0.0291987959690208,0.0518332944521098,2.71346744750608,0.1281,2.38493300010568,0.541,0.354326856359677,0.212587809567476,0.345737981667778,0.231408315017408,0.141739046792201,0.11432966665037,True,0.696813824939661,0.0921391971612566,0.336642508283271,141.041246137303
1406,26731,1011:1038,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1038,NU7441,DNAPK,Genome integrity,Targeted,Experimental only,10.0,0.625151271151149,0.0937078651033825,0.538548063598659,9.39532777125929,13.1524,0.877120878603092,0.846007566542399,0.129783928965525,0.336674006534692,0.185577157347285,0.151096849187407,6.79347729607713,2.1666,2.60185047518216,10.9858,0.548333232211935,0.487693388872173,0.528882705627471,0.438305856121602,0.0606398433397622,0.0905768495058688,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
1407,26732,1011:1042,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1042,Doramapimod,"p38, JNK2",JNK and p38 signaling,Targeted,Early clinical trials,10.0,0.694837195121466,0.14063140813819,0.625572291175824,10.3133376632727,24.8516,0.924832719310745,0.883027527526416,0.0746249889660712,0.434670896146319,0.222680113270798,0.211990782875521,7.07688756034557,2.6369,3.23645010292709,22.2147,0.642608172642436,0.517055485723975,0.613560370441498,0.499931401216908,0.125552686918461,0.11362896922459,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
1408,26733,1561:1050,Breast,EFM-19,SIDM01056,906851,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.540937808170589,0.0694012423300404,0.737157298075507,11.6387252260689,62.2781,0.906655695661718,0.923794476419454,0.0311174310228662,0.398756253097918,0.256982540989819,0.141773712108099,8.74461234091916,8.3776,2.89411288514971,53.9005,0.49044434477663,0.437521756330278,0.499715359274436,0.440954165899937,0.0529225884463522,0.0587611933744992,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
1409,26733,1510:1050,Breast,EFM-19,SIDM01056,906851,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.997285569050969,0.0694012423300404,0.737157298075507,11.6387252260689,62.2781,0.906655695661718,0.923794476419454,0.0510628871515345,0.735156335491307,0.561429910300633,0.173726425190673,9.64781991460189,15.668,1.99090531146698,46.6101,0.904194641381298,0.833743046895062,0.921286900102116,0.854617102876395,0.0704515944862366,0.066669797225721,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
1410,26733,1011:1050,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.673466396828793,0.0694012423300404,0.737157298075507,11.6387252260689,62.2781,0.906655695661718,0.923794476419454,0.132435503056131,0.49645066943096,0.100122145649016,0.396328523781944,4.53469357713499,0.4527,7.10403164893387,61.8254,0.6106021445216,0.351564279200966,0.622144537444551,0.363761756584169,0.259037865320633,0.258382780860382,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
1411,26733,1594:1050,Breast,EFM-19,SIDM01056,906851,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.863294005320047,0.0694012423300404,0.737157298075507,11.6387252260689,62.2781,0.906655695661718,0.923794476419454,0.0503177183239781,0.636383476406508,0.611827421746862,0.0245560546596463,11.2751094966384,48.4034,0.363615729430499,13.8747,0.782710426954038,0.798383449545089,0.797506233640686,0.78905331399422,-0.0156730225910514,0.0084529196464654,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
1412,26733,1011:1051,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1051,Alisertib,AURKA,Mitosis,Targeted,Advanced clinical trials,10.0,0.673466396828793,0.0846378760086382,0.63693116825082,10.438208469203,27.0984,0.833994839111004,0.887487202575958,0.112500240173555,0.428951738909833,0.0551639121020826,0.373787826807751,2.81628841139384,0.1376,7.62192005780914,26.9608,0.561667499269897,0.24447532797879,0.597692808550495,0.277265463028163,0.317192171291107,0.320427345522333,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
1413,25021,1011:1080,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1080,Paclitaxel,Microtubule stabiliser,Mitosis,Chemotherapeutic,FDA approved in breast,0.1,0.794088730360431,0.0921743822562348,0.274731170307792,6.5160709573547,0.0179,0.701668731671322,0.682631478166938,0.1005466626779,0.21816092622015,0.0677915859335951,0.150369340286555,2.93181118095123,0.0015,3.58425977640347,0.0164,0.557187232266494,0.304870295859489,0.542069963801648,0.333677459448311,0.252316936407005,0.208392504353337,True,0.904416820919878,0.0974601943778396,0.0802773793942531,506.394160987749
1414,25022,1011:1085,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1085,Sorafenib,"PDGFR, KIT, VEGFR, RAF","Other, kinases",Targeted,FDA approved,10.0,0.785558979550154,0.0548139785909962,0.566339734503023,9.6830207168784,16.055,0.874348161662092,0.858422022902349,0.131268910075633,0.4448932639149,0.165941266997963,0.278951996916937,5.62889391162512,0.9665,4.05412680525327,15.0885,0.686852049646826,0.510749005825492,0.674341128334548,0.487572784960119,0.176103043821334,0.186768343374429,True,0.904416820919878,0.0974601943778396,0.0802773793942531,506.394160987749
1415,25830,1011:1096,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1096,Tozasertib,"AURKA, AURKB, AURKC, others",Mitosis,Targeted,Early clinical trials,5.0,0.683766773426401,0.0686423864607738,0.886877048324554,14.2691088113923,192.8101,0.952916935226828,0.969936651599522,0.196075907004657,0.606417057758811,0.123529259061952,0.482887798696859,5.13143224196673,0.3423,9.13767656942552,192.4678,0.651572938143423,0.314896375372945,0.663210454692212,0.399632765259213,0.336676562770477,0.263577689433,True,0.69726247590643,0.079796795175027,0.337729563413539,141.08803728045
1416,25830,1011:1129,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1129,PF-4708671,S6K1,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.793896605144426,0.0887035717415753,0.804979529349321,12.6276067303854,123.6,0.895175382361551,0.945731985511707,0.0312848225408143,0.639070515561184,0.363774471817888,0.275296043743296,8.57131536970161,7.4294,4.05629136068382,116.1706,0.710676697065699,0.624506874442089,0.750813412674242,0.64012828613832,0.0861698226236096,0.110685126535921,True,0.69726247590643,0.079796795175027,0.337729563413539,141.08803728045
1417,25831,1011:1192,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.643443866084715,0.063451419619327,0.653996826074724,10.6290557000705,30.931,0.88322335154813,0.894044651505737,0.0685935262918921,0.420810246176653,0.0726139578105509,0.348196288366103,3.72397466834342,0.2581,6.90508103172711,30.6729,0.568304647936428,0.273431328823133,0.575267547017213,0.308375484587499,0.294873319113295,0.266892062429714,True,0.69726247590643,0.079796795175027,0.337729563413539,141.08803728045
1418,26735,1011:1553,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1553,Uprosertib,"AKT1, AKT2, AKT3",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.706927207428837,0.074777855308618,0.406155626839414,8.02797032005424,5.0979,0.739239880227854,0.776853084541154,0.0837231520386543,0.287122463063096,0.0648046715976093,0.222317791465486,3.13170185181517,0.1712,4.89626846823907,4.9267,0.522588784149505,0.28182666018952,0.549178581637156,0.307509945695324,0.240762123959986,0.241668635941833,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
1419,26735,1011:1560,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.625,1560,Alpelisib,PI3Kalpha,PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.817987301508881,0.0738976921601839,0.363332705781581,7.56471083575723,3.6977,0.728278685608096,0.749788124701042,0.0769431095621019,0.297201539552196,0.0664119908573,0.230789548694896,2.79166027798395,0.1352,4.77305055777328,3.5625,0.595722716787001,0.31042963558195,0.61331716482761,0.335285852569728,0.285293081205052,0.278031312257882,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
1420,26736,1510:1564,Breast,EFM-19,SIDM01056,906851,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.941637030580712,0.0724750994642436,0.79367930115802,12.4473037071278,54.5396,0.908670827371159,0.942204963359737,0.0503185180014539,0.747357820375813,0.782948371844363,-0.0355905514685504,13.0841184791924,84.8032,-0.636814772064652,-30.2636,0.855638099661096,0.881942014259502,0.887215083896472,0.898148636934303,-0.0263039145984053,-0.0109335530378313,True,1.00344554167563,0.0904766268881112,-0.0272216516846095,-14859.1356151873
1421,25021,1011:2169,Breast,EFM-19,SIDM01056,906851,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,2169,AZD6482,PI3Kbeta,PI3K/MTOR signaling,Targeted,Experimental only,10.0,0.794088730360431,0.0758870117279521,0.729944309044146,11.5442923676973,58.3322,0.915525318155197,0.921346788462576,0.0957290572112679,0.579640549602688,0.287597128279946,0.292043421322743,7.55186874390276,3.665,3.99242362379452,54.6672,0.72700833750669,0.615354289254294,0.731631101471908,0.594783193757878,0.111654048252396,0.13684790771403,True,0.904416820919878,0.0974601943778396,0.0802773793942531,506.394160987749
1422,26074,1012:1032,Breast,CAL-85-1,SIDM00928,910852,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.778661433386566,0.0937083846695414,0.578263564388448,9.63381065110113,15.5166,0.886673964018918,0.891022926453466,0.0824707576835494,0.450271535921934,0.246697503106334,0.2035740328156,7.45705863448588,3.4319,2.17675201661525,12.0847,0.690418819769519,0.60665716564412,0.693805189092549,0.601248473241788,0.0837616541253994,0.0925567158507613,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1423,26074,1011:1032,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.817170892155919,0.0937083846695414,0.578263564388448,9.63381065110113,15.5166,0.886673964018918,0.891022926453466,0.0959598233323414,0.47254015281257,0.236710786947991,0.235829365864579,7.19889694900635,2.8696,2.43491370209478,12.647,0.724564154228765,0.588411072656903,0.728117999741357,0.616610962024003,0.136153081571862,0.111507037717354,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1424,26074,1510:1032,Breast,CAL-85-1,SIDM00928,910852,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.789785871687268,0.0937083846695414,0.578263564388448,9.63381065110113,15.5166,0.886673964018918,0.891022926453466,0.107854284861077,0.456704393265517,0.237330859390131,0.219373533875387,7.303441696886,3.0852,2.33036895421513,12.4314,0.700282569575087,0.536524786703888,0.703717318662392,0.60163419268666,0.163757782871198,0.102083125975731,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1425,26074,1372:1032,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.589879095677782,0.0937083846695414,0.578263564388448,9.63381065110113,15.5166,0.886673964018918,0.891022926453466,0.126912631099189,0.341105588424869,0.153952352216805,0.187153236208064,6.91005391418429,2.3489,2.72375673691683,13.1677,0.523030436056514,0.362254185796491,0.525595798084542,0.433057450986491,0.160776250260023,0.0925383470980509,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1426,26077,1049:1050,Breast,CAL-85-1,SIDM00928,910852,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.972899760817548,0.126105962267638,0.639743732111963,10.1530745596688,22.2387,0.928016045511206,0.911082593601509,0.113617668379444,0.622406523956254,0.627448509878285,-0.0050419859220307,10.198370161833,22.948,-0.0452956021641882,-0.709299999999999,0.902866588712698,0.92109872231958,0.886392037399939,0.887951386141953,-0.0182321336068814,-0.0015593487420131,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1427,26077,1372:1050,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.90246862315611,0.126105962267638,0.639743732111963,10.1530745596688,22.2387,0.928016045511206,0.911082593601509,0.170106632421541,0.577348645091835,0.419228794586156,0.158119850505678,8.71467655635164,8.2056,1.43839800331718,14.0331,0.837505362859276,0.742962265043984,0.822223453829052,0.764960226757241,0.0945430978152912,0.0572632270718108,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1428,26077,1011:1050,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1050,ZM447439,"AURKA, AURKB",Mitosis,Targeted,Experimental only,10.0,0.843414557913867,0.126105962267638,0.639743732111963,10.1530745596688,22.2387,0.928016045511206,0.911082593601509,0.0904560891053783,0.539569176997379,0.207236847844077,0.332332329153302,6.7478418405998,2.0991,3.40523271906902,20.1396,0.782702242761808,0.603528146799701,0.768420322905436,0.609245559257266,0.179174095962107,0.15917476364817,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1429,26080,1058:1564,Breast,CAL-85-1,SIDM00928,910852,1058,Pictilisib,PI3K (class 1),PI3K/MTOR signaling,Targeted,Early clinical trials,0.125,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.959269445036784,0.105494849345881,0.546557058544957,9.37502502823281,6.4843,0.832907209590575,0.879837542069893,0.0559223506320084,0.524295486231358,0.416777505310868,0.10751798092049,8.47066042575883,3.4644,0.904364602473985,3.0199,0.798982436711087,0.769729018951914,0.844001270703915,0.80041532450545,0.0292534177591733,0.0435859461984653,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1430,26080,1049:1564,Breast,CAL-85-1,SIDM00928,910852,1049,PD173074,"FGFR1, FGFR2, FGFR3",RTK signaling,Targeted,Experimental only,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.978930123147457,0.105494849345881,0.546557058544957,9.37502502823281,6.4843,0.832907209590575,0.879837542069893,0.0657839489034657,0.535041168628526,0.606370025881332,-0.071328857252806,9.9780608525191,9.8491,-0.603035824286286,-3.3648,0.815357957254906,0.845856724464229,0.861299473408237,0.885609632222044,-0.0304987672093223,-0.0243101588138075,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1431,26080,1561:1564,Breast,CAL-85-1,SIDM00928,910852,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.870330392365924,0.105494849345881,0.546557058544957,9.37502502823281,6.4843,0.832907209590575,0.879837542069893,0.049802524204894,0.475685219213797,0.179007767667963,0.296677451545834,6.28689115953205,0.7625,3.08813386870077,5.7218,0.724904458527372,0.577805176458045,0.76574935320796,0.598537291641655,0.147099282069327,0.167212061566305,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1432,26080,1510:1564,Breast,CAL-85-1,SIDM00928,910852,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.864409985073035,0.105494849345881,0.546557058544957,9.37502502823281,6.4843,0.832907209590575,0.879837542069893,0.0888046589056307,0.472449378818408,0.366055339543491,0.106394039274917,8.38048954988373,3.2545,0.994535478349082,3.2298,0.719973308609412,0.656573625253225,0.760540356607333,0.716884288287135,0.0633996833561871,0.043656068320198,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1433,26080,1083:1564,Breast,CAL-85-1,SIDM00928,910852,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.96077310347585,0.105494849345881,0.546557058544957,9.37502502823281,6.4843,0.832907209590575,0.879837542069893,0.122947881301092,0.52511732136487,0.254248145457403,0.270869175907467,6.94776994869785,1.2056,2.42725507953496,5.2787,0.800234844665747,0.684990227502932,0.845324245849056,0.707950644005487,0.115244617162815,0.137373601843568,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1434,26080,1012:1564,Breast,CAL-85-1,SIDM00928,910852,1012,Vorinostat,"HDAC inhibitor Class I, IIa, IIb, IV",Chromatin histone acetylation,Targeted,FDA approved,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.856135082364858,0.105494849345881,0.546557058544957,9.37502502823281,6.4843,0.832907209590575,0.879837542069893,0.113985109498801,0.467926672334481,0.117860642252748,0.350066030081733,5.3157713340556,0.389,4.05925369417721,6.0953,0.71308108248511,0.47204422779614,0.753259786547702,0.522499508648385,0.24103685468897,0.230760277899317,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1435,26080,1011:1564,Breast,CAL-85-1,SIDM00928,910852,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.843425705032519,0.105494849345881,0.546557058544957,9.37502502823281,6.4843,0.832907209590575,0.879837542069893,0.0562734300477876,0.46098027244378,0.030079198027787,0.430901074415993,2.37910982839139,0.0508,6.99591519984142,6.4335,0.702495350475599,0.284822425765007,0.742077599234379,0.307720033796241,0.417672924710592,0.434357565438138,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1436,26080,1053:1564,Breast,CAL-85-1,SIDM00928,910852,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.932781313306323,0.105494849345881,0.546557058544957,9.37502502823281,6.4843,0.832907209590575,0.879837542069893,0.118840293650085,0.509818210866405,0.201614305938208,0.308203904928198,6.41317573344909,0.8323,2.96184929478372,5.652,0.776920280824201,0.613283608993496,0.820696017988162,0.650485678471102,0.163636671830705,0.17021033951706,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1437,26081,1372:1632,Breast,CAL-85-1,SIDM00928,910852,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.785858225627208,0.0690909658518501,0.944249792898121,14.6815392980939,205.2928,0.964976843829371,0.988562899347757,0.0651121240267085,0.742046466795776,0.687301983366899,0.0547444834288774,12.8997503234078,59.7038,1.78178897468607,145.589,0.758334990263093,0.726960884508269,0.776870286002316,0.764868434412367,0.031374105754824,0.0120018515899493,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1438,26081,1083:1632,Breast,CAL-85-1,SIDM00928,910852,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.908926619819609,0.0690909658518501,0.944249792898121,14.6815392980939,205.2928,0.964976843829371,0.988562899347757,0.183528449550996,0.858253772524255,0.410660778600348,0.447592993923908,8.61172852874148,3.0562,6.0698107693524,202.2366,0.877093140866025,0.604069338782098,0.898531134583229,0.76543962738309,0.273023802083927,0.13309150720014,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1439,26081,1594:1632,Breast,CAL-85-1,SIDM00928,910852,1594,OSI-027,"MTORC1, MTORC2",PI3K/MTOR signaling,Targeted,Early clinical trials,0.25,1632,Ribociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved in breast,4.0,0.89265512895499,0.0690909658518501,0.944249792898121,14.6815392980939,205.2928,0.964976843829371,0.988562899347757,0.0227756858326045,0.842889420645195,0.844339747847678,-0.0014503272024833,14.7443791419059,214.4324,-0.0628398438120108,-9.1396,0.861391528967086,0.89265512895499,0.882445742397391,0.882751651187434,-0.0312635999879035,-0.0003059087900428,True,0.283149477858129,0.0547067666777218,1.2001884730147,40.9736599459934
1440,25063,1011:1192,Breast,JIMT-1,SIDM01037,1298157,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,2.5,1192,GSK269962A,"ROCK1, ROCK2",Cytoskeleton,Targeted,Experimental only,10.0,0.814711339772979,0.0567803555264476,0.649995092101866,10.6186372213777,30.7085,0.883626109038289,0.890411097507956,0.0576795550337116,0.529558372332172,0.125945422692438,0.403612949639734,4.55723461947766,0.4598,6.06140260190004,30.2487,0.719900211152969,0.408491649292263,0.725428018199435,0.44100791436851,0.311408561860706,0.284420103830926,True,0.419830927171027,0.0621161558904039,0.827490334639781,59.0850993592943
